data_2mcy_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mcy _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB3' HG21 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.753 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.699 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.699 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HB3' HD12 ' A' ' 86' ' ' ILE . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.503 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.535 HG23 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.535 ' HG3' HG23 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.559 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.753 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.634 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.474 ' CE2' HG13 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.559 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.653 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.503 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.873 ' SG ' HD12 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.61 ' HZ1' ' ND2' ' A' ' 177' ' ' ASN . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.873 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.425 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.634 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.501 HG23 ' N ' ' A' ' 108' ' ' GLY . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.445 ' HB3' HD13 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.501 ' N ' HG23 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.541 HG12 ' SG ' ' A' ' 63' ' ' CYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.445 HD13 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.601 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.636 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.572 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.485 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.476 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.571 HD21 ' HA ' ' A' ' 154' ' ' CYS . 93.5 m-20 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.43 ' H ' ' CG2' ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.572 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.539 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.636 ' OD1' ' HB3' ' A' ' 125' ' ' CYS . 3.9 t-20 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.473 ' CB ' HD22 ' A' ' 143' ' ' ASN . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.451 HG22 ' OG ' ' A' ' 171' ' ' SER . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.518 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.571 ' HA ' HD21 ' A' ' 133' ' ' ASN . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.534 HD22 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.558 HG22 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.558 ' CD2' HG22 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.569 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.569 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.451 ' OG ' HG22 ' A' ' 151' ' ' THR . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.581 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.605 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.61 ' ND2' ' HZ1' ' A' ' 92' ' ' LYS . 9.8 m120 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . 0.403 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.403 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.581 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.605 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.485 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.584 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.499 ' SG ' ' ND2' ' A' ' 133' ' ' ASN . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.584 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.883 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.883 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.415 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.589 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.469 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.464 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.464 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.473 HG11 ' N ' ' A' ' 77' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.473 ' N ' HG11 ' A' ' 76' ' ' VAL . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.418 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.431 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.454 HG23 HG23 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.411 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.564 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 96' ' ' LEU . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.487 ' HB3' HG22 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.419 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.545 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.538 HG12 HG23 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.449 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.407 HG21 HG22 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.538 HG23 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.449 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.545 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.537 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.536 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.536 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.592 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.559 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.564 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.45 ' HB ' ' HD1' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.472 HG21 ' OD1' ' A' ' 133' ' ' ASN . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.472 ' OD1' HG21 ' A' ' 132' ' ' THR . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.514 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.514 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.433 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.45 ' HD1' ' HB ' ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.659 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.659 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.582 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.428 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.474 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.637 ' O ' HG11 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.434 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.592 ' HZ1' ' HA ' ' A' ' 110' ' ' THR . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.514 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.571 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.571 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.616 ' C ' ' HD2' ' A' ' 69' ' ' PRO . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.616 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.539 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.401 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.401 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.525 HG21 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.525 ' H ' HG21 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.423 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.568 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.44 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.429 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.423 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.46 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.615 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.539 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.448 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.481 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.58 ' NH1' HD11 ' A' ' 97' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.489 HD11 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.715 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.639 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.684 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.564 ' SG ' HG21 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.592 ' HA ' ' HZ1' ' A' ' 61' ' ' LYS . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.564 HG21 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.454 ' HG1' ' HB2' ' A' ' 102' ' ' ALA . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.438 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HG3' ' N ' ' A' ' 99' ' ' SER . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.715 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.421 ' HB3' HD13 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 122' ' ' ARG . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.501 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.689 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.483 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.451 HG21 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.476 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.503 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.689 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.503 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.476 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.43 ' CB ' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . 0.43 ' H ' ' CB ' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.511 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.548 ' HA ' ' HA ' ' A' ' 191' ' ' CYS . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.542 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.42 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 149' ' ' VAL . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.428 ' O ' HG21 ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.471 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.553 ' HB2' HD11 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.553 HD11 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.483 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.42 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 192' ' ' ILE . 22.6 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.613 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.604 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.487 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.418 ' CG1' HG11 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.436 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.587 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.613 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.701 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.481 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.587 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.733 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.487 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.426 ' SG ' HD12 ' A' ' 96' ' ' LEU . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.486 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.486 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.43 HD11 ' HA ' ' A' ' 97' ' ' ILE . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.425 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.685 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.733 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.701 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.481 HG12 ' CD1' ' A' ' 82' ' ' PHE . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.51 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.668 HG23 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.51 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 117' ' ' THR . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.465 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.425 ' HG3' ' C ' ' A' ' 99' ' ' SER . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.435 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.625 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.426 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.576 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.426 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.537 HG22 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.461 ' ND2' ' HB2' ' A' ' 191' ' ' CYS . 34.1 m-80 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.411 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.537 ' O ' HG22 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.445 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.517 HD12 ' CG2' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.683 ' ND2' HG12 ' A' ' 150' ' ' VAL . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.625 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 55.5 m80 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.683 HG12 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.517 ' CG2' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.523 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.549 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.637 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.549 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.478 HD21 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.442 HG21 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.478 ' H ' HD21 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.436 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.427 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.427 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.452 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.426 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.436 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.516 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.516 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.526 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.514 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.59 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.59 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.479 ' HG2' HG22 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.825 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.474 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.494 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.479 HG22 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.431 ' HD1' HG21 ' A' ' 76' ' ' VAL . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.431 HG21 ' HD1' ' A' ' 75' ' ' HIS . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.508 HD11 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.816 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.464 HG23 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.464 ' N ' HG23 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.673 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.52 HD13 ' HG ' ' A' ' 100' ' ' SER 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 97' ' ' ILE 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.586 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.727 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.52 ' HG ' HD13 ' A' ' 96' ' ' LEU . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.514 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.469 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.469 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.825 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.727 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.816 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.482 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.608 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.536 ' CD1' ' HA ' ' A' ' 142' ' ' GLU . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.549 ' HB2' ' OH ' ' A' ' 152' ' ' TYR . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.826 HG22 ' O ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.826 ' O ' HG22 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.465 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.536 ' HA ' ' CD1' ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.608 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.62 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.465 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.602 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.51 HG21 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.51 ' CD2' HG21 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.508 ' HG ' ' H ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.508 ' H ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.492 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.731 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.731 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.754 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.647 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.647 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.435 ' HA ' ' HG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.754 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.632 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.477 ' HB3' HG23 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.492 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.435 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.435 HG12 ' HG3' ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.553 ' OG ' ' HG2' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.465 ' HA ' HG11 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.452 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.452 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.454 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.553 ' HG2' ' OG ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.48 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.537 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.742 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.773 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.479 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.615 ' SG ' HD23 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.581 ' NH2' ' HA3' ' A' ' 182' ' ' GLY . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.615 HD23 ' SG ' ' A' ' 90' ' ' CYS . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.773 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 80' ' ' ILE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.499 ' CG2' ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.487 ' CD1' HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 106' ' ' ILE . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.487 HG22 ' CD1' ' A' ' 106' ' ' ILE . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.499 ' HB2' ' CG2' ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.519 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.409 ' HD3' ' CG2' ' A' ' 115' ' ' THR . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.431 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.567 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.574 ' CD1' ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.525 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.491 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.682 HG23 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.682 ' C ' HG23 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.458 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.506 HD11 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.478 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.574 ' HB3' ' CD1' ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.564 HD22 ' HB3' ' A' ' 148' ' ' SER . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.564 ' HB3' HD22 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.506 ' HB ' HD11 ' A' ' 137' ' ' ILE . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.508 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.774 ' SG ' HD11 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.763 ' O ' HG21 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.609 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.634 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.546 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.774 HD11 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.566 ' N ' HD21 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.505 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.578 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.671 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.428 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.671 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.401 ' CE2' ' HB3' ' A' ' 128' ' ' PRO . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.524 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.491 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.501 ' NE2' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.501 HG13 ' NE2' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 111' ' ' VAL . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.476 ' HD3' HG21 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.525 ' HD3' HG23 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.419 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.449 ' HD3' ' C ' ' A' ' 67' ' ' PRO . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.415 HG21 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.606 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.606 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.422 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.476 HG21 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.609 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.6 ' CD1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.422 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.2 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.438 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.8 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.559 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.559 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.545 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.43 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.657 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.507 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.6 ' HA ' ' CD1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.565 HG13 ' CD1' ' A' ' 82' ' ' PHE . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.502 ' H ' HG23 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.456 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.528 ' HB2' ' CG1' ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.43 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.525 HG23 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.8 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.506 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' THR . . . . . 0.613 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 134' ' ' GLY . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.595 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.613 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.475 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.638 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.475 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.518 ' ND2' ' HH2' ' A' ' 184' ' ' TRP . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.506 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.504 ' CG1' HD22 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.638 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.458 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.432 ' HD3' HD11 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.571 ' SG ' HD13 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.595 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.497 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.68 HD21 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.68 ' N ' HD21 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.436 ' H ' HD21 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.458 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.439 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.439 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.423 ' H ' ' C ' ' A' ' 175' ' ' THR . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . 0.522 ' CG ' ' H ' ' A' ' 179' ' ' ASP . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.529 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.499 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.499 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.608 HD11 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.608 ' O ' HD11 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.438 ' NE2' HG13 ' A' ' 192' ' ' ILE . 11.3 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.438 HG13 ' NE2' ' A' ' 190' ' ' GLN . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.535 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.516 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.715 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.715 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.564 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.513 ' HD2' ' HB2' ' A' ' 66' ' ' PRO . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.647 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.595 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.647 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.564 HG23 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.504 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.426 HG23 ' N ' ' A' ' 92' ' ' LYS . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.426 ' N ' HG23 ' A' ' 91' ' ' THR . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.42 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.47 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.56 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.457 ' HB1' HD13 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 82' ' ' PHE . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.474 ' CG2' ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.516 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.449 ' OD1' HG21 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.614 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.614 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.501 HG21 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.533 ' HG2' HD13 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.668 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.616 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.441 ' CD2' ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.444 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.47 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.441 ' HG2' ' CD2' ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.465 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.668 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 50.0 m80 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.616 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.465 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.558 HG21 ' O ' ' A' ' 172' ' ' ILE . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.444 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.47 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.517 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.585 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.528 ' N ' HD22 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.482 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.558 ' O ' HG21 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.526 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.477 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.475 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.475 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.428 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.594 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.585 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.594 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HZ2' ' H ' ' A' ' 111' ' ' VAL . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.834 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.834 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.546 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.546 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.447 ' HB ' HG22 ' A' ' 86' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.552 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.552 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.459 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.54 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.613 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.459 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.579 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.76 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.514 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.59 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.403 ' SG ' ' CD1' ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.614 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.414 ' HB3' ' CB ' ' A' ' 118' ' ' PRO . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.53 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.434 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.76 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.579 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.501 ' HG1' ' HG2' ' A' ' 85' ' ' GLN . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.705 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.43 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.539 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.592 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.614 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.5 HG23 ' HE ' ' A' ' 95' ' ' ARG . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.776 HD11 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.484 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.623 HD11 ' O ' ' A' ' 189' ' ' PRO . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.822 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 15.1 m120 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.526 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.506 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.416 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.776 ' OE1' HD11 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.541 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.451 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.427 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.4 HG23 ' CE1' ' A' ' 152' ' ' TYR . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.506 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.548 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.415 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.822 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.475 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.61 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.61 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.578 ' CB ' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.586 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.586 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.444 ' HB3' ' CD2' ' A' ' 166' ' ' LEU . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.434 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.598 ' O ' HG21 ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.805 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.805 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.459 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.441 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.623 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.523 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.523 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.67 ' SG ' HG11 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.66 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.518 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.527 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' MET . . . . . 0.558 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 76' ' ' VAL . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.405 HG21 ' N ' ' A' ' 78' ' ' LYS . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.405 ' N ' HG21 ' A' ' 77' ' ' ILE . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.605 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.621 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' SER . . . . . 0.558 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.422 HG21 ' N ' ' A' ' 92' ' ' LYS . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.422 ' N ' HG21 ' A' ' 91' ' ' THR . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.5 ' HB3' HG12 ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.537 HD11 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.525 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.758 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.673 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.813 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.67 HG11 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.505 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.537 ' HB2' HD11 ' A' ' 96' ' ' LEU . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.609 ' O ' HD21 ' A' ' 127' ' ' LEU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.609 HD21 ' O ' ' A' ' 126' ' ' GLY . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.559 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.558 HG23 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.758 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.758 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.559 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.573 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 10.6 m120 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.518 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.573 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.539 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.632 ' SG ' HD11 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.433 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.57 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.431 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.435 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.632 HD11 ' SG ' ' A' ' 154' ' ' CYS . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.623 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.41 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.409 ' HB3' HD21 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.456 ' O ' HG21 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.414 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.653 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.482 HD21 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.41 ' O ' ' HB2' ' A' ' 180' ' ' GLN . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.473 ' CB ' HD12 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.653 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.675 HD11 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.675 ' O ' HD11 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.414 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.632 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.632 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.63 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.63 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.512 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.512 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.479 ' N ' ' O ' ' A' ' 76' ' ' VAL . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.591 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.619 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.693 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.55 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.542 ' HG2' HG21 ' A' ' 123' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.55 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.585 HG12 ' O ' ' A' ' 119' ' ' ILE . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.47 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.619 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.558 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.599 ' OG ' HD12 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.599 HD12 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.42 HG23 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.499 ' HG2' HD11 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . 0.585 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.81 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.542 HG21 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.591 HG22 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.517 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.591 ' H ' HG22 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.546 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.709 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.639 HD13 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.709 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.541 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.475 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.81 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.448 HG21 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.441 HG23 ' OG ' ' A' ' 171' ' ' SER . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.547 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.639 ' HE ' HD13 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.594 ' SG ' HD11 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.517 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.511 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.626 ' N ' HD22 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.413 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.441 ' OG ' HG23 ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.656 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.656 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.475 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.411 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.467 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.1 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.467 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.751 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.776 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.751 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.62 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.776 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.599 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.4 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.555 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . 0.43 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.439 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.555 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.707 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.745 HG13 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.441 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 99' ' ' SER . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.563 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.996 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.507 HD13 ' CD1' ' A' ' 152' ' ' TYR . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.461 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.788 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 13.6 m120 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.505 ' H ' HG22 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.465 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.688 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.493 HD13 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . 0.583 ' HB3' HD22 ' A' ' 143' ' ' ASN . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.688 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.583 HD22 ' HB3' ' A' ' 140' ' ' ASN . 10.6 m120 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.996 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.524 ' N ' ' ND1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.493 ' CG2' HD13 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.507 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.788 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.63 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.461 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.461 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.436 HG22 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.466 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.614 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.614 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.435 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.414 ' O ' HG22 ' A' ' 175' ' ' THR . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.507 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.541 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.431 HD13 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.431 ' O ' HD13 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.414 ' O ' HD12 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.429 ' NE2' HD11 ' A' ' 192' ' ' ILE . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.476 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.429 HD11 ' NE2' ' A' ' 190' ' ' GLN . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.86 ' HZ3' ' N ' ' A' ' 110' ' ' THR . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.553 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.731 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.429 ' HB3' HD11 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.53 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.446 HG23 HG23 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.731 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.553 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.648 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.634 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.53 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.608 ' SG ' HD11 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.543 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.608 HD11 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.413 HD12 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.699 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.648 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.672 HG21 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.86 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.581 ' CG1' ' SG ' ' A' ' 104' ' ' CYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.421 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.488 ' OG1' ' HA ' ' A' ' 102' ' ' ALA . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.699 ' HG3' ' N ' ' A' ' 99' ' ' SER . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.413 ' HB3' HD12 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.448 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.543 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.619 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.491 HD21 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.499 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.44 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.404 ' HA ' HG21 ' A' ' 131' ' ' ILE . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.486 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.544 HD13 ' CG2' ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.486 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.491 ' HB3' HD21 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.619 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.511 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.544 ' CG2' HD13 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.499 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.546 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.54 ' N ' HD22 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.414 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.562 ' CD2' HG21 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.511 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.562 HG21 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.468 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.465 ' CG ' ' HG1' ' A' ' 175' ' ' THR . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.444 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.468 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.444 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.432 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.408 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.408 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.497 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.629 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.431 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.587 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.57 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.57 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.484 HD12 HG22 ' A' ' 77' ' ' ILE . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD3' ' HA ' ' A' ' 78' ' ' LYS . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.629 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.585 HE22 ' CB ' ' A' ' 103' ' ' THR . 91.9 mm-40 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.511 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.712 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.48 HD12 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.614 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.555 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.423 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.746 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.585 ' CB ' HE22 ' A' ' 85' ' ' GLN . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.586 ' CD1' HG21 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.586 HG21 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.587 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.614 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . 0.48 ' HB3' HD12 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.45 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.764 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.498 HD21 ' HD2' ' A' ' 128' ' ' PRO . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.498 ' HD2' HD21 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.726 HG22 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.616 ' HB3' ' ND2' ' A' ' 155' ' ' ASN . 67.6 m-80 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.562 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.726 ' N ' HG22 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.798 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.69 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.69 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.667 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . 0.493 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.764 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.766 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.667 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.497 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.453 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.798 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.564 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.616 ' ND2' ' HB3' ' A' ' 133' ' ' ASN . 18.1 p30 -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.491 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.601 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.64 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.64 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HB3' HD21 ' A' ' 166' ' ' LEU . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.453 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.446 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.766 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.635 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.549 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.511 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.449 ' OD2' HG22 ' A' ' 175' ' ' THR . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.418 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.418 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.549 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.485 ' C ' HG21 ' A' ' 175' ' ' THR . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.635 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.437 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.626 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.601 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.626 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.608 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.619 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.619 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.75 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.539 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.482 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.656 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.755 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.634 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.75 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' THR . . . . . 0.419 HG21 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.419 ' H ' HG21 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.557 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.41 HD21 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.43 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.755 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.499 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.477 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.684 HG12 ' CG2' ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.484 ' OG ' HD12 ' A' ' 112' ' ' ILE . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.44 ' N ' HG21 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.684 ' CG2' HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.484 HD12 ' OG ' ' A' ' 107' ' ' SER . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.608 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.532 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.532 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.501 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.43 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.403 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.543 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.736 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.427 HD21 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.579 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.623 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.485 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.574 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.542 ' CG1' ' HG2' ' A' ' 153' ' ' ARG . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.574 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.427 ' HA ' HD21 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.579 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.435 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.736 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.531 ' CG2' HD13 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.623 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.542 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.535 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.418 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.494 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.494 ' O ' ' HE3' ' A' ' 162' ' ' LYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 191' ' ' CYS . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HB3' HD22 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.412 ' O ' HG21 ' A' ' 175' ' ' THR . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.656 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.656 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.499 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.505 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.606 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.606 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HZ2' ' HA ' ' A' ' 110' ' ' THR . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.696 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.611 ' SG ' HG23 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.432 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.774 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.774 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.481 ' HB ' HG22 ' A' ' 86' ' ' ILE . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.491 HG23 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.491 ' HG2' HG23 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.696 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.614 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.727 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.773 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.543 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.646 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.646 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.618 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.656 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.727 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.614 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' THR . . . . . 0.503 ' HG1' ' HG2' ' A' ' 85' ' ' GLN . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.546 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.502 ' O ' HG23 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.611 HG23 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.401 ' CD1' ' HG ' ' A' ' 107' ' ' SER . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.422 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.656 ' HG3' ' N ' ' A' ' 99' ' ' SER . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.773 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.647 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.621 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.525 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.409 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.402 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.416 ' CG ' ' H ' ' A' ' 136' ' ' PHE . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.66 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.795 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.48 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.496 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.5 HD21 ' HH2' ' A' ' 184' ' ' TRP . 61.3 t30 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.647 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.621 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.432 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.436 ' CB ' HD22 ' A' ' 143' ' ' ASN . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.402 HG21 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.66 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.795 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.401 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.538 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.519 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.519 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.582 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.434 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.459 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.503 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.402 ' O ' HG21 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.432 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.585 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.585 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . 0.596 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.547 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.596 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.5 ' HH2' HD21 ' A' ' 143' ' ' ASN . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.503 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.534 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.582 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.588 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.515 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . 0.564 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.453 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.431 HG21 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.431 ' HG2' HG21 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.535 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.515 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.535 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.441 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.449 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.496 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.538 ' N ' HD21 ' A' ' 96' ' ' LEU . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . 0.416 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' SER . . . . . 0.536 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.645 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.686 ' SG ' HG23 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.488 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.523 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.408 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.686 HG23 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.408 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.429 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.488 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' THR . . . . . 0.564 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.493 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.791 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.716 HD11 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.837 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.411 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.526 HD21 ' HB2' ' A' ' 191' ' ' CYS . 94.2 m-20 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.791 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.666 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.479 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.462 ' SG ' HD13 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.722 ' O ' HG23 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.887 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.565 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.887 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.428 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.609 ' CD2' HG22 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.651 ' N ' HD22 ' A' ' 166' ' ' LEU . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . 0.483 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.402 ' H ' HG21 ' A' ' 167' ' ' VAL . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . 0.479 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.603 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.591 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.603 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.637 ' HB3' ' C ' ' A' ' 181' ' ' VAL . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . 0.546 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . 0.716 ' O ' HD11 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.607 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.441 ' O ' HD11 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . 0.837 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.459 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.498 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.526 ' HB2' HD21 ' A' ' 133' ' ' ASN . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.498 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.8 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.511 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.794 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.561 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.452 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.509 HG22 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.509 ' H ' HG22 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.543 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.794 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.513 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.543 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.691 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.404 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.42 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.557 ' NE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.521 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.691 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.509 ' SG ' HG11 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.584 HG12 ' CG2' ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.8 ' HB ' ' O ' ' A' ' 61' ' ' LYS . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . 0.724 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . 0.55 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.724 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.557 HG23 ' NE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.506 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.798 HG22 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.798 ' O ' HG22 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.417 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.439 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' SER . . . . . 0.504 ' O ' HG23 ' A' ' 139' ' ' THR . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 138' ' ' SER . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . 0.432 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 10.9 m120 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.531 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.553 HD22 ' HB2' ' A' ' 148' ' ' SER . 14.2 t-20 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.49 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.553 ' HB2' HD22 ' A' ' 143' ' ' ASN . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.439 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.417 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.501 ' SG ' HD11 ' A' ' 166' ' ' LEU . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.492 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.51 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.501 HD11 ' SG ' ' A' ' 154' ' ' CYS . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.49 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.796 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.796 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.418 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.51 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.418 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.555 ' HD3' HG22 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.49 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.431 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.477 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.576 HG13 ' OG ' ' A' ' 62' ' ' SER . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.598 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.477 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.431 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . 0.628 ' HG3' HD22 ' A' ' 177' ' ' ASN . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.482 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.722 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.503 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.609 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . 0.449 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.481 HG12 HG23 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.485 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' THR . . . . . 0.479 ' O ' HG23 ' A' ' 106' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.555 HG22 ' HD3' ' A' ' 61' ' ' LYS . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.485 ' CD1' ' HB3' ' A' ' 107' ' ' SER . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.503 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . 0.722 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.647 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . 0.47 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . 0.431 ' HB2' ' HB1' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.767 HG23 ' O ' ' A' ' 135' ' ' ASP . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 190' ' ' GLN . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . 0.55 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.489 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . 0.767 ' O ' HG23 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.542 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.637 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.513 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.647 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . 0.409 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.637 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.542 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.795 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.524 ' CA ' HG11 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . 0.756 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . 0.756 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.524 HG11 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.499 ' CB ' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.795 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.603 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . 0.511 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.664 HG21 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.682 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . 0.628 HD22 ' HG3' ' A' ' 92' ' ' LYS . 89.6 m-20 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 185' ' ' SER . . . . . 0.452 ' HG ' ' CG2' ' A' ' 175' ' ' THR . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB1' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.495 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.499 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.43 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LYS . . . . . 0.571 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.527 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ARG . . . . . 0.706 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.706 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' ASP . . . . . 0.413 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . 0.708 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' LYS . . . . . 0.437 ' C ' ' H ' ' A' ' 80' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . 0.458 ' CA ' HG11 ' A' ' 76' ' ' VAL . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . 0.527 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.488 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' PHE . . . . . 0.506 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' SER . . . . . 0.421 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' GLN . . . . . 0.498 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . 0.694 ' O ' ' HA ' ' A' ' 101' ' ' SER . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' TYR . . . . . 0.708 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' CYS . . . . . 0.458 ' SG ' HD12 ' A' ' 96' ' ' LEU . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' ARG . . . . . 0.476 ' CZ ' HG21 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' LEU . . . . . 0.458 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' ILE . . . . . 0.455 HG23 ' O ' ' A' ' 97' ' ' ILE . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' SER . . . . . 0.557 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' SER . . . . . 0.694 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ILE . . . . . 0.634 ' CD1' HG23 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' VAL . . . . . 0.634 HG23 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 115' ' ' THR . . . . . 0.557 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 116' ' ' GLU . . . . . 0.442 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.944 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' ILE . . . . . 0.567 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' PRO . . . . . 0.666 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . 0.78 HG22 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' GLY . . . . . 0.78 ' C ' HG22 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' PHE . . . . . 0.41 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' ILE . . . . . 0.592 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ARG . . . . . 0.435 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' ASN . . . . . 0.731 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 6.5 t30 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' HIS . . . . . 0.944 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' SER . . . . . 0.731 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' THR . . . . . 0.592 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' TYR . . . . . 0.41 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' ARG . . . . . 0.523 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.478 ' SG ' HD11 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' ASN . . . . . 0.449 ' O ' HG23 ' A' ' 163' ' ' VAL . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' VAL . . . . . 0.522 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' PHE . . . . . 0.522 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' LEU . . . . . 0.535 HD22 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' VAL . . . . . 0.535 ' O ' HD22 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' THR . . . . . 0.533 ' O ' HG21 ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' SER . . . . . 0.601 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 182' ' ' GLY . . . . . 0.601 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 189' ' ' PRO . . . . . 0.512 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 191' ' ' CYS . . . . . 0.442 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 192' ' ' ILE . . . . . 0.544 HG13 ' HG3' ' A' ' 190' ' ' GLN . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB3' HG21 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.49 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.753 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.699 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.699 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.409 ' HB3' HD12 ' A' ' 86' ' ' ILE . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.503 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.527 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.535 HG23 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.535 ' HG3' HG23 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.559 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.753 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.634 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.474 ' CE2' HG13 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.559 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.506 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.653 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.503 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.873 ' SG ' HD12 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.61 ' HZ1' ' ND2' ' A' ' 177' ' ' ASN . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . . . . . . . . . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.873 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.425 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.601 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.506 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.634 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.501 HG23 ' N ' ' A' ' 108' ' ' GLY . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.445 ' HB3' HD13 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.501 ' N ' HG23 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.541 HG12 ' SG ' ' A' ' 63' ' ' CYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.445 HD13 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.601 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.636 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.572 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.485 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.476 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.571 HD21 ' HA ' ' A' ' 154' ' ' CYS . 93.5 m-20 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.43 ' H ' ' CG2' ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.572 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.539 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.636 ' OD1' ' HB3' ' A' ' 125' ' ' CYS . 3.9 t-20 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.473 ' CB ' HD22 ' A' ' 143' ' ' ASN . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.451 HG22 ' OG ' ' A' ' 171' ' ' SER . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.518 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.571 ' HA ' HD21 ' A' ' 133' ' ' ASN . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.534 HD22 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.558 HG22 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.558 ' CD2' HG22 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.479 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.569 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.569 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.451 ' OG ' HG22 ' A' ' 151' ' ' THR . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.581 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.605 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.61 ' ND2' ' HZ1' ' A' ' 92' ' ' LYS . 9.8 m120 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . 0.403 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.403 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.581 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.605 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.485 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.584 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.499 ' SG ' ' ND2' ' A' ' 133' ' ' ASN . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.584 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.489 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.418 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.883 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.883 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.415 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.589 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.469 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.464 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.464 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.473 HG11 ' N ' ' A' ' 77' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.473 ' N ' HG11 ' A' ' 76' ' ' VAL . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.431 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.418 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.431 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.454 HG23 HG23 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.411 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.564 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.571 HD23 ' N ' ' A' ' 96' ' ' LEU . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.487 ' HB3' HG22 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.419 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.409 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.545 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.537 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.538 HG12 HG23 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.449 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.407 HG21 HG22 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.538 HG23 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.449 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.545 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.537 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.536 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.536 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.589 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.592 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.559 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.464 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.564 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.45 ' HB ' ' HD1' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.472 HG21 ' OD1' ' A' ' 133' ' ' ASN . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.472 ' OD1' HG21 ' A' ' 132' ' ' THR . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.514 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.514 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.464 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.433 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.45 ' HD1' ' HB ' ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.659 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.659 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.582 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.637 HG11 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.428 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.406 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.4 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.402 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.402 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.4 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.474 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.637 ' O ' HG11 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.434 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.592 ' HZ1' ' HA ' ' A' ' 110' ' ' THR . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.514 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.571 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.571 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.616 ' C ' ' HD2' ' A' ' 69' ' ' PRO . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.616 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.539 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.401 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.401 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.44 HG11 HG21 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.525 HG21 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.525 ' H ' HG21 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.423 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.568 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.44 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.429 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.423 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.46 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.615 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.539 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.448 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.481 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.58 ' NH1' HD11 ' A' ' 97' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.489 HD11 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.715 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.639 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.684 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.403 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.46 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.564 ' SG ' HG21 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.445 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.592 ' HA ' ' HZ1' ' A' ' 61' ' ' LYS . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.564 HG21 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.454 ' HG1' ' HB2' ' A' ' 102' ' ' ALA . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.438 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HG3' ' N ' ' A' ' 99' ' ' SER . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.715 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.421 ' HB3' HD13 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.44 HH11 ' HD2' ' A' ' 122' ' ' ARG . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.501 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.689 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.483 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.451 HG21 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.476 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.451 ' H ' HG21 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.503 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.689 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.441 HG22 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.503 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.476 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.43 ' CB ' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . 0.43 ' H ' ' CB ' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.511 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.548 ' HA ' ' HA ' ' A' ' 191' ' ' CYS . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.542 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.42 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.441 ' O ' HG22 ' A' ' 149' ' ' VAL . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.428 ' O ' HG21 ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.471 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.553 ' HB2' HD11 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.553 HD11 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.483 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.42 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.571 ' HB2' HG13 ' A' ' 192' ' ' ILE . 22.6 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.571 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.481 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.613 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.604 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.487 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.418 ' CG1' HG11 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.458 HG23 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.436 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.587 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.613 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.701 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.481 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.587 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.733 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.685 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.487 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.426 ' SG ' HD12 ' A' ' 96' ' ' LEU . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.486 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.486 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.43 HD11 ' HA ' ' A' ' 97' ' ' ILE . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.425 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.685 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.733 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.701 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.481 HG12 ' CD1' ' A' ' 82' ' ' PHE . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.51 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.668 HG23 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.51 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.431 ' C ' ' H ' ' A' ' 117' ' ' THR . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.465 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.425 ' HG3' ' C ' ' A' ' 99' ' ' SER . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.435 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.625 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.426 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.576 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.426 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.537 HG22 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.461 ' ND2' ' HB2' ' A' ' 191' ' ' CYS . 34.1 m-80 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.411 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.537 ' O ' HG22 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.445 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.517 HD12 ' CG2' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.495 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.683 ' ND2' HG12 ' A' ' 150' ' ' VAL . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.625 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 55.5 m80 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.683 HG12 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.517 ' CG2' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.523 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.549 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.637 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.637 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.549 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.478 HD21 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.442 HG21 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.478 ' H ' HD21 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.436 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.427 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.427 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.452 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.426 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.436 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.516 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.475 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.516 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.526 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.514 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.59 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.59 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.479 ' HG2' HG22 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.825 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.474 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.494 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.479 HG22 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.431 ' HD1' HG21 ' A' ' 76' ' ' VAL . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.431 HG21 ' HD1' ' A' ' 75' ' ' HIS . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.526 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.508 HD11 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.816 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.464 HG23 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.464 ' N ' HG23 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.673 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.52 HD13 ' HG ' ' A' ' 100' ' ' SER 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.442 HD11 ' HA ' ' A' ' 97' ' ' ILE 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.586 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.727 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.52 ' HG ' HD13 ' A' ' 96' ' ' LEU . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.514 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.469 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.469 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.825 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.727 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.816 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.62 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.482 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.608 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.536 ' CD1' ' HA ' ' A' ' 142' ' ' GLU . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.549 ' HB2' ' OH ' ' A' ' 152' ' ' TYR . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.826 HG22 ' O ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.826 ' O ' HG22 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.465 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.486 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.536 ' HA ' ' CD1' ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.608 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.62 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.424 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.465 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.602 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.51 HG21 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.51 ' CD2' HG21 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.508 ' HG ' ' H ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.508 ' H ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.492 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.731 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.424 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.731 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.754 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.647 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.647 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.435 ' HA ' ' HG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.754 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.632 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.477 ' HB3' HG23 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.492 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.435 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.435 HG12 ' HG3' ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.428 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.553 ' OG ' ' HG2' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.465 ' HA ' HG11 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.452 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.452 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.433 ' O ' HG13 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.433 HG13 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.454 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.553 ' HG2' ' OG ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.48 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.537 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.742 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.773 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.479 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.615 ' SG ' HD23 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.581 ' NH2' ' HA3' ' A' ' 182' ' ' GLY . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.615 HD23 ' SG ' ' A' ' 90' ' ' CYS . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.72 ' O ' HG23 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.773 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.742 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.537 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.488 ' SG ' ' O ' ' A' ' 80' ' ' ILE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.499 ' CG2' ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.487 ' CD1' HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.402 ' O ' ' HA ' ' A' ' 106' ' ' ILE . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.487 HG22 ' CD1' ' A' ' 106' ' ' ILE . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.499 ' HB2' ' CG2' ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.72 HG23 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.519 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.409 ' HD3' ' CG2' ' A' ' 115' ' ' THR . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.431 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.567 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.431 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.574 ' CD1' ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.525 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.491 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.682 HG23 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.682 ' C ' HG23 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.458 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.506 HD11 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.478 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.574 ' HB3' ' CD1' ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.564 HD22 ' HB3' ' A' ' 148' ' ' SER . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.505 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.564 ' HB3' HD22 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.506 ' HB ' HD11 ' A' ' 137' ' ' ILE . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.508 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.774 ' SG ' HD11 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.763 ' O ' HG21 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.454 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.609 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.763 HG21 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.634 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.546 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.774 HD11 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.566 ' N ' HD21 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.497 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.505 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.578 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.671 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.428 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.671 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.401 ' CE2' ' HB3' ' A' ' 128' ' ' PRO . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.524 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.491 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.501 ' NE2' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.501 HG13 ' NE2' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.609 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.456 ' SG ' HG22 ' A' ' 111' ' ' VAL . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.476 ' HD3' HG21 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.525 ' HD3' HG23 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.419 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.449 ' HD3' ' C ' ' A' ' 67' ' ' PRO . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.4 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.415 HG21 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.606 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.606 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.422 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.476 HG21 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.609 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.6 ' CD1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.422 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.2 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.438 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.8 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.559 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.559 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.545 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.43 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.657 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.507 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.6 ' HA ' ' CD1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.565 HG13 ' CD1' ' A' ' 82' ' ' PHE . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.502 ' H ' HG23 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.456 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.528 ' HB2' ' CG1' ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.43 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.525 HG23 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.8 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.506 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' THR . . . . . 0.613 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.407 HG23 ' N ' ' A' ' 134' ' ' GLY . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.595 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.613 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.475 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.638 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.475 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.518 ' ND2' ' HH2' ' A' ' 184' ' ' TRP . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.506 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.504 ' CG1' HD22 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.638 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.458 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.432 ' HD3' HD11 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.571 ' SG ' HD13 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.595 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.497 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.502 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.488 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.68 HD21 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.68 ' N ' HD21 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.436 ' H ' HD21 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.458 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.439 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.439 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.423 ' H ' ' C ' ' A' ' 175' ' ' THR . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . 0.522 ' CG ' ' H ' ' A' ' 179' ' ' ASP . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.529 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.499 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.499 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.608 HD11 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.608 ' O ' HD11 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.438 ' NE2' HG13 ' A' ' 192' ' ' ILE . 11.3 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.488 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.438 HG13 ' NE2' ' A' ' 190' ' ' GLN . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.535 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.516 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.715 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.715 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.564 ' HG3' HG23 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.513 ' HD2' ' HB2' ' A' ' 66' ' ' PRO . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.481 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.481 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.647 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.478 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.595 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.647 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.564 HG23 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.504 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.722 ' SG ' HD12 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.426 HG23 ' N ' ' A' ' 92' ' ' LYS . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.426 ' N ' HG23 ' A' ' 91' ' ' THR . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.722 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.42 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.47 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.56 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.548 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.457 ' HB1' HD13 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.595 ' HB3' ' HA ' ' A' ' 82' ' ' PHE . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.42 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.474 ' CG2' ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.516 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.449 ' OD1' HG21 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.614 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.614 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.501 HG21 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.533 ' HG2' HD13 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.459 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.484 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.668 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.616 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.441 ' CD2' ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.444 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.47 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.441 ' HG2' ' CD2' ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.465 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.668 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 50.0 m80 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.616 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.465 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.558 HG21 ' O ' ' A' ' 172' ' ' ILE . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.444 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.47 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.517 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.585 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.536 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.528 ' N ' HD22 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.482 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.558 ' O ' HG21 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.526 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.428 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.477 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.475 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.475 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.428 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.594 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.585 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.594 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.401 ' HZ2' ' H ' ' A' ' 111' ' ' VAL . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.613 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.834 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.834 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.546 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.546 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.447 ' HB ' HG22 ' A' ' 86' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.552 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.552 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.459 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.54 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.613 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.459 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.579 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.76 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.514 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.59 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.403 ' SG ' ' CD1' ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.614 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.414 ' HB3' ' CB ' ' A' ' 118' ' ' PRO . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.53 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.434 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.76 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.579 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.501 ' HG1' ' HG2' ' A' ' 85' ' ' GLN . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.705 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.43 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.539 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.539 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.592 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.614 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.5 HG23 ' HE ' ' A' ' 95' ' ' ARG . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.541 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.776 HD11 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.484 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.623 HD11 ' O ' ' A' ' 189' ' ' PRO . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.822 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 15.1 m120 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.526 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.506 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.416 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.776 ' OE1' HD11 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.541 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.451 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.427 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.4 HG23 ' CE1' ' A' ' 152' ' ' TYR . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.506 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.548 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.415 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.822 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.475 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.61 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.61 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.578 ' CB ' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.409 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.586 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.586 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.444 ' HB3' ' CD2' ' A' ' 166' ' ' LEU . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.434 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.476 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.598 ' O ' HG21 ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.805 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.805 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.459 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.441 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.623 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.523 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.523 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.67 ' SG ' HG11 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.66 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.66 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.518 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.527 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.527 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' MET . . . . . 0.558 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.598 HG22 ' O ' ' A' ' 76' ' ' VAL . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.405 HG21 ' N ' ' A' ' 78' ' ' LYS . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.405 ' N ' HG21 ' A' ' 77' ' ' ILE . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.605 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.813 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.621 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.758 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' SER . . . . . 0.558 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.422 HG21 ' N ' ' A' ' 92' ' ' LYS . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.422 ' N ' HG21 ' A' ' 91' ' ' THR . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.5 ' HB3' HG12 ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.537 HD11 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.49 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.525 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.758 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.673 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.813 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.67 HG11 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.505 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.537 ' HB2' HD11 ' A' ' 96' ' ' LEU . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.468 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.518 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.609 ' O ' HD21 ' A' ' 127' ' ' LEU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.609 HD21 ' O ' ' A' ' 126' ' ' GLY . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.559 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.463 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.558 HG23 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.558 ' O ' HG23 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.758 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.758 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.559 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.573 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 10.6 m120 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.518 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.573 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.44 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.539 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.632 ' SG ' HD11 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.433 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.57 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.431 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.435 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.463 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.632 HD11 ' SG ' ' A' ' 154' ' ' CYS . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.623 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.41 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.409 ' HB3' HD21 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.44 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.456 ' O ' HG21 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.414 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.653 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.482 HD21 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.41 ' O ' ' HB2' ' A' ' 180' ' ' GLN . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.473 ' CB ' HD12 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.653 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.675 HD11 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.675 ' O ' HD11 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.414 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.632 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.463 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.632 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.591 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.513 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.63 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.63 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.512 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.512 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.479 ' N ' ' O ' ' A' ' 76' ' ' VAL . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.513 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.591 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.619 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.693 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.415 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.55 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.542 ' HG2' HG21 ' A' ' 123' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.55 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.585 HG12 ' O ' ' A' ' 119' ' ' ILE . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.47 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.415 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.693 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.619 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.503 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.558 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.599 ' OG ' HD12 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.599 HD12 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.42 HG23 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.499 ' HG2' HD11 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . 0.585 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.81 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.542 HG21 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.583 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.411 ' HB2' ' HB3' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.591 HG22 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.517 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.591 ' H ' HG22 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.546 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.709 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.639 HD13 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.709 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.541 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.475 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.81 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.448 HG21 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.441 HG23 ' OG ' ' A' ' 171' ' ' SER . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.547 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.639 ' HE ' HD13 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.594 ' SG ' HD11 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.517 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.511 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.626 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.626 ' N ' HD22 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.413 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.441 ' OG ' HG23 ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.656 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.656 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.475 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.411 ' HB3' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.467 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.1 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.467 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.751 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.776 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.751 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.62 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.776 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.599 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.4 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.499 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.555 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.485 ' SG ' HD23 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . 0.43 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.563 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.485 HD23 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.439 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.555 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.599 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.567 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.707 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.599 HD11 ' CG2' ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.745 HG13 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.441 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.441 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.482 ' HD3' ' O ' ' A' ' 99' ' ' SER . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.563 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.996 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.61 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.507 HD13 ' CD1' ' A' ' 152' ' ' TYR . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.461 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.788 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 13.6 m120 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.505 ' H ' HG22 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.465 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.688 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.493 HD13 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . 0.583 ' HB3' HD22 ' A' ' 143' ' ' ASN . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.688 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.583 HD22 ' HB3' ' A' ' 140' ' ' ASN . 10.6 m120 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.996 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.524 ' N ' ' ND1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.493 ' CG2' HD13 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.507 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.788 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.63 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.461 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.461 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.436 HG22 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.466 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.476 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.614 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.614 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.435 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.414 ' O ' HG22 ' A' ' 175' ' ' THR . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.507 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.541 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.541 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.431 HD13 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.431 ' O ' HD13 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.414 ' O ' HD12 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.429 ' NE2' HD11 ' A' ' 192' ' ' ILE . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.476 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.429 HD11 ' NE2' ' A' ' 190' ' ' GLN . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.86 ' HZ3' ' N ' ' A' ' 110' ' ' THR . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.553 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.731 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.482 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.482 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.429 ' HB3' HD11 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.53 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.446 HG23 HG23 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.731 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.553 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.438 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.648 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.634 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.53 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.608 ' SG ' HD11 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.543 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.608 HD11 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.413 HD12 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.592 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.699 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.634 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.648 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.438 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.672 HG21 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.86 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.581 ' CG1' ' SG ' ' A' ' 104' ' ' CYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.421 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.488 ' OG1' ' HA ' ' A' ' 102' ' ' ALA . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.699 ' HG3' ' N ' ' A' ' 99' ' ' SER . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.413 ' HB3' HD12 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.448 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.543 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.448 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.619 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.491 HD21 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.413 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.499 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.44 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.404 ' HA ' HG21 ' A' ' 131' ' ' ILE . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.486 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.544 HD13 ' CG2' ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . 0.417 HD22 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.486 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.491 ' HB3' HD21 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.619 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.511 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.544 ' CG2' HD13 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.499 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.546 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.496 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.496 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.546 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.497 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.54 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.54 ' N ' HD22 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.414 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.562 ' CD2' HG21 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.511 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.562 HG21 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.468 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.465 ' CG ' ' HG1' ' A' ' 175' ' ' THR . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.444 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.468 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.444 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.432 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.408 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.497 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.408 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.497 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.629 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.431 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.587 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.57 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.57 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.484 HD12 HG22 ' A' ' 77' ' ' ILE . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.428 ' HD3' ' HA ' ' A' ' 78' ' ' LYS . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.629 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.585 HE22 ' CB ' ' A' ' 103' ' ' THR . 91.9 mm-40 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.746 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.511 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.712 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.465 HD23 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.48 HD12 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.614 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.555 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.423 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.746 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.585 ' CB ' HE22 ' A' ' 85' ' ' GLN . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.586 ' CD1' HG21 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.586 HG21 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.43 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.46 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.587 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.614 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.712 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . 0.48 ' HB3' HD12 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.45 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.764 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.442 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.442 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.498 HD21 ' HD2' ' A' ' 128' ' ' PRO . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.498 ' HD2' HD21 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.726 HG22 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.616 ' HB3' ' ND2' ' A' ' 155' ' ' ASN . 67.6 m-80 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.562 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.726 ' N ' HG22 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.798 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . 0.549 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.69 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.69 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.667 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . 0.493 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.764 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.766 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.667 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.497 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.453 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.798 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.564 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.616 ' ND2' ' HB3' ' A' ' 133' ' ' ASN . 18.1 p30 -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.491 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . 0.491 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.601 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.64 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.64 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.456 ' HB3' HD21 ' A' ' 166' ' ' LEU . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.453 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.446 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.766 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.635 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.549 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.511 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.449 ' OD2' HG22 ' A' ' 175' ' ' THR . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.418 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.418 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.549 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.485 ' C ' HG21 ' A' ' 175' ' ' THR . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.635 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.437 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.626 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.601 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.626 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.608 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.619 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.619 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.656 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.75 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.539 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.482 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.656 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' SER . . . . . . . . . . . . . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.755 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.634 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.75 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' THR . . . . . 0.419 HG21 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.419 ' H ' HG21 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.557 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.41 HD21 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.405 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.43 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.63 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.755 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.499 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.477 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.684 HG12 ' CG2' ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.484 ' OG ' HD12 ' A' ' 112' ' ' ILE . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.44 ' N ' HG21 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.684 ' CG2' HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.484 HD12 ' OG ' ' A' ' 107' ' ' SER . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.608 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.532 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.532 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.501 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.43 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.557 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.403 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.543 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.403 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.736 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.427 HD21 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.579 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.623 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.485 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.574 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.542 ' CG1' ' HG2' ' A' ' 153' ' ' ARG . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.574 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.427 ' HA ' HD21 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.579 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.435 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.736 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.531 ' CG2' HD13 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.623 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.542 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.535 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.418 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.418 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.494 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.494 ' O ' ' HE3' ' A' ' 162' ' ' LYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.603 ' HA ' ' HA ' ' A' ' 191' ' ' CYS . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.491 ' HB3' HD22 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.412 ' O ' HG21 ' A' ' 175' ' ' THR . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.656 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.656 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.499 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.505 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.606 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.603 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.606 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.459 ' HZ2' ' HA ' ' A' ' 110' ' ' THR . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.696 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.611 ' SG ' HG23 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.467 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.432 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.774 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.774 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.481 ' HB ' HG22 ' A' ' 86' ' ' ILE . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.491 HG23 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.491 ' HG2' HG23 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.681 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.696 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.546 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.681 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.614 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.657 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.727 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.773 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.543 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.646 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.646 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.618 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.656 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.727 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.614 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' THR . . . . . 0.503 ' HG1' ' HG2' ' A' ' 85' ' ' GLN . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.546 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.502 ' O ' HG23 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.502 HG23 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.611 HG23 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.401 ' CD1' ' HG ' ' A' ' 107' ' ' SER . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.422 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.656 ' HG3' ' N ' ' A' ' 99' ' ' SER . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.773 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.647 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.621 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.473 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.473 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.525 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.409 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.402 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.416 ' CG ' ' H ' ' A' ' 136' ' ' PHE . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.66 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.795 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.48 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.496 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.5 HD21 ' HH2' ' A' ' 184' ' ' TRP . 61.3 t30 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.647 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.621 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.432 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.436 ' CB ' HD22 ' A' ' 143' ' ' ASN . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.402 HG21 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.66 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.795 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.401 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.538 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.519 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.519 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.582 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.434 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.459 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.459 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.503 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.402 ' O ' HG21 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.432 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.585 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.585 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . 0.596 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.547 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.596 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.5 ' HH2' HD21 ' A' ' 143' ' ' ASN . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.503 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.534 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.582 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.45 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.456 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.588 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.588 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.515 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . 0.564 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.437 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.453 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.431 HG21 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.431 ' HG2' HG21 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.535 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.515 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.45 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.535 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.441 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.449 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.496 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.538 ' N ' HD21 ' A' ' 96' ' ' LEU . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . 0.416 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' SER . . . . . . . . . . . . . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' SER . . . . . 0.536 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.645 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.441 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.686 ' SG ' HG23 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.488 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.523 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.408 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.686 HG23 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.408 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.429 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.488 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' THR . . . . . 0.564 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.493 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.418 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.791 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.716 HD11 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.444 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.837 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.411 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.526 HD21 ' HB2' ' A' ' 191' ' ' CYS . 94.2 m-20 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.791 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.666 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.479 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.462 ' SG ' HD13 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.722 ' O ' HG23 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.887 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.565 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.887 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.428 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.722 HG23 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.609 ' CD2' HG22 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.651 HD22 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.651 ' N ' HD22 ' A' ' 166' ' ' LEU . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . 0.483 ' H ' HD22 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.402 ' H ' HG21 ' A' ' 167' ' ' VAL . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.437 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . 0.479 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.603 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.591 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.603 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.637 ' HB3' ' C ' ' A' ' 181' ' ' VAL . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . 0.546 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . 0.716 ' O ' HD11 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.546 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.607 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.441 ' O ' HD11 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . 0.837 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.459 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.498 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.526 ' HB2' HD21 ' A' ' 133' ' ' ASN . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.498 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.8 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.511 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.794 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.561 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.561 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.452 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.452 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.509 HG22 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.509 ' H ' HG22 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.543 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.794 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.481 ' HG2' ' N ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.513 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.543 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.691 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.404 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.42 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.557 ' NE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.472 HD23 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.521 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.691 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.467 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.509 ' SG ' HG11 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . 0.55 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.584 HG12 ' CG2' ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.8 ' HB ' ' O ' ' A' ' 61' ' ' LYS . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . 0.724 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . 0.55 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.724 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . 0.521 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.557 HG23 ' NE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.506 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.485 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.798 HG22 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.798 ' O ' HG22 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.417 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.439 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' SER . . . . . 0.504 ' O ' HG23 ' A' ' 139' ' ' THR . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 138' ' ' SER . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . 0.432 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 10.9 m120 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.531 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.553 HD22 ' HB2' ' A' ' 148' ' ' SER . 14.2 t-20 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.49 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.553 ' HB2' HD22 ' A' ' 143' ' ' ASN . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . 0.401 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.439 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.417 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.501 ' SG ' HD11 ' A' ' 166' ' ' LEU . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.492 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.458 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.51 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.501 HD11 ' SG ' ' A' ' 154' ' ' CYS . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.49 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' SER . . . . . 0.401 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.796 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.796 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.404 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.418 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.51 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.418 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.555 ' HD3' HG22 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . 0.433 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.454 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.454 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.49 ' HB3' ' CD1' ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.431 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.477 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.576 HG13 ' OG ' ' A' ' 62' ' ' SER . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.598 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.477 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.425 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.431 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . 0.628 ' HG3' HD22 ' A' ' 177' ' ' ASN . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.482 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.722 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.503 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.609 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.425 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . 0.449 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.481 HG12 HG23 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.485 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' THR . . . . . 0.479 ' O ' HG23 ' A' ' 106' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.555 HG22 ' HD3' ' A' ' 61' ' ' LYS . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.485 ' CD1' ' HB3' ' A' ' 107' ' ' SER . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.503 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . 0.722 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.647 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.413 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . 0.47 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . 0.431 ' HB2' ' HB1' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.767 HG23 ' O ' ' A' ' 135' ' ' ASP . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' THR . . . . . 0.452 ' OG1' ' HB2' ' A' ' 190' ' ' GLN . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . 0.55 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.489 ' H ' HG21 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . 0.767 ' O ' HG23 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.542 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.637 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.481 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.481 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.513 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.647 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . 0.409 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.637 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.542 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.795 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.524 ' CA ' HG11 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . 0.756 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . 0.756 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.524 HG11 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.499 ' CB ' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.795 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.603 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . 0.664 ' CE2' HG21 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . 0.511 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.664 HG21 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.682 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . 0.628 HD22 ' HG3' ' A' ' 92' ' ' LYS . 89.6 m-20 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.682 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . 0.552 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 185' ' ' SER . . . . . 0.452 ' HG ' ' CG2' ' A' ' 175' ' ' THR . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . 0.431 ' HB1' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.495 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.545 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.499 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.43 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LYS . . . . . 0.571 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.527 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ARG . . . . . 0.706 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.706 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ASP . . . . . 0.413 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . 0.708 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' VAL . . . . . 0.473 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.49 HG23 HG23 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' LYS . . . . . 0.437 ' C ' ' H ' ' A' ' 80' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . 0.458 ' CA ' HG11 ' A' ' 76' ' ' VAL . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . 0.527 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.488 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PHE . . . . . 0.506 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' SER . . . . . 0.421 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLN . . . . . 0.498 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . 0.694 ' O ' ' HA ' ' A' ' 101' ' ' SER . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' TYR . . . . . 0.708 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' CYS . . . . . 0.458 ' SG ' HD12 ' A' ' 96' ' ' LEU . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ARG . . . . . 0.476 ' CZ ' HG21 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' LEU . . . . . 0.458 HD12 ' SG ' ' A' ' 90' ' ' CYS . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ILE . . . . . 0.455 HG23 ' O ' ' A' ' 97' ' ' ILE . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' SER . . . . . 0.557 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' SER . . . . . 0.694 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ALA . . . . . 0.498 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ILE . . . . . 0.634 ' CD1' HG23 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' VAL . . . . . 0.634 HG23 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' THR . . . . . 0.557 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' GLU . . . . . 0.442 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' PRO . . . . . . . . . . . . . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.944 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' ILE . . . . . 0.567 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' PRO . . . . . 0.666 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . 0.78 HG22 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' GLY . . . . . 0.78 ' C ' HG22 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' PHE . . . . . 0.41 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' ILE . . . . . 0.592 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 9.6 m120 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ARG . . . . . 0.435 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLU . . . . . 0.435 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' ASN . . . . . 0.731 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 6.5 t30 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' HIS . . . . . 0.944 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' SER . . . . . 0.731 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' THR . . . . . 0.592 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' TYR . . . . . 0.41 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' ARG . . . . . 0.523 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.478 ' SG ' HD11 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' ASN . . . . . 0.449 ' O ' HG23 ' A' ' 163' ' ' VAL . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' VAL . . . . . 0.522 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' PHE . . . . . 0.522 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' GLU . . . . . 0.438 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' LEU . . . . . 0.535 HD22 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' VAL . . . . . 0.535 ' O ' HD22 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' PRO . . . . . 0.512 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' THR . . . . . 0.533 ' O ' HG21 ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' SER . . . . . 0.601 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 182' ' ' GLY . . . . . 0.601 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 189' ' ' PRO . . . . . 0.512 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 191' ' ' CYS . . . . . 0.442 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 192' ' ' ILE . . . . . 0.544 HG13 ' HG3' ' A' ' 190' ' ' GLN . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.638 ' HD3' HG23 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.681 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.681 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.511 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.456 ' HB ' HG22 ' A' ' 86' ' ' ILE . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.639 HG22 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.639 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.585 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.771 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.647 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.766 ' HZ ' HD11 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.585 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.674 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.403 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.511 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.623 ' SG ' HD13 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 95' ' ' ARG . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.623 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.619 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.674 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.647 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.766 HD11 ' HZ ' ' A' ' 82' ' ' PHE . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.693 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.469 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.638 HG23 ' HD3' ' A' ' 61' ' ' LYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.693 HD11 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.407 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.436 HG21 ' H ' ' A' ' 99' ' ' SER . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 118' ' ' PRO . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.619 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.814 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.733 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.553 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.602 ' HB3' HD21 ' A' ' 155' ' ' ASN . 7.9 m120 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.553 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.443 ' O ' HG21 ' A' ' 131' ' ' ILE . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.535 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.814 ' ND2' ' HB3' ' A' ' 125' ' ' CYS . 53.1 t30 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.505 ' SG ' HD12 ' A' ' 166' ' ' LEU . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.602 HD21 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.566 HG23 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.566 ' CD2' HG23 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.534 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.65 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.415 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.615 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 69.3 m-20 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 178' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.431 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.435 ' HB ' ' H ' ' A' ' 184' ' ' TRP . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.607 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.615 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.733 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.638 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.638 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.871 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.871 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.635 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 60.5 m80 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.504 HG21 HG22 ' A' ' 86' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.453 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.559 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.662 HD12 ' HG2' ' A' ' 118' ' ' PRO . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 97' ' ' ILE . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.78 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.754 ' HB3' HG21 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.447 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.543 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.622 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.746 HG12 HG22 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.568 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.46 HG23 HG23 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.746 HG22 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.568 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.543 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.622 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.754 HG21 ' HB3' ' A' ' 99' ' ' SER . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.542 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.635 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.78 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.559 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.405 ' HG ' ' HB3' ' A' ' 142' ' ' GLU . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.588 HD13 ' HB3' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.479 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.509 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 136' ' ' PHE . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.405 ' HB3' ' HG ' ' A' ' 127' ' ' LEU . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.479 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.429 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.588 ' HB3' HD13 ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.677 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.677 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.606 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.479 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.489 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.653 ' O ' HG13 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.494 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.556 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.526 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.56 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.689 ' HD3' HD12 ' A' ' 86' ' ' ILE . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.614 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.541 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.471 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.471 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.474 HG11 HG22 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.724 HG23 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.724 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.457 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.583 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.473 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.473 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.457 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.457 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.689 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.541 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.436 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.489 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.512 ' HB3' HG12 ' A' ' 123' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.748 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.829 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.7 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.651 ' SG ' HG22 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.651 HG22 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 99' ' ' SER . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.829 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.748 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.599 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.699 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.514 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.567 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.567 ' H ' HG23 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.412 ' O ' HG21 ' A' ' 131' ' ' ILE . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.517 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.699 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.517 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.415 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.434 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.542 ' HB3' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' GLY . . . . . 0.542 ' H ' ' HB3' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.554 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.558 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.558 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.88 ' HB2' HD13 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.439 ' HG2' HG23 ' A' ' 181' ' ' VAL . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.46 HG13 ' HB2' ' A' ' 95' ' ' ARG . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.88 HD13 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.517 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.625 ' HB2' HG13 ' A' ' 192' ' ' ILE . 83.2 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.625 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.625 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.6 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.413 ' CG ' HG21 ' A' ' 86' ' ' ILE . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.492 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.664 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.625 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.712 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.494 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.664 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.718 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.706 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.492 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.535 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.521 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.4 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.706 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.718 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.568 HD13 HG23 ' A' ' 111' ' ' VAL . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.633 HG22 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.419 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.461 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.535 ' HG2' HD12 ' A' ' 96' ' ' LEU . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.402 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.43 ' HA ' ' ND1' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.424 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.411 HD22 ' HB3' ' A' ' 142' ' ' GLU . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.642 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.446 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.69 HG21 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.66 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.69 ' O ' HG21 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.452 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HB ' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.41 ' CB ' HG12 ' A' ' 150' ' ' VAL . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.508 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.508 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.642 ' H ' ' HD3' ' A' ' 128' ' ' PRO . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.43 ' ND1' ' HA ' ' A' ' 124' ' ' PRO . 39.9 m-70 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.628 HG13 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.67 ' HB ' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.528 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.645 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.663 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.645 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.574 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.649 HD23 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.649 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.425 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.45 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.45 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.458 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.446 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.567 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.574 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.567 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.469 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.591 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.591 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.5 ' HG2' HG23 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.9 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.5 HG23 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.426 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.449 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.572 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.659 HD12 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.818 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.4 HG22 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.4 ' N ' HG22 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.682 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.46 HD21 ' HD2' ' A' ' 88' ' ' TYR 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.409 HD11 ' HB3' ' A' ' 121' ' ' ASP 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.677 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.765 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.469 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.488 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.9 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.818 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.409 ' HB3' HD11 ' A' ' 97' ' ' ILE . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.755 HG21 ' HA2' ' A' ' 182' ' ' GLY . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.639 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.891 HD12 ' HD2' ' A' ' 128' ' ' PRO . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.891 ' HD2' HD12 ' A' ' 127' ' ' LEU . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.838 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 155' ' ' ASN . 93.7 m-20 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.838 ' C ' HG21 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.51 HG22 ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.504 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.887 ' HA ' HD13 ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.648 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.513 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.638 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 133' ' ' ASN . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.531 HG23 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.531 ' CD2' HG23 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.537 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.537 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.621 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.455 HD11 ' HE2' ' A' ' 152' ' ' TYR . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.812 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.513 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.812 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.785 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.627 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.627 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.418 ' HA ' ' OG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.785 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.72 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.615 ' HB3' HG21 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 189' ' ' PRO . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.621 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.463 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.463 HG12 ' HG3' ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB3' HG21 ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.609 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.43 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.43 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.0 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.43 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.585 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.5 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.741 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.806 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.5 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.484 ' SG ' HD22 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.594 ' HE ' HG23 ' A' ' 123' ' ' ILE . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.525 HD12 ' HG2' ' A' ' 118' ' ' PRO . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.444 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.669 ' O ' HG21 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.806 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.51 HG23 ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.592 HD13 HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.612 ' HB2' HD12 ' A' ' 112' ' ' ILE . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 63' ' ' CYS . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.612 HD12 ' HB2' ' A' ' 107' ' ' SER . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.51 ' HB2' HG23 ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.669 HG21 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.514 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.525 ' HG2' HD12 ' A' ' 96' ' ' LEU . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.421 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.594 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.717 HD11 ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.601 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.556 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.428 HG22 ' H ' ' A' ' 131' ' ' ILE . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.83 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.83 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.45 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.525 HD12 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.717 ' HB3' HD11 ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.601 ' H ' ' HG3' ' A' ' 128' ' ' PRO . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 145' ' ' HIS . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.412 ' HB2' ' CD2' ' A' ' 144' ' ' PHE . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.599 ' HB3' HD21 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.531 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.409 HH11 HG13 ' A' ' 137' ' ' ILE . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.773 ' SG ' HD12 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.768 ' O ' HG22 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.604 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.636 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.773 HD12 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.621 ' N ' HD23 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.458 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.401 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.54 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.67 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.67 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.535 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.476 ' HB2' HD21 ' A' ' 166' ' ' LEU . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.431 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.602 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.431 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' HG22 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.543 ' HD3' HG21 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.455 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 72' ' ' GLY . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.626 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.626 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.539 ' H ' HG22 ' A' ' 76' ' ' VAL . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.593 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.592 ' CE1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.453 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 97.6 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.801 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.471 ' SG ' HD22 ' A' ' 96' ' ' LEU . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.562 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.407 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.491 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.559 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.592 ' HA ' ' CE1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.57 HG22 ' H ' ' A' ' 108' ' ' GLY . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.57 ' H ' HG22 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.539 ' HB2' HG12 ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.491 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.543 HG21 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.407 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.801 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.542 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' THR . . . . . 0.631 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.447 HD13 ' HB3' ' A' ' 152' ' ' TYR . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.631 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.465 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.663 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.465 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.556 HD21 ' CG1' ' A' ' 150' ' ' VAL . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.542 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.556 ' CG1' HD21 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.663 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.495 ' HD3' HD12 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.575 ' SG ' HD12 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.495 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.536 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.548 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.449 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.449 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.449 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 178' ' ' ASP . . . . . 0.511 ' HB3' HD11 ' A' ' 183' ' ' ILE . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.53 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.532 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.532 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.573 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.573 ' O ' HD12 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.418 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 190' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 192' ' ' ILE . . . . . . . . . . . . . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.544 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.718 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.718 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.748 ' HG3' HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.585 ' HB3' HG23 ' A' ' 117' ' ' THR . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 76' ' ' VAL . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.7 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.628 HG22 ' HD3' ' A' ' 66' ' ' PRO . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.608 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.7 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.748 HG21 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.537 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.655 ' SG ' HD13 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.731 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.655 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.413 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.601 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' HD11 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.749 ' SG ' HG22 ' A' ' 111' ' ' VAL . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.478 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.749 HG22 ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.544 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.648 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.648 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.585 HG23 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.495 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.731 ' HD2' ' HE ' ' A' ' 95' ' ' ARG . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.647 HD21 ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.447 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 131' ' ' ILE . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.476 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.647 ' HG2' HD21 ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.485 ' ND1' ' HA ' ' A' ' 124' ' ' PRO . 33.3 m-70 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.597 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.473 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.586 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.473 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.476 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.519 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.539 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.577 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.531 ' N ' HD23 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.586 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.503 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.536 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.458 HG23 HG13 ' A' ' 183' ' ' ILE . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.458 HG13 HG23 ' A' ' 181' ' ' VAL . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.672 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.539 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.672 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.686 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.844 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.844 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.0 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.535 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.535 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.451 HG21 HG23 ' A' ' 80' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.579 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.579 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.686 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.817 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.526 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.548 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.788 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.533 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.584 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.483 ' SG ' HD13 ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.613 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.483 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.755 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.538 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.788 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.817 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.445 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.561 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.561 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.428 ' HB2' ' HA ' ' A' ' 116' ' ' GLU . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.474 HG21 ' H ' ' A' ' 99' ' ' SER . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 113' ' ' TRP . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.755 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.802 HD13 ' HA3' ' A' ' 182' ' ' GLY . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.689 HD12 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.881 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.967 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 75.5 m-20 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.881 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.433 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.689 ' OE1' HD12 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.445 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.531 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.55 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.967 ' HA ' ' ND2' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.543 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.543 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.435 HG23 ' CD1' ' A' ' 164' ' ' PHE . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.613 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.613 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.426 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.807 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.807 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.802 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.448 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.445 ' HB1' HD13 ' A' ' 131' ' ' ILE . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.642 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.579 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB2' ' CG2' ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.705 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.657 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.657 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.557 ' CG ' HG21 ' A' ' 76' ' ' VAL . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.506 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' MET . . . . . 0.684 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.557 HG21 ' CG ' ' A' ' 66' ' ' PRO . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.609 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.819 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.628 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' SER . . . . . 0.684 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 122' ' ' ARG . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.489 ' HG2' ' HA ' ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.583 HD12 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.643 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.847 ' HB2' HG21 ' A' ' 115' ' ' THR . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.772 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.693 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.819 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.464 HG12 HG22 ' A' ' 111' ' ' VAL . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.416 ' O ' HG23 ' A' ' 106' ' ' ILE . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.705 HG12 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.847 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.643 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 142' ' ' GLU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.463 ' HA ' HD13 ' A' ' 127' ' ' LEU . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.64 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.577 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.462 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.76 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.545 HD13 ' HD3' ' A' ' 153' ' ' ARG . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.76 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.64 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.579 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 96.6 m-20 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.401 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.541 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.579 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.562 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.545 ' HD3' HD13 ' A' ' 137' ' ' ILE . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.633 ' SG ' HD12 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.435 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.586 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.459 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.465 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.532 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.634 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.416 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.496 HG21 ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.774 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.459 HD22 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.481 ' HB2' HD11 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.774 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.761 ' O ' HD12 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.496 ' HA ' HG21 ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.418 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.685 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.685 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.518 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.529 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.529 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.574 HG23 ' H ' ' A' ' 78' ' ' LYS . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.574 ' H ' HG23 ' A' ' 77' ' ' ILE . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.444 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.518 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.618 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.623 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.714 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.511 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.61 HH11 HD13 ' A' ' 97' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.555 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.822 HD11 ' HB3' ' A' ' 121' ' ' ASP . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.561 ' H ' HG21 ' A' ' 115' ' ' THR . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.455 ' HA ' ' HG3' ' A' ' 118' ' ' PRO . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.623 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.404 HG12 ' HB ' ' A' ' 111' ' ' VAL . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.56 ' OG ' HD11 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.404 ' HB ' HG12 ' A' ' 106' ' ' ILE . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.56 HD11 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.561 HG21 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.555 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.605 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.822 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.818 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.569 HG23 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.42 HD13 ' HG2' ' A' ' 142' ' ' GLU . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.624 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.645 HG23 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.645 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.706 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.856 HD12 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.706 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.561 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.818 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.424 HG22 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.528 ' HB ' HG21 ' A' ' 137' ' ' ILE . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.567 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.856 ' HE ' HD12 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.598 ' SG ' HD12 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.508 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.654 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.654 ' N ' HD23 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.45 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.509 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.736 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.736 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.412 ' HB3' ' CG1' ' A' ' 183' ' ' ILE . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 180' ' ' GLN . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.624 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.509 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.483 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.483 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.787 ' SG ' HG12 ' A' ' 111' ' ' VAL . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.641 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.641 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 66' ' ' PRO . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.416 HG22 ' HG3' ' A' ' 78' ' ' LYS . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.416 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.76 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.767 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.654 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.76 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.606 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.1 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.404 ' SG ' HD22 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.441 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.532 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.488 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.457 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.607 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.747 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.643 HD13 HG22 ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 112' ' ' ILE . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.787 HG12 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.44 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HG2' HD12 ' A' ' 96' ' ' LEU . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 1.015 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.606 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.571 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.936 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 62.6 m-20 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.571 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.484 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.677 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.677 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 1.015 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.593 ' H ' ' HD1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.492 ' CG2' HD12 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.489 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.936 ' HA ' ' ND2' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.64 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.529 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.529 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.401 ' HE3' ' HA ' ' A' ' 165' ' ' GLU . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.466 HG23 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.503 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.545 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.624 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.518 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.544 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.415 ' O ' HD11 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.407 ' O ' HG23 ' A' ' 167' ' ' VAL . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 165' ' ' GLU . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.788 ' HD3' HG23 ' A' ' 111' ' ' VAL . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.542 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.527 ' HB3' HG21 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.536 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 88' ' ' TYR . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.68 HG21 HG22 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.756 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.651 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.68 HG22 HG21 ' A' ' 76' ' ' VAL . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.536 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.588 ' SG ' HD13 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.636 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.588 HD13 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.746 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.687 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.659 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.651 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.401 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.773 HG23 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.406 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.765 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.788 HG23 ' HD3' ' A' ' 61' ' ' LYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.401 ' HB2' HG12 ' A' ' 105' ' ' ILE . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.498 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.746 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ILE . . . . . 0.403 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.436 ' HB3' HD11 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.636 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.634 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.562 HD23 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.422 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.664 HG23 ' H ' ' A' ' 134' ' ' GLY . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.45 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.664 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.559 HD12 HG22 ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.562 ' HB3' HD23 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.634 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.624 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.559 HG22 HD12 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.52 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.597 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.597 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.561 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.561 ' N ' HD23 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.424 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.624 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.51 HG22 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.469 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 178' ' ' ASP . . . . . 0.434 ' HB3' ' O ' ' A' ' 185' ' ' SER . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.449 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.449 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.434 ' O ' ' HB3' ' A' ' 178' ' ' ASP . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.449 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.454 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.454 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.54 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.66 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.578 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.59 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.636 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.595 HG22 ' HG2' ' A' ' 78' ' ' LYS . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.595 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.572 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.66 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.572 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.52 ' HB3' ' HB2' ' A' ' 101' ' ' SER . 17.6 mm100 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.759 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 100' ' ' SER . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.487 ' SG ' HD13 ' A' ' 96' ' ' LEU . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.521 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.701 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.487 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.684 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.611 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.45 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.759 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.585 ' CD1' HG22 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.585 HG22 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.532 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.59 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.701 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.505 ' HB3' HD11 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.464 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.789 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.436 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.538 ' HG ' ' HB2' ' A' ' 142' ' ' GLU . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.512 ' HD2' HD23 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.443 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.742 HG21 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.471 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 27.1 m120 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.742 ' N ' HG21 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.809 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ASN . . . . . 0.575 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.817 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.817 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.7 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.505 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.789 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.844 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.7 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 172' ' ' ILE . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 171' ' ' SER . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.504 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.809 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.558 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.491 ' HB2' ' HD2' ' A' ' 156' ' ' PRO . 0.5 OUTLIER -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.509 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.653 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.661 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.661 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.844 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.812 HG21 ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.64 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.521 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.428 ' HB3' ' H ' ' A' ' 180' ' ' GLN . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.56 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.56 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.64 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 143' ' ' ASN . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 185' ' ' SER . . . . . 0.812 ' HA ' HG21 ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.443 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.471 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.689 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.689 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.408 ' HB3' ' OE1' ' A' ' 81' ' ' GLN . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.624 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.635 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.635 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.76 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.442 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.667 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.408 ' OE1' ' HB3' ' A' ' 62' ' ' SER . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.442 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.675 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.76 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.522 ' H ' HG22 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' HG23 ' A' ' 123' ' ' ILE . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.411 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.429 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.432 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.645 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.726 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' THR . . . . . 0.571 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.487 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.78 HG22 HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.583 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.624 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.524 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.524 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.506 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.432 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.538 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.411 ' HB3' HD11 ' A' ' 97' ' ' ILE . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.596 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.733 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.558 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.647 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.469 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.469 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.558 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.635 HD12 HG22 ' A' ' 151' ' ' THR . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.558 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.459 ' HA ' HD22 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.558 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.407 ' HB2' ' OG ' ' A' ' 148' ' ' SER . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.403 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.733 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.407 ' OG ' ' HB2' ' A' ' 144' ' ' PHE . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.635 HG22 HD12 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.647 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.551 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.525 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.514 ' HB2' ' HB3' ' A' ' 191' ' ' CYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 1.004 HD21 ' HB3' ' A' ' 170' ' ' PRO . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 1.004 ' HB3' HD21 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.68 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.68 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.518 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.578 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.439 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.693 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.693 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.705 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.578 ' SG ' HG22 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HB3' HD12 ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.772 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.772 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 79' ' ' GLY . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.478 HG22 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.478 ' HG2' HG22 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.665 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.705 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.567 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.665 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.67 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.733 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.766 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' CYS . . . . . 0.498 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.637 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.637 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.783 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.653 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.403 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.733 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.567 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.463 ' O ' HG22 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.578 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.783 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.766 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.659 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.67 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.525 ' H ' HG22 ' A' ' 123' ' ' ILE . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.475 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.528 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.408 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.423 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.663 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.812 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' SER . . . . . 0.496 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.494 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.437 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 1.3 t-20 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.659 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.67 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.663 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.812 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.534 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.49 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.49 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.606 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.46 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.46 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.607 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.494 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.607 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 177' ' ' ASN . . . . . 0.607 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.642 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.642 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.457 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.607 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.589 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.606 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.589 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.567 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.55 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.568 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.516 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.499 HG22 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.499 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.608 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.55 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.608 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.44 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.468 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.652 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.402 ' HB3' HD11 ' A' ' 96' ' ' LEU . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' LYS . . . . . 0.506 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.571 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.603 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.512 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.402 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.561 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.652 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.683 ' SG ' HG22 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.464 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.553 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.683 HG22 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.428 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.492 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.464 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.568 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.603 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.795 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.437 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.795 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.678 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.478 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.466 ' SG ' HD12 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.742 ' O ' HG22 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.881 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.587 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.881 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.639 ' CD2' HG23 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.727 HG12 HD12 ' A' ' 192' ' ' ILE . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.426 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 172' ' ' ILE . . . . . 0.478 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.59 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.61 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.668 ' CB ' ' H ' ' A' ' 183' ' ' ILE . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 180' ' ' GLN . . . . . 0.615 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 181' ' ' VAL . . . . . 0.726 ' O ' HD13 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.615 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.668 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.432 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 187' ' ' PRO . . . . . 0.765 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.568 ' HB3' HG21 ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.559 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.5 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.727 HD12 HG12 ' A' ' 167' ' ' VAL . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.784 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.532 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.805 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.551 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.451 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.531 HG23 ' HA3' ' A' ' 79' ' ' GLY . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.676 HG23 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.676 ' H ' HG23 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.599 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.498 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.515 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.599 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.456 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.428 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.705 ' HE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.421 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.721 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.498 ' SG ' HG12 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 1.02 HG12 HG22 ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 1.02 HG22 HG12 ' A' ' 106' ' ' ILE . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' TRP . . . . . 0.734 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.578 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.734 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 117' ' ' THR . . . . . 0.403 HG23 ' HD2' ' A' ' 118' ' ' PRO . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.705 HG23 ' HE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.504 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.731 HG21 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.731 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.424 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.448 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 92.6 m-20 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.469 ' ND2' ' HB2' ' A' ' 125' ' ' CYS . 3.0 t30 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.497 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.448 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.569 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' PRO . . . . . 0.5 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 167' ' ' VAL . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.51 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.4 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 171' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.807 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 179' ' ' ASP . . . . . 0.411 ' OD2' HG23 ' A' ' 183' ' ' ILE . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.807 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.411 HG23 ' OD2' ' A' ' 179' ' ' ASP . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.504 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.445 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.445 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HD3' HG23 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.599 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.584 ' HB3' HD13 ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.454 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.532 HG22 HG23 ' A' ' 80' ' ' ILE . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.502 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG22 ' HD3' ' A' ' 66' ' ' PRO . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.599 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.502 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.605 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.454 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' LEU . . . . . 0.613 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.562 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' CYS . . . . . 0.461 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.424 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.729 HG12 HG22 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.492 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.493 HG23 HG23 ' A' ' 112' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 HG12 ' A' ' 106' ' ' ILE . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.493 HG23 HG23 ' A' ' 110' ' ' THR . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.424 ' HB2' HG12 ' A' ' 105' ' ' ILE . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.562 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 120' ' ' CYS . . . . . 0.613 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.654 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' CYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' LEU . . . . . 0.501 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 128' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' PRO . . . . . 0.652 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.772 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' THR . . . . . 0.613 HG21 ' HB2' ' A' ' 191' ' ' CYS . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' ASN . . . . . 0.565 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.772 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' ASP . . . . . 0.7 ' O ' HG21 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.651 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ASN . . . . . 0.502 HD21 ' HZ ' ' A' ' 144' ' ' PHE . 91.2 m-20 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.501 ' HG2' HD21 ' A' ' 127' ' ' LEU . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.524 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' PHE . . . . . 0.502 ' HZ ' HD21 ' A' ' 140' ' ' ASN . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.654 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.651 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.8 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 155' ' ' ASN . . . . . 0.42 HD21 ' C ' ' A' ' 155' ' ' ASN . 0.2 OUTLIER -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.697 ' CA ' HG13 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' ARG . . . . . 0.897 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.897 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.697 HG13 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.619 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.8 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.599 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 168' ' ' GLY . . . . . 0.41 ' O ' ' HD3' ' A' ' 170' ' ' PRO . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 169' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' O ' ' A' ' 168' ' ' GLY . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' TYR . . . . . 0.691 ' CE2' HG22 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 174' ' ' CYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.691 HG22 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.788 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.788 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 183' ' ' ILE . . . . . 0.555 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 184' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 188' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.525 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.558 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.619 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LYS . . . . . 0.599 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ARG . . . . . 0.688 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.688 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.0 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' ASP . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PRO . . . . . 0.72 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 71' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.718 HG21 HG22 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.439 HG22 ' HG2' ' A' ' 78' ' ' LYS . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' LYS . . . . . 0.439 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.46 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.557 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 82' ' ' PHE . . . . . 0.521 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' SER . . . . . 0.46 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' GLN . . . . . 0.45 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ILE . . . . . 0.718 HG22 HG21 ' A' ' 76' ' ' VAL . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' TYR . . . . . 0.72 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' THR . . . . . 0.841 HG23 ' HD2' ' A' ' 94' ' ' TYR . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' TYR . . . . . 0.841 ' HD2' HG23 ' A' ' 91' ' ' THR . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 95' ' ' ARG . . . . . 0.427 ' CZ ' HG23 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 121' ' ' ASP . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 98' ' ' GLY . . . . . 0.412 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' SER . . . . . 0.56 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 100' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' ILE . . . . . 0.412 HG12 ' HB2' ' A' ' 114' ' ' ASP . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ILE . . . . . 0.729 ' CD1' HG22 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 110' ' ' THR . . . . . 0.44 HG22 HG23 ' A' ' 112' ' ' ILE . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 110' ' ' THR . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 114' ' ' ASP . . . . . 0.412 ' HB2' HG12 ' A' ' 105' ' ' ILE . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 115' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 116' ' ' GLU . . . . . 0.435 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ASP . . . . . 0.528 ' HB3' HD11 ' A' ' 97' ' ' ILE . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.978 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' ILE . . . . . 0.569 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 124' ' ' PRO . . . . . 0.679 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.799 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' GLY . . . . . 0.799 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 136' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 137' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ARG . . . . . 0.45 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 143' ' ' ASN . . . . . 0.743 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 8.2 t-20 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 145' ' ' HIS . . . . . 0.978 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' SER . . . . . 0.743 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' THR . . . . . 0.616 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 152' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 153' ' ' ARG . . . . . 0.502 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 154' ' ' CYS . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' VAL . . . . . 0.511 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' PHE . . . . . 0.511 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 165' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 166' ' ' LEU . . . . . 0.589 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' VAL . . . . . 0.589 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' PRO . . . . . 0.638 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 175' ' ' THR . . . . . 0.513 HG23 ' O ' ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 176' ' ' SER . . . . . 0.69 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 182' ' ' GLY . . . . . 0.69 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 189' ' ' PRO . . . . . 0.638 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 190' ' ' GLN . . . . . 0.548 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 192' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 167' ' ' VAL . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.638 ' HD3' HG23 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.681 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.681 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.511 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.456 ' HB ' HG22 ' A' ' 86' ' ' ILE . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.639 HG22 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.639 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.585 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.771 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.647 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.766 ' HZ ' HD11 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.585 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.674 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.403 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.511 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.623 ' SG ' HD13 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 95' ' ' ARG . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.623 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.619 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.674 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.647 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.766 HD11 ' HZ ' ' A' ' 82' ' ' PHE . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.693 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.469 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.638 HG23 ' HD3' ' A' ' 61' ' ' LYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.693 HD11 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.407 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.436 HG21 ' H ' ' A' ' 99' ' ' SER . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 118' ' ' PRO . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.619 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.814 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.733 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.553 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.602 ' HB3' HD21 ' A' ' 155' ' ' ASN . 7.9 m120 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.553 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.443 ' O ' HG21 ' A' ' 131' ' ' ILE . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.535 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.814 ' ND2' ' HB3' ' A' ' 125' ' ' CYS . 53.1 t30 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.505 ' SG ' HD12 ' A' ' 166' ' ' LEU . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.602 HD21 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.566 HG23 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.566 ' CD2' HG23 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.534 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.65 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.415 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.615 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 69.3 m-20 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 178' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.431 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.435 ' HB ' ' H ' ' A' ' 184' ' ' TRP . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.607 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.615 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.733 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.638 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.638 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.871 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.871 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.635 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 60.5 m80 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.504 HG21 HG22 ' A' ' 86' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.453 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.559 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.662 HD12 ' HG2' ' A' ' 118' ' ' PRO . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 97' ' ' ILE . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.78 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.754 ' HB3' HG21 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.447 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.543 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.622 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.746 HG12 HG22 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.568 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.46 HG23 HG23 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.746 HG22 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.568 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.543 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.622 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.754 HG21 ' HB3' ' A' ' 99' ' ' SER . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.542 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.635 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.78 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.559 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.405 ' HG ' ' HB3' ' A' ' 142' ' ' GLU . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.588 HD13 ' HB3' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.479 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.509 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 136' ' ' PHE . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.405 ' HB3' ' HG ' ' A' ' 127' ' ' LEU . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.479 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.429 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.588 ' HB3' HD13 ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.677 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.677 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.606 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.479 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.489 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.653 ' O ' HG13 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.494 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.556 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.526 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.56 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.689 ' HD3' HD12 ' A' ' 86' ' ' ILE . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.614 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.541 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.471 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.471 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.474 HG11 HG22 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.724 HG23 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.724 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.457 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.583 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.473 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.473 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.457 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.457 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.689 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.541 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.436 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.489 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.512 ' HB3' HG12 ' A' ' 123' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.748 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.829 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.7 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.651 ' SG ' HG22 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.651 HG22 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 99' ' ' SER . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.829 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.748 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.599 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.699 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.514 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.567 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.567 ' H ' HG23 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.412 ' O ' HG21 ' A' ' 131' ' ' ILE . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.517 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.699 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.517 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.415 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.434 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.542 ' HB3' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' GLY . . . . . 0.542 ' H ' ' HB3' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.554 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.558 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.558 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.88 ' HB2' HD13 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.439 ' HG2' HG23 ' A' ' 181' ' ' VAL . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.46 HG13 ' HB2' ' A' ' 95' ' ' ARG . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.88 HD13 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.517 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.625 ' HB2' HG13 ' A' ' 192' ' ' ILE . 83.2 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.625 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.625 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.6 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.413 ' CG ' HG21 ' A' ' 86' ' ' ILE . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.492 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.664 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.625 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.712 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.494 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.664 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.718 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.706 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.492 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.535 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.521 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.4 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.706 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.718 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.568 HD13 HG23 ' A' ' 111' ' ' VAL . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.633 HG22 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.419 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.461 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.535 ' HG2' HD12 ' A' ' 96' ' ' LEU . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.402 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.43 ' HA ' ' ND1' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.424 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.411 HD22 ' HB3' ' A' ' 142' ' ' GLU . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.642 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.446 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.69 HG21 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.66 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.69 ' O ' HG21 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.452 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HB ' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.41 ' CB ' HG12 ' A' ' 150' ' ' VAL . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.508 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.508 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.642 ' H ' ' HD3' ' A' ' 128' ' ' PRO . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.43 ' ND1' ' HA ' ' A' ' 124' ' ' PRO . 39.9 m-70 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.628 HG13 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.67 ' HB ' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.528 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.645 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.663 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.645 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.574 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.649 HD23 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.649 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.425 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.45 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.45 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.458 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.446 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.567 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.574 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.567 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.469 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.591 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.591 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.5 ' HG2' HG23 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.9 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.5 HG23 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.426 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.449 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.572 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.659 HD12 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.818 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.4 HG22 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.4 ' N ' HG22 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.682 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.46 HD21 ' HD2' ' A' ' 88' ' ' TYR 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.409 HD11 ' HB3' ' A' ' 121' ' ' ASP 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.677 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.765 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.469 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.488 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.9 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.818 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.409 ' HB3' HD11 ' A' ' 97' ' ' ILE . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.755 HG21 ' HA2' ' A' ' 182' ' ' GLY . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.639 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.891 HD12 ' HD2' ' A' ' 128' ' ' PRO . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.891 ' HD2' HD12 ' A' ' 127' ' ' LEU . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.838 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 155' ' ' ASN . 93.7 m-20 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.838 ' C ' HG21 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.51 HG22 ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.504 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.887 ' HA ' HD13 ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.648 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.513 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.638 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 133' ' ' ASN . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.531 HG23 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.531 ' CD2' HG23 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.537 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.537 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.621 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.455 HD11 ' HE2' ' A' ' 152' ' ' TYR . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.812 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.513 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.812 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.785 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.627 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.627 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.418 ' HA ' ' OG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.785 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.72 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.615 ' HB3' HG21 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 189' ' ' PRO . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.621 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.463 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.463 HG12 ' HG3' ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB3' HG21 ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.609 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.43 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.43 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.0 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.43 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.585 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.5 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.741 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.806 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.5 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.484 ' SG ' HD22 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.594 ' HE ' HG23 ' A' ' 123' ' ' ILE . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.525 HD12 ' HG2' ' A' ' 118' ' ' PRO . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.444 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.669 ' O ' HG21 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.806 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.51 HG23 ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.592 HD13 HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.612 ' HB2' HD12 ' A' ' 112' ' ' ILE . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 63' ' ' CYS . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.612 HD12 ' HB2' ' A' ' 107' ' ' SER . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.51 ' HB2' HG23 ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.669 HG21 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.514 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.525 ' HG2' HD12 ' A' ' 96' ' ' LEU . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.421 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.594 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.717 HD11 ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.601 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.556 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.428 HG22 ' H ' ' A' ' 131' ' ' ILE . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.83 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.83 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.45 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.525 HD12 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 51.7 t30 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.717 ' HB3' HD11 ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.601 ' H ' ' HG3' ' A' ' 128' ' ' PRO . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 145' ' ' HIS . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.412 ' HB2' ' CD2' ' A' ' 144' ' ' PHE . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.599 ' HB3' HD21 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.531 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.409 HH11 HG13 ' A' ' 137' ' ' ILE . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.773 ' SG ' HD12 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.768 ' O ' HG22 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.604 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.636 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.773 HD12 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.621 ' N ' HD23 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.458 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.401 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.54 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.67 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.67 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.535 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.476 ' HB2' HD21 ' A' ' 166' ' ' LEU . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.431 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.602 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.431 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' HG22 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.543 ' HD3' HG21 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.455 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 72' ' ' GLY . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.626 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.626 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.539 ' H ' HG22 ' A' ' 76' ' ' VAL . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.593 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.592 ' CE1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.453 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 97.6 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.801 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.471 ' SG ' HD22 ' A' ' 96' ' ' LEU . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.562 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.407 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.491 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.559 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.592 ' HA ' ' CE1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.57 HG22 ' H ' ' A' ' 108' ' ' GLY . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.57 ' H ' HG22 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.539 ' HB2' HG12 ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.491 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.543 HG21 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.407 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.801 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.542 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' THR . . . . . 0.631 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.447 HD13 ' HB3' ' A' ' 152' ' ' TYR . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.631 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.465 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.663 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.465 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.556 HD21 ' CG1' ' A' ' 150' ' ' VAL . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 97.0 m-70 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.542 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.556 ' CG1' HD21 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.663 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.495 ' HD3' HD12 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.575 ' SG ' HD12 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.495 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.536 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.548 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.449 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.449 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.449 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' ASP . . . . . 0.511 ' HB3' HD11 ' A' ' 183' ' ' ILE . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.53 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.532 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.532 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.573 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.573 ' O ' HD12 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.418 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 190' ' ' GLN . . . . . . . . . . . . . 3.7 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 192' ' ' ILE . . . . . . . . . . . . . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.544 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.718 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.718 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.748 ' HG3' HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.585 ' HB3' HG23 ' A' ' 117' ' ' THR . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 76' ' ' VAL . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.7 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.628 HG22 ' HD3' ' A' ' 66' ' ' PRO . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.608 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.7 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.748 HG21 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.537 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.655 ' SG ' HD13 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.731 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.655 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.413 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.601 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' HD11 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.749 ' SG ' HG22 ' A' ' 111' ' ' VAL . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.478 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.749 HG22 ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.544 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.648 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.648 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.585 HG23 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.495 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.731 ' HD2' ' HE ' ' A' ' 95' ' ' ARG . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.647 HD21 ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.447 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 131' ' ' ILE . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.476 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.647 ' HG2' HD21 ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.485 ' ND1' ' HA ' ' A' ' 124' ' ' PRO . 33.3 m-70 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.597 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.473 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.586 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.473 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.476 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.519 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.539 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.577 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.531 ' N ' HD23 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.586 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.503 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.536 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.458 HG23 HG13 ' A' ' 183' ' ' ILE . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.458 HG13 HG23 ' A' ' 181' ' ' VAL . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.672 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.539 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.672 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.686 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.844 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.844 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.0 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.535 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.535 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.451 HG21 HG23 ' A' ' 80' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.579 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.579 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.686 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.817 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.526 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.548 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.788 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.533 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.584 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.483 ' SG ' HD13 ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.613 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.483 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.755 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.538 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.788 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.817 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.445 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.561 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.561 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.428 ' HB2' ' HA ' ' A' ' 116' ' ' GLU . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.474 HG21 ' H ' ' A' ' 99' ' ' SER . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 113' ' ' TRP . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.755 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.802 HD13 ' HA3' ' A' ' 182' ' ' GLY . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.689 HD12 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.881 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.967 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 75.5 m-20 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.881 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.433 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.689 ' OE1' HD12 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.445 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.531 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.55 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.967 ' HA ' ' ND2' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.416 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.543 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.543 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.435 HG23 ' CD1' ' A' ' 164' ' ' PHE . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.613 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.613 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.426 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.807 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 80.6 m-20 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.807 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.802 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.448 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.445 ' HB1' HD13 ' A' ' 131' ' ' ILE . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.642 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.579 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB2' ' CG2' ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.705 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.657 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.657 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.557 ' CG ' HG21 ' A' ' 76' ' ' VAL . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.506 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' MET . . . . . 0.684 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.557 HG21 ' CG ' ' A' ' 66' ' ' PRO . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.609 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.819 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.628 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' SER . . . . . 0.684 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 122' ' ' ARG . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.489 ' HG2' ' HA ' ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.583 HD12 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.643 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.847 ' HB2' HG21 ' A' ' 115' ' ' THR . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.772 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.693 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.819 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.464 HG12 HG22 ' A' ' 111' ' ' VAL . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.416 ' O ' HG23 ' A' ' 106' ' ' ILE . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.705 HG12 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.847 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.643 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 142' ' ' GLU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.463 ' HA ' HD13 ' A' ' 127' ' ' LEU . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.64 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.577 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.462 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.76 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.545 HD13 ' HD3' ' A' ' 153' ' ' ARG . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.76 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.64 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.579 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 96.6 m-20 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.401 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.541 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.579 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.562 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.545 ' HD3' HD13 ' A' ' 137' ' ' ILE . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.633 ' SG ' HD12 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.435 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.586 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.459 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.465 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.532 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.634 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.416 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.496 HG21 ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.774 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.459 HD22 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.481 ' HB2' HD11 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.774 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.761 ' O ' HD12 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.496 ' HA ' HG21 ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.418 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.685 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.685 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.518 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.529 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 64.4 t30 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.529 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.574 HG23 ' H ' ' A' ' 78' ' ' LYS . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.574 ' H ' HG23 ' A' ' 77' ' ' ILE . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.444 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.518 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.618 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.623 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.714 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.511 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.61 HH11 HD13 ' A' ' 97' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.555 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.822 HD11 ' HB3' ' A' ' 121' ' ' ASP . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.561 ' H ' HG21 ' A' ' 115' ' ' THR . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.455 ' HA ' ' HG3' ' A' ' 118' ' ' PRO . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.623 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.404 HG12 ' HB ' ' A' ' 111' ' ' VAL . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.56 ' OG ' HD11 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.404 ' HB ' HG12 ' A' ' 106' ' ' ILE . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.56 HD11 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.561 HG21 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.555 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.605 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.822 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.818 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.569 HG23 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.42 HD13 ' HG2' ' A' ' 142' ' ' GLU . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.624 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.645 HG23 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.645 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.706 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.856 HD12 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.2 m-20 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.706 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.561 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.818 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.424 HG22 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.528 ' HB ' HG21 ' A' ' 137' ' ' ILE . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.567 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.856 ' HE ' HD12 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.598 ' SG ' HD12 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.508 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.654 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.654 ' N ' HD23 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.45 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.509 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.736 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.736 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.412 ' HB3' ' CG1' ' A' ' 183' ' ' ILE . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 180' ' ' GLN . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.624 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.509 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.483 ' HG3' HG12 ' A' ' 192' ' ' ILE . 3.9 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.483 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.787 ' SG ' HG12 ' A' ' 111' ' ' VAL . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.641 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.641 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 66' ' ' PRO . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.416 HG22 ' HG3' ' A' ' 78' ' ' LYS . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.416 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.76 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.767 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.654 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.76 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.606 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.1 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.404 ' SG ' HD22 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.441 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.532 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.488 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.457 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.607 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.747 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.643 HD13 HG22 ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 112' ' ' ILE . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.787 HG12 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.44 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HG2' HD12 ' A' ' 96' ' ' LEU . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 1.015 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.606 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.571 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.936 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 62.6 m-20 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.571 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.484 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.677 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.677 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 90.1 m-20 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 1.015 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.593 ' H ' ' HD1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.492 ' CG2' HD12 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.489 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.936 ' HA ' ' ND2' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.64 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.529 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.529 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.401 ' HE3' ' HA ' ' A' ' 165' ' ' GLU . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.466 HG23 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.503 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.545 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.624 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.518 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.544 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.415 ' O ' HD11 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.407 ' O ' HG23 ' A' ' 167' ' ' VAL . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 165' ' ' GLU . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.788 ' HD3' HG23 ' A' ' 111' ' ' VAL . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.542 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.527 ' HB3' HG21 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.536 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 88' ' ' TYR . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.68 HG21 HG22 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.756 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.651 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.68 HG22 HG21 ' A' ' 76' ' ' VAL . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.536 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.588 ' SG ' HD13 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.636 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.588 HD13 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.746 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.687 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.659 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.651 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.401 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.773 HG23 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.406 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.765 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.788 HG23 ' HD3' ' A' ' 61' ' ' LYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.401 ' HB2' HG12 ' A' ' 105' ' ' ILE . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.498 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.746 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ILE . . . . . 0.403 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.436 ' HB3' HD11 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.636 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.634 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.562 HD23 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.422 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.664 HG23 ' H ' ' A' ' 134' ' ' GLY . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.45 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.664 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.559 HD12 HG22 ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.562 ' HB3' HD23 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.634 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.624 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.559 HG22 HD12 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.52 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.597 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 1.2 t-20 -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.597 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.561 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.561 ' N ' HD23 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.424 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.624 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.51 HG22 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.469 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 178' ' ' ASP . . . . . 0.434 ' HB3' ' O ' ' A' ' 185' ' ' SER . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.449 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.449 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.434 ' O ' ' HB3' ' A' ' 178' ' ' ASP . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.449 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.454 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.454 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.54 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.66 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.578 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.59 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.636 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.595 HG22 ' HG2' ' A' ' 78' ' ' LYS . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.595 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.572 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.66 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.572 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.52 ' HB3' ' HB2' ' A' ' 101' ' ' SER . 17.6 mm100 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.759 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 100' ' ' SER . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.487 ' SG ' HD13 ' A' ' 96' ' ' LEU . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.521 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.701 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.487 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.684 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.611 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.45 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.759 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.585 ' CD1' HG22 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.585 HG22 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.532 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.59 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.701 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.505 ' HB3' HD11 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.464 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.789 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.436 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.538 ' HG ' ' HB2' ' A' ' 142' ' ' GLU . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.512 ' HD2' HD23 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.443 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.742 HG21 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.471 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 27.1 m120 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.742 ' N ' HG21 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.809 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ASN . . . . . 0.575 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.817 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.817 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.7 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.505 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.789 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.844 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.7 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 172' ' ' ILE . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 171' ' ' SER . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.504 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.809 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.558 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.491 ' HB2' ' HD2' ' A' ' 156' ' ' PRO . 0.5 OUTLIER -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.509 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.653 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.661 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.661 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.844 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.812 HG21 ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.64 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.521 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.428 ' HB3' ' H ' ' A' ' 180' ' ' GLN . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.56 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.56 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.64 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 143' ' ' ASN . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 185' ' ' SER . . . . . 0.812 ' HA ' HG21 ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.443 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.471 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.689 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.689 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.408 ' HB3' ' OE1' ' A' ' 81' ' ' GLN . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.624 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.635 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.635 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.76 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.442 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.667 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.408 ' OE1' ' HB3' ' A' ' 62' ' ' SER . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.442 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.675 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.76 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.522 ' H ' HG22 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' HG23 ' A' ' 123' ' ' ILE . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.411 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.429 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.432 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.645 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.726 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' THR . . . . . 0.571 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.487 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.78 HG22 HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.583 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.624 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.524 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.524 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.506 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.432 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.538 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.411 ' HB3' HD11 ' A' ' 97' ' ' ILE . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.596 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.733 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.558 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.647 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.469 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.469 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.558 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.635 HD12 HG22 ' A' ' 151' ' ' THR . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.558 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.459 ' HA ' HD22 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.558 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.407 ' HB2' ' OG ' ' A' ' 148' ' ' SER . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.403 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.733 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.407 ' OG ' ' HB2' ' A' ' 144' ' ' PHE . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.635 HG22 HD12 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.647 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.551 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.525 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.514 ' HB2' ' HB3' ' A' ' 191' ' ' CYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 1.004 HD21 ' HB3' ' A' ' 170' ' ' PRO . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 1.004 ' HB3' HD21 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.68 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.68 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.518 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.578 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.439 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.693 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.693 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.705 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.578 ' SG ' HG22 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HB3' HD12 ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.772 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.772 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 79' ' ' GLY . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.478 HG22 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.478 ' HG2' HG22 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.665 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.705 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.567 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.665 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.67 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.733 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.766 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' CYS . . . . . 0.498 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.637 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.637 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.783 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.653 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.403 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.733 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.567 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.463 ' O ' HG22 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.578 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.783 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.766 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.659 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.67 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.525 ' H ' HG22 ' A' ' 123' ' ' ILE . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.475 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.528 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.408 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.423 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.663 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.812 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' SER . . . . . 0.496 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 92.8 m-20 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.494 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.437 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 1.3 t-20 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.659 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.67 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.663 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.812 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.534 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.49 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.49 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.606 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.46 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.46 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.607 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.494 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.607 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' ASN . . . . . 0.607 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.642 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.642 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.457 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.607 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.589 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.606 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.589 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.567 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.55 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.568 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.516 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.499 HG22 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.499 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.608 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.55 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.608 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.44 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.468 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.652 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.402 ' HB3' HD11 ' A' ' 96' ' ' LEU . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' LYS . . . . . 0.506 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.571 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.603 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.512 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.402 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.561 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.652 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.683 ' SG ' HG22 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.464 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.553 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.683 HG22 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.428 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.492 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.464 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.568 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.603 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.795 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.437 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 13.4 m120 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.795 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.678 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.478 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.466 ' SG ' HD12 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.742 ' O ' HG22 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.881 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.587 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.881 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.639 ' CD2' HG23 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.727 HG12 HD12 ' A' ' 192' ' ' ILE . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.426 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 172' ' ' ILE . . . . . 0.478 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.59 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.61 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.668 ' CB ' ' H ' ' A' ' 183' ' ' ILE . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 180' ' ' GLN . . . . . 0.615 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 181' ' ' VAL . . . . . 0.726 ' O ' HD13 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.615 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.668 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.432 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 187' ' ' PRO . . . . . 0.765 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.568 ' HB3' HG21 ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.559 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.5 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.727 HD12 HG12 ' A' ' 167' ' ' VAL . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.784 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.532 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.805 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.551 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.451 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.531 HG23 ' HA3' ' A' ' 79' ' ' GLY . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.676 HG23 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.676 ' H ' HG23 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.599 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.498 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.515 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.599 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.456 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.428 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.705 ' HE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.421 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.721 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.498 ' SG ' HG12 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 1.02 HG12 HG22 ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 1.02 HG22 HG12 ' A' ' 106' ' ' ILE . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' TRP . . . . . 0.734 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.578 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.734 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' THR . . . . . 0.403 HG23 ' HD2' ' A' ' 118' ' ' PRO . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.705 HG23 ' HE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.504 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.731 HG21 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.731 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.424 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.448 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 92.6 m-20 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.469 ' ND2' ' HB2' ' A' ' 125' ' ' CYS . 3.0 t30 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.497 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.448 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.569 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' PRO . . . . . 0.5 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 167' ' ' VAL . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.51 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.4 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 171' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.807 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 179' ' ' ASP . . . . . 0.411 ' OD2' HG23 ' A' ' 183' ' ' ILE . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.807 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.411 HG23 ' OD2' ' A' ' 179' ' ' ASP . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.504 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.445 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.445 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HD3' HG23 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.599 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.584 ' HB3' HD13 ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.454 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.532 HG22 HG23 ' A' ' 80' ' ' ILE . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.502 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG22 ' HD3' ' A' ' 66' ' ' PRO . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.599 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.502 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.605 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.454 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' LEU . . . . . 0.613 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.562 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' CYS . . . . . 0.461 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.424 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.729 HG12 HG22 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.492 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.493 HG23 HG23 ' A' ' 112' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 HG12 ' A' ' 106' ' ' ILE . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.493 HG23 HG23 ' A' ' 110' ' ' THR . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.424 ' HB2' HG12 ' A' ' 105' ' ' ILE . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.562 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.654 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' CYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' LEU . . . . . 0.501 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 128' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' PRO . . . . . 0.652 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.772 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' THR . . . . . 0.613 HG21 ' HB2' ' A' ' 191' ' ' CYS . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' ASN . . . . . 0.565 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.772 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' ASP . . . . . 0.7 ' O ' HG21 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.651 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ASN . . . . . 0.502 HD21 ' HZ ' ' A' ' 144' ' ' PHE . 91.2 m-20 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.501 ' HG2' HD21 ' A' ' 127' ' ' LEU . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.524 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' PHE . . . . . 0.502 ' HZ ' HD21 ' A' ' 140' ' ' ASN . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.654 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.651 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.8 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 155' ' ' ASN . . . . . 0.42 HD21 ' C ' ' A' ' 155' ' ' ASN . 0.2 OUTLIER -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.697 ' CA ' HG13 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' ARG . . . . . 0.897 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.897 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.697 HG13 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.619 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.8 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.599 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 168' ' ' GLY . . . . . 0.41 ' O ' ' HD3' ' A' ' 170' ' ' PRO . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 169' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' O ' ' A' ' 168' ' ' GLY . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' TYR . . . . . 0.691 ' CE2' HG22 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 174' ' ' CYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.691 HG22 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.788 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.6 m120 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.788 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 183' ' ' ILE . . . . . 0.555 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 184' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 188' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.525 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.558 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.619 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LYS . . . . . 0.599 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ARG . . . . . 0.688 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.688 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.0 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ASP . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PRO . . . . . 0.72 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 71' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.718 HG21 HG22 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.439 HG22 ' HG2' ' A' ' 78' ' ' LYS . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' LYS . . . . . 0.439 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.46 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.557 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PHE . . . . . 0.521 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' SER . . . . . 0.46 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLN . . . . . 0.45 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ILE . . . . . 0.718 HG22 HG21 ' A' ' 76' ' ' VAL . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' TYR . . . . . 0.72 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' THR . . . . . 0.841 HG23 ' HD2' ' A' ' 94' ' ' TYR . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' TYR . . . . . 0.841 ' HD2' HG23 ' A' ' 91' ' ' THR . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ARG . . . . . 0.427 ' CZ ' HG23 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 121' ' ' ASP . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' GLY . . . . . 0.412 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' SER . . . . . 0.56 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 100' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' ILE . . . . . 0.412 HG12 ' HB2' ' A' ' 114' ' ' ASP . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ILE . . . . . 0.729 ' CD1' HG22 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' THR . . . . . 0.44 HG22 HG23 ' A' ' 112' ' ' ILE . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 110' ' ' THR . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ASP . . . . . 0.412 ' HB2' HG12 ' A' ' 105' ' ' ILE . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 115' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 116' ' ' GLU . . . . . 0.435 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ASP . . . . . 0.528 ' HB3' HD11 ' A' ' 97' ' ' ILE . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.978 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' ILE . . . . . 0.569 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 124' ' ' PRO . . . . . 0.679 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.799 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' GLY . . . . . 0.799 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 136' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 137' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 91.6 m-20 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ARG . . . . . 0.45 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 143' ' ' ASN . . . . . 0.743 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 8.2 t-20 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 145' ' ' HIS . . . . . 0.978 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' SER . . . . . 0.743 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' THR . . . . . 0.616 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 152' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 153' ' ' ARG . . . . . 0.502 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 154' ' ' CYS . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' VAL . . . . . 0.511 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' PHE . . . . . 0.511 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 165' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 166' ' ' LEU . . . . . 0.589 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' VAL . . . . . 0.589 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' PRO . . . . . 0.638 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 175' ' ' THR . . . . . 0.513 HG23 ' O ' ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 176' ' ' SER . . . . . 0.69 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 182' ' ' GLY . . . . . 0.69 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 189' ' ' PRO . . . . . 0.638 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 190' ' ' GLN . . . . . 0.548 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 192' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 167' ' ' VAL . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.638 ' HD3' HG23 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.681 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.681 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.511 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.456 ' HB ' HG22 ' A' ' 86' ' ' ILE . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.639 HG22 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.639 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.585 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.771 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.647 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.766 ' HZ ' HD11 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.585 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.674 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.403 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.511 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.623 ' SG ' HD13 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 95' ' ' ARG . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.623 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.619 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.674 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.647 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.766 HD11 ' HZ ' ' A' ' 82' ' ' PHE . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.693 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.469 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.638 HG23 ' HD3' ' A' ' 61' ' ' LYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.693 HD11 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.407 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.436 HG21 ' H ' ' A' ' 99' ' ' SER . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 118' ' ' PRO . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.619 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.664 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.733 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.553 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.7 HD22 ' HA ' ' A' ' 154' ' ' CYS . 93.5 m-20 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.553 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.443 ' O ' HG21 ' A' ' 131' ' ' ILE . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.535 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.664 ' OD1' ' HB3' ' A' ' 125' ' ' CYS . 3.9 t-20 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.56 ' CB ' HD21 ' A' ' 143' ' ' ASN . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.7 ' HA ' HD22 ' A' ' 133' ' ' ASN . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.602 HD21 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.566 HG23 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.566 ' CD2' HG23 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.534 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.65 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.415 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.615 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.431 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.435 ' HB ' ' H ' ' A' ' 184' ' ' TRP . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.607 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.615 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.733 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.638 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.638 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.871 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.871 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.635 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.504 HG21 HG22 ' A' ' 86' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.453 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.559 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.662 HD12 ' HG2' ' A' ' 118' ' ' PRO . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 97' ' ' ILE . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.78 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.754 ' HB3' HG21 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.447 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.543 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.622 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.746 HG12 HG22 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.568 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.46 HG23 HG23 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.746 HG22 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.568 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.543 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.622 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.754 HG21 ' HB3' ' A' ' 99' ' ' SER . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.542 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.635 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.78 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.559 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.405 ' HG ' ' HB3' ' A' ' 142' ' ' GLU . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.588 HD13 ' HB3' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.479 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.509 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 136' ' ' PHE . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.405 ' HB3' ' HG ' ' A' ' 127' ' ' LEU . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.479 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.429 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.588 ' HB3' HD13 ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.677 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.409 HD22 ' N ' ' A' ' 155' ' ' ASN . 0.9 OUTLIER -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.677 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.606 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.479 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.489 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.653 ' O ' HG13 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.494 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.556 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.526 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.56 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.689 ' HD3' HD12 ' A' ' 86' ' ' ILE . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.614 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.541 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.471 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.471 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.474 HG11 HG22 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.724 HG23 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.724 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.457 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.583 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.473 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.473 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.457 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.457 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.689 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.541 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.436 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.489 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.512 ' HB3' HG12 ' A' ' 123' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.748 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.829 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.7 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.651 ' SG ' HG22 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.651 HG22 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 99' ' ' SER . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.829 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.748 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.599 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.699 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.514 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.567 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.567 ' H ' HG23 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.412 ' O ' HG21 ' A' ' 131' ' ' ILE . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.517 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.699 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.517 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.415 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.434 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.542 ' HB3' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . 0.542 ' H ' ' HB3' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.554 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.558 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.558 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.88 ' HB2' HD13 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.439 ' HG2' HG23 ' A' ' 181' ' ' VAL . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.46 HG13 ' HB2' ' A' ' 95' ' ' ARG . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.88 HD13 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.517 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.625 ' HB2' HG13 ' A' ' 192' ' ' ILE . 22.6 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.625 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.625 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.6 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.413 ' CG ' HG21 ' A' ' 86' ' ' ILE . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.492 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.664 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.625 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.712 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.494 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.664 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.718 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.706 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.492 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.535 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.521 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.4 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.706 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.718 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.568 HD13 HG23 ' A' ' 111' ' ' VAL . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.633 HG22 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.419 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.461 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.535 ' HG2' HD12 ' A' ' 96' ' ' LEU . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.402 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.644 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.424 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.411 HD22 ' HB3' ' A' ' 142' ' ' GLU . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.642 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.446 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.69 HG21 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.473 ' ND2' ' HB2' ' A' ' 191' ' ' CYS . 34.1 m-80 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.66 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.69 ' O ' HG21 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.452 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HB ' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.41 ' CB ' HG12 ' A' ' 150' ' ' VAL . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.508 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.508 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.642 ' H ' ' HD3' ' A' ' 128' ' ' PRO . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.644 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 55.5 m80 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.628 HG13 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.67 ' HB ' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.528 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.645 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.663 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.645 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.574 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.649 HD23 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.649 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.425 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.45 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.45 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.458 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.446 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.567 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.574 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.567 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.469 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.591 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.591 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.5 ' HG2' HG23 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.9 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.5 HG23 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.426 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.449 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.572 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.659 HD12 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.818 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.4 HG22 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.4 ' N ' HG22 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.682 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.46 HD21 ' HD2' ' A' ' 88' ' ' TYR 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.409 HD11 ' HB3' ' A' ' 121' ' ' ASP 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.677 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.765 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.469 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.488 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.9 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.818 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.409 ' HB3' HD11 ' A' ' 97' ' ' ILE . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.755 HG21 ' HA2' ' A' ' 182' ' ' GLY . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.639 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.891 HD12 ' HD2' ' A' ' 128' ' ' PRO . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.891 ' HD2' HD12 ' A' ' 127' ' ' LEU . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.838 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 155' ' ' ASN . 11.2 m120 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.838 ' C ' HG21 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.51 HG22 ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.504 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.887 ' HA ' HD13 ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.648 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.513 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.638 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 133' ' ' ASN . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.531 HG23 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.531 ' CD2' HG23 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.537 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.537 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.621 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.455 HD11 ' HE2' ' A' ' 152' ' ' TYR . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.812 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.513 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.812 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.785 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.627 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.627 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.418 ' HA ' ' OG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.785 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.72 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.615 ' HB3' HG21 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 189' ' ' PRO . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.621 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.54 HE21 HD11 ' A' ' 192' ' ' ILE . 13.2 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.54 HD11 HE21 ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB3' HG21 ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.609 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.43 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.43 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.428 ' HD2' HD22 ' A' ' 65' ' ' ASN . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.43 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.585 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.5 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.741 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.806 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.5 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.484 ' SG ' HD22 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.594 ' HE ' HG23 ' A' ' 123' ' ' ILE . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.525 HD12 ' HG2' ' A' ' 118' ' ' PRO . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.444 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.669 ' O ' HG21 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.806 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.51 HG23 ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.592 HD13 HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.612 ' HB2' HD12 ' A' ' 112' ' ' ILE . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 63' ' ' CYS . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.612 HD12 ' HB2' ' A' ' 107' ' ' SER . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.51 ' HB2' HG23 ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.669 HG21 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.514 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.525 ' HG2' HD12 ' A' ' 96' ' ' LEU . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.421 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.594 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.717 HD11 ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.601 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.556 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.428 HG22 ' H ' ' A' ' 131' ' ' ILE . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.83 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.83 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.45 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.525 HD12 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.717 ' HB3' HD11 ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.601 ' H ' ' HG3' ' A' ' 128' ' ' PRO . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 145' ' ' HIS . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.412 ' HB2' ' CD2' ' A' ' 144' ' ' PHE . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.599 ' HB3' HD21 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.531 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.409 HH11 HG13 ' A' ' 137' ' ' ILE . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.773 ' SG ' HD12 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.768 ' O ' HG22 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.604 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.636 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.773 HD12 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.621 ' N ' HD23 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.458 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.401 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.54 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.67 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.67 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.535 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.476 ' HB2' HD21 ' A' ' 166' ' ' LEU . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.524 ' NE2' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.602 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.524 HG13 ' NE2' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' HG22 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.543 ' HD3' HG21 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.455 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 72' ' ' GLY . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.626 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.626 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.539 ' H ' HG22 ' A' ' 76' ' ' VAL . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.593 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.592 ' CE1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.453 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.2 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.801 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.471 ' SG ' HD22 ' A' ' 96' ' ' LEU . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.562 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.407 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.491 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.559 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.592 ' HA ' ' CE1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.57 HG22 ' H ' ' A' ' 108' ' ' GLY . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.57 ' H ' HG22 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.539 ' HB2' HG12 ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.491 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.543 HG21 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.407 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.801 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.542 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . 0.631 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.447 HD13 ' HB3' ' A' ' 152' ' ' TYR . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.631 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.465 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.663 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.465 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.556 HD21 ' CG1' ' A' ' 150' ' ' VAL . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.542 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.556 ' CG1' HD21 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.663 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.495 ' HD3' HD12 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.575 ' SG ' HD12 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.495 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.536 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.548 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.449 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.449 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.449 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . 0.511 ' HB3' HD11 ' A' ' 183' ' ' ILE . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.53 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.532 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.532 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.573 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.573 ' O ' HD12 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.418 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.451 ' NE2' HG13 ' A' ' 192' ' ' ILE . 11.3 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.451 HG13 ' NE2' ' A' ' 190' ' ' GLN . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.544 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.718 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.718 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.748 ' HG3' HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.585 ' HB3' HG23 ' A' ' 117' ' ' THR . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 76' ' ' VAL . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.7 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.628 HG22 ' HD3' ' A' ' 66' ' ' PRO . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.608 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.7 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.748 HG21 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.537 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.655 ' SG ' HD13 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.731 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.655 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.413 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.601 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' HD11 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.749 ' SG ' HG22 ' A' ' 111' ' ' VAL . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.478 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.749 HG22 ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.544 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.648 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.648 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.585 HG23 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.495 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.731 ' HD2' ' HE ' ' A' ' 95' ' ' ARG . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.647 HD21 ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.447 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 131' ' ' ILE . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.476 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.647 ' HG2' HD21 ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.694 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 50.0 m80 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.597 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.473 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.586 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.473 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.476 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.519 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.539 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.577 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.531 ' N ' HD23 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.586 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.503 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.536 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.458 HG23 HG13 ' A' ' 183' ' ' ILE . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.458 HG13 HG23 ' A' ' 181' ' ' VAL . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.672 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.539 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.672 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.686 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.844 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.844 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.535 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.535 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.451 HG21 HG23 ' A' ' 80' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.579 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.579 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.686 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.817 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.526 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.548 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.788 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.533 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.584 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.483 ' SG ' HD13 ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.613 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.483 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.755 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.538 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.788 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.817 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.445 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.561 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.561 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.428 ' HB2' ' HA ' ' A' ' 116' ' ' GLU . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.474 HG21 ' H ' ' A' ' 99' ' ' SER . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 113' ' ' TRP . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.755 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.802 HD13 ' HA3' ' A' ' 182' ' ' GLY . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.689 HD12 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.881 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.819 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 15.1 m120 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.881 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.433 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.689 ' OE1' HD12 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.445 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.531 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.55 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.819 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.474 HD22 ' ND2' ' A' ' 133' ' ' ASN . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.543 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.543 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.435 HG23 ' CD1' ' A' ' 164' ' ' PHE . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.613 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.613 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.426 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.807 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.807 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.802 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.448 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.445 ' HB1' HD13 ' A' ' 131' ' ' ILE . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.642 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.579 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB2' ' CG2' ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.705 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.657 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.657 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.557 ' CG ' HG21 ' A' ' 76' ' ' VAL . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.506 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . 0.684 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.557 HG21 ' CG ' ' A' ' 66' ' ' PRO . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.609 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.819 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.628 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . 0.684 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 122' ' ' ARG . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.489 ' HG2' ' HA ' ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.583 HD12 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.643 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.847 ' HB2' HG21 ' A' ' 115' ' ' THR . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.772 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.693 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.819 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.464 HG12 HG22 ' A' ' 111' ' ' VAL . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.416 ' O ' HG23 ' A' ' 106' ' ' ILE . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.705 HG12 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.847 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.643 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 142' ' ' GLU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.463 ' HA ' HD13 ' A' ' 127' ' ' LEU . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.64 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.577 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.462 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.76 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.545 HD13 ' HD3' ' A' ' 153' ' ' ARG . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.76 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.64 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.579 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 10.6 m120 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.401 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.541 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.579 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.562 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.545 ' HD3' HD13 ' A' ' 137' ' ' ILE . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.633 ' SG ' HD12 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.435 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.586 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.459 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.465 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.532 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.634 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.416 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.496 HG21 ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.774 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.459 HD22 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.481 ' HB2' HD11 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.774 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.761 ' O ' HD12 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.496 ' HA ' HG21 ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.418 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.685 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.685 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.518 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.529 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.529 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.574 HG23 ' H ' ' A' ' 78' ' ' LYS . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.574 ' H ' HG23 ' A' ' 77' ' ' ILE . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.444 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.518 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.618 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.623 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.714 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.511 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.61 HH11 HD13 ' A' ' 97' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.555 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.822 HD11 ' HB3' ' A' ' 121' ' ' ASP . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.561 ' H ' HG21 ' A' ' 115' ' ' THR . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.455 ' HA ' ' HG3' ' A' ' 118' ' ' PRO . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.623 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.404 HG12 ' HB ' ' A' ' 111' ' ' VAL . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.56 ' OG ' HD11 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.404 ' HB ' HG12 ' A' ' 106' ' ' ILE . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.56 HD11 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.561 HG21 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.555 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.605 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.822 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.818 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.569 HG23 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.42 HD13 ' HG2' ' A' ' 142' ' ' GLU . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.624 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.645 HG23 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.645 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.706 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.856 HD12 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.706 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.561 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.818 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.424 HG22 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.528 ' HB ' HG21 ' A' ' 137' ' ' ILE . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.567 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.856 ' HE ' HD12 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.598 ' SG ' HD12 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.508 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.654 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.654 ' N ' HD23 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.45 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.509 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.736 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.736 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.412 ' HB3' ' CG1' ' A' ' 183' ' ' ILE . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 180' ' ' GLN . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.624 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.509 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.483 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.1 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.483 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.787 ' SG ' HG12 ' A' ' 111' ' ' VAL . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.641 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.641 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 66' ' ' PRO . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.416 HG22 ' HG3' ' A' ' 78' ' ' LYS . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.416 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.76 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.767 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.654 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.76 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.606 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.4 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.404 ' SG ' HD22 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.441 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.532 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.488 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.457 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.607 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.747 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.643 HD13 HG22 ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 112' ' ' ILE . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.787 HG12 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.44 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HG2' HD12 ' A' ' 96' ' ' LEU . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 1.015 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.606 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.571 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.786 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 13.6 m120 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.571 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.484 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.677 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . 0.578 ' HB3' HD21 ' A' ' 143' ' ' ASN . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.677 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.578 HD21 ' HB3' ' A' ' 140' ' ' ASN . 10.6 m120 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 1.015 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.593 ' H ' ' HD1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.492 ' CG2' HD12 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.489 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.786 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.64 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.529 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.529 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.401 ' HE3' ' HA ' ' A' ' 165' ' ' GLU . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.466 HG23 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.503 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.545 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.624 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.518 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.544 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.415 ' O ' HD11 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.407 ' O ' HG23 ' A' ' 167' ' ' VAL . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 165' ' ' GLU . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.788 ' HD3' HG23 ' A' ' 111' ' ' VAL . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.542 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.527 ' HB3' HG21 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.536 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 88' ' ' TYR . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.68 HG21 HG22 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.756 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.651 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.68 HG22 HG21 ' A' ' 76' ' ' VAL . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.536 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.588 ' SG ' HD13 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.636 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.588 HD13 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.746 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.687 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.659 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.651 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.401 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.773 HG23 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.406 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.765 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.788 HG23 ' HD3' ' A' ' 61' ' ' LYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.401 ' HB2' HG12 ' A' ' 105' ' ' ILE . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.498 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.746 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . 0.403 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.436 ' HB3' HD11 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.636 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.634 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.562 HD23 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.422 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.664 HG23 ' H ' ' A' ' 134' ' ' GLY . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.45 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.664 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.559 HD12 HG22 ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.562 ' HB3' HD23 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.634 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.624 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.559 HG22 HD12 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.52 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.597 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.597 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.561 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.561 ' N ' HD23 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.424 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.624 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.51 HG22 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.469 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . 0.434 ' HB3' ' O ' ' A' ' 185' ' ' SER . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.449 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.449 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.434 ' O ' ' HB3' ' A' ' 178' ' ' ASP . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.449 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.454 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.454 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.54 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.66 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.578 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.59 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.636 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.595 HG22 ' HG2' ' A' ' 78' ' ' LYS . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.595 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.572 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.66 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.572 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.605 HE22 ' CB ' ' A' ' 103' ' ' THR . 91.9 mm-40 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.759 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 100' ' ' SER . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.487 ' SG ' HD13 ' A' ' 96' ' ' LEU . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.521 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.701 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.487 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.684 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.611 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.45 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.759 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.605 ' CB ' HE22 ' A' ' 85' ' ' GLN . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.585 ' CD1' HG22 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.585 HG22 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.532 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.59 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.701 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.505 ' HB3' HD11 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.464 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.789 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.436 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.538 ' HG ' ' HB2' ' A' ' 142' ' ' GLU . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.512 ' HD2' HD23 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.443 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.742 HG21 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.621 ' HB3' ' ND2' ' A' ' 155' ' ' ASN . 67.6 m-80 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.742 ' N ' HG21 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.809 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . 0.575 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.817 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.817 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.7 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.505 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.789 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.844 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.7 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 172' ' ' ILE . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 171' ' ' SER . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.504 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.809 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.558 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.621 ' ND2' ' HB3' ' A' ' 133' ' ' ASN . 18.1 p30 -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.509 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.653 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.661 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.661 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.844 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.812 HG21 ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.64 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.521 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.428 ' HB3' ' H ' ' A' ' 180' ' ' GLN . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.56 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.56 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.64 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 143' ' ' ASN . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . 0.812 ' HA ' HG21 ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.443 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.471 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.689 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.689 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.408 ' HB3' ' OE1' ' A' ' 81' ' ' GLN . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.624 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.635 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.635 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.76 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.442 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.667 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.408 ' OE1' ' HB3' ' A' ' 62' ' ' SER . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.442 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.675 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.76 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.522 ' H ' HG22 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' HG23 ' A' ' 123' ' ' ILE . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.411 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.429 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.432 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.645 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.726 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . 0.571 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.487 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.78 HG22 HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.583 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.624 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.524 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.524 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.506 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.432 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.538 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.411 ' HB3' HD11 ' A' ' 97' ' ' ILE . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.596 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.733 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.558 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.647 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.469 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.469 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.558 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.635 HD12 HG22 ' A' ' 151' ' ' THR . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.558 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.459 ' HA ' HD22 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.558 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . 0.407 ' HB2' ' OG ' ' A' ' 148' ' ' SER . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.403 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.733 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.407 ' OG ' ' HB2' ' A' ' 144' ' ' PHE . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.635 HG22 HD12 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.647 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.551 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.525 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.514 ' HB2' ' HB3' ' A' ' 191' ' ' CYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 1.004 HD21 ' HB3' ' A' ' 170' ' ' PRO . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 1.004 ' HB3' HD21 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.68 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.68 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.518 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.578 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.439 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.693 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.693 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.705 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.578 ' SG ' HG22 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HB3' HD12 ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.772 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.772 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 79' ' ' GLY . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.478 HG22 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.478 ' HG2' HG22 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.665 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.705 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.567 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.665 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.67 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.733 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.766 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . 0.498 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.637 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.637 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.783 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.653 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.403 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.733 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.567 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.463 ' O ' HG22 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.578 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.783 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.766 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.659 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.67 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.525 ' H ' HG22 ' A' ' 123' ' ' ILE . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.475 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.528 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.408 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.423 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.663 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.812 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . 0.496 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.494 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.571 HD22 ' HH2' ' A' ' 184' ' ' TRP . 61.3 t30 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.659 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.67 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.419 ' CB ' HD21 ' A' ' 143' ' ' ASN . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.663 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.812 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.534 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.49 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.49 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.606 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.46 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.46 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.607 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.494 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.607 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.607 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.642 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.642 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.571 ' HH2' HD22 ' A' ' 143' ' ' ASN . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.607 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.589 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.606 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.589 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.567 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.55 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.568 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.516 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.499 HG22 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.499 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.608 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.55 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.608 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.44 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.468 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.652 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.402 ' HB3' HD11 ' A' ' 96' ' ' LEU . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.506 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.571 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.603 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.512 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.402 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.561 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.652 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.683 ' SG ' HG22 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.464 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.553 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.683 HG22 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.428 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.492 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.464 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.568 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.603 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.795 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.437 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.571 HD22 ' HB2' ' A' ' 191' ' ' CYS . 94.2 m-20 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.795 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.678 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.478 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.466 ' SG ' HD12 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.742 ' O ' HG22 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.881 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.587 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.881 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.639 ' CD2' HG23 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.727 HG12 HD12 ' A' ' 192' ' ' ILE . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.426 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . 0.478 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.59 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.61 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.668 ' CB ' ' H ' ' A' ' 183' ' ' ILE . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . 0.615 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . 0.726 ' O ' HD13 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.615 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.668 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.432 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . 0.765 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.568 ' HB3' HG21 ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.559 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.571 ' HB2' HD22 ' A' ' 133' ' ' ASN . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.727 HD12 HG12 ' A' ' 167' ' ' VAL . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.784 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.532 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.805 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.551 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.451 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.531 HG23 ' HA3' ' A' ' 79' ' ' GLY . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.676 HG23 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.676 ' H ' HG23 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.599 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.498 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.515 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.599 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.456 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.428 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.705 ' HE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.421 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.721 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.498 ' SG ' HG12 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 1.02 HG12 HG22 ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 1.02 HG22 HG12 ' A' ' 106' ' ' ILE . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . 0.734 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.578 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.734 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . 0.403 HG23 ' HD2' ' A' ' 118' ' ' PRO . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.705 HG23 ' HE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.504 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.731 HG21 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.731 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.424 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.448 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 10.9 m120 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.643 HD21 ' HB2' ' A' ' 148' ' ' SER . 14.2 t-20 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.497 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.643 ' HB2' HD21 ' A' ' 143' ' ' ASN . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.448 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.569 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . 0.5 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 167' ' ' VAL . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.51 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.4 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.807 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . 0.411 ' OD2' HG23 ' A' ' 183' ' ' ILE . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.807 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.411 HG23 ' OD2' ' A' ' 179' ' ' ASP . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.504 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.445 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.445 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HD3' HG23 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.599 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.584 ' HB3' HD13 ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.454 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.532 HG22 HG23 ' A' ' 80' ' ' ILE . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.502 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.568 HG22 ' HD3' ' A' ' 66' ' ' PRO . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.599 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.502 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.605 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.454 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . 0.691 ' HG3' HD21 ' A' ' 177' ' ' ASN . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . 0.613 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.562 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . 0.461 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.424 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.729 HG12 HG22 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.492 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.493 HG23 HG23 ' A' ' 112' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 HG12 ' A' ' 106' ' ' ILE . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.493 HG23 HG23 ' A' ' 110' ' ' THR . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.424 ' HB2' HG12 ' A' ' 105' ' ' ILE . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.562 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . 0.613 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.654 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . 0.501 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . 0.652 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.772 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . 0.613 HG21 ' HB2' ' A' ' 191' ' ' CYS . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . 0.565 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.772 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . 0.7 ' O ' HG21 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.651 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.501 ' HG2' HD21 ' A' ' 127' ' ' LEU . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.524 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.654 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.651 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.8 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.697 ' CA ' HG13 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . 0.897 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.897 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.697 HG13 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.619 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.8 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.599 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . 0.41 ' O ' ' HD3' ' A' ' 170' ' ' PRO . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' O ' ' A' ' 168' ' ' GLY . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . 0.691 ' CE2' HG22 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.691 HG22 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.788 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . 0.691 HD21 ' HG3' ' A' ' 92' ' ' LYS . 89.6 m-20 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.788 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . 0.555 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.525 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.558 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.619 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LYS . . . . . 0.599 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ARG . . . . . 0.688 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.688 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' ASP . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . 0.72 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.718 HG21 HG22 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.439 HG22 ' HG2' ' A' ' 78' ' ' LYS . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' LYS . . . . . 0.439 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.46 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.557 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' PHE . . . . . 0.521 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' SER . . . . . 0.46 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' GLN . . . . . 0.45 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . 0.718 HG22 HG21 ' A' ' 76' ' ' VAL . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' TYR . . . . . 0.72 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' THR . . . . . 0.841 HG23 ' HD2' ' A' ' 94' ' ' TYR . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' TYR . . . . . 0.841 ' HD2' HG23 ' A' ' 91' ' ' THR . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' ARG . . . . . 0.427 ' CZ ' HG23 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 121' ' ' ASP . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' GLY . . . . . 0.412 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' SER . . . . . 0.56 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' ILE . . . . . 0.412 HG12 ' HB2' ' A' ' 114' ' ' ASP . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ILE . . . . . 0.729 ' CD1' HG22 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' THR . . . . . 0.44 HG22 HG23 ' A' ' 112' ' ' ILE . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 110' ' ' THR . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 114' ' ' ASP . . . . . 0.412 ' HB2' HG12 ' A' ' 105' ' ' ILE . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 115' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 116' ' ' GLU . . . . . 0.435 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ASP . . . . . 0.528 ' HB3' HD11 ' A' ' 97' ' ' ILE . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.978 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' ILE . . . . . 0.569 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' PRO . . . . . 0.679 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.799 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' GLY . . . . . 0.799 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' ASN . . . . . 0.414 ' HA ' HD22 ' A' ' 140' ' ' ASN . 9.6 m120 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ARG . . . . . 0.45 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' ASN . . . . . 0.743 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 6.5 t30 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' HIS . . . . . 0.978 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' SER . . . . . 0.743 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' THR . . . . . 0.616 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' ARG . . . . . 0.502 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 154' ' ' CYS . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' VAL . . . . . 0.511 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' PHE . . . . . 0.511 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' LEU . . . . . 0.589 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' VAL . . . . . 0.589 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' PRO . . . . . 0.638 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' THR . . . . . 0.513 HG23 ' O ' ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' SER . . . . . 0.69 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 182' ' ' GLY . . . . . 0.69 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 189' ' ' PRO . . . . . 0.638 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 190' ' ' GLN . . . . . 0.548 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 192' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 167' ' ' VAL . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.638 ' HD3' HG23 ' A' ' 111' ' ' VAL . 88.2 tttt . . . . . 0 CA--C 1.549 0.908 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.515 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.1 m -80.29 155.6 27.2 Favored 'General case' 0 C--N 1.311 -1.082 0 N-CA-C 112.565 0.58 . . . . 0.0 112.565 -178.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.771 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -77.1 -179.76 5.78 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 121.714 0.768 . . . . 0.0 112.589 179.757 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.681 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 50.8 ttp85 -66.49 -18.17 65.21 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 114.32 -1.309 . . . . 0.0 113.967 -175.294 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.681 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 3.1 m120 93.22 144.03 0.04 OUTLIER Pre-proline 0 N--CA 1.482 1.169 0 O-C-N 124.721 1.263 . . . . 0.0 108.691 -173.887 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.44 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 47.7 Cg_endo -72.76 139.71 31.08 Favored 'Trans proline' 0 CA--C 1.552 1.395 0 C-N-CA 122.438 2.092 . . . . 0.0 114.665 -177.119 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.44 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 17.1 Cg_exo -62.6 149.03 92.46 Favored 'Trans proline' 0 C--N 1.354 0.852 0 C-N-CA 124.065 3.177 . . . . 0.0 111.324 173.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.409 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 15.3 p-10 -98.93 109.22 53.01 Favored Pre-proline 0 CA--C 1.563 1.453 0 N-CA-C 114.774 1.398 . . . . 0.0 114.774 -173.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.511 ' HG3' ' CE1' ' A' ' 88' ' ' TYR . 16.6 Cg_exo -61.13 146.23 97.84 Favored 'Trans proline' 0 C--N 1.357 1.001 0 C-N-CA 123.827 3.018 . . . . 0.0 112.688 172.133 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 84.2 t -75.59 134.38 29.32 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.081 0 CA-C-O 121.349 0.595 . . . . 0.0 111.066 175.223 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.74 34.47 19.9 Favored 'General case' 0 N--CA 1.477 0.89 0 CA-C-O 122.313 1.054 . . . . 0.0 110.788 -173.202 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -136.64 154.74 22.25 Favored Glycine 0 N--CA 1.44 -1.05 0 CA-C-N 114.021 -1.445 . . . . 0.0 109.607 177.048 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 78.2 mtm -89.84 -90.41 0.14 Allowed 'General case' 0 CA--C 1.545 0.785 0 CA-C-N 117.657 0.728 . . . . 0.0 111.221 -177.607 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 14.5 p -139.72 141.65 34.17 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.529 0 C-N-CA 123.461 0.704 . . . . 0.0 109.546 -177.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.549 ' HB3' ' HB ' ' A' ' 86' ' ' ILE . 90.0 m-70 -66.16 -40.82 90.83 Favored 'General case' 0 N--CA 1.475 0.823 0 N-CA-C 113.116 0.784 . . . . 0.0 113.116 -178.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.456 ' HB ' HG22 ' A' ' 86' ' ' ILE . 5.5 p -133.54 138.07 51.67 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.029 0 CA-C-O 120.387 0.137 . . . . 0.0 111.352 -175.379 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.639 HG22 ' HG3' ' A' ' 78' ' ' LYS . 96.4 mt -64.35 -44.45 97.2 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.061 0 CA-C-O 121.97 0.89 . . . . 0.0 108.803 178.498 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.639 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.2 mttt -162.18 120.0 2.17 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.051 -1.833 . . . . 0.0 106.051 -177.099 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.585 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . 148.2 59.97 0.01 OUTLIER Glycine 0 C--N 1.278 -2.648 0 C-N-CA 117.045 -2.503 . . . . 0.0 112.568 179.71 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.771 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.4 pt -102.1 -3.12 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.239 0 C-N-CA 120.622 -0.431 . . . . 0.0 110.664 178.778 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.647 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 98.6 mt-30 -81.51 -174.54 5.02 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 -173.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.766 ' HZ ' HD11 ' A' ' 106' ' ' ILE . 58.4 m-85 -59.21 -44.49 92.27 Favored 'General case' 0 N--CA 1.51 2.571 0 CA-C-O 121.331 0.586 . . . . 0.0 112.25 -176.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -89.56 16.08 57.22 Favored Glycine 0 C--N 1.291 -1.931 0 CA-C-N 115.385 -0.825 . . . . 0.0 112.95 -173.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.585 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 44.7 m -126.62 154.63 43.72 Favored 'General case' 0 C--N 1.298 -1.667 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -175.281 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 84.2 mt-30 -128.72 148.81 50.87 Favored 'General case' 0 N--CA 1.441 -0.918 0 CA-C-O 120.91 0.386 . . . . 0.0 111.34 -172.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.674 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -108.6 127.94 64.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.827 175.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.403 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.7 mmtt -100.01 144.38 29.13 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 -176.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.511 ' CE1' ' HG3' ' A' ' 69' ' ' PRO . 2.4 t80 -136.26 109.24 7.65 Favored 'General case' 0 C--O 1.243 0.717 0 N-CA-C 113.965 1.098 . . . . 0.0 113.965 179.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 20.6 p -84.38 163.88 19.26 Favored 'General case' 0 C--N 1.321 -0.658 0 C-N-CA 123.982 0.913 . . . . 0.0 110.377 169.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.623 ' SG ' HD13 ' A' ' 96' ' ' LEU . 80.9 m -129.39 160.89 31.69 Favored 'General case' 0 N--CA 1.479 0.98 0 N-CA-C 112.793 0.664 . . . . 0.0 112.793 176.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 m -63.13 141.41 58.78 Favored 'General case' 0 N--CA 1.445 -0.723 0 N-CA-C 108.496 -0.927 . . . . 0.0 108.496 172.259 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -59.18 132.73 54.88 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.543 0.687 . . . . 0.0 111.529 -173.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 99.65 -5.98 58.71 Favored Glycine 0 C--N 1.34 0.776 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.499 -174.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -116.95 145.77 43.42 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 123.464 0.705 . . . . 0.0 109.765 176.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.413 HH11 ' HD2' ' A' ' 95' ' ' ARG . 7.3 ptp180 -125.29 176.94 6.42 Favored 'General case' 0 C--N 1.314 -0.968 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 174.405 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.623 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.2 mm? -95.32 125.07 39.7 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-O 121.762 0.792 . . . . 0.0 108.99 176.493 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 31.3 mm -64.31 -43.51 97.17 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.509 0 CA-C-N 113.93 -1.486 . . . . 0.0 112.73 -179.979 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -102.62 -96.98 2.36 Favored Glycine 0 C--N 1.308 -0.999 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.617 -172.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.619 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 9.1 t -139.04 124.51 19.35 Favored 'General case' 0 N--CA 1.433 -1.296 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.007 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.1 p -63.9 -20.14 65.62 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 122.708 0.403 . . . . 0.0 111.947 -172.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.674 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 4.6 m -127.37 150.03 49.79 Favored 'General case' 0 N--CA 1.418 -2.034 0 N-CA-C 106.88 -1.526 . . . . 0.0 106.88 174.061 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.491 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -129.48 148.51 51.39 Favored 'General case' 0 CA--C 1.463 -2.373 0 CA-C-O 120.832 0.348 . . . . 0.0 110.105 -179.202 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 55.9 m -114.57 128.62 56.42 Favored 'General case' 0 N--CA 1.406 -2.634 0 N-CA-C 106.463 -1.68 . . . . 0.0 106.463 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.647 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 43.0 t -71.24 129.86 39.97 Favored 'General case' 0 C--N 1.273 -2.759 0 CA-C-O 120.999 0.428 . . . . 0.0 112.103 179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -139.58 179.78 2.67 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.56 0 C-N-CA 123.468 0.707 . . . . 0.0 112.295 -177.265 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.766 HD11 ' HZ ' ' A' ' 82' ' ' PHE . 97.1 mt -113.35 125.61 70.64 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.247 0 CA-C-O 121.758 0.79 . . . . 0.0 110.973 170.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.693 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.4 p -64.62 -33.4 75.85 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.622 174.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.469 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 164.06 -70.28 0.2 Allowed Glycine 0 N--CA 1.424 -2.127 0 CA-C-N 113.913 -1.494 . . . . 0.0 109.634 -179.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 28.1 p-10 -71.98 -39.09 69.53 Favored 'General case' 0 CA--C 1.563 1.48 0 N-CA-C 113.616 0.969 . . . . 0.0 113.616 178.028 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.3 t -147.6 171.78 15.06 Favored 'General case' 0 C--O 1.241 0.62 0 C-N-CA 119.469 -0.892 . . . . 0.0 111.713 -171.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.638 HG23 ' HD3' ' A' ' 61' ' ' LYS . 87.1 t -93.08 119.38 40.7 Favored 'Isoleucine or valine' 0 C--O 1.238 0.465 0 CA-C-O 122.234 1.016 . . . . 0.0 111.961 -176.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.693 HD11 ' HB3' ' A' ' 107' ' ' SER . 45.1 pt -134.74 166.5 28.31 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 C-N-CA 125.596 1.558 . . . . 0.0 110.389 -179.761 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.407 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 96.9 m95 -81.4 141.21 34.17 Favored 'General case' 0 C--N 1.297 -1.682 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 -176.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -62.85 -39.0 93.06 Favored 'General case' 0 N--CA 1.499 1.988 0 CA-C-O 121.182 0.515 . . . . 0.0 112.197 179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.436 HG21 ' H ' ' A' ' 99' ' ' SER . 25.5 m -97.58 -20.89 17.39 Favored 'General case' 0 C--N 1.316 -0.886 0 CA-C-N 115.589 -0.732 . . . . 0.0 112.017 -174.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 61.4 16.75 7.74 Favored 'General case' 0 N--CA 1.486 1.368 0 C-N-CA 123.396 0.678 . . . . 0.0 111.074 -172.245 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.403 ' HA ' ' HD3' ' A' ' 118' ' ' PRO . 13.0 m 72.5 126.42 0.03 OUTLIER Pre-proline 0 C--O 1.215 -0.749 0 CA-C-N 114.591 -1.186 . . . . 0.0 114.027 179.939 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.619 ' HG3' ' O ' ' A' ' 99' ' ' SER . 2.8 Cg_exo -67.91 153.37 75.59 Favored 'Trans proline' 0 N--CA 1.442 -1.54 0 C-N-CA 123.662 2.908 . . . . 0.0 110.823 177.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.5 mm -107.2 129.23 61.31 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.447 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 175.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.455 ' SG ' ' CZ ' ' A' ' 88' ' ' TYR . 98.9 m -72.22 111.35 7.35 Favored 'General case' 0 CA--C 1.511 -0.523 0 N-CA-C 107.935 -1.135 . . . . 0.0 107.935 179.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.7 t0 -116.44 159.99 21.22 Favored 'General case' 0 C--N 1.292 -1.921 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.9 mtt180 -62.38 136.53 57.96 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . . . . . . . . . 82.8 mt -54.32 107.77 0.95 Allowed Pre-proline 0 N--CA 1.442 -0.841 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.675 -175.888 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -56.38 -33.97 93.12 Favored 'Trans proline' 0 C--O 1.2 -1.404 0 C-N-CA 122.374 2.05 . . . . 0.0 112.84 178.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.664 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 0.1 OUTLIER 50.96 35.81 13.52 Favored 'General case' 0 C--N 1.366 1.305 0 CA-C-O 121.868 0.842 . . . . 0.0 109.413 179.231 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -65.1 146.57 50.32 Favored Glycine 0 CA--C 1.49 -1.515 0 CA-C-N 114.211 -1.359 . . . . 0.0 113.227 -171.326 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? 38.1 96.14 0.04 OUTLIER Pre-proline 0 C--O 1.241 0.618 0 C-N-CA 124.753 1.221 . . . . 0.0 112.588 -173.543 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.564 ' HG2' ' CZ ' ' A' ' 136' ' ' PHE . 61.5 Cg_exo -50.18 156.32 3.86 Favored 'Trans proline' 0 C--N 1.359 1.113 0 C-N-CA 121.519 1.479 . . . . 0.0 111.31 -178.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.733 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.0 Cg_exo -61.9 147.19 95.73 Favored 'Trans proline' 0 N--CA 1.439 -1.724 0 C-N-CA 121.442 1.428 . . . . 0.0 110.791 -176.421 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 15.8 p -76.55 165.21 25.11 Favored 'General case' 0 N--CA 1.417 -2.085 0 CA-C-O 122.058 0.933 . . . . 0.0 110.761 -176.829 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.553 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.1 tp -125.95 156.25 35.89 Favored 'Isoleucine or valine' 0 N--CA 1.416 -2.154 0 CA-C-N 114.352 -1.295 . . . . 0.0 109.697 -173.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 78.7 m -62.02 -47.78 83.23 Favored 'General case' 0 C--N 1.291 -1.939 0 CA-C-N 114.768 -1.106 . . . . 0.0 112.623 178.247 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.7 HD22 ' HA ' ' A' ' 154' ' ' CYS . 93.5 m-20 -77.27 -49.69 14.51 Favored 'General case' 0 N--CA 1.484 1.25 0 N-CA-C 118.057 2.614 . . . . 0.0 118.057 -177.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.553 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 159.7 100.85 0.17 Allowed Glycine 0 C--N 1.313 -0.695 0 C-N-CA 121.528 -0.368 . . . . 0.0 112.586 -177.694 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.443 ' O ' HG21 ' A' ' 131' ' ' ILE . 90.9 m-20 40.91 -144.44 0.04 OUTLIER 'General case' 0 CA--C 1.552 1.056 0 C-N-CA 125.334 1.454 . . . . 0.0 114.334 -178.476 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.564 ' CZ ' ' HG2' ' A' ' 128' ' ' PRO . 34.7 p90 -150.69 169.88 20.54 Favored 'General case' 0 CA--C 1.497 -1.078 0 C-N-CA 124.022 0.929 . . . . 0.0 111.471 -170.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.7 mm -103.11 119.3 51.36 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.864 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.472 178.224 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.0 t -159.45 156.25 27.99 Favored 'General case' 0 N--CA 1.406 -2.629 0 CA-C-N 114.241 -1.345 . . . . 0.0 108.71 173.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 38.8 p -65.45 -32.24 73.76 Favored 'General case' 0 N--CA 1.429 -1.495 0 CA-C-O 120.456 0.169 . . . . 0.0 110.691 177.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -112.31 125.32 54.05 Favored 'General case' 0 N--CA 1.463 0.197 0 N-CA-C 108.179 -1.045 . . . . 0.0 108.179 176.599 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.535 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 69.1 ttt180 -65.03 -42.96 93.87 Favored 'General case' 0 C--O 1.212 -0.92 0 C-N-CA 119.827 -0.749 . . . . 0.0 111.782 179.789 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 57.9 mp0 -106.62 142.36 36.4 Favored 'General case' 0 C--O 1.242 0.711 0 CA-C-O 121.868 0.842 . . . . 0.0 110.154 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.664 ' OD1' ' HB3' ' A' ' 125' ' ' CYS . 3.9 t-20 -86.31 149.08 25.3 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 115.738 1.755 . . . . 0.0 115.738 -170.497 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 18.9 m-30 -101.28 -156.59 0.56 Allowed 'General case' 0 C--O 1.197 -1.665 0 CA-C-N 113.785 -1.552 . . . . 0.0 107.969 171.04 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 92.2 m-70 -70.56 -179.39 2.1 Favored 'General case' 0 N--CA 1.484 1.274 0 N-CA-C 115.148 1.536 . . . . 0.0 115.148 -174.09 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 76.6 t80 -53.76 140.32 30.16 Favored 'General case' 0 CA--C 1.546 0.812 0 CA-C-N 111.78 -2.464 . . . . 0.0 112.442 -173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.42 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 105.88 -4.33 39.09 Favored Glycine 0 C--N 1.338 0.665 0 CA-C-N 114.811 -1.086 . . . . 0.0 112.243 -177.047 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.56 ' CB ' HD21 ' A' ' 143' ' ' ASN . 20.3 p -76.57 158.0 31.52 Favored 'General case' 0 C--O 1.245 0.829 0 CA-C-O 121.012 0.434 . . . . 0.0 111.046 178.114 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -141.6 140.82 30.7 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.928 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.066 179.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -131.86 160.62 42.3 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 107.644 -1.243 . . . . 0.0 107.644 177.302 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 59.6 m -122.55 128.96 51.42 Favored 'General case' 0 N--CA 1.438 -1.044 0 C-N-CA 119.267 -0.973 . . . . 0.0 110.297 -179.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.529 ' CE2' ' HB3' ' A' ' 136' ' ' PHE . 88.5 m-85 -104.63 134.23 48.13 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 178.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 43.8 ptt85 -137.09 145.57 44.07 Favored 'General case' 0 N--CA 1.413 -2.297 0 N-CA-C 108.093 -1.077 . . . . 0.0 108.093 178.806 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.7 ' HA ' HD22 ' A' ' 133' ' ' ASN . 74.7 m -88.31 140.86 29.05 Favored 'General case' 0 C--N 1.293 -1.85 0 N-CA-C 105.907 -1.886 . . . . 0.0 105.907 -178.37 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.602 HD21 ' HB3' ' A' ' 133' ' ' ASN . 0.1 OUTLIER -106.49 147.15 34.42 Favored Pre-proline 0 C--N 1.303 -1.446 0 N-CA-C 115.587 1.699 . . . . 0.0 115.587 -166.631 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_exo -63.42 146.03 92.89 Favored 'Trans proline' 0 N--CA 1.446 -1.312 0 C-N-CA 122.554 2.169 . . . . 0.0 109.382 169.109 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -90.53 -73.64 1.27 Allowed Glycine 0 N--CA 1.444 -0.82 0 C-N-CA 118.863 -1.637 . . . . 0.0 114.15 -179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.6 t -62.58 -42.78 99.77 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 111.827 0.306 . . . . 0.0 111.827 179.173 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 170.55 -97.02 0.12 Allowed Glycine 0 C--O 1.208 -1.482 0 N-CA-C 110.143 -1.183 . . . . 0.0 110.143 -177.362 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -64.73 -37.06 93.88 Favored Glycine 0 N--CA 1.471 0.984 0 C-N-CA 120.788 -0.72 . . . . 0.0 113.51 176.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.2 ttt180 -66.23 131.91 47.22 Favored 'General case' 0 N--CA 1.481 1.118 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 98.6 mttt -87.89 136.33 33.01 Favored 'General case' 0 CA--C 1.479 -1.763 0 CA-C-N 115.303 -0.862 . . . . 0.0 111.545 171.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.566 HG23 ' CD2' ' A' ' 164' ' ' PHE . 17.2 m -120.31 -7.62 10.62 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.238 0 CA-C-N 113.531 -1.668 . . . . 0.0 111.454 177.063 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.566 ' CD2' HG23 ' A' ' 163' ' ' VAL . 43.9 m-85 -131.75 152.26 51.06 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 113.434 0.902 . . . . 0.0 113.434 -172.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.534 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 78.8 mm-40 -117.01 165.09 13.76 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 124.765 1.29 . . . . 0.0 107.798 175.915 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 6.6 tt -131.17 154.94 47.85 Favored 'General case' 0 N--CA 1.481 1.085 0 CA-C-N 119.132 0.878 . . . . 0.0 108.82 -179.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.65 ' N ' HD23 ' A' ' 166' ' ' LEU . 74.0 t -61.53 -45.36 98.81 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.91 0 N-CA-C 111.936 0.347 . . . . 0.0 111.936 -172.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.415 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 141.18 -9.41 2.72 Favored Glycine 0 C--O 1.22 -0.73 0 C-N-CA 120.001 -1.095 . . . . 0.0 113.389 -179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -130.74 74.41 80.09 Favored Pre-proline 0 C--N 1.313 -1.01 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.103 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_endo -68.3 -21.33 41.6 Favored 'Trans proline' 0 C--N 1.362 1.239 0 C-N-CA 123.154 2.57 . . . . 0.0 116.691 -175.333 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 28.3 m -115.83 121.92 43.85 Favored 'General case' 0 C--N 1.312 -1.049 0 C-N-CA 119.471 -0.892 . . . . 0.0 110.51 -170.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.5 pt -123.2 154.13 28.77 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.495 0 C-N-CA 120.414 -0.514 . . . . 0.0 111.027 -173.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 50.7 p90 -141.93 158.2 44.06 Favored 'General case' 0 N--CA 1.425 -1.706 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.419 -177.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.607 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 88.4 m -75.87 113.89 13.87 Favored 'General case' 0 C--N 1.293 -1.883 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.976 -175.654 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.615 ' CG2' ' HA ' ' A' ' 185' ' ' SER . 9.4 t -132.27 -14.66 2.96 Favored 'General case' 0 CA--C 1.57 1.717 0 N-CA-C 113.547 0.944 . . . . 0.0 113.547 179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 92.9 p 43.82 40.46 3.16 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 116.482 2.03 . . . . 0.0 116.482 179.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 9.8 m120 -95.41 6.65 48.43 Favored 'General case' 0 N--CA 1.502 2.147 0 N-CA-C 113.189 0.811 . . . . 0.0 113.189 174.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . 0.431 ' OD2' ' HG2' ' A' ' 180' ' ' GLN . 38.9 t70 -81.37 167.01 19.93 Favored 'General case' 0 C--N 1.309 -1.172 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.482 175.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -67.78 -18.11 64.76 Favored 'General case' 0 CA--C 1.541 0.626 0 O-C-N 123.497 0.498 . . . . 0.0 110.94 -179.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.431 ' HG2' ' OD2' ' A' ' 178' ' ' ASP . 94.1 mm-40 -62.9 172.09 1.88 Allowed 'General case' 0 CA--C 1.559 1.316 0 CA-C-N 115.835 -0.621 . . . . 0.0 110.854 175.426 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 76.2 t -62.28 -44.62 99.35 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.101 0 CA-C-N 115.643 -0.708 . . . . 0.0 111.396 -176.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 177.07 109.94 0.26 Allowed Glycine 0 CA--C 1.476 -2.364 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 177.012 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.435 ' HB ' ' H ' ' A' ' 184' ' ' TRP . 1.4 pp -138.07 -165.56 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.315 -0.906 0 CA-C-O 121.608 0.718 . . . . 0.0 112.222 -176.065 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.607 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 81.3 m95 -69.02 -169.43 0.18 Allowed 'General case' 0 N--CA 1.435 -1.193 0 C-N-CA 125.634 1.574 . . . . 0.0 111.642 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.615 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.7 p -63.94 -23.13 67.22 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 121.592 0.71 . . . . 0.0 110.293 179.733 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.69 -176.21 45.53 Favored Glycine 0 CA--C 1.479 -2.209 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 174.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -71.17 153.87 62.14 Favored 'Trans proline' 0 N--CA 1.425 -2.535 0 C-N-CA 121.823 1.682 . . . . 0.0 108.834 174.966 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.733 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -47.24 133.01 9.55 Favored Pre-proline 0 CA--C 1.506 -0.725 0 O-C-N 123.536 0.522 . . . . 0.0 110.184 -179.548 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -66.46 155.24 71.07 Favored 'Trans proline' 0 CA--C 1.475 -2.46 0 C-N-CA 122.124 1.883 . . . . 0.0 109.553 176.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.638 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.2 pt20 -118.03 153.41 33.74 Favored 'General case' 0 C--N 1.256 -3.499 0 C-N-CA 119.021 -1.072 . . . . 0.0 110.142 -175.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.534 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 72.7 m -79.22 67.8 5.03 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.11 0.957 . . . . 0.0 111.111 -178.092 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.638 HG12 ' HG3' ' A' ' 190' ' ' GLN . 39.2 mm . . . . . 0 C--O 1.253 1.248 0 CA-C-N 114.048 -1.433 . . . . 0.0 111.354 176.499 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB2' HG21 ' A' ' 111' ' ' VAL . 99.1 mttt . . . . . 0 CA--C 1.505 -0.764 0 N-CA-C 109.961 -0.385 . . . . 0.0 109.961 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.456 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 27.2 p -80.58 164.64 22.76 Favored 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.896 -0.779 . . . . 0.0 108.896 173.454 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 80.2 m -83.97 173.38 11.22 Favored 'General case' 0 C--N 1.269 -2.901 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 177.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.871 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 93.0 mtt180 -63.24 -38.17 90.1 Favored 'General case' 0 CA--C 1.484 -1.588 0 CA-C-O 118.849 -0.596 . . . . 0.0 111.743 -174.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.871 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 125.06 142.02 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.969 0 O-C-N 125.913 2.008 . . . . 0.0 109.686 -172.676 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.475 ' HG3' HG21 ' A' ' 86' ' ' ILE . 77.9 Cg_exo -51.24 146.75 22.81 Favored 'Trans proline' 0 C--O 1.213 -0.77 0 C-N-CA 123.054 2.503 . . . . 0.0 111.432 172.986 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.635 ' HG2' HG21 ' A' ' 117' ' ' THR . 52.9 Cg_exo -54.2 -37.31 87.73 Favored 'Trans proline' 0 CA--C 1.529 0.256 0 C-N-CA 122.204 1.936 . . . . 0.0 111.403 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 74.1 m-20 51.31 58.46 16.44 Favored Pre-proline 0 C--N 1.319 -0.748 0 N-CA-C 114.558 1.318 . . . . 0.0 114.558 178.604 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.526 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 58.5 Cg_endo -71.58 -169.31 0.41 Allowed 'Trans proline' 0 CA--C 1.553 1.468 0 C-N-CA 121.674 1.583 . . . . 0.0 109.357 170.742 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 75.5 t -67.04 134.26 30.36 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.888 -0.508 . . . . 0.0 110.483 -178.335 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 60.6 36.16 19.83 Favored 'General case' 0 C--N 1.353 0.759 0 CA-C-O 121.627 0.727 . . . . 0.0 110.481 -174.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.483 ' O ' ' HB3' ' A' ' 73' ' ' MET . . . -62.95 -34.73 90.72 Favored Glycine 0 CA--C 1.524 0.622 0 CA-C-N 114.818 -1.083 . . . . 0.0 113.965 -178.963 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.483 ' HB3' ' O ' ' A' ' 72' ' ' GLY . 57.1 ttm 84.07 79.83 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.427 0 N-CA-C 108.484 -0.932 . . . . 0.0 108.484 -176.414 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 28.8 t -94.26 60.58 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.71 0.766 . . . . 0.0 110.54 -173.501 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 96.8 m-70 -101.59 -15.34 17.1 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.549 -0.751 . . . . 0.0 111.723 176.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.504 HG21 HG22 ' A' ' 86' ' ' ILE . 14.0 p -64.29 -42.43 95.4 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.004 0 N-CA-C 112.883 0.698 . . . . 0.0 112.883 -174.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 96.6 mt 15.6 -70.83 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.598 0 C-N-CA 126.517 1.927 . . . . 0.0 115.779 -171.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.6 mmtt -63.95 -41.47 97.58 Favored 'General case' 0 C--N 1.301 -1.508 0 CA-C-O 121.183 0.516 . . . . 0.0 111.862 -178.503 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.487 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -76.24 38.43 1.38 Allowed Glycine 0 C--N 1.338 0.677 0 CA-C-N 115.532 -0.758 . . . . 0.0 114.402 -175.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.8 pt -106.42 0.48 10.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.342 0 O-C-N 122.479 -0.424 . . . . 0.0 110.066 178.61 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.456 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 92.5 mm-40 -76.01 -173.67 2.41 Favored 'General case' 0 C--N 1.312 -1.032 0 CA-C-O 121.113 0.482 . . . . 0.0 110.384 -173.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -64.6 129.59 40.41 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.683 177.416 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 83.84 -5.23 79.92 Favored Glycine 0 C--N 1.337 0.615 0 CA-C-N 115.293 -0.867 . . . . 0.0 112.155 -179.811 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.487 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 64.2 m -82.67 151.47 26.25 Favored 'General case' 0 CA--C 1.543 0.705 0 N-CA-C 112.325 0.491 . . . . 0.0 112.325 178.927 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 85.2 mt-30 -106.53 154.02 21.48 Favored 'General case' 0 CA--C 1.51 -0.563 0 CA-C-O 121.354 0.597 . . . . 0.0 110.925 178.77 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.504 HG22 HG21 ' A' ' 76' ' ' VAL . 46.6 pt -122.64 147.76 26.68 Favored 'Isoleucine or valine' 0 CA--C 1.489 -1.388 0 CA-C-N 115.199 -0.909 . . . . 0.0 109.066 174.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -118.71 139.43 51.55 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -178.947 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.445 ' HE1' ' HA2' ' A' ' 72' ' ' GLY . 82.4 t80 -134.83 147.22 49.87 Favored 'General case' 0 C--N 1.298 -1.634 0 CA-C-O 120.665 0.269 . . . . 0.0 110.562 174.063 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 66.8 m -129.74 152.74 48.92 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.38 -0.373 . . . . 0.0 110.997 -175.15 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.453 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.7 m -113.06 163.75 14.32 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 -178.403 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 22.3 p -76.97 168.54 19.93 Favored 'General case' 0 CA--C 1.547 0.843 0 C-N-CA 123.191 0.596 . . . . 0.0 110.876 -178.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 13.4 tmtt? -61.05 129.11 39.74 Favored 'General case' 0 N--CA 1.472 0.649 0 CA-C-O 121.957 0.884 . . . . 0.0 111.376 -172.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 87.36 1.6 83.65 Favored Glycine 0 N--CA 1.441 -0.972 0 CA-C-N 113.903 -1.499 . . . . 0.0 111.787 -177.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.1 m-85 -120.61 141.61 50.17 Favored 'General case' 0 N--CA 1.468 0.444 0 O-C-N 122.765 -0.256 . . . . 0.0 111.391 -178.781 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.559 ' NE ' ' HD2' ' A' ' 124' ' ' PRO 0.25 36.7 ptt180 -125.63 -177.96 4.09 Favored 'General case' 0 CA--C 1.492 -1.276 0 CA-C-O 122.162 0.982 . . . . 0.0 110.485 176.529 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.662 HD12 ' HG2' ' A' ' 118' ' ' PRO . 1.1 mm? -96.31 125.81 41.08 Favored 'General case' 0 N--CA 1.405 -2.711 0 CA-C-N 113.407 -1.724 . . . . 0.0 107.547 174.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.4 HD13 ' HA ' ' A' ' 97' ' ' ILE . 32.5 mm -64.3 -43.69 97.2 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 N-CA-C 113.178 0.807 . . . . 0.0 113.178 178.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.78 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -99.43 -111.56 3.23 Favored Glycine 0 C--N 1.293 -1.829 0 CA-C-N 114.555 -1.202 . . . . 0.0 110.744 -173.964 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.754 ' HB3' HG21 ' A' ' 115' ' ' THR . 24.9 t -122.4 129.84 52.49 Favored 'General case' 0 N--CA 1.436 -1.144 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 176.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.447 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 0.9 OUTLIER -66.05 -16.19 63.7 Favored 'General case' 0 C--N 1.282 -2.356 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.611 179.331 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.416 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 26.4 p -135.22 155.49 50.57 Favored 'General case' 0 C--N 1.31 -1.136 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -139.57 151.63 46.21 Favored 'General case' 0 C--N 1.297 -1.69 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.505 -176.75 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.1 m -108.21 126.0 52.29 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 173.717 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.543 ' HB2' ' CE3' ' A' ' 113' ' ' TRP . 39.0 t -85.19 128.2 34.58 Favored 'General case' 0 C--N 1.265 -3.093 0 CA-C-N 115.215 -0.902 . . . . 0.0 113.27 -176.745 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.622 HG12 ' HB3' ' A' ' 114' ' ' ASP . 2.1 pp -130.95 167.05 26.96 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.8 -174.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.746 HG12 HG22 ' A' ' 111' ' ' VAL . 91.1 mt -99.91 112.49 32.55 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.347 0 C-N-CA 120.316 -0.554 . . . . 0.0 109.856 177.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.568 ' HB3' HD11 ' A' ' 112' ' ' ILE . 77.9 p -68.53 -38.8 81.17 Favored 'General case' 0 CA--C 1.516 -0.332 0 N-CA-C 114.048 1.129 . . . . 0.0 114.048 178.715 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -160.38 -98.47 0.14 Allowed Glycine 0 N--CA 1.425 -2.074 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 -176.638 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -97.09 9.7 41.37 Favored 'General case' 0 C--N 1.308 -1.234 0 CA-C-O 120.889 0.376 . . . . 0.0 111.169 177.987 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.46 HG23 HG23 ' A' ' 112' ' ' ILE . 2.5 t -147.06 165.61 29.39 Favored 'General case' 0 CA--C 1.506 -0.725 0 O-C-N 121.073 -1.017 . . . . 0.0 112.272 -177.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.746 HG22 HG12 ' A' ' 106' ' ' ILE . 47.7 t -105.33 122.68 58.93 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.355 0 CA-C-O 122.216 1.008 . . . . 0.0 109.352 179.37 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.568 HD11 ' HB3' ' A' ' 107' ' ' SER . 49.1 pt -132.75 166.0 30.66 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 CA-C-N 113.582 -1.644 . . . . 0.0 111.108 -178.602 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.543 ' CE3' ' HB2' ' A' ' 104' ' ' CYS . 49.4 m95 -88.06 125.88 34.8 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 107.43 -1.322 . . . . 0.0 107.43 178.121 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.622 ' HB3' HG12 ' A' ' 105' ' ' ILE . 55.0 p-10 -71.56 -35.67 70.68 Favored 'General case' 0 N--CA 1.49 1.531 0 N-CA-C 114.101 1.149 . . . . 0.0 114.101 -174.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.754 HG21 ' HB3' ' A' ' 99' ' ' SER . 13.0 m -61.94 -43.6 98.51 Favored 'General case' 0 C--N 1.31 -1.116 0 N-CA-C 114.368 1.248 . . . . 0.0 114.368 -167.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.542 ' HB2' ' O ' ' A' ' 115' ' ' THR . 98.3 mt-10 88.11 47.96 0.01 OUTLIER 'General case' 0 N--CA 1.483 1.213 0 O-C-N 124.056 0.848 . . . . 0.0 109.453 -175.305 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.635 HG21 ' HG2' ' A' ' 67' ' ' PRO . 24.8 m -6.63 123.19 0.01 OUTLIER Pre-proline 0 N--CA 1.504 2.227 0 O-C-N 125.479 1.737 . . . . 0.0 113.785 176.164 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.78 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 89.2 Cg_endo -72.46 159.58 48.83 Favored 'Trans proline' 0 CA--C 1.504 -0.993 1 C-N-CA 125.394 4.063 . . . . 0.0 115.096 -172.511 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.4 mt -106.69 130.07 59.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 CA-C-N 114.094 -1.412 . . . . 0.0 108.577 176.706 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.558 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 97.6 m -71.72 138.82 48.81 Favored 'General case' 0 N--CA 1.451 -0.378 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -176.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -148.26 167.07 26.1 Favored 'General case' 0 C--N 1.293 -1.848 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 85.6 mtp180 -62.81 126.47 27.44 Favored 'General case' 0 CA--C 1.506 -0.746 0 N-CA-C 106.379 -1.711 . . . . 0.0 106.379 179.823 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' HIS . 39.6 mt -48.53 104.06 0.4 Allowed Pre-proline 0 CA--C 1.475 -1.925 0 O-C-N 124.697 1.248 . . . . 0.0 112.954 -169.861 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.559 ' HD2' ' NE ' ' A' ' 95' ' ' ARG . 22.1 Cg_exo -63.09 142.18 86.26 Favored 'Trans proline' 0 N--CA 1.418 -2.932 0 N-CA-C 107.597 -1.732 . . . . 0.0 107.597 174.072 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 67.9 m -115.76 128.91 56.22 Favored 'General case' 0 C--N 1.257 -3.451 0 N-CA-C 106.121 -1.807 . . . . 0.0 106.121 176.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -63.09 148.44 50.26 Favored Glycine 0 N--CA 1.422 -2.279 0 C-N-CA 119.631 -1.271 . . . . 0.0 110.628 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.405 ' HG ' ' HB3' ' A' ' 142' ' ' GLU . 7.9 tt -43.08 129.4 3.32 Favored Pre-proline 0 N--CA 1.445 -0.714 0 O-C-N 124.488 0.758 . . . . 0.0 109.186 -179.124 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.03 130.4 30.68 Favored 'Trans proline' 0 CA--C 1.495 -1.428 0 C-N-CA 121.222 1.281 . . . . 0.0 109.592 -174.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.9 Cg_endo -60.75 140.88 93.07 Favored 'Trans proline' 0 N--CA 1.44 -1.619 0 C-N-CA 120.86 1.04 . . . . 0.0 112.039 -173.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.0 m -70.24 136.4 49.9 Favored 'General case' 0 N--CA 1.43 -1.469 0 CA-C-N 115.352 -0.84 . . . . 0.0 111.59 -177.066 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.588 HD13 ' HB3' ' A' ' 152' ' ' TYR . 10.9 tp -69.19 154.07 8.5 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.728 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.648 178.102 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 74.7 m -61.64 -45.19 95.13 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.447 -178.108 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 -98.08 7.89 45.62 Favored 'General case' 0 CA--C 1.538 0.501 0 N-CA-C 116.249 1.944 . . . . 0.0 116.249 -173.428 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.479 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 157.91 -98.98 0.18 Allowed Glycine 0 N--CA 1.464 0.524 0 C-N-CA 118.323 -1.894 . . . . 0.0 114.54 -178.44 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -148.25 -175.72 5.01 Favored 'General case' 0 CA--C 1.547 0.859 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 -175.327 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.509 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 36.9 p90 -111.53 162.89 14.64 Favored 'General case' 0 C--N 1.295 -1.785 0 C-N-CA 123.217 0.607 . . . . 0.0 111.333 -176.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 9.7 tt -64.79 -29.72 48.2 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.748 0 N-CA-C 112.975 0.732 . . . . 0.0 112.975 -171.006 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.407 ' HB3' ' CE1' ' A' ' 136' ' ' PHE . 34.0 t -64.73 141.68 58.69 Favored 'General case' 0 CA--C 1.556 1.204 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 177.456 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 98.8 m -62.35 -44.5 96.35 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 113.574 0.953 . . . . 0.0 113.574 -176.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 13.2 m120 -95.77 140.95 29.82 Favored 'General case' 0 C--N 1.323 -0.547 0 C-N-CA 120.634 -0.426 . . . . 0.0 110.304 -172.17 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.509 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.69 -43.86 98.06 Favored 'General case' 0 N--CA 1.475 0.798 0 N-CA-C 114.585 1.328 . . . . 0.0 114.585 -175.601 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.405 ' HB3' ' HG ' ' A' ' 127' ' ' LEU . 12.6 pt-20 -124.73 128.89 49.49 Favored 'General case' 0 C--N 1.278 -2.529 0 C-N-CA 119.57 -0.852 . . . . 0.0 111.481 177.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 -91.34 164.51 13.82 Favored 'General case' 0 CA--C 1.494 -1.179 0 CA-C-N 115.421 -0.809 . . . . 0.0 112.378 -179.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -92.27 117.38 29.83 Favored 'General case' 0 N--CA 1.433 -1.294 0 CA-C-O 121.626 0.726 . . . . 0.0 110.675 -169.79 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.479 ' HB2' ' O ' ' A' ' 123' ' ' ILE . 36.5 p-80 25.88 -143.71 0.0 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 126.536 1.934 . . . . 0.0 114.979 179.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.429 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 70.8 t80 -66.71 139.09 57.81 Favored 'General case' 0 C--N 1.324 -0.517 0 C-N-CA 124.343 1.057 . . . . 0.0 112.587 -177.036 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.06 10.44 36.85 Favored Glycine 0 C--N 1.344 1.011 0 C-N-CA 120.251 -0.976 . . . . 0.0 112.823 -177.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 24.9 p -106.66 146.28 30.94 Favored 'General case' 0 C--O 1.248 1.002 0 N-CA-C 112.196 0.443 . . . . 0.0 112.196 179.426 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -137.61 140.85 40.71 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.65 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 175.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.1 m -131.62 156.5 42.67 Favored 'Isoleucine or valine' 0 CA--C 1.497 -1.071 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 176.229 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 61.5 m -124.07 131.1 53.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -179.487 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.588 ' HB3' HD13 ' A' ' 131' ' ' ILE . 96.6 m-85 -105.18 140.05 38.92 Favored 'General case' 0 C--N 1.319 -0.719 0 CA-C-O 121.12 0.486 . . . . 0.0 110.603 -176.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 17.5 ptm180 -137.1 152.4 49.96 Favored 'General case' 0 N--CA 1.428 -1.537 0 C-N-CA 120.456 -0.498 . . . . 0.0 110.169 178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.677 ' HB2' ' CD1' ' A' ' 164' ' ' PHE . 75.0 m -92.03 146.54 23.65 Favored 'General case' 0 C--N 1.315 -0.92 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.496 -177.048 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.409 HD22 ' N ' ' A' ' 155' ' ' ASN . 0.9 OUTLIER -90.48 151.46 44.26 Favored Pre-proline 0 C--N 1.317 -0.814 0 N-CA-C 112.932 0.716 . . . . 0.0 112.932 -174.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.3 Cg_endo -72.31 159.62 49.06 Favored 'Trans proline' 0 N--CA 1.453 -0.896 0 C-N-CA 123.359 2.706 . . . . 0.0 109.624 171.622 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.7 -163.33 0.54 Allowed Glycine 0 CA--C 1.526 0.724 0 C-N-CA 120.628 -0.796 . . . . 0.0 111.986 179.119 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 22.1 m -58.98 -40.76 85.78 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.076 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -90.44 177.16 42.21 Favored Glycine 0 N--CA 1.441 -1.031 0 C-N-CA 120.753 -0.736 . . . . 0.0 111.841 175.457 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -75.72 50.06 2.5 Favored Glycine 0 CA--C 1.533 1.17 0 N-CA-C 113.71 0.244 . . . . 0.0 113.71 -179.333 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 77.1 ttt180 -125.64 136.76 53.6 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 113.322 0.86 . . . . 0.0 113.322 -177.394 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 63.1 tttm -68.53 120.47 14.63 Favored 'General case' 0 CA--C 1.508 -0.643 0 CA-C-O 121.506 0.669 . . . . 0.0 109.926 173.563 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 33.1 m -119.06 5.2 6.82 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.921 178.872 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.677 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 42.3 p90 -125.29 156.14 39.09 Favored 'General case' 0 CA--C 1.507 -0.702 0 N-CA-C 114.235 1.198 . . . . 0.0 114.235 -163.172 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.419 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.8 mt-10 -135.51 145.94 47.59 Favored 'General case' 0 N--CA 1.438 -1.064 0 CA-C-N 113.726 -1.579 . . . . 0.0 107.48 174.762 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.606 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -115.22 154.12 29.61 Favored 'General case' 0 C--N 1.304 -1.384 0 N-CA-C 109.877 -0.416 . . . . 0.0 109.877 -178.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 190' ' ' GLN . 27.7 m -61.92 -41.73 92.0 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.285 0 O-C-N 123.507 0.505 . . . . 0.0 111.506 -178.264 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 143.0 -21.01 2.31 Favored Glycine 0 C--N 1.349 1.283 0 C-N-CA 118.256 -1.926 . . . . 0.0 116.045 173.847 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.451 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 68.4 tt0 -123.54 68.79 41.76 Favored Pre-proline 0 C--O 1.207 -1.177 0 CA-C-N 118.109 0.955 . . . . 0.0 110.523 179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.479 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 41.9 Cg_endo -67.13 -19.67 50.78 Favored 'Trans proline' 0 CA--C 1.538 0.689 0 C-N-CA 122.644 2.23 . . . . 0.0 115.143 -173.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.6 m -100.95 122.68 43.91 Favored 'General case' 0 C--N 1.317 -0.846 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -175.865 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.3 pt -127.21 154.97 38.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.794 0 CA-C-O 120.454 0.169 . . . . 0.0 111.169 179.509 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.3 p90 -142.73 155.89 44.93 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-O 121.18 0.514 . . . . 0.0 111.337 178.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.6 t -82.5 88.62 6.62 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 178.607 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -70.51 -34.97 72.91 Favored 'General case' 0 N--CA 1.472 0.655 0 CA-C-N 114.496 -1.229 . . . . 0.0 110.816 -172.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.409 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 91.0 p 37.04 18.25 0.0 OUTLIER 'General case' 0 CA--C 1.557 1.245 0 C-N-CA 127.155 2.182 . . . . 0.0 115.733 -172.236 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 10.4 m120 -101.17 6.11 42.97 Favored 'General case' 0 N--CA 1.475 0.783 0 O-C-N 121.189 -0.944 . . . . 0.0 113.14 -178.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 -87.66 -173.65 4.42 Favored 'General case' 0 C--N 1.318 -0.763 0 C-N-CA 123.218 0.607 . . . . 0.0 112.34 -179.63 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 30.9 t70 -60.93 -39.45 89.45 Favored 'General case' 0 N--CA 1.471 0.603 0 CA-C-N 116.061 -0.518 . . . . 0.0 111.838 -175.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 64.4 tp60 -99.49 125.65 45.28 Favored 'General case' 0 N--CA 1.433 -1.291 0 N-CA-C 106.298 -1.742 . . . . 0.0 106.298 172.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.409 ' O ' ' HB2' ' A' ' 176' ' ' SER . 14.6 p -63.31 -43.39 98.6 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.711 0 N-CA-C 115.545 1.683 . . . . 0.0 115.545 -166.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -102.06 78.82 0.36 Allowed Glycine 0 N--CA 1.477 1.372 0 C-N-CA 118.356 -1.878 . . . . 0.0 114.207 -175.026 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.87 161.56 40.62 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.731 0 N-CA-C 114.749 1.389 . . . . 0.0 114.749 179.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 91.0 m95 -98.24 167.02 11.12 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 114.453 -1.248 . . . . 0.0 107.844 172.949 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.8 m -59.34 -41.69 89.78 Favored 'General case' 0 C--N 1.316 -0.872 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -169.43 157.6 29.48 Favored Glycine 0 N--CA 1.433 -1.506 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.893 177.272 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.91 145.87 96.7 Favored 'Trans proline' 0 C--N 1.344 0.327 0 C-N-CA 122.518 2.145 . . . . 0.0 109.789 175.735 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -35.02 110.25 0.4 Allowed Pre-proline 0 N--CA 1.476 0.867 0 O-C-N 123.915 0.76 . . . . 0.0 112.387 179.884 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.489 ' HB3' ' CG2' ' A' ' 167' ' ' VAL . 21.9 Cg_exo -62.45 147.52 94.75 Favored 'Trans proline' 0 CA--C 1.486 -1.888 0 C-N-CA 123.122 2.548 . . . . 0.0 109.418 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.653 ' O ' HG13 ' A' ' 167' ' ' VAL . 12.6 pt20 -127.01 158.6 36.49 Favored 'General case' 0 C--N 1.288 -2.07 0 C-N-CA 117.735 -1.586 . . . . 0.0 114.927 -165.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.419 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 61.5 m -80.36 69.74 6.88 Favored 'General case' 0 N--CA 1.431 -1.383 0 CA-C-N 114.157 -1.383 . . . . 0.0 110.229 -170.722 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.494 HG12 ' HG3' ' A' ' 190' ' ' GLN . 43.3 mm . . . . . 0 C--O 1.254 1.339 0 CA-C-N 114.497 -1.229 . . . . 0.0 111.566 176.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.556 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 99.3 mttt . . . . . 0 N--CA 1.441 -0.92 0 N-CA-C 112.92 0.711 . . . . 0.0 112.92 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 27.5 p -140.73 156.68 46.14 Favored 'General case' 0 CA--C 1.509 -0.626 0 N-CA-C 107.015 -1.476 . . . . 0.0 107.015 177.094 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.583 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -79.13 -179.64 6.82 Favored 'General case' 0 C--N 1.311 -1.069 0 CA-C-O 121.895 0.855 . . . . 0.0 112.923 -171.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.526 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 26.3 mmm180 -60.36 -32.38 71.22 Favored 'General case' 0 CA--C 1.491 -1.303 0 CA-C-N 114.487 -1.233 . . . . 0.0 111.185 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.56 ' CG ' ' HD2' ' A' ' 66' ' ' PRO . 25.4 t-20 100.64 147.17 0.02 OUTLIER Pre-proline 0 C--N 1.351 0.649 0 O-C-N 125.089 1.493 . . . . 0.0 109.156 -178.726 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.56 ' HD2' ' CG ' ' A' ' 65' ' ' ASN . 0.1 OUTLIER -17.89 155.97 0.0 OUTLIER 'Trans proline' 0 CA--C 1.565 2.035 1 C-N-CA 126.778 4.986 . . . . 0.0 119.322 -178.95 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.689 ' HD3' HD12 ' A' ' 86' ' ' ILE . 17.7 Cg_exo -62.81 147.17 94.99 Favored 'Trans proline' 0 C--N 1.354 0.867 0 C-N-CA 125.19 3.926 . . . . 0.0 115.96 -170.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.411 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 24.5 t70 -49.86 -37.93 29.91 Favored Pre-proline 0 CA--C 1.572 1.793 0 N-CA-C 116.182 1.919 . . . . 0.0 116.182 179.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.614 ' HD2' ' C ' ' A' ' 67' ' ' PRO . 70.4 Cg_endo -65.94 153.78 76.71 Favored 'Trans proline' 0 C--N 1.371 1.733 0 C-N-CA 122.863 2.375 . . . . 0.0 115.101 -175.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 14.6 p -61.29 -30.3 47.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 C-N-CA 125.504 1.522 . . . . 0.0 114.203 -169.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 43.2 t-20 -62.59 -40.3 96.48 Favored 'General case' 0 C--N 1.281 -2.394 0 O-C-N 123.547 0.529 . . . . 0.0 111.021 -175.296 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.541 ' N ' ' HE1' ' A' ' 88' ' ' TYR . . . -61.17 158.94 29.67 Favored Glycine 0 C--N 1.341 0.835 0 C-N-CA 121.143 -0.551 . . . . 0.0 112.986 -175.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.471 ' HG2' ' H ' ' A' ' 75' ' ' HIS . 49.9 ttp -123.6 143.03 50.47 Favored 'General case' 0 CA--C 1.544 0.727 0 CA-C-O 121.123 0.487 . . . . 0.0 112.08 -173.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 94.3 t -65.71 -26.1 38.06 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.173 0 CA-C-N 114.88 -1.054 . . . . 0.0 112.272 -177.262 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.471 ' H ' ' HG2' ' A' ' 73' ' ' MET . 49.0 t-80 -36.22 -33.56 0.04 OUTLIER 'General case' 0 N--CA 1.502 2.155 0 N-CA-C 116.252 1.945 . . . . 0.0 116.252 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.474 HG11 HG22 ' A' ' 86' ' ' ILE . 20.3 t -71.06 129.41 34.96 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.444 0 C-N-CA 117.131 -1.827 . . . . 0.0 108.622 -173.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.724 HG23 ' H ' ' A' ' 78' ' ' LYS . 17.9 tt -113.23 -70.64 0.83 Allowed 'Isoleucine or valine' 0 N--CA 1.472 0.639 0 N-CA-C 114.184 1.179 . . . . 0.0 114.184 -175.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.724 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.8 mmtt -96.38 -4.27 42.19 Favored 'General case' 0 CA--C 1.491 -1.319 0 CA-C-O 121.344 0.592 . . . . 0.0 111.674 176.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.457 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -75.53 1.68 56.42 Favored Glycine 0 N--CA 1.443 -0.857 0 CA-C-N 115.094 -0.957 . . . . 0.0 111.06 178.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.583 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -101.34 -4.21 9.3 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.611 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 -179.136 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.473 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 58.9 tt0 -88.02 176.98 7.07 Favored 'General case' 0 C--N 1.293 -1.875 0 N-CA-C 109.696 -0.483 . . . . 0.0 109.696 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.473 ' H ' ' HG2' ' A' ' 81' ' ' GLN . 76.2 t80 -59.19 131.37 50.82 Favored 'General case' 0 C--O 1.218 -0.564 0 CA-C-O 121.239 0.542 . . . . 0.0 110.871 -177.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.8 19.5 63.33 Favored Glycine 0 C--N 1.341 0.824 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.789 -178.245 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.457 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 71.2 m -128.59 155.11 45.46 Favored 'General case' 0 CA--C 1.556 1.182 0 N-CA-C 112.949 0.722 . . . . 0.0 112.949 -177.224 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.457 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -125.13 149.5 47.81 Favored 'General case' 0 C--N 1.376 1.721 0 C-N-CA 122.914 0.486 . . . . 0.0 111.403 -177.783 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.689 HD12 ' HD3' ' A' ' 67' ' ' PRO . 47.1 pt -102.62 -6.9 9.26 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.555 0 N-CA-C 116.86 2.17 . . . . 0.0 116.86 -175.057 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt 42.51 97.74 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.052 0 N-CA-C 114.677 1.362 . . . . 0.0 114.677 -175.294 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.541 ' HE1' ' N ' ' A' ' 72' ' ' GLY . 83.1 t80 -116.63 144.42 44.42 Favored 'General case' 0 C--N 1.35 0.628 0 O-C-N 121.739 -0.601 . . . . 0.0 111.706 178.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 73.8 m -128.4 153.77 46.73 Favored 'General case' 0 CA--C 1.538 0.513 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.813 -177.81 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.436 ' SG ' HD13 ' A' ' 96' ' ' LEU . 73.5 m -108.65 166.73 10.58 Favored 'General case' 0 N--CA 1.474 0.754 0 CA-C-N 116.439 -0.346 . . . . 0.0 111.601 -175.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 25.0 m -70.6 162.55 28.7 Favored 'General case' 0 CA--C 1.553 1.078 0 O-C-N 124.022 0.826 . . . . 0.0 108.903 178.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -62.99 132.31 51.59 Favored 'General case' 0 CA--C 1.548 0.873 0 CA-C-O 121.055 0.455 . . . . 0.0 110.602 -174.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.489 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 87.74 0.51 83.8 Favored Glycine 0 C--O 1.241 0.549 0 CA-C-N 115.952 -0.567 . . . . 0.0 112.593 -179.231 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -118.08 144.04 45.94 Favored 'General case' 0 C--N 1.312 -1.022 0 CA-C-O 121.234 0.54 . . . . 0.0 110.423 178.04 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.512 ' HB3' HG12 ' A' ' 123' ' ' ILE . 0.0 OUTLIER -134.65 161.6 34.68 Favored 'General case' 0 CA--C 1.482 -1.649 0 CA-C-O 121.606 0.717 . . . . 0.0 110.988 -177.276 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.516 HD12 ' HB2' ' A' ' 118' ' ' PRO . 3.7 mm? -79.22 133.55 36.68 Favored 'General case' 0 C--N 1.309 -1.156 0 CA-C-N 115.374 -0.83 . . . . 0.0 109.982 -177.425 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.748 HG12 ' O ' ' A' ' 119' ' ' ILE . 46.7 mm -67.17 -25.31 33.61 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.656 0.741 . . . . 0.0 110.746 176.652 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.829 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -130.59 -119.23 2.09 Favored Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 114.785 -1.098 . . . . 0.0 112.102 -172.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.7 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.0 t -113.43 125.66 54.49 Favored 'General case' 0 C--N 1.316 -0.891 0 N-CA-C 108.972 -0.751 . . . . 0.0 108.972 -178.72 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.42 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 78.1 p -62.67 -23.24 67.02 Favored 'General case' 0 C--N 1.312 -1.05 0 CA-C-O 121.506 0.669 . . . . 0.0 111.594 -179.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.8 p -112.31 139.01 48.21 Favored 'General case' 0 N--CA 1.415 -2.21 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 175.06 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.457 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -126.15 147.66 49.58 Favored 'General case' 0 CA--C 1.465 -2.327 0 N-CA-C 108.898 -0.779 . . . . 0.0 108.898 179.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.0 m -114.03 126.24 54.89 Favored 'General case' 0 N--CA 1.393 -3.304 0 CA-C-O 121.748 0.785 . . . . 0.0 109.415 -177.422 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.651 ' SG ' HG22 ' A' ' 111' ' ' VAL . 35.7 t -73.36 123.11 23.17 Favored 'General case' 0 C--N 1.289 -2.022 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.85 178.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.3 pt -129.12 161.98 37.42 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.658 0 CA-C-N 115.25 -0.887 . . . . 0.0 109.645 -179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.485 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 86.1 mt -105.56 122.28 58.79 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.317 0 CA-C-O 121.778 0.799 . . . . 0.0 111.527 -178.969 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -86.82 168.56 13.36 Favored 'General case' 0 C--O 1.247 0.957 0 N-CA-C 106.849 -1.537 . . . . 0.0 106.849 168.719 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.84 -42.06 99.7 Favored Glycine 0 N--CA 1.437 -1.245 0 C-N-CA 118.345 -1.883 . . . . 0.0 111.856 -178.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.0 t0 -63.57 -50.63 68.71 Favored 'General case' 0 CA--C 1.553 1.088 0 C-N-CA 119.98 -0.688 . . . . 0.0 111.857 179.435 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.4 t -159.29 -166.25 1.77 Allowed 'General case' 0 N--CA 1.472 0.675 0 O-C-N 121.963 -0.46 . . . . 0.0 110.865 -175.048 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.651 HG22 ' SG ' ' A' ' 104' ' ' CYS . 11.7 p -109.23 125.76 66.33 Favored 'Isoleucine or valine' 0 C--O 1.244 0.77 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.168 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 41.8 pt -131.03 163.5 36.78 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 114.109 -1.405 . . . . 0.0 112.594 -172.688 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.5 m95 -81.21 137.25 35.88 Favored 'General case' 0 N--CA 1.437 -1.104 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 178.4 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.3 p-10 -64.56 -37.15 86.57 Favored 'General case' 0 C--O 1.242 0.709 0 C-N-CA 120.688 -0.405 . . . . 0.0 112.053 -176.331 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.506 HG21 ' HB3' ' A' ' 99' ' ' SER . 50.4 p -96.48 -14.17 22.54 Favored 'General case' 0 C--N 1.31 -1.12 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 70.7 mt-10 59.01 19.12 6.89 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.599 -0.728 . . . . 0.0 110.44 -174.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.445 HG21 ' HB3' ' A' ' 67' ' ' PRO . 10.1 m 61.42 123.54 0.02 OUTLIER Pre-proline 0 CA--C 1.536 0.431 0 N-CA-C 114.796 1.406 . . . . 0.0 114.796 -179.265 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.829 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.6 Cg_exo -62.58 147.47 94.75 Favored 'Trans proline' 0 C--N 1.321 -0.917 0 C-N-CA 124.044 3.163 . . . . 0.0 112.06 175.095 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.748 ' O ' HG12 ' A' ' 97' ' ' ILE . 97.5 mt -86.3 131.76 33.83 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.94 0 N-CA-C 109.314 -0.625 . . . . 0.0 109.314 173.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 90.7 m -72.08 125.81 28.19 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 176.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.599 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.6 t0 -142.85 160.41 40.39 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 116.082 -0.508 . . . . 0.0 109.956 -177.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.0 ttp85 -64.05 133.98 54.1 Favored 'General case' 0 N--CA 1.479 1.006 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -172.808 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.513 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 10.9 mt -67.47 108.71 2.8 Favored Pre-proline 0 N--CA 1.472 0.656 0 N-CA-C 114.562 1.319 . . . . 0.0 114.562 -167.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -77.8 113.36 3.45 Favored 'Trans proline' 0 N--CA 1.429 -2.306 0 C-N-CA 121.096 1.198 . . . . 0.0 109.414 170.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.699 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 61.5 m -73.83 -31.75 63.36 Favored 'General case' 0 C--N 1.278 -2.539 0 CA-C-O 121.717 0.77 . . . . 0.0 112.268 174.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.94 -149.27 47.54 Favored Glycine 0 C--O 1.227 -0.333 0 CA-C-N 115.062 -0.972 . . . . 0.0 112.856 175.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.3 mm? -72.85 133.19 82.34 Favored Pre-proline 0 CA--C 1.498 -1.054 0 N-CA-C 109.115 -0.698 . . . . 0.0 109.115 174.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -71.57 173.08 13.06 Favored 'Trans proline' 0 N--CA 1.437 -1.812 0 C-N-CA 121.303 1.336 . . . . 0.0 109.217 176.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.514 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 21.9 Cg_exo -61.38 143.94 98.04 Favored 'Trans proline' 0 N--CA 1.436 -1.878 0 N-CA-C 108.941 -1.215 . . . . 0.0 108.941 177.385 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.2 p -78.88 165.84 23.07 Favored 'General case' 0 N--CA 1.417 -2.11 0 C-N-CA 119.905 -0.718 . . . . 0.0 109.216 177.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.567 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -109.77 143.74 19.3 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.418 0 CA-C-O 121.776 0.798 . . . . 0.0 110.514 -174.324 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.3 m -59.89 -45.96 90.87 Favored 'General case' 0 C--N 1.272 -2.772 0 CA-C-N 114.027 -1.442 . . . . 0.0 112.477 -173.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 18.3 m120 -98.47 -11.67 22.08 Favored 'General case' 0 C--N 1.312 -1.052 0 N-CA-C 115.441 1.645 . . . . 0.0 115.441 -172.706 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.567 ' H ' HG23 ' A' ' 131' ' ' ILE . . . -176.93 -104.31 0.18 Allowed Glycine 0 N--CA 1.478 1.461 0 C-N-CA 119.104 -1.522 . . . . 0.0 114.047 -177.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.412 ' O ' HG21 ' A' ' 131' ' ' ILE . 52.9 p30 -141.56 -152.71 0.42 Allowed 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 120.933 0.397 . . . . 0.0 112.029 -178.7 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 48.2 p90 -131.25 152.95 50.01 Favored 'General case' 0 C--O 1.237 0.435 0 CA-C-O 121.23 0.538 . . . . 0.0 110.74 179.96 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.517 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 20.4 tt -67.53 -26.96 36.86 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.437 0 N-CA-C 114.238 1.199 . . . . 0.0 114.238 -169.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 44.5 t -62.09 136.3 57.89 Favored 'General case' 0 N--CA 1.443 -0.811 0 CA-C-O 122.154 0.978 . . . . 0.0 111.466 -171.629 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 92.0 m -63.36 -45.02 93.11 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.027 -1.442 . . . . 0.0 111.708 177.793 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -87.16 107.52 18.5 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-O 122.395 1.093 . . . . 0.0 110.436 -176.631 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.406 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.6 ttt-85 -68.98 135.9 51.65 Favored 'General case' 0 N--CA 1.438 -1.032 0 CA-C-N 115.18 -0.918 . . . . 0.0 108.695 175.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.406 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 15.8 pt-20 53.95 86.63 0.05 OUTLIER 'General case' 0 CA--C 1.546 0.795 0 O-C-N 124.333 1.021 . . . . 0.0 110.914 -177.492 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 45.3 m-80 -76.01 -174.61 2.75 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 114.775 -1.102 . . . . 0.0 113.421 -175.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 93.5 m-85 -70.02 143.76 52.45 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.025 -172.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.411 ' O ' ' SG ' ' A' ' 125' ' ' CYS . 0.2 OUTLIER -23.66 -107.07 0.0 OUTLIER 'General case' 0 N--CA 1.497 1.912 0 O-C-N 125.447 1.717 . . . . 0.0 114.529 -174.223 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.699 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 86.3 t80 -84.04 138.09 33.26 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 112.911 0.708 . . . . 0.0 112.911 -178.778 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 91.09 16.03 54.8 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 114.544 0.578 . . . . 0.0 114.544 175.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.0 p -76.27 156.9 33.07 Favored 'General case' 0 N--CA 1.438 -1.042 0 CA-C-N 117.375 0.588 . . . . 0.0 110.175 176.105 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -141.19 140.47 32.09 Favored 'Isoleucine or valine' 0 C--N 1.351 0.645 0 CA-C-N 116.664 -0.244 . . . . 0.0 111.206 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.4 m -135.13 157.94 40.74 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.494 0 CA-C-O 121.389 0.614 . . . . 0.0 111.171 176.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.517 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 90.2 m -125.41 128.41 48.06 Favored 'General case' 0 CA--C 1.551 0.995 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 176.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.415 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 96.1 m-85 -91.48 145.47 24.59 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.967 0.728 . . . . 0.0 112.967 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 89.6 mtm180 -127.24 149.66 49.9 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 108.968 -0.752 . . . . 0.0 108.968 -177.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.434 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 83.4 m -90.69 132.44 35.79 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-O 121.291 0.567 . . . . 0.0 110.27 179.434 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.511 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 4.7 t30 -74.0 136.77 76.23 Favored Pre-proline 0 N--CA 1.438 -1.044 0 CA-C-N 114.192 -1.367 . . . . 0.0 112.257 -171.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.542 ' HB3' ' H ' ' A' ' 160' ' ' GLY . 24.2 Cg_exo -62.06 145.03 96.72 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 122.797 2.331 . . . . 0.0 112.135 179.537 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -82.4 -91.88 0.6 Allowed Glycine 0 C--N 1.341 0.829 0 C-N-CA 120.032 -1.08 . . . . 0.0 112.294 -179.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 19.0 m -61.3 -42.29 98.41 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.322 0.582 . . . . 0.0 110.755 178.545 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 162.15 93.65 0.1 OUTLIER Glycine 0 C--O 1.215 -1.089 0 C-N-CA 120.601 -0.809 . . . . 0.0 113.225 178.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . 0.542 ' H ' ' HB3' ' A' ' 156' ' ' PRO . . . 78.84 1.53 84.44 Favored Glycine 0 C--N 1.333 0.409 0 O-C-N 123.634 0.256 . . . . 0.0 113.543 174.139 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 79.9 mtp85 -65.1 -37.45 87.52 Favored 'General case' 0 N--CA 1.47 0.543 0 N-CA-C 113.222 0.823 . . . . 0.0 113.222 -178.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 11.5 ttmt 61.42 75.62 0.4 Allowed 'General case' 0 N--CA 1.487 1.391 0 CA-C-O 122.054 0.93 . . . . 0.0 109.052 -169.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 10.9 m -101.47 3.06 10.68 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 CA-C-N 114.115 -1.402 . . . . 0.0 111.196 -175.726 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.554 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 96.9 m-85 -112.9 143.42 44.2 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.528 -178.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 98.6 mt-10 -108.93 124.21 50.32 Favored 'General case' 0 C--O 1.208 -1.127 0 O-C-N 123.327 0.392 . . . . 0.0 110.282 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.558 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.8 tp -75.46 156.02 35.66 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 109.058 -0.719 . . . . 0.0 109.058 179.195 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.558 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 9.9 p -61.53 -34.18 60.47 Favored 'Isoleucine or valine' 0 CA--C 1.549 0.911 0 CA-C-N 115.828 -0.624 . . . . 0.0 112.585 -177.505 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 141.44 -21.86 2.56 Favored Glycine 0 CA--C 1.525 0.678 0 C-N-CA 119.139 -1.505 . . . . 0.0 115.234 175.13 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -137.49 79.7 34.82 Favored Pre-proline 0 C--O 1.212 -0.914 0 CA-C-N 118.153 0.976 . . . . 0.0 110.977 -179.174 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.517 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 56.8 Cg_endo -69.13 -18.05 40.13 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 124.114 3.209 . . . . 0.0 115.982 -176.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 9.3 p -92.02 121.07 33.24 Favored 'General case' 0 N--CA 1.468 0.463 0 C-N-CA 119.606 -0.838 . . . . 0.0 113.254 -172.616 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.8 pt -129.0 156.16 41.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.208 178.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 49.3 p90 -143.87 160.14 41.3 Favored 'General case' 0 C--N 1.309 -1.17 0 CA-C-N 116.444 -0.343 . . . . 0.0 110.222 -178.654 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.439 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 37.4 t -78.43 110.4 13.47 Favored 'General case' 0 C--N 1.301 -1.511 0 CA-C-O 121.856 0.836 . . . . 0.0 112.402 -176.926 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.422 HG23 ' O ' ' A' ' 175' ' ' THR . 4.1 t -150.14 73.8 1.17 Allowed 'General case' 0 N--CA 1.429 -1.511 0 CA-C-N 113.751 -1.568 . . . . 0.0 109.514 -178.295 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.461 ' HB2' ' H ' ' A' ' 183' ' ' ILE . 43.2 t -63.15 137.63 58.29 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.305 -179.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -159.88 -85.86 0.03 OUTLIER 'General case' 0 CA--C 1.537 0.463 0 C-N-CA 119.828 -0.749 . . . . 0.0 112.648 -179.961 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 13.3 p-10 -64.51 -40.71 96.13 Favored 'General case' 0 C--O 1.236 0.386 0 N-CA-C 112.452 0.538 . . . . 0.0 112.452 -176.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.88 ' HB2' HD13 ' A' ' 183' ' ' ILE . 71.6 m-20 -73.8 143.07 46.13 Favored 'General case' 0 N--CA 1.441 -0.904 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 168.282 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.439 ' HG2' HG23 ' A' ' 181' ' ' VAL . 57.4 tt0 -39.39 -93.03 0.0 OUTLIER 'General case' 0 CA--C 1.553 1.061 0 O-C-N 124.972 1.42 . . . . 0.0 114.132 -172.685 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.46 HG13 ' HB2' ' A' ' 95' ' ' ARG . 54.5 t -127.23 133.1 68.87 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.827 0 N-CA-C 114.086 1.143 . . . . 0.0 114.086 -176.092 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 69.82 65.77 2.45 Favored Glycine 0 N--CA 1.478 1.446 0 N-CA-C 116.475 1.35 . . . . 0.0 116.475 170.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.88 HD13 ' HB2' ' A' ' 179' ' ' ASP . 20.4 pt -126.46 162.09 31.27 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.929 0 CA-C-O 122.209 1.004 . . . . 0.0 111.421 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 55.1 m95 -87.14 175.8 7.9 Favored 'General case' 0 C--N 1.306 -1.313 0 CA-C-N 114.372 -1.285 . . . . 0.0 109.409 174.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.5 t -60.73 -43.25 98.12 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 120.973 0.416 . . . . 0.0 110.911 -177.061 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.12 161.59 31.67 Favored Glycine 0 N--CA 1.433 -1.558 0 C-N-CA 120.368 -0.92 . . . . 0.0 111.778 179.339 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_exo -62.51 146.03 95.49 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.939 2.426 . . . . 0.0 109.737 175.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.514 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -45.22 115.08 2.45 Favored Pre-proline 0 CA--C 1.541 0.628 0 O-C-N 123.942 0.776 . . . . 0.0 112.18 -177.516 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.517 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 20.8 Cg_exo -62.22 146.06 96.02 Favored 'Trans proline' 0 CA--C 1.502 -1.124 0 C-N-CA 122.479 2.119 . . . . 0.0 110.826 177.643 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.625 ' HB2' HG13 ' A' ' 192' ' ' ILE . 22.6 mt-30 -112.93 175.28 5.5 Favored 'General case' 0 CA--C 1.481 -1.693 0 C-N-CA 119.005 -1.078 . . . . 0.0 111.758 -168.714 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.554 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 67.6 m -92.89 50.17 1.53 Allowed 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 112.754 -2.021 . . . . 0.0 107.129 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.625 HG13 ' HB2' ' A' ' 190' ' ' GLN . 97.1 mt . . . . . 0 C--O 1.259 1.564 0 CA-C-N 114.513 -1.222 . . . . 0.0 110.805 -178.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 87.8 tttt . . . . . 0 N--CA 1.427 -1.592 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.48 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 90.7 p -74.68 153.41 38.91 Favored 'General case' 0 CA--C 1.498 -1.031 0 C-N-CA 120.353 -0.539 . . . . 0.0 111.092 -179.582 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.625 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.9 OUTLIER -78.55 -174.68 3.95 Favored 'General case' 0 C--N 1.315 -0.893 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 178.87 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.6 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 55.5 mmm-85 -90.07 7.04 39.77 Favored 'General case' 0 CA--C 1.484 -1.576 0 N-CA-C 112.554 0.575 . . . . 0.0 112.554 -176.519 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.6 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.2 t-20 78.52 142.69 0.09 OUTLIER Pre-proline 0 CA--C 1.502 -0.89 0 N-CA-C 107.536 -1.283 . . . . 0.0 107.536 -176.358 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.413 ' CG ' HG21 ' A' ' 86' ' ' ILE . 75.0 Cg_exo -52.35 134.38 51.24 Favored 'Trans proline' 0 N--CA 1.453 -0.903 0 C-N-CA 122.216 1.944 . . . . 0.0 113.01 -177.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_exo -55.59 -35.74 93.26 Favored 'Trans proline' 0 N--CA 1.478 0.59 0 C-N-CA 123.357 2.705 . . . . 0.0 109.492 177.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER 71.17 116.63 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.617 0 N-CA-C 114.964 1.468 . . . . 0.0 114.964 170.726 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.492 ' HD2' ' CE1' ' A' ' 88' ' ' TYR . 20.4 Cg_exo -63.4 147.3 93.55 Favored 'Trans proline' 0 N--CA 1.435 -1.93 0 C-N-CA 122.724 2.283 . . . . 0.0 109.567 167.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.0 t -66.23 134.01 30.39 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 CA-C-O 121.143 0.497 . . . . 0.0 110.598 -174.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 2.2 p30 61.9 28.53 17.41 Favored 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 126.534 1.934 . . . . 0.0 112.019 -174.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -79.65 172.4 54.94 Favored Glycine 0 N--CA 1.424 -2.13 0 C-N-CA 120.019 -1.086 . . . . 0.0 111.334 174.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.1 tpp -120.2 143.01 48.48 Favored 'General case' 0 C--N 1.284 -2.267 0 CA-C-O 121.586 0.708 . . . . 0.0 111.415 -179.533 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.445 ' CG1' HG12 ' A' ' 76' ' ' VAL . 43.8 t -122.09 130.82 74.24 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.552 178.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 67.0 m80 -127.8 51.32 1.95 Allowed 'General case' 0 C--N 1.315 -0.935 0 N-CA-C 108.472 -0.936 . . . . 0.0 108.472 179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.8 p -123.83 129.93 74.17 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.194 0 C-N-CA 118.481 -1.287 . . . . 0.0 110.739 -173.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.9 tt -91.83 -50.59 12.44 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.056 0 CA-C-O 121.325 0.583 . . . . 0.0 112.437 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.456 ' O ' ' HG2' ' A' ' 81' ' ' GLN . 75.8 mmtt -132.8 3.16 3.77 Favored 'General case' 0 N--CA 1.477 0.91 0 N-CA-C 109.219 -0.66 . . . . 0.0 109.219 179.17 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.664 ' CA ' ' HB3' ' A' ' 84' ' ' SER . . . -80.73 31.06 2.51 Favored Glycine 0 C--N 1.311 -0.819 0 N-CA-C 115.738 1.055 . . . . 0.0 115.738 -169.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.625 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 47.8 pt -102.8 -2.71 9.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 175.396 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.712 ' O ' ' HB3' ' A' ' 104' ' ' CYS . 92.4 mm-40 -79.48 178.84 7.83 Favored 'General case' 0 C--N 1.299 -1.619 0 CA-C-N 114.577 -1.192 . . . . 0.0 109.798 -174.542 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.494 ' CD1' HG12 ' A' ' 106' ' ' ILE . 66.3 t80 -62.65 131.24 48.32 Favored 'General case' 0 C--N 1.304 -1.384 0 CA-C-N 114.199 -1.364 . . . . 0.0 109.468 172.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.74 21.95 65.15 Favored Glycine 0 N--CA 1.446 -0.659 0 C-N-CA 120.274 -0.965 . . . . 0.0 112.909 -179.741 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.664 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 64.2 m -127.95 156.1 43.19 Favored 'General case' 0 C--O 1.247 0.923 0 N-CA-C 112.127 0.417 . . . . 0.0 112.127 -176.842 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.718 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 86.3 mt-30 -127.18 156.74 41.34 Favored 'General case' 0 N--CA 1.483 1.182 0 O-C-N 123.869 0.731 . . . . 0.0 112.478 -173.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.706 ' O ' ' HA ' ' A' ' 101' ' ' SER . 0.2 OUTLIER -124.78 152.67 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.493 0 CA-C-N 114.322 -1.308 . . . . 0.0 108.186 174.569 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.645 ' HD3' ' OG ' ' A' ' 101' ' ' SER . 75.6 mmtt -109.32 146.06 34.97 Favored 'General case' 0 C--O 1.243 0.729 0 C-N-CA 120.708 -0.397 . . . . 0.0 111.722 -174.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.492 ' CE1' ' HD2' ' A' ' 69' ' ' PRO . 40.7 m-85 -132.28 151.88 51.63 Favored 'General case' 0 CA--C 1.504 -0.809 0 N-CA-C 116.026 1.862 . . . . 0.0 116.026 179.54 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 47.2 t -135.48 143.53 45.9 Favored 'General case' 0 C--N 1.35 0.6 0 CA-C-N 114.355 -1.293 . . . . 0.0 109.616 -178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.1 m -120.68 162.12 20.24 Favored 'General case' 0 N--CA 1.438 -1.07 0 CA-C-N 115.985 -0.552 . . . . 0.0 111.217 -179.117 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 19.7 p -77.77 167.23 21.88 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 123.813 0.845 . . . . 0.0 110.834 177.321 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -60.71 132.07 52.7 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 122.049 0.928 . . . . 0.0 112.333 -172.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.82 1.4 80.15 Favored Glycine 0 C--N 1.339 0.715 0 CA-C-N 114.269 -1.332 . . . . 0.0 112.363 179.176 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 88.6 m-85 -120.36 145.31 47.28 Favored 'General case' 0 C--N 1.321 -0.645 0 O-C-N 122.414 -0.462 . . . . 0.0 111.252 -179.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.506 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 3.0 ppt_? -137.6 164.47 28.69 Favored 'General case' 0 C--N 1.31 -1.115 0 N-CA-C 109.538 -0.542 . . . . 0.0 109.538 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.535 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -83.47 128.35 34.44 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 32.2 mm -64.68 -43.29 96.61 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.074 0 CA-C-O 122.131 0.967 . . . . 0.0 112.235 179.806 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.521 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -95.92 -124.79 4.57 Favored Glycine 0 CA--C 1.466 -3.002 0 CA-C-N 113.87 -1.514 . . . . 0.0 109.532 -175.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 42.5 t -114.41 125.78 54.23 Favored 'General case' 0 C--N 1.283 -2.316 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 177.252 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.4 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -59.2 -31.63 69.2 Favored 'General case' 0 C--N 1.313 -0.993 0 N-CA-C 110.013 -0.365 . . . . 0.0 110.013 -179.779 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.706 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 16.8 m -114.27 120.13 39.38 Favored 'General case' 0 N--CA 1.428 -1.553 0 N-CA-C 108.707 -0.849 . . . . 0.0 108.707 176.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.718 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -100.93 150.01 23.31 Favored 'General case' 0 CA--C 1.478 -1.791 0 CA-C-N 115.795 -0.639 . . . . 0.0 110.355 -178.497 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.5 m -115.09 125.48 53.55 Favored 'General case' 0 C--N 1.299 -1.618 0 CA-C-O 122.082 0.944 . . . . 0.0 109.53 178.664 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.712 ' HB3' ' O ' ' A' ' 81' ' ' GLN . 54.0 t -73.66 129.66 38.4 Favored 'General case' 0 C--N 1.297 -1.689 0 CA-C-N 114.964 -1.016 . . . . 0.0 110.635 177.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 15.0 pt -131.38 168.99 22.6 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.514 0 C-N-CA 122.805 0.442 . . . . 0.0 111.07 -179.245 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.568 HD13 HG23 ' A' ' 111' ' ' VAL . 45.9 mm -97.27 117.89 42.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 173.619 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.529 ' HB2' ' CG1' ' A' ' 112' ' ' ILE . 42.0 t -63.09 -42.58 99.64 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 122.29 1.043 . . . . 0.0 109.14 175.784 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 156.94 -73.62 0.23 Allowed Glycine 0 N--CA 1.419 -2.437 0 N-CA-C 109.593 -1.403 . . . . 0.0 109.593 -178.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 37.5 p-10 -66.14 -36.63 83.63 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 120.964 0.411 . . . . 0.0 111.49 175.291 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 13.5 t -144.77 179.24 7.44 Favored 'General case' 0 N--CA 1.442 -0.825 0 CA-C-O 121.087 0.47 . . . . 0.0 110.35 -175.749 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.633 HG22 ' SG ' ' A' ' 104' ' ' CYS . 14.7 p -107.61 122.8 62.38 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.383 0 CA-C-O 121.88 0.848 . . . . 0.0 109.636 -178.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.529 ' CG1' ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -131.66 164.39 34.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.91 0 CA-C-N 114.77 -1.105 . . . . 0.0 112.466 -177.751 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.419 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.5 m95 -80.86 136.93 36.16 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 108.874 -0.788 . . . . 0.0 108.874 -179.348 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 8.9 p-10 -66.49 -36.12 81.96 Favored 'General case' 0 CA--C 1.49 -1.363 0 N-CA-C 107.104 -1.443 . . . . 0.0 107.104 -178.015 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 84.5 m -122.4 126.26 47.6 Favored 'General case' 0 N--CA 1.396 -3.138 0 N-CA-C 105.229 -2.137 . . . . 0.0 105.229 171.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.461 ' O ' ' HB ' ' A' ' 117' ' ' THR . 95.2 mt-10 -75.63 15.63 0.47 Allowed 'General case' 0 C--N 1.279 -2.461 0 O-C-N 123.991 0.807 . . . . 0.0 111.731 -173.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.461 ' HB ' ' O ' ' A' ' 116' ' ' GLU . 92.1 m 83.62 121.49 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.601 0 C-N-CA 124.106 0.962 . . . . 0.0 110.645 -177.797 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.535 ' HG2' HD12 ' A' ' 96' ' ' LEU . 83.2 Cg_endo -70.8 156.71 60.12 Favored 'Trans proline' 0 N--CA 1.46 -0.493 0 C-N-CA 124.414 3.409 . . . . 0.0 113.394 -177.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 50.4 mm -109.02 130.64 61.61 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.757 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 84.6 m -66.95 107.94 2.41 Favored 'General case' 0 N--CA 1.442 -0.831 0 CA-C-O 121.548 0.689 . . . . 0.0 109.338 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 51.7 t0 -117.06 157.62 25.54 Favored 'General case' 0 C--N 1.303 -1.419 0 N-CA-C 107.911 -1.144 . . . . 0.0 107.911 177.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 77.3 ttt-85 -67.44 129.9 41.35 Favored 'General case' 0 N--CA 1.44 -0.97 0 N-CA-C 108.443 -0.947 . . . . 0.0 108.443 -177.19 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.402 HG12 ' HB3' ' A' ' 95' ' ' ARG . 14.4 mt -50.79 110.23 1.65 Allowed Pre-proline 0 N--CA 1.476 0.858 0 O-C-N 124.292 0.995 . . . . 0.0 112.397 -170.377 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.644 ' HA ' ' CD2' ' A' ' 145' ' ' HIS . 51.8 Cg_exo -54.51 -39.83 86.35 Favored 'Trans proline' 0 C--O 1.197 -1.552 0 C-N-CA 122.458 2.105 . . . . 0.0 113.481 -179.089 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.424 ' O ' ' HZ2' ' A' ' 184' ' ' TRP . 0.9 OUTLIER 30.47 34.26 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.473 0 O-C-N 124.863 1.352 . . . . 0.0 114.219 -177.733 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -71.64 141.12 31.54 Favored Glycine 0 N--CA 1.428 -1.869 0 C-N-CA 120.438 -0.887 . . . . 0.0 113.996 -174.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.411 HD22 ' HB3' ' A' ' 142' ' ' GLU . 0.2 OUTLIER 58.97 106.37 0.03 OUTLIER Pre-proline 0 CA--C 1.537 0.471 0 C-N-CA 123.763 0.825 . . . . 0.0 111.843 178.921 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.642 ' HD3' ' H ' ' A' ' 143' ' ' ASN . 73.4 Cg_endo -77.03 167.11 25.65 Favored 'Trans proline' 0 N--CA 1.452 -0.932 0 C-N-CA 122.168 1.912 . . . . 0.0 108.36 178.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.446 ' HG2' ' H ' ' A' ' 188' ' ' ALA . 32.4 Cg_exo -60.34 139.52 87.14 Favored 'Trans proline' 0 N--CA 1.442 -1.505 0 CA-C-N 120.51 1.218 . . . . 0.0 109.195 178.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 20.8 m -73.83 134.1 43.29 Favored 'General case' 0 N--CA 1.425 -1.703 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 177.769 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.69 HG21 ' O ' ' A' ' 135' ' ' ASP . 11.3 tp -72.87 138.19 21.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.565 0 CA-C-O 121.025 0.441 . . . . 0.0 110.218 -176.901 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 93.0 m -61.82 -48.29 81.25 Favored 'General case' 0 C--N 1.3 -1.55 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.473 ' ND2' ' HB2' ' A' ' 191' ' ' CYS . 34.1 m-80 -65.16 -41.58 94.57 Favored 'General case' 0 N--CA 1.476 0.864 0 N-CA-C 117.089 2.255 . . . . 0.0 117.089 178.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.66 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 146.23 100.58 0.27 Allowed Glycine 0 CA--C 1.545 1.944 0 C-N-CA 118.783 -1.675 . . . . 0.0 113.737 -177.329 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.69 ' O ' HG21 ' A' ' 131' ' ' ILE . 99.4 m-20 57.7 -175.86 0.07 Allowed 'General case' 0 CA--C 1.555 1.156 0 N-CA-C 116.209 1.929 . . . . 0.0 116.209 174.367 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.452 ' HB3' ' CD1' ' A' ' 152' ' ' TYR . 39.4 p90 -141.98 169.45 17.56 Favored 'General case' 0 N--CA 1.443 -0.803 0 CA-C-N 114.214 -1.357 . . . . 0.0 112.819 -171.803 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.67 HD12 ' HB ' ' A' ' 151' ' ' THR . 90.3 mt -63.05 -43.45 99.02 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.882 0 N-CA-C 115.211 1.56 . . . . 0.0 115.211 -175.362 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.41 ' CB ' HG12 ' A' ' 150' ' ' VAL . 37.9 t -62.04 143.06 57.13 Favored 'General case' 0 C--N 1.316 -0.862 0 CA-C-O 121.404 0.621 . . . . 0.0 111.973 -171.596 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.1 4.09 41.86 Favored 'General case' 0 N--CA 1.436 -1.163 0 CA-C-N 114.512 -1.222 . . . . 0.0 110.987 -177.368 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -91.22 7.43 40.8 Favored 'General case' 0 C--O 1.215 -0.725 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.508 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 78.2 ttt-85 42.47 85.68 0.02 OUTLIER 'General case' 0 C--O 1.248 0.982 0 N-CA-C 115.022 1.49 . . . . 0.0 115.022 -179.143 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.508 ' HB2' ' O ' ' A' ' 141' ' ' ARG . 6.4 mm-40 86.76 151.95 0.06 Allowed 'General case' 0 C--O 1.248 0.997 0 O-C-N 124.946 1.404 . . . . 0.0 109.069 172.675 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.642 ' H ' ' HD3' ' A' ' 128' ' ' PRO . 92.4 m-20 -99.22 141.19 32.32 Favored 'General case' 0 C--N 1.289 -2.05 0 CA-C-O 121.012 0.434 . . . . 0.0 111.472 179.937 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 80.5 m-85 -104.21 -101.57 0.31 Allowed 'General case' 0 N--CA 1.428 -1.533 0 C-N-CA 119.158 -1.017 . . . . 0.0 111.241 178.752 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.644 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 55.5 m80 -84.85 -177.57 6.61 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-O 121.607 0.718 . . . . 0.0 112.91 -172.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.5 t80 -56.37 137.12 53.23 Favored 'General case' 0 CA--C 1.513 -0.447 0 CA-C-N 114.875 -1.057 . . . . 0.0 111.919 -170.967 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 97.97 -7.04 62.46 Favored Glycine 0 N--CA 1.438 -1.199 0 CA-C-N 115.027 -0.988 . . . . 0.0 112.562 178.24 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 64.3 m -74.82 144.32 43.54 Favored 'General case' 0 C--N 1.31 -1.147 0 N-CA-C 109.622 -0.51 . . . . 0.0 109.622 177.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.8 p -140.9 140.16 33.26 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.742 0 N-CA-C 112.066 0.395 . . . . 0.0 112.066 -178.679 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.628 HG13 ' ND2' ' A' ' 143' ' ' ASN . 30.9 m -132.02 158.89 43.37 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.822 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.506 173.65 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.67 ' HB ' HD12 ' A' ' 137' ' ' ILE . 73.3 m -126.1 133.72 51.56 Favored 'General case' 0 N--CA 1.429 -1.502 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 -179.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.528 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 93.3 m-85 -104.21 140.46 37.8 Favored 'General case' 0 C--N 1.31 -1.119 0 N-CA-C 112.626 0.602 . . . . 0.0 112.626 -174.697 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 90.9 mtm180 -124.11 149.76 45.85 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 115.492 -0.777 . . . . 0.0 110.321 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.645 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 99.1 m -91.4 137.29 32.48 Favored 'General case' 0 C--N 1.292 -1.919 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 178.373 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -63.3 133.5 95.49 Favored Pre-proline 0 N--CA 1.481 1.084 0 N-CA-C 114.544 1.312 . . . . 0.0 114.544 -169.011 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.663 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 22.2 Cg_exo -62.81 145.33 94.73 Favored 'Trans proline' 0 N--CA 1.451 -1.023 0 C-N-CA 122.075 1.85 . . . . 0.0 109.548 168.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -127.23 138.95 10.85 Favored Glycine 0 N--CA 1.438 -1.167 0 C-N-CA 119.977 -1.106 . . . . 0.0 112.474 -179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 15.0 m 48.74 25.47 1.01 Allowed 'General case' 0 N--CA 1.479 1.024 0 CA-C-O 121.761 0.791 . . . . 0.0 111.472 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 146.92 -165.87 28.45 Favored Glycine 0 N--CA 1.424 -2.108 0 N-CA-C 109.316 -1.514 . . . . 0.0 109.316 -176.289 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -81.56 33.42 2.55 Favored Glycine 0 C--N 1.312 -0.772 0 CA-C-N 117.23 0.515 . . . . 0.0 112.684 177.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.663 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 95.7 mtt-85 -96.34 133.34 40.84 Favored 'General case' 0 CA--C 1.474 -1.978 0 C-N-CA 119.738 -0.785 . . . . 0.0 110.852 -177.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.6 mttp -86.84 105.62 17.16 Favored 'General case' 0 CA--C 1.463 -2.39 0 C-N-CA 118.258 -1.377 . . . . 0.0 109.713 171.25 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 15.4 m -102.1 4.48 10.55 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.668 0 CA-C-N 112.444 -2.162 . . . . 0.0 110.209 -175.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.645 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 81.2 m-85 -126.53 148.29 49.74 Favored 'General case' 0 N--CA 1.418 -2.072 0 CA-C-N 114.412 -1.267 . . . . 0.0 108.269 176.905 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.574 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 83.4 tt0 -114.69 145.32 42.18 Favored 'General case' 0 C--O 1.185 -2.333 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 -177.262 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.649 HD23 ' H ' ' A' ' 168' ' ' GLY . 1.5 tt -109.32 157.1 19.2 Favored 'General case' 0 C--N 1.305 -1.363 0 CA-C-O 121.216 0.531 . . . . 0.0 110.712 -175.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.446 HG23 ' O ' ' A' ' 190' ' ' GLN . 53.0 t -60.87 -45.23 98.51 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.722 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.655 -173.123 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.649 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 138.6 -10.76 3.46 Favored Glycine 0 CA--C 1.494 -1.254 0 C-N-CA 118.924 -1.608 . . . . 0.0 114.05 176.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.461 ' O ' ' HG2' ' A' ' 189' ' ' PRO . 26.8 tt0 -125.24 61.13 33.05 Favored Pre-proline 0 C--O 1.211 -0.962 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 178.721 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -66.24 -21.55 54.77 Favored 'Trans proline' 0 C--N 1.366 1.488 0 C-N-CA 122.621 2.214 . . . . 0.0 113.555 -173.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.8 m -96.52 122.69 39.7 Favored 'General case' 0 C--N 1.302 -1.477 0 CA-C-O 121.212 0.53 . . . . 0.0 110.295 -176.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.425 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.0 pt -128.25 152.6 36.59 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.764 0 CA-C-N 115.793 -0.639 . . . . 0.0 111.35 -179.096 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.69 ' CD2' HG22 ' A' ' 175' ' ' THR . 20.5 p90 -147.45 160.93 42.02 Favored 'General case' 0 CA--C 1.503 -0.849 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.708 -179.687 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 22.9 t -77.21 107.59 9.71 Favored 'General case' 0 C--N 1.325 -0.458 0 N-CA-C 108.21 -1.033 . . . . 0.0 108.21 177.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.69 HG22 ' CD2' ' A' ' 173' ' ' TYR . 1.6 p -116.28 18.61 15.21 Favored 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 115.416 -0.811 . . . . 0.0 110.303 -172.415 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 11.3 t -58.53 -42.52 87.96 Favored 'General case' 0 C--N 1.292 -1.922 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -162.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.7 t30 -61.48 -41.04 96.65 Favored 'General case' 0 C--N 1.295 -1.793 0 CA-C-N 118.979 0.809 . . . . 0.0 112.044 -172.794 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 33.4 t70 -63.01 -43.17 99.5 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 114.369 1.248 . . . . 0.0 114.369 -176.107 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -132.32 -87.68 0.45 Allowed 'General case' 0 N--CA 1.486 1.341 0 C-N-CA 117.835 -1.546 . . . . 0.0 113.607 -176.585 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.45 ' CG ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -82.08 139.79 34.23 Favored 'General case' 0 N--CA 1.468 0.469 0 C-N-CA 122.748 0.419 . . . . 0.0 109.974 -177.156 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 19.4 t -86.86 130.34 37.0 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.761 0 N-CA-C 113.464 0.913 . . . . 0.0 113.464 -170.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 74.08 25.71 70.53 Favored Glycine 0 CA--C 1.502 -0.719 0 CA-C-N 115.583 -0.735 . . . . 0.0 114.13 173.377 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.45 HG12 ' CG ' ' A' ' 180' ' ' GLN . 2.2 pp -127.06 161.64 33.66 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.236 0 N-CA-C 115.442 1.645 . . . . 0.0 115.442 -172.095 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.458 ' HH2' ' CB ' ' A' ' 143' ' ' ASN . 84.0 m95 -93.13 156.85 16.6 Favored 'General case' 0 CA--C 1.494 -1.174 0 CA-C-N 112.514 -2.13 . . . . 0.0 106.564 174.598 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 78.3 p -57.65 -33.18 68.04 Favored 'General case' 0 C--O 1.24 0.585 0 C-N-CA 120.082 -0.647 . . . . 0.0 110.092 -172.485 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -157.6 152.01 23.26 Favored Glycine 0 N--CA 1.423 -2.208 0 C-N-CA 119.707 -1.235 . . . . 0.0 111.147 174.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.8 146.27 96.67 Favored 'Trans proline' 0 CA--C 1.488 -1.822 0 N-CA-C 107.276 -1.856 . . . . 0.0 107.276 170.86 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.446 ' H ' ' HG2' ' A' ' 129' ' ' PRO . . . -50.69 112.84 3.16 Favored Pre-proline 0 C--O 1.245 0.816 0 O-C-N 123.133 0.27 . . . . 0.0 111.269 -173.911 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.461 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 23.0 Cg_exo -61.81 145.61 97.08 Favored 'Trans proline' 0 CA--C 1.495 -1.462 0 C-N-CA 122.114 1.876 . . . . 0.0 111.411 -177.534 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.567 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -111.89 165.62 11.92 Favored 'General case' 0 N--CA 1.421 -1.893 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.376 -171.247 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.574 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 82.3 m -81.06 75.29 8.04 Favored 'General case' 0 C--N 1.276 -2.592 0 CA-C-N 115.301 -0.863 . . . . 0.0 111.614 -172.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.567 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.7 mt . . . . . 0 C--O 1.255 1.387 0 C-N-CA 125.044 1.338 . . . . 0.0 110.325 176.155 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.404 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 68.8 mttm . . . . . 0 CA--C 1.499 -1.0 0 CA-C-O 121.287 0.565 . . . . 0.0 111.584 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 50.5 m -133.36 151.71 51.87 Favored 'General case' 0 N--CA 1.419 -2.023 0 N-CA-C 106.719 -1.586 . . . . 0.0 106.719 172.245 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.469 ' SG ' HG22 ' A' ' 111' ' ' VAL . 64.0 m -85.9 -169.99 2.9 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.177 -1.009 . . . . 0.0 112.679 -174.392 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.591 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 27.8 mmm180 -84.73 11.59 8.78 Favored 'General case' 0 N--CA 1.446 -0.636 0 CA-C-N 115.187 -0.915 . . . . 0.0 112.507 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.591 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 1.8 t30 77.36 153.22 0.14 Allowed Pre-proline 0 C--N 1.353 0.717 0 O-C-N 123.549 0.531 . . . . 0.0 110.769 177.419 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.5 ' HG2' HG23 ' A' ' 74' ' ' VAL . 0.0 OUTLIER -22.16 161.26 0.0 OUTLIER 'Trans proline' 0 CA--C 1.571 2.369 1 C-N-CA 126.223 4.615 . . . . 0.0 117.146 173.883 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.9 ' CG ' HG21 ' A' ' 117' ' ' THR . 51.9 Cg_exo -55.09 -37.19 94.16 Favored 'Trans proline' 0 N--CA 1.509 2.416 1 C-N-CA 125.865 4.377 . . . . 0.0 117.039 -162.46 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.477 ' HB3' ' O ' ' A' ' 67' ' ' PRO . 33.0 t70 92.64 58.63 0.02 OUTLIER Pre-proline 0 C--N 1.301 -1.524 0 O-C-N 125.861 1.975 . . . . 0.0 109.75 -167.929 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.554 ' HD3' ' HB2' ' A' ' 67' ' ' PRO . 16.9 Cg_exo -59.87 149.07 85.82 Favored 'Trans proline' 0 N--CA 1.438 -1.754 0 C-N-CA 122.499 2.133 . . . . 0.0 110.207 171.106 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 42.4 t -106.15 130.68 57.39 Favored 'Isoleucine or valine' 0 CA--C 1.479 -1.756 0 N-CA-C 106.229 -1.767 . . . . 0.0 106.229 -179.246 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 58.71 34.49 23.81 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 114.171 -1.377 . . . . 0.0 109.089 -169.398 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -137.58 152.6 21.68 Favored Glycine 0 N--CA 1.444 -0.793 0 CA-C-N 115.36 -0.837 . . . . 0.0 111.641 -178.337 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.1 mtt -96.31 -179.16 4.55 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.869 -0.166 . . . . 0.0 111.376 -178.292 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.5 HG23 ' HG2' ' A' ' 66' ' ' PRO . 5.2 p -105.17 114.18 44.08 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.868 0 CA-C-O 122.05 0.929 . . . . 0.0 110.949 -176.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 49.8 t-80 -67.31 -42.07 84.27 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-N 114.536 -1.211 . . . . 0.0 113.091 -178.276 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 54.8 t -120.62 130.6 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.989 0 C-N-CA 120.79 -0.364 . . . . 0.0 110.802 -173.382 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 9.8 tp -102.75 -59.61 3.28 Favored 'Isoleucine or valine' 0 CA--C 1.555 1.135 0 N-CA-C 113.431 0.901 . . . . 0.0 113.431 179.684 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -97.82 -9.18 26.9 Favored 'General case' 0 N--CA 1.482 1.146 0 N-CA-C 115.004 1.483 . . . . 0.0 115.004 178.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.426 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -92.55 41.91 2.73 Favored Glycine 0 C--N 1.304 -1.224 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 179.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.449 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.6 pt -104.65 -0.83 10.0 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 CA-C-N 114.798 -0.701 . . . . 0.0 110.227 -176.396 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.572 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.1 mt-30 -68.99 179.49 1.83 Allowed 'General case' 0 N--CA 1.428 -1.553 0 CA-C-O 121.744 0.783 . . . . 0.0 112.074 -172.301 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 73.7 t80 -61.21 127.84 33.46 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.81 178.24 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.91 -17.69 57.52 Favored Glycine 0 CA--C 1.528 0.853 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.402 179.028 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.426 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 9.6 m -75.55 152.05 37.83 Favored 'General case' 0 CA--C 1.547 0.863 0 CA-C-O 120.652 0.263 . . . . 0.0 110.586 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.7 mt-30 -125.76 154.25 42.8 Favored 'General case' 0 N--CA 1.438 -1.041 0 CA-C-O 122.166 0.984 . . . . 0.0 112.733 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.659 HD12 ' HD3' ' A' ' 67' ' ' PRO . 43.4 pt -124.82 149.48 29.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.006 0 CA-C-N 113.619 -1.628 . . . . 0.0 108.775 177.788 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 11.5 mptt -115.16 148.54 38.91 Favored 'General case' 0 C--N 1.305 -1.326 0 CA-C-N 116.566 -0.288 . . . . 0.0 110.894 179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.818 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 43.2 t80 -135.75 159.93 40.12 Favored 'General case' 0 N--CA 1.424 -1.762 0 N-CA-C 106.903 -1.517 . . . . 0.0 106.903 -177.273 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 36.5 p -150.81 159.36 44.59 Favored 'General case' 0 C--O 1.245 0.822 0 CA-C-N 118.828 0.74 . . . . 0.0 109.455 179.873 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 77.6 m -125.19 157.93 35.25 Favored 'General case' 0 N--CA 1.445 -0.703 0 N-CA-C 112.622 0.601 . . . . 0.0 112.622 -173.108 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.4 HG22 ' N ' ' A' ' 92' ' ' LYS . 38.4 m -81.04 165.46 21.65 Favored 'General case' 0 C--N 1.31 -1.114 0 CA-C-N 114.79 -1.095 . . . . 0.0 109.944 177.774 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.4 ' N ' HG22 ' A' ' 91' ' ' THR . 87.8 tttt -62.15 130.92 47.66 Favored 'General case' 0 C--O 1.212 -0.887 0 CA-C-O 121.563 0.697 . . . . 0.0 111.528 -176.668 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 96.19 -16.44 61.1 Favored Glycine 0 C--N 1.352 1.444 0 CA-C-N 115.291 -0.868 . . . . 0.0 112.515 178.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.4 m-85 -119.61 141.42 49.32 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 176.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.682 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 34.8 ptt180 -124.7 174.62 7.76 Favored 'General case' 0 CA--C 1.473 -2.017 0 CA-C-O 122.7 1.238 . . . . 0.0 112.695 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.46 HD21 ' HD2' ' A' ' 88' ' ' TYR 0.319 48.5 mt -78.89 123.17 26.98 Favored 'General case' 0 N--CA 1.404 -2.726 0 CA-C-N 112.787 -2.006 . . . . 0.0 106.5 170.814 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.409 HD11 ' HB3' ' A' ' 121' ' ' ASP 0.254 31.6 mm -64.82 -43.26 96.42 Favored 'Isoleucine or valine' 0 C--N 1.262 -3.212 0 N-CA-C 115.157 1.54 . . . . 0.0 115.157 -179.923 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.677 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.34 -47.55 0.46 Allowed Glycine 0 C--N 1.291 -1.928 0 C-N-CA 120.167 -1.016 . . . . 0.0 114.708 -166.051 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.765 ' O ' ' HG2' ' A' ' 118' ' ' PRO . 22.3 t -157.36 174.55 15.25 Favored 'General case' 0 N--CA 1.413 -2.292 0 N-CA-C 108.251 -1.018 . . . . 0.0 108.251 -172.216 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 5.7 m -106.85 -2.31 21.53 Favored 'General case' 0 C--N 1.269 -2.93 0 CA-C-O 121.393 0.616 . . . . 0.0 110.166 169.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 31.6 p -153.76 163.97 39.12 Favored 'General case' 0 N--CA 1.469 0.485 0 C-N-CA 123.772 0.829 . . . . 0.0 109.696 -174.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -137.75 148.26 45.43 Favored 'General case' 0 CA--C 1.483 -1.618 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 176.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 82.1 m -116.84 130.1 56.5 Favored 'General case' 0 C--N 1.289 -2.057 0 N-CA-C 108.526 -0.916 . . . . 0.0 108.526 177.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 18.3 m -66.49 134.96 53.52 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.727 177.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 21.1 pt -129.15 167.57 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.865 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 176.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . . . . . . . . . 50.8 mm -98.78 120.92 48.75 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.682 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.688 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 46.2 t -127.77 127.97 44.51 Favored 'General case' 0 N--CA 1.429 -1.482 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 174.395 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 60.16 -134.2 50.59 Favored Glycine 0 CA--C 1.538 1.491 0 C-N-CA 118.646 -1.74 . . . . 0.0 111.057 -176.149 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.6 m-20 -93.5 -0.59 56.29 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 111.766 0.284 . . . . 0.0 111.766 177.402 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 96.7 m -124.09 131.58 53.56 Favored 'General case' 0 N--CA 1.42 -1.959 0 CA-C-O 121.498 0.666 . . . . 0.0 112.767 -172.673 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.469 HG22 ' SG ' ' A' ' 63' ' ' CYS . 8.9 p -81.8 120.4 33.27 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.091 0 N-CA-C 108.272 -1.01 . . . . 0.0 108.272 176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.5 pp -127.28 163.43 30.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.266 0 C-N-CA 124.005 0.922 . . . . 0.0 113.227 -179.306 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 67.7 m95 -81.56 120.81 25.53 Favored 'General case' 0 CA--C 1.503 -0.84 0 N-CA-C 106.593 -1.632 . . . . 0.0 106.593 178.66 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 26.0 t0 -64.0 -44.02 93.93 Favored 'General case' 0 C--N 1.313 -1.001 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 -175.587 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.488 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 25.2 m -68.25 -23.95 64.84 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.711 179.54 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.488 ' HG2' ' O ' ' A' ' 115' ' ' THR . 21.7 pt-20 59.46 17.23 5.82 Favored 'General case' 0 N--CA 1.492 1.664 0 C-N-CA 126.371 1.868 . . . . 0.0 110.332 -169.634 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.9 HG21 ' CG ' ' A' ' 67' ' ' PRO . 3.2 m 62.56 133.43 0.03 OUTLIER Pre-proline 0 C--N 1.311 -1.092 0 CA-C-N 114.005 -1.452 . . . . 0.0 114.322 -179.977 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 99' ' ' SER . 20.5 Cg_exo -62.56 146.67 95.43 Favored 'Trans proline' 0 C--N 1.319 -1.021 0 C-N-CA 123.669 2.913 . . . . 0.0 113.603 177.054 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 47.8 mm -111.28 131.19 63.22 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.064 0 CA-C-N 115.219 -0.9 . . . . 0.0 109.953 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.818 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 77.4 m -69.2 127.35 32.77 Favored 'General case' 0 C--O 1.242 0.666 0 N-CA-C 107.953 -1.129 . . . . 0.0 107.953 -176.823 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.409 ' HB3' HD11 ' A' ' 97' ' ' ILE . 54.1 t0 -146.6 169.96 17.9 Favored 'General case' 0 C--N 1.297 -1.707 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 -176.254 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 99.7 mtt180 -64.99 136.23 56.56 Favored 'General case' 0 C--N 1.302 -1.473 0 C-N-CA 119.376 -0.93 . . . . 0.0 111.375 -175.614 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.755 HG21 ' HA2' ' A' ' 182' ' ' GLY . 23.6 mt -70.19 109.8 5.54 Favored Pre-proline 0 C--N 1.308 -1.226 0 CA-C-N 114.336 -1.302 . . . . 0.0 112.004 -174.911 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.453 ' C ' ' H ' ' A' ' 126' ' ' GLY . 51.9 Cg_exo -56.52 -37.9 96.46 Favored 'Trans proline' 0 CA--C 1.541 0.847 0 C-N-CA 122.304 2.003 . . . . 0.0 111.4 173.869 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 47.7 t 66.88 -35.64 0.25 Allowed 'General case' 0 N--CA 1.5 2.059 0 C-N-CA 124.639 1.175 . . . . 0.0 111.934 -177.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.639 ' O ' ' HB3' ' A' ' 143' ' ' ASN . . . 82.59 169.26 43.74 Favored Glycine 0 CA--C 1.478 -2.239 0 CA-C-N 115.419 -0.81 . . . . 0.0 113.373 172.166 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.891 HD12 ' HD2' ' A' ' 128' ' ' PRO . 53.8 tp -61.14 131.48 92.06 Favored Pre-proline 0 N--CA 1.434 -1.237 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 176.953 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.891 ' HD2' HD12 ' A' ' 127' ' ' LEU . 12.3 Cg_exo -63.73 164.81 20.16 Favored 'Trans proline' 0 N--CA 1.449 -1.137 0 C-N-CA 122.546 2.164 . . . . 0.0 111.324 -175.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -60.42 142.21 97.49 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.142 1.228 . . . . 0.0 110.617 -178.139 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.4 m -67.92 133.29 48.86 Favored 'General case' 0 N--CA 1.431 -1.416 0 N-CA-C 109.742 -0.466 . . . . 0.0 109.742 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.838 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.6 tp -73.53 151.13 7.58 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.228 0 CA-C-O 121.482 0.658 . . . . 0.0 112.307 -176.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.9 m -63.3 -47.3 82.86 Favored 'General case' 0 C--N 1.295 -1.778 0 N-CA-C 113.857 1.058 . . . . 0.0 113.857 177.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.428 ' HB3' ' HB2' ' A' ' 155' ' ' ASN . 11.2 m120 -115.61 -2.64 12.44 Favored 'General case' 0 N--CA 1.5 2.062 0 N-CA-C 118.04 2.607 . . . . 0.0 118.04 -174.694 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.838 ' C ' HG21 ' A' ' 131' ' ' ILE . . . 166.46 131.54 1.27 Allowed Glycine 0 N--CA 1.484 1.878 0 O-C-N 121.069 -1.019 . . . . 0.0 111.266 -178.529 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.1 p-10 -64.19 172.92 2.18 Favored 'General case' 0 CA--C 1.51 -0.593 0 CA-C-O 121.641 0.734 . . . . 0.0 112.181 -167.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 41.5 p90 -68.44 147.09 52.55 Favored 'General case' 0 N--CA 1.422 -1.868 0 CA-C-O 122.74 1.257 . . . . 0.0 114.148 -171.058 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.51 HG22 ' HB ' ' A' ' 151' ' ' THR . 19.3 tt -66.48 -25.86 36.22 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.942 0 CA-C-N 113.295 -1.775 . . . . 0.0 112.404 -168.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 45.5 t -60.13 141.63 55.56 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-O 121.718 0.771 . . . . 0.0 109.692 -174.736 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.9 p -66.47 -31.14 71.69 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 114.518 -1.219 . . . . 0.0 111.184 -177.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 94.1 m-20 -95.48 133.97 38.86 Favored 'General case' 0 N--CA 1.43 -1.442 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 -176.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.504 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 99.7 mtt180 -103.01 138.72 39.51 Favored 'General case' 0 CA--C 1.476 -1.876 0 N-CA-C 114.153 1.168 . . . . 0.0 114.153 176.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.887 ' HA ' HD13 ' A' ' 127' ' ' LEU . 95.2 mt-10 84.38 125.06 0.04 OUTLIER 'General case' 0 CA--C 1.548 0.893 0 CA-C-N 112.727 -2.033 . . . . 0.0 110.526 171.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 126' ' ' GLY . 3.5 t-20 -87.24 108.24 18.85 Favored 'General case' 0 N--CA 1.489 1.519 0 N-CA-C 113.58 0.955 . . . . 0.0 113.58 -173.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 81.3 m-85 -64.0 -46.93 82.33 Favored 'General case' 0 CA--C 1.552 1.033 0 CA-C-N 114.884 -1.053 . . . . 0.0 113.69 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -152.71 176.42 11.78 Favored 'General case' 0 N--CA 1.494 1.766 0 N-CA-C 114.675 1.361 . . . . 0.0 114.675 -171.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.648 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 79.7 t80 -63.34 140.4 58.87 Favored 'General case' 0 N--CA 1.476 0.861 0 C-N-CA 125.459 1.504 . . . . 0.0 112.845 -179.456 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.513 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 102.14 -4.6 52.21 Favored Glycine 0 N--CA 1.468 0.788 0 CA-C-N 115.043 -0.981 . . . . 0.0 113.655 179.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 31.5 t -73.66 146.15 44.76 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-O 121.569 0.7 . . . . 0.0 111.297 179.264 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -133.73 139.2 49.22 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 O-C-N 121.892 -0.505 . . . . 0.0 109.671 175.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 26.9 m -132.47 160.06 42.77 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.074 0 N-CA-C 109.276 -0.638 . . . . 0.0 109.276 178.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.51 ' HB ' HG22 ' A' ' 137' ' ' ILE . 86.5 m -124.47 128.05 48.41 Favored 'General case' 0 N--CA 1.427 -1.619 0 CA-C-O 121.379 0.609 . . . . 0.0 111.127 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.638 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 84.2 m-85 -93.68 144.13 25.68 Favored 'General case' 0 CA--C 1.491 -1.314 0 N-CA-C 113.39 0.885 . . . . 0.0 113.39 179.226 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 37.2 ptt-85 -133.25 145.9 50.94 Favored 'General case' 0 N--CA 1.404 -2.755 0 C-N-CA 120.269 -0.572 . . . . 0.0 109.582 -178.259 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 91.9 m -89.81 140.16 29.87 Favored 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 107.592 -1.262 . . . . 0.0 107.592 -178.935 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.428 ' HB2' ' HB3' ' A' ' 133' ' ' ASN . 0.9 OUTLIER -60.44 121.29 59.14 Favored Pre-proline 0 CA--C 1.497 -1.081 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.789 -177.341 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -62.3 146.09 95.88 Favored 'Trans proline' 0 N--CA 1.428 -2.355 0 C-N-CA 122.501 2.134 . . . . 0.0 109.54 174.122 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.89 178.16 29.78 Favored Glycine 0 C--N 1.287 -2.148 0 N-CA-C 109.067 -1.613 . . . . 0.0 109.067 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 42.3 t -61.41 137.27 58.24 Favored 'General case' 0 C--N 1.308 -1.229 0 C-N-CA 119.055 -1.058 . . . . 0.0 109.313 -174.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 82.02 12.51 80.96 Favored Glycine 0 N--CA 1.433 -1.512 0 CA-C-N 115.382 -0.827 . . . . 0.0 113.696 -178.385 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.09 20.32 70.34 Favored Glycine 0 CA--C 1.535 1.289 0 C-N-CA 119.842 -1.171 . . . . 0.0 114.106 176.625 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 44.4 ttm180 -94.37 172.05 8.44 Favored 'General case' 0 C--N 1.303 -1.445 0 C-N-CA 123.461 0.705 . . . . 0.0 111.757 -179.572 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -102.09 108.39 19.79 Favored 'General case' 0 CA--C 1.479 -1.782 0 CA-C-O 122.538 1.161 . . . . 0.0 112.627 -179.104 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.531 HG23 ' CD2' ' A' ' 164' ' ' PHE . 34.9 m -112.21 -5.39 11.41 Favored 'Isoleucine or valine' 0 N--CA 1.408 -2.557 0 CA-C-N 113.373 -1.739 . . . . 0.0 109.342 174.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.531 ' CD2' HG23 ' A' ' 163' ' ' VAL . 84.0 m-85 -127.87 147.46 50.45 Favored 'General case' 0 CA--C 1.502 -0.867 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.975 177.784 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 85.1 tt0 -116.67 121.36 41.44 Favored 'General case' 0 C--O 1.198 -1.606 0 CA-C-N 115.212 -0.903 . . . . 0.0 109.371 177.936 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.537 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 5.5 tp -76.15 155.85 34.26 Favored 'General case' 0 C--N 1.316 -0.861 0 N-CA-C 108.089 -1.078 . . . . 0.0 108.089 175.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.537 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 11.7 p -60.88 -27.86 42.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 C-N-CA 122.864 0.466 . . . . 0.0 110.388 -176.48 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.97 -16.97 10.08 Favored Glycine 0 C--N 1.349 1.257 0 C-N-CA 120.961 -0.637 . . . . 0.0 114.377 176.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 27.8 tt0 -125.83 75.59 70.93 Favored Pre-proline 0 C--N 1.312 -1.058 0 CA-C-N 117.766 0.783 . . . . 0.0 108.973 177.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.621 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 32.2 Cg_endo -66.48 -21.8 52.72 Favored 'Trans proline' 0 N--CA 1.451 -1.014 0 C-N-CA 123.363 2.708 . . . . 0.0 114.973 -175.629 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 11.9 p -88.93 131.66 35.04 Favored 'General case' 0 N--CA 1.418 -2.04 0 CA-C-O 121.626 0.726 . . . . 0.0 111.628 -177.477 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.455 HD11 ' HE2' ' A' ' 152' ' ' TYR . 48.4 pt -129.36 154.54 40.29 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.769 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.162 176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.812 ' CD2' HG22 ' A' ' 175' ' ' THR . 3.9 p90 -147.75 161.85 40.4 Favored 'General case' 0 C--N 1.309 -1.175 0 N-CA-C 112.556 0.576 . . . . 0.0 112.556 -176.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.513 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 97.5 m -70.65 92.69 0.87 Allowed 'General case' 0 CA--C 1.557 1.247 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 176.491 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.812 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.3 p -115.01 16.97 17.06 Favored 'General case' 0 N--CA 1.491 1.594 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.763 -172.183 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.785 ' CB ' ' H ' ' A' ' 182' ' ' GLY . 11.8 t -59.12 136.97 58.12 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 112.337 0.495 . . . . 0.0 112.337 -162.348 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -126.75 -90.73 0.53 Allowed 'General case' 0 C--N 1.354 0.801 0 N-CA-C 114.724 1.379 . . . . 0.0 114.724 -171.256 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 44.4 p-10 -72.15 -43.23 64.96 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 117.857 2.54 . . . . 0.0 117.857 -168.005 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.627 ' O ' ' HG2' ' A' ' 180' ' ' GLN . 26.4 t70 -63.21 -48.55 77.81 Favored 'General case' 0 N--CA 1.494 1.727 0 CA-C-N 119.418 1.008 . . . . 0.0 110.822 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.627 ' HG2' ' O ' ' A' ' 179' ' ' ASP . 90.7 mm-40 -178.87 -167.42 0.11 Allowed 'General case' 0 CA--C 1.486 -1.486 0 C-N-CA 128.597 2.759 . . . . 0.0 106.444 178.036 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.418 ' HA ' ' OG ' ' A' ' 176' ' ' SER . 15.6 m -116.45 129.7 72.48 Favored 'Isoleucine or valine' 0 N--CA 1.4 -2.954 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.864 174.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.785 ' H ' ' CB ' ' A' ' 176' ' ' SER . . . 135.89 47.35 0.08 OUTLIER Glycine 0 CA--C 1.499 -0.945 0 CA-C-N 114.896 -1.047 . . . . 0.0 115.448 178.336 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.72 ' H ' ' HB2' ' A' ' 176' ' ' SER . 46.0 pt -138.52 -175.64 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.099 0 N-CA-C 108.196 -1.038 . . . . 0.0 108.196 175.033 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.43 ' CH2' ' HG3' ' A' ' 128' ' ' PRO . 88.1 m95 -108.39 162.76 13.81 Favored 'General case' 0 C--N 1.307 -1.275 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.185 177.859 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.615 ' HB3' HG21 ' A' ' 175' ' ' THR . 78.1 p -58.62 -33.63 70.25 Favored 'General case' 0 C--N 1.315 -0.927 0 CA-C-O 121.119 0.485 . . . . 0.0 111.203 -177.091 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -170.45 172.45 44.07 Favored Glycine 0 CA--C 1.481 -2.035 0 N-CA-C 110.238 -1.145 . . . . 0.0 110.238 175.529 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 22.8 Cg_exo -62.17 146.59 95.96 Favored 'Trans proline' 0 CA--C 1.495 -1.469 0 C-N-CA 122.534 2.156 . . . . 0.0 109.398 174.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.432 ' HA ' ' HD3' ' A' ' 189' ' ' PRO . . . -36.43 127.76 0.7 Allowed Pre-proline 0 CA--C 1.542 0.664 0 O-C-N 124.62 1.2 . . . . 0.0 110.698 -179.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.621 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.9 Cg_exo -60.92 144.67 99.62 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 121.924 1.75 . . . . 0.0 109.31 -175.367 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.54 HE21 HD11 ' A' ' 192' ' ' ILE . 13.2 pt20 -112.56 153.27 27.78 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-O 121.825 0.822 . . . . 0.0 113.067 -166.808 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 62.7 m -82.43 71.86 9.5 Favored 'General case' 0 N--CA 1.402 -2.856 0 CA-C-N 114.252 -1.34 . . . . 0.0 109.376 -174.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.54 HD11 HE21 ' A' ' 190' ' ' GLN . 21.9 mm . . . . . 0 C--O 1.265 1.918 0 CA-C-N 113.664 -1.607 . . . . 0.0 112.821 172.815 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.473 ' HB3' HG21 ' A' ' 111' ' ' VAL . 61.6 tttm . . . . . 0 N--CA 1.428 -1.571 0 N-CA-C 108.693 -0.854 . . . . 0.0 108.693 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 5.5 m -79.9 155.85 27.57 Favored 'General case' 0 C--N 1.287 -2.125 0 CA-C-N 115.991 -0.55 . . . . 0.0 110.38 179.67 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.609 ' HA ' HG12 ' A' ' 111' ' ' VAL . 0.1 OUTLIER -78.6 -172.85 3.12 Favored 'General case' 0 N--CA 1.446 -0.662 0 C-N-CA 118.234 -1.386 . . . . 0.0 109.546 179.899 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.43 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 30.2 mmt180 -76.96 -8.12 56.82 Favored 'General case' 0 C--N 1.31 -1.134 0 N-CA-C 114.206 1.188 . . . . 0.0 114.206 -173.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.43 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 82.99 147.81 0.1 Allowed Pre-proline 0 N--CA 1.469 0.507 0 O-C-N 123.941 0.775 . . . . 0.0 109.073 -176.93 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.428 ' HD2' HD22 ' A' ' 65' ' ' ASN . 51.5 Cg_exo -55.46 143.92 75.49 Favored 'Trans proline' 0 N--CA 1.457 -0.662 0 C-N-CA 122.252 1.968 . . . . 0.0 112.052 -179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.446 ' O ' ' HB2' ' A' ' 68' ' ' ASP . 1.0 OUTLIER -64.29 -20.91 67.18 Favored 'Trans proline' 0 C--N 1.359 1.087 0 C-N-CA 122.4 2.066 . . . . 0.0 110.989 177.661 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.446 ' HB2' ' O ' ' A' ' 67' ' ' PRO . 78.1 m-20 88.56 73.93 0.05 OUTLIER Pre-proline 0 N--CA 1.479 0.981 0 C-N-CA 124.919 1.288 . . . . 0.0 111.843 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.1 Cg_exo -63.13 146.69 94.42 Favored 'Trans proline' 0 N--CA 1.451 -1.002 0 C-N-CA 122.936 2.424 . . . . 0.0 111.964 177.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 78.1 t -68.19 141.55 17.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 CA-C-N 115.288 -0.869 . . . . 0.0 112.237 179.761 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 63.7 35.39 11.45 Favored 'General case' 0 N--CA 1.498 1.947 0 N-CA-C 114.376 1.25 . . . . 0.0 114.376 -179.011 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -161.55 129.4 2.1 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 119.986 -1.102 . . . . 0.0 113.181 173.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.5 ttm -126.92 136.04 51.74 Favored 'General case' 0 C--O 1.238 0.476 0 CA-C-O 121.218 0.532 . . . . 0.0 111.05 178.604 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.426 ' O ' HG12 ' A' ' 76' ' ' VAL . 55.8 t -123.32 134.61 65.78 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 CA-C-N 115.331 -0.849 . . . . 0.0 109.705 -176.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 5.3 t-80 -58.57 -41.78 86.48 Favored 'General case' 0 CA--C 1.546 0.806 0 N-CA-C 108.728 -0.842 . . . . 0.0 108.728 -177.525 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 ' O ' ' A' ' 74' ' ' VAL . 7.2 p 18.56 74.05 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 115.309 1.596 . . . . 0.0 115.309 177.212 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 6.9 tp -89.29 -49.52 13.92 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.695 176.556 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -115.56 9.83 15.47 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 121.481 0.658 . . . . 0.0 109.711 174.452 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.43 ' C ' ' HB2' ' A' ' 84' ' ' SER . . . -77.06 8.98 27.9 Favored Glycine 0 N--CA 1.435 -1.418 0 CA-C-N 115.067 -0.969 . . . . 0.0 111.628 -177.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.488 ' O ' ' SG ' ' A' ' 104' ' ' CYS . 46.5 pt -106.88 3.24 10.1 Favored 'Isoleucine or valine' 0 C--O 1.19 -2.054 0 N-CA-C 113.128 0.788 . . . . 0.0 113.128 178.321 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.585 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.5 mt-30 -94.6 170.86 9.17 Favored 'General case' 0 C--N 1.288 -2.096 0 O-C-N 120.656 -1.277 . . . . 0.0 112.928 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.5 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 91.6 t80 -60.42 127.46 31.85 Favored 'General case' 0 C--N 1.31 -1.123 0 C-N-CA 118.75 -1.18 . . . . 0.0 109.058 -174.906 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 91.37 -2.39 78.0 Favored Glycine 0 CA--C 1.544 1.904 0 CA-C-N 115.104 -0.953 . . . . 0.0 112.63 -176.197 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 103' ' ' THR . 91.7 p -78.94 166.51 22.3 Favored 'General case' 0 CA--C 1.509 -0.611 0 C-N-CA 123.641 0.777 . . . . 0.0 111.96 178.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.741 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 88.0 mt-30 -139.77 150.16 44.43 Favored 'General case' 0 N--CA 1.43 -1.431 0 CA-C-N 115.276 -0.874 . . . . 0.0 111.086 174.182 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.806 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.5 pt -125.79 150.45 31.18 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.3 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 173.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.5 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 11.1 mptt -125.67 139.13 53.81 Favored 'General case' 0 N--CA 1.48 1.032 0 C-N-CA 119.528 -0.869 . . . . 0.0 110.28 -174.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . 0.268 62.5 m-85 -122.89 130.53 52.97 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 116.715 2.117 . . . . 0.0 116.715 173.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 25.4 p -87.89 163.82 16.19 Favored 'General case' 0 CA--C 1.552 1.028 0 CA-C-N 114.4 -1.273 . . . . 0.0 112.238 174.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.484 ' SG ' HD22 ' A' ' 96' ' ' LEU . 82.9 m -137.44 172.85 12.36 Favored 'General case' 0 C--O 1.242 0.669 0 N-CA-C 109.57 -0.53 . . . . 0.0 109.57 173.506 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 16.8 p -77.39 166.7 22.79 Favored 'General case' 0 CA--C 1.552 1.022 0 C-N-CA 122.72 0.408 . . . . 0.0 110.537 176.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -65.31 133.38 51.29 Favored 'General case' 0 CA--C 1.543 0.684 0 CA-C-O 121.342 0.592 . . . . 0.0 112.361 -174.336 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.82 4.12 90.19 Favored Glycine 0 N--CA 1.476 1.343 0 CA-C-N 115.237 -0.892 . . . . 0.0 111.947 -177.724 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -118.9 144.55 46.35 Favored 'General case' 0 C--N 1.308 -1.214 0 C-N-CA 123.752 0.821 . . . . 0.0 110.742 177.848 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.594 ' HE ' HG23 ' A' ' 123' ' ' ILE . 11.0 ptp180 -133.56 170.12 15.98 Favored 'General case' 0 CA--C 1.497 -1.086 0 N-CA-C 108.363 -0.976 . . . . 0.0 108.363 173.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.525 HD12 ' HG2' ' A' ' 118' ' ' PRO . 3.3 mm? -78.45 132.04 37.13 Favored 'General case' 0 N--CA 1.417 -2.108 0 N-CA-C 106.678 -1.601 . . . . 0.0 106.678 173.014 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 50.0 mm -66.64 -23.6 31.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 CA-C-O 122.055 0.931 . . . . 0.0 111.727 177.73 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.444 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -117.59 -131.08 4.45 Favored Glycine 0 C--N 1.3 -1.44 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.669 ' O ' HG21 ' A' ' 115' ' ' THR . 45.5 m -107.4 120.21 41.55 Favored 'General case' 0 C--N 1.297 -1.706 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 178.439 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 76.3 p -62.02 -41.53 98.2 Favored 'General case' 0 CA--C 1.493 -1.213 0 C-N-CA 119.752 -0.779 . . . . 0.0 110.072 -179.828 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.806 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.3 m -83.45 150.26 26.15 Favored 'General case' 0 N--CA 1.411 -2.382 0 CA-C-N 115.326 -0.852 . . . . 0.0 111.066 176.178 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.741 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -139.28 145.08 38.7 Favored 'General case' 0 C--N 1.293 -1.89 0 CA-C-O 121.391 0.615 . . . . 0.0 110.832 176.991 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.546 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.6 m -122.4 131.67 53.99 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.237 -1.347 . . . . 0.0 108.606 178.642 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.5 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.265 56.3 m -60.96 136.4 58.07 Favored 'General case' 0 N--CA 1.479 0.98 0 C-N-CA 118.887 -1.125 . . . . 0.0 109.11 176.611 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.51 HG23 ' HB2' ' A' ' 114' ' ' ASP . 1.1 pt -130.47 165.09 31.63 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 CA-C-N 116.24 -0.436 . . . . 0.0 109.987 175.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.592 HD13 HG22 ' A' ' 111' ' ' VAL . 46.5 mm -101.35 119.56 49.72 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 C-N-CA 120.196 -0.602 . . . . 0.0 109.47 178.564 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.612 ' HB2' HD12 ' A' ' 112' ' ' ILE . 11.5 t -62.72 -42.71 99.79 Favored 'General case' 0 CA--C 1.505 -0.763 0 N-CA-C 108.879 -0.786 . . . . 0.0 108.879 176.113 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -174.55 -68.48 0.05 OUTLIER Glycine 0 N--CA 1.418 -2.546 0 N-CA-C 109.584 -1.406 . . . . 0.0 109.584 -179.104 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -116.64 11.42 14.68 Favored 'General case' 0 CA--C 1.557 1.214 0 CA-C-O 121.06 0.457 . . . . 0.0 110.934 177.33 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.3 t -146.28 168.44 21.06 Favored 'General case' 0 C--O 1.238 0.473 0 O-C-N 121.944 -0.472 . . . . 0.0 111.265 -175.257 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.609 HG12 ' HA ' ' A' ' 63' ' ' CYS . 41.7 t -111.37 126.78 68.78 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.103 0 CA-C-O 121.93 0.871 . . . . 0.0 110.463 -177.733 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.612 HD12 ' HB2' ' A' ' 107' ' ' SER . 0.2 OUTLIER -134.88 166.7 27.67 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.589 0 CA-C-N 113.351 -1.75 . . . . 0.0 109.643 177.692 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 98.9 m95 -81.57 133.41 35.38 Favored 'General case' 0 CA--C 1.546 0.804 0 C-N-CA 119.832 -0.747 . . . . 0.0 109.355 179.754 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.51 ' HB2' HG23 ' A' ' 105' ' ' ILE . 23.2 t70 -64.1 -41.48 97.27 Favored 'General case' 0 N--CA 1.483 1.225 0 CA-C-O 121.689 0.757 . . . . 0.0 111.022 178.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.669 HG21 ' O ' ' A' ' 99' ' ' SER . 92.2 m -62.96 -44.52 95.84 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 114.479 -1.237 . . . . 0.0 114.257 -176.766 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.514 ' HB2' ' O ' ' A' ' 115' ' ' THR . 97.7 mt-10 79.26 12.26 1.29 Allowed 'General case' 0 N--CA 1.499 1.994 0 C-N-CA 124.339 1.055 . . . . 0.0 108.947 -173.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER 50.2 115.11 0.0 OUTLIER Pre-proline 0 N--CA 1.485 1.3 0 C-N-CA 125.82 1.648 . . . . 0.0 114.732 -179.427 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.525 ' HG2' HD12 ' A' ' 96' ' ' LEU . 84.3 Cg_endo -73.78 159.28 45.64 Favored 'Trans proline' 0 CA--C 1.528 0.207 1 C-N-CA 125.592 4.195 . . . . 0.0 114.547 -178.322 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -109.55 131.05 61.51 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.062 0 CA-C-N 114.99 -1.004 . . . . 0.0 109.586 176.503 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 99.9 m -70.36 130.7 42.65 Favored 'General case' 0 C--O 1.24 0.565 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 53.4 t0 -153.63 176.09 12.48 Favored 'General case' 0 C--N 1.302 -1.467 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.421 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 27.0 mmm180 -66.57 137.72 56.97 Favored 'General case' 0 CA--C 1.512 -0.5 0 N-CA-C 108.965 -0.754 . . . . 0.0 108.965 -176.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.594 HG23 ' HE ' ' A' ' 95' ' ' ARG . 54.4 mt -67.09 110.5 5.2 Favored Pre-proline 0 C--N 1.317 -0.837 0 N-CA-C 113.21 0.818 . . . . 0.0 113.21 -174.138 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.421 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 52.8 Cg_exo -56.14 -35.2 94.8 Favored 'Trans proline' 0 C--N 1.351 0.702 0 C-N-CA 122.77 2.313 . . . . 0.0 110.981 172.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 89.65 -8.12 0.39 Allowed 'General case' 0 N--CA 1.471 0.62 0 C-N-CA 125.481 1.512 . . . . 0.0 112.234 179.967 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.43 22.8 72.21 Favored Glycine 0 C--O 1.247 0.965 0 C-N-CA 120.637 -0.792 . . . . 0.0 113.199 174.296 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.717 HD11 ' HB3' ' A' ' 142' ' ' GLU . 9.0 tp 72.09 138.39 0.06 OUTLIER Pre-proline 0 N--CA 1.448 -0.557 0 C-N-CA 123.746 0.818 . . . . 0.0 110.333 -177.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.601 ' HG3' ' H ' ' A' ' 143' ' ' ASN . 94.7 Cg_endo -83.01 153.43 14.56 Favored 'Trans proline' 0 N--CA 1.439 -1.708 0 C-N-CA 122.118 1.879 . . . . 0.0 111.602 -176.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.556 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 42.3 Cg_endo -62.87 144.51 93.54 Favored 'Trans proline' 0 N--CA 1.452 -0.935 0 C-N-CA 122.14 1.893 . . . . 0.0 111.361 176.585 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.428 HG22 ' H ' ' A' ' 131' ' ' ILE . 20.4 m -76.88 165.92 24.04 Favored 'General case' 0 C--N 1.315 -0.918 0 N-CA-C 107.215 -1.402 . . . . 0.0 107.215 177.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.83 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.7 tp -103.44 140.27 22.11 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.699 0 CA-C-O 122.048 0.928 . . . . 0.0 112.549 -171.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.9 m -60.37 -46.45 89.91 Favored 'General case' 0 C--N 1.301 -1.501 0 CA-C-N 114.364 -1.289 . . . . 0.0 112.93 179.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 22.2 m120 -111.34 -29.87 7.64 Favored 'General case' 0 N--CA 1.479 0.981 0 N-CA-C 116.111 1.893 . . . . 0.0 116.111 -170.324 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.83 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -171.21 132.83 2.57 Favored Glycine 0 C--N 1.309 -0.951 0 C-N-CA 120.147 -1.025 . . . . 0.0 111.521 -179.74 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 46.0 p-10 -55.3 -178.33 0.02 OUTLIER 'General case' 0 N--CA 1.484 1.262 0 C-N-CA 123.984 0.914 . . . . 0.0 112.805 -173.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.45 ' HZ ' ' N ' ' A' ' 142' ' ' GLU . 49.5 p90 -102.08 162.06 13.2 Favored 'General case' 0 N--CA 1.425 -1.723 0 CA-C-O 122.37 1.081 . . . . 0.0 113.582 -173.549 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.525 HD12 ' HB ' ' A' ' 151' ' ' THR . 86.1 mt -64.38 -42.11 94.36 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 CA-C-N 112.544 -2.117 . . . . 0.0 113.577 -175.413 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 19.3 m -61.17 143.78 54.88 Favored 'General case' 0 C--N 1.301 -1.505 0 CA-C-O 121.563 0.697 . . . . 0.0 110.707 -176.563 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.3 p -65.53 -34.67 78.8 Favored 'General case' 0 CA--C 1.539 0.53 0 N-CA-C 115.397 1.629 . . . . 0.0 115.397 -167.513 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -98.62 111.74 24.01 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 -179.644 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.514 ' HG2' ' HG3' ' A' ' 142' ' ' GLU . 61.7 ttp180 -65.21 135.22 55.16 Favored 'General case' 0 N--CA 1.448 -0.568 0 C-N-CA 120.245 -0.582 . . . . 0.0 109.646 -176.791 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.717 ' HB3' HD11 ' A' ' 127' ' ' LEU . 98.2 mt-10 69.46 98.66 0.06 Allowed 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 122.374 1.083 . . . . 0.0 111.09 -178.428 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.601 ' H ' ' HG3' ' A' ' 128' ' ' PRO . 21.5 t-20 -70.16 143.52 52.27 Favored 'General case' 0 CA--C 1.554 1.106 0 N-CA-C 116.514 2.042 . . . . 0.0 116.514 -169.418 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.412 ' CD2' ' HB2' ' A' ' 145' ' ' HIS . 49.9 p90 -71.79 -42.9 66.56 Favored 'General case' 0 CA--C 1.576 1.959 0 N-CA-C 119.435 3.124 . . . . 0.0 119.435 -177.203 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.412 ' HB2' ' CD2' ' A' ' 144' ' ' PHE . 0.1 OUTLIER -153.6 170.0 21.89 Favored 'General case' 0 N--CA 1.52 3.051 0 N-CA-C 116.63 2.085 . . . . 0.0 116.63 -167.999 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.54 ' HA ' ' HB3' ' A' ' 174' ' ' CYS . 83.3 t80 -63.03 133.51 54.67 Favored 'General case' 0 C--N 1.358 0.941 0 CA-C-N 114.438 -1.255 . . . . 0.0 112.244 173.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.36 -15.99 59.54 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 114.353 -1.294 . . . . 0.0 111.268 -179.061 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.599 ' HB3' HD21 ' A' ' 143' ' ' ASN . 70.8 m -77.6 149.39 34.79 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-N 115.673 -0.263 . . . . 0.0 110.412 176.851 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.401 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -130.01 136.86 57.91 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.282 0 CA-C-O 121.067 0.461 . . . . 0.0 110.393 179.528 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 17.4 m -122.08 133.05 69.61 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.264 178.145 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 85.1 m -111.73 125.28 53.81 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.477 -174.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.531 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 97.2 m-85 -105.28 143.4 33.51 Favored 'General case' 0 CA--C 1.491 -1.32 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.361 -174.23 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.409 HH11 HG13 ' A' ' 137' ' ' ILE . 79.7 mtm-85 -124.53 146.9 48.74 Favored 'General case' 0 N--CA 1.415 -2.195 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 -171.122 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.773 ' SG ' HD12 ' A' ' 166' ' ' LEU . 97.9 m -97.22 159.57 14.84 Favored 'General case' 0 C--N 1.306 -1.286 0 N-CA-C 107.017 -1.475 . . . . 0.0 107.017 175.218 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.768 ' O ' HG22 ' A' ' 163' ' ' VAL . 32.3 m-80 -73.02 114.59 32.23 Favored Pre-proline 0 C--N 1.321 -0.642 0 N-CA-C 113.635 0.976 . . . . 0.0 113.635 -169.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 154' ' ' CYS . 7.9 Cg_exo -70.95 153.64 63.36 Favored 'Trans proline' 0 CA--C 1.544 1.006 0 C-N-CA 124.386 3.391 . . . . 0.0 111.839 173.025 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -86.25 -158.01 30.57 Favored Glycine 0 N--CA 1.442 -0.935 0 N-CA-C 111.136 -0.785 . . . . 0.0 111.136 176.625 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 41.2 t -60.87 -43.56 98.23 Favored 'General case' 0 N--CA 1.451 -0.417 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 177.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -94.07 -171.56 38.55 Favored Glycine 0 C--O 1.237 0.317 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.818 176.01 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -72.34 -0.63 47.25 Favored Glycine 0 C--N 1.339 0.74 0 C-N-CA 121.431 -0.414 . . . . 0.0 112.255 -179.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -65.4 131.64 46.97 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 110.162 -0.311 . . . . 0.0 110.162 178.033 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.604 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 30.2 tttp -82.62 121.22 26.54 Favored 'General case' 0 N--CA 1.434 -1.268 0 N-CA-C 104.929 -2.248 . . . . 0.0 104.929 175.061 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.768 HG22 ' O ' ' A' ' 155' ' ' ASN . 21.4 m -69.21 -33.94 60.67 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.613 0 CA-C-O 122.015 0.912 . . . . 0.0 110.699 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.636 ' CZ ' ' HB2' ' A' ' 155' ' ' ASN 0.309 8.7 p90 -132.01 151.17 51.9 Favored 'General case' 0 N--CA 1.398 -3.038 0 CA-C-N 114.059 -1.428 . . . . 0.0 114.086 175.717 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.602 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 69.3 mt-10 -84.74 149.67 25.61 Favored 'General case' 0 C--O 1.192 -1.932 0 CA-C-N 113.02 -1.9 . . . . 0.0 111.775 -167.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.773 HD12 ' SG ' ' A' ' 154' ' ' CYS . 7.2 tt -117.16 165.45 13.4 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 106.951 -1.5 . . . . 0.0 106.951 177.5 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.621 ' N ' HD23 ' A' ' 166' ' ' LEU . 53.5 t -61.04 -45.0 99.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.449 0 N-CA-C 111.907 0.336 . . . . 0.0 111.907 -175.824 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.458 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 132.91 -12.87 5.05 Favored Glycine 0 CA--C 1.484 -1.895 0 N-CA-C 110.28 -1.128 . . . . 0.0 110.28 -178.728 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 4.3 tp10 -114.7 63.26 1.41 Allowed Pre-proline 0 N--CA 1.437 -1.112 0 CA-C-N 114.23 -0.985 . . . . 0.0 108.543 175.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -66.0 -21.77 56.15 Favored 'Trans proline' 0 C--N 1.379 2.173 0 C-N-CA 121.117 1.212 . . . . 0.0 110.871 -179.439 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.534 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 48.8 m -101.42 123.07 44.9 Favored 'General case' 0 N--CA 1.414 -2.265 0 CA-C-N 114.913 -1.04 . . . . 0.0 108.352 179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.5 pt -124.68 152.14 30.6 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.325 0 C-N-CA 119.69 -0.804 . . . . 0.0 109.404 179.167 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.401 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 47.7 p90 -142.6 158.39 43.71 Favored 'General case' 0 CA--C 1.477 -1.832 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.009 -177.244 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.54 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 16.6 t -70.26 108.24 4.09 Favored 'General case' 0 C--N 1.304 -1.404 0 C-N-CA 119.979 -0.688 . . . . 0.0 109.262 -177.084 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.559 HG23 ' O ' ' A' ' 175' ' ' THR . 15.0 t -128.2 72.61 1.43 Allowed 'General case' 0 N--CA 1.44 -0.956 0 CA-C-O 124.058 1.885 . . . . 0.0 109.931 175.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.67 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 74.2 m -70.49 -12.99 61.93 Favored 'General case' 0 C--N 1.277 -2.559 0 CA-C-N 112.542 -2.117 . . . . 0.0 110.563 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.0 m-20 -63.48 -40.46 97.16 Favored 'General case' 0 C--N 1.303 -1.419 0 CA-C-N 114.188 -1.369 . . . . 0.0 111.484 -178.134 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 66.6 t0 -84.89 -101.77 0.06 Allowed 'General case' 0 CA--C 1.568 1.643 0 N-CA-C 115.127 1.528 . . . . 0.0 115.127 -169.113 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 27.4 t70 -62.75 -43.9 97.61 Favored 'General case' 0 N--CA 1.481 1.078 0 N-CA-C 113.961 1.097 . . . . 0.0 113.961 -170.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 183' ' ' ILE . 65.4 tp60 -149.31 166.99 27.33 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 -177.231 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 20.6 m -106.22 132.85 52.32 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.279 0 CA-C-O 121.953 0.883 . . . . 0.0 110.956 -176.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.67 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 86.89 29.53 23.1 Favored Glycine 0 N--CA 1.418 -2.544 0 CA-C-N 114.253 -1.339 . . . . 0.0 113.141 -175.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 180' ' ' GLN . 42.4 pt -125.0 166.44 20.61 Favored 'Isoleucine or valine' 0 C--O 1.238 0.494 0 CA-C-O 122.378 1.085 . . . . 0.0 111.853 -175.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.401 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 89.6 m95 -97.44 159.87 14.66 Favored 'General case' 0 C--N 1.305 -1.348 0 CA-C-N 113.25 -1.795 . . . . 0.0 109.34 177.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.535 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 77.8 p -58.05 -33.65 69.23 Favored 'General case' 0 N--CA 1.473 0.724 0 CA-C-O 121.4 0.619 . . . . 0.0 109.772 -175.059 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -154.49 135.6 4.8 Favored Glycine 0 N--CA 1.409 -3.155 0 N-CA-C 108.981 -1.648 . . . . 0.0 108.981 172.158 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . 0.413 ' O ' ' C ' ' A' ' 188' ' ' ALA . 24.2 Cg_exo -61.18 144.92 99.17 Favored 'Trans proline' 0 N--CA 1.436 -1.909 0 N-CA-C 107.28 -1.854 . . . . 0.0 107.28 174.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -22.13 109.99 0.13 Allowed Pre-proline 0 C--O 1.247 0.927 0 O-C-N 125.229 1.58 . . . . 0.0 111.834 -172.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.476 ' HB2' HD21 ' A' ' 166' ' ' LEU . 30.6 Cg_endo -61.58 144.04 97.37 Favored 'Trans proline' 0 CA--C 1.483 -2.069 0 C-N-CA 121.993 1.795 . . . . 0.0 111.666 -173.459 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.524 ' NE2' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -108.93 146.28 34.06 Favored 'General case' 0 N--CA 1.403 -2.819 0 CA-C-N 114.651 -1.159 . . . . 0.0 113.005 -171.266 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.602 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 62.5 m -80.32 73.17 7.2 Favored 'General case' 0 N--CA 1.422 -1.85 0 CA-C-N 114.585 -1.189 . . . . 0.0 109.675 -176.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.524 HG13 ' NE2' ' A' ' 190' ' ' GLN . 44.6 mm . . . . . 0 C--O 1.259 1.601 0 CA-C-N 113.273 -1.785 . . . . 0.0 110.776 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 44.8 mtmt . . . . . 0 CA--C 1.493 -1.247 0 N-CA-C 111.266 0.099 . . . . 0.0 111.266 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.598 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 1.9 t -74.36 141.71 45.15 Favored 'General case' 0 N--CA 1.429 -1.5 0 O-C-N 123.836 0.71 . . . . 0.0 112.115 171.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 62.0 m -92.84 -163.61 1.07 Allowed 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 115.257 -0.883 . . . . 0.0 112.777 -175.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.473 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 67.7 mtt180 -63.06 -39.61 95.24 Favored 'General case' 0 CA--C 1.511 -0.523 0 CA-C-O 118.45 -0.786 . . . . 0.0 111.326 -173.556 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.473 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 5.6 t30 126.03 146.65 0.0 OUTLIER Pre-proline 0 N--CA 1.506 2.331 0 O-C-N 125.361 1.663 . . . . 0.0 109.36 -177.001 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.593 ' HD3' HG22 ' A' ' 80' ' ' ILE . 13.3 Cg_exo -36.47 165.17 0.01 OUTLIER 'Trans proline' 0 CA--C 1.544 0.994 0 C-N-CA 125.189 3.926 . . . . 0.0 113.724 174.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.543 ' HD3' HG21 ' A' ' 117' ' ' THR . 39.0 Cg_endo -63.28 -23.9 72.17 Favored 'Trans proline' 0 C--N 1.364 1.369 0 C-N-CA 121.614 1.543 . . . . 0.0 110.775 -174.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.455 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 14.6 t70 50.29 43.4 1.64 Allowed Pre-proline 0 CA--C 1.552 1.036 0 CA-C-N 114.331 -1.304 . . . . 0.0 113.151 177.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.496 ' HB2' ' H ' ' A' ' 72' ' ' GLY . 18.6 Cg_exo -62.66 144.34 93.95 Favored 'Trans proline' 0 C--N 1.381 2.281 0 CA-C-N 119.876 0.991 . . . . 0.0 110.686 175.378 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 10.7 p -64.58 -37.84 81.11 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.82 0.819 . . . . 0.0 109.454 174.16 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -63.63 -40.16 96.18 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 114.062 -1.426 . . . . 0.0 111.029 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.496 ' H ' ' HB2' ' A' ' 69' ' ' PRO . . . -95.76 -178.85 36.42 Favored Glycine 0 C--O 1.223 -0.571 0 N-CA-C 115.877 1.111 . . . . 0.0 115.877 -172.747 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mmm -123.14 152.66 40.92 Favored 'General case' 0 CA--C 1.483 -1.605 0 CA-C-N 113.918 -1.141 . . . . 0.0 109.342 176.888 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.7 t -117.38 131.35 70.37 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.83 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 -176.309 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 78.0 m80 -128.78 88.54 2.74 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-O 120.934 0.397 . . . . 0.0 110.011 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.539 HG22 ' H ' ' A' ' 79' ' ' GLY . 5.7 p -141.37 139.42 32.56 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 177.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.626 HG23 ' H ' ' A' ' 78' ' ' LYS . 10.6 tp -71.81 -64.54 0.79 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.98 0 C-N-CA 119.271 -0.971 . . . . 0.0 109.898 175.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.626 ' H ' HG23 ' A' ' 77' ' ' ILE . 75.7 mmtt -150.8 12.54 0.69 Allowed 'General case' 0 C--O 1.237 0.396 0 C-N-CA 126.026 1.73 . . . . 0.0 106.415 174.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.539 ' H ' HG22 ' A' ' 76' ' ' VAL . . . -76.48 51.03 2.92 Favored Glycine 0 C--O 1.216 -0.991 0 CA-C-N 113.837 -1.529 . . . . 0.0 114.273 -170.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.593 HG22 ' HD3' ' A' ' 66' ' ' PRO . 49.7 pt -102.82 3.33 10.68 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.324 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 179.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.598 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 83.5 mt-30 -85.26 -174.96 5.5 Favored 'General case' 0 C--N 1.295 -1.771 0 CA-C-N 114.087 -1.415 . . . . 0.0 112.539 -172.701 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.592 ' CE1' ' HA ' ' A' ' 105' ' ' ILE . 82.7 t80 -58.73 -46.27 87.76 Favored 'General case' 0 N--CA 1.517 2.923 0 CA-C-N 115.315 -0.857 . . . . 0.0 113.195 -179.907 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -95.5 22.09 40.89 Favored Glycine 0 C--N 1.261 -3.632 0 N-CA-C 111.975 -0.45 . . . . 0.0 111.975 -175.248 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.453 ' HB3' ' CA ' ' A' ' 79' ' ' GLY . 58.0 m -126.44 151.98 47.01 Favored 'General case' 0 N--CA 1.416 -2.128 0 CA-C-O 122.013 0.911 . . . . 0.0 110.831 -173.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.416 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.2 mt-30 -125.41 134.72 52.03 Favored 'General case' 0 CA--C 1.507 -0.676 0 CA-C-N 114.397 -1.274 . . . . 0.0 111.025 -176.27 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.669 ' O ' ' HA ' ' A' ' 101' ' ' SER . 44.1 pt -99.82 129.3 50.64 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.468 0 CA-C-N 114.498 -1.228 . . . . 0.0 110.918 177.259 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HD2' ' N ' ' A' ' 87' ' ' LYS . 12.1 mptt -99.0 140.49 33.07 Favored 'General case' 0 C--N 1.315 -0.912 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.752 -177.168 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.801 ' HE1' ' SG ' ' A' ' 120' ' ' CYS . 45.1 t80 -142.34 149.53 39.56 Favored 'General case' 0 N--CA 1.433 -1.285 0 N-CA-C 108.215 -1.031 . . . . 0.0 108.215 178.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 68.5 m -132.27 151.31 51.89 Favored 'General case' 0 N--CA 1.446 -0.639 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 178.468 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.471 ' SG ' HD22 ' A' ' 96' ' ' LEU . 72.1 m -116.74 166.34 12.25 Favored 'General case' 0 C--O 1.245 0.837 0 N-CA-C 109.341 -0.615 . . . . 0.0 109.341 179.026 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 20.1 p -80.11 166.13 21.79 Favored 'General case' 0 N--CA 1.44 -0.96 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 178.045 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -64.02 132.95 52.15 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-O 120.99 0.424 . . . . 0.0 110.317 -179.243 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 94.23 -5.38 71.39 Favored Glycine 0 C--O 1.256 1.484 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.298 -176.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -124.82 143.32 50.88 Favored 'General case' 0 CA--C 1.54 0.588 0 CA-C-O 120.983 0.42 . . . . 0.0 111.301 179.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.562 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 4.0 ptt180 -138.49 164.32 29.71 Favored 'General case' 0 CA--C 1.49 -1.331 0 CA-C-O 121.505 0.669 . . . . 0.0 111.52 178.284 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.562 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.9 mm? -77.19 137.69 39.01 Favored 'General case' 0 N--CA 1.421 -1.891 0 CA-C-N 114.968 -1.014 . . . . 0.0 108.712 176.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.505 ' O ' HG22 ' A' ' 97' ' ' ILE . 51.3 mm -85.7 17.04 0.52 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 CA-C-O 122.356 1.074 . . . . 0.0 109.208 -179.34 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.407 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -159.48 -137.0 2.14 Favored Glycine 0 N--CA 1.431 -1.646 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.258 -178.641 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.491 ' HB2' HG21 ' A' ' 115' ' ' THR . 75.3 m -108.78 120.57 42.87 Favored 'General case' 0 C--N 1.285 -2.226 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 -179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.2 p -60.99 -33.43 73.23 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.148 -174.619 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 63.7 m -111.48 122.0 46.68 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.07 176.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.416 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -106.31 145.21 31.93 Favored 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 115.71 -0.677 . . . . 0.0 111.16 -179.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 59.3 m -110.91 127.29 55.41 Favored 'General case' 0 N--CA 1.424 -1.749 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 176.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.559 ' CB ' ' HA ' ' A' ' 82' ' ' PHE . 16.4 m -71.68 142.44 49.87 Favored 'General case' 0 C--N 1.279 -2.458 0 CA-C-N 115.657 -0.701 . . . . 0.0 111.386 176.162 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.592 ' HA ' ' CE1' ' A' ' 82' ' ' PHE . 2.4 pp -128.1 161.85 35.51 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.178 0 N-CA-C 107.642 -1.244 . . . . 0.0 107.642 174.198 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.57 HG22 ' H ' ' A' ' 108' ' ' GLY . 82.2 mt -106.43 125.31 62.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.881 0 C-N-CA 119.458 -0.897 . . . . 0.0 109.634 -177.773 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 58.6 m -85.77 -9.23 57.42 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.587 -178.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.57 ' H ' HG22 ' A' ' 106' ' ' ILE . . . 149.8 -102.35 0.23 Allowed Glycine 0 CA--C 1.483 -1.964 0 N-CA-C 110.04 -1.224 . . . . 0.0 110.04 -179.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 72.8 m-20 -78.99 -6.56 56.61 Favored 'General case' 0 C--N 1.315 -0.914 0 N-CA-C 111.717 0.266 . . . . 0.0 111.717 -179.479 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.6 t -143.55 162.22 36.43 Favored 'General case' 0 CA--C 1.482 -1.638 0 N-CA-C 109.138 -0.689 . . . . 0.0 109.138 -176.664 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . . . . . . . . . 11.7 p -118.83 127.97 75.7 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.731 0 CA-C-O 122.116 0.96 . . . . 0.0 109.838 -179.37 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.08 163.65 31.53 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.739 0 CA-C-N 114.757 -1.111 . . . . 0.0 113.046 -179.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.3 m95 -79.84 132.11 36.03 Favored 'General case' 0 N--CA 1.448 -0.537 0 N-CA-C 106.947 -1.501 . . . . 0.0 106.947 -176.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.539 ' HB2' HG12 ' A' ' 105' ' ' ILE . 30.6 t70 -96.19 -9.45 30.49 Favored 'General case' 0 N--CA 1.482 1.148 0 CA-C-O 121.502 0.668 . . . . 0.0 112.159 -175.562 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.491 HG21 ' HB2' ' A' ' 99' ' ' SER . 0.9 OUTLIER -100.4 -6.45 25.67 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -177.377 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 57.6 mp0 46.83 60.26 3.48 Favored 'General case' 0 N--CA 1.471 0.605 0 C-N-CA 123.323 0.649 . . . . 0.0 112.734 -176.346 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.543 HG21 ' HD3' ' A' ' 67' ' ' PRO . 28.4 m -9.7 120.99 0.03 OUTLIER Pre-proline 0 N--CA 1.487 1.423 0 O-C-N 125.25 1.594 . . . . 0.0 114.38 174.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.407 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 93.0 Cg_endo -72.66 157.62 51.99 Favored 'Trans proline' 0 N--CA 1.452 -0.953 1 C-N-CA 125.41 4.073 . . . . 0.0 114.301 -175.216 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 96.7 mt -113.74 131.49 65.44 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.802 0 CA-C-N 114.082 -1.417 . . . . 0.0 109.294 178.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.801 ' SG ' ' HE1' ' A' ' 88' ' ' TYR . 72.7 m -68.95 135.19 50.59 Favored 'General case' 0 N--CA 1.473 0.724 0 N-CA-C 108.274 -1.01 . . . . 0.0 108.274 -178.936 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -148.05 165.39 30.92 Favored 'General case' 0 C--N 1.274 -2.698 0 N-CA-C 104.501 -2.407 . . . . 0.0 104.501 177.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.9 ttt180 -65.14 130.64 44.1 Favored 'General case' 0 N--CA 1.431 -1.403 0 N-CA-C 107.771 -1.196 . . . . 0.0 107.771 -178.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.542 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 65.2 mt -48.18 105.25 0.48 Allowed Pre-proline 0 CA--C 1.494 -1.18 0 O-C-N 124.523 1.14 . . . . 0.0 112.014 -171.204 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_exo -62.18 140.51 83.96 Favored 'Trans proline' 0 N--CA 1.419 -2.888 0 N-CA-C 107.196 -1.886 . . . . 0.0 107.196 173.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.485 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.2 OUTLIER -94.23 -23.99 17.66 Favored 'General case' 0 C--N 1.286 -2.19 0 C-N-CA 119.909 -0.716 . . . . 0.0 110.523 -179.403 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.91 -172.6 53.07 Favored Glycine 0 N--CA 1.415 -2.727 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 -176.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 5.6 mp -78.06 137.69 61.12 Favored Pre-proline 0 N--CA 1.423 -1.806 0 C-N-CA 118.508 -1.277 . . . . 0.0 109.126 174.927 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_endo -72.12 152.91 57.04 Favored 'Trans proline' 0 N--CA 1.436 -1.907 0 C-N-CA 121.611 1.541 . . . . 0.0 110.869 -178.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 84.1 Cg_endo -67.75 154.47 73.11 Favored 'Trans proline' 0 N--CA 1.445 -1.379 0 C-N-CA 122.432 2.088 . . . . 0.0 110.275 174.999 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . 0.631 ' OG1' ' HA ' ' A' ' 135' ' ' ASP . 9.5 t -102.88 157.65 16.82 Favored 'General case' 0 C--N 1.291 -1.94 0 C-N-CA 119.583 -0.847 . . . . 0.0 110.89 -175.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.447 HD13 ' HB3' ' A' ' 152' ' ' TYR . 11.4 tp -80.41 161.67 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 121.648 0.737 . . . . 0.0 110.277 -175.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 71.2 m -61.43 -44.83 96.44 Favored 'General case' 0 C--N 1.295 -1.786 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.217 -179.746 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 98.0 m-20 -97.43 11.99 34.81 Favored 'General case' 0 N--CA 1.485 1.304 0 N-CA-C 114.315 1.228 . . . . 0.0 114.315 -174.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.433 ' N ' HG23 ' A' ' 131' ' ' ILE . . . 166.86 -126.48 1.45 Allowed Glycine 0 C--O 1.21 -1.351 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -179.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.631 ' HA ' ' OG1' ' A' ' 130' ' ' THR . 98.2 m-20 -123.7 -89.96 0.58 Allowed 'General case' 0 C--N 1.35 0.629 0 CA-C-O 121.632 0.73 . . . . 0.0 110.943 174.864 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.465 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 25.3 p90 -161.17 166.78 27.33 Favored 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 124.323 1.049 . . . . 0.0 112.98 -177.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.663 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 16.1 tt -101.2 6.38 9.88 Favored 'Isoleucine or valine' 0 CA--C 1.551 0.989 0 N-CA-C 109.32 -0.622 . . . . 0.0 109.32 -174.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 36.8 t -62.74 146.2 52.98 Favored 'General case' 0 N--CA 1.477 0.88 0 CA-C-O 121.46 0.648 . . . . 0.0 112.672 -169.21 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.0 m -62.42 -45.48 92.92 Favored 'General case' 0 N--CA 1.437 -1.122 0 CA-C-N 114.335 -1.302 . . . . 0.0 110.044 -178.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -101.69 131.32 48.01 Favored 'General case' 0 CA--C 1.536 0.408 0 N-CA-C 108.677 -0.86 . . . . 0.0 108.677 175.01 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.465 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 77.4 ttt-85 -65.03 -42.57 94.22 Favored 'General case' 0 C--O 1.205 -1.28 0 CA-C-O 121.535 0.683 . . . . 0.0 111.712 -175.457 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -119.6 138.13 53.42 Favored 'General case' 0 C--N 1.317 -0.807 0 O-C-N 121.076 -1.015 . . . . 0.0 110.179 -175.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.556 HD21 ' CG1' ' A' ' 150' ' ' VAL . 92.0 m-20 -98.64 133.74 42.55 Favored 'General case' 0 N--CA 1.435 -1.21 0 CA-C-O 121.538 0.685 . . . . 0.0 112.776 -170.703 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.8 m-85 -90.97 -59.57 2.13 Favored 'General case' 0 N--CA 1.436 -1.129 0 N-CA-C 115.076 1.509 . . . . 0.0 115.076 -174.591 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 75.5 m80 -143.77 -173.0 3.85 Favored 'General case' 0 C--N 1.341 0.237 0 N-CA-C 113.453 0.909 . . . . 0.0 113.453 -170.611 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.542 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 77.8 t80 -61.27 139.02 58.23 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 124.315 1.046 . . . . 0.0 111.981 -174.458 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.85 -9.71 60.23 Favored Glycine 0 N--CA 1.44 -1.056 0 CA-C-N 114.96 -1.018 . . . . 0.0 111.807 -179.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 48.1 t -70.45 141.73 52.03 Favored 'General case' 0 N--CA 1.431 -1.376 0 N-CA-C 109.305 -0.628 . . . . 0.0 109.305 175.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -138.41 143.04 33.57 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 O-C-N 123.228 0.33 . . . . 0.0 110.411 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.556 ' CG1' HD21 ' A' ' 143' ' ' ASN . 34.2 m -131.16 158.97 43.36 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-O 121.206 0.526 . . . . 0.0 109.626 176.635 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.663 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -124.31 131.56 53.52 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 116.179 -0.464 . . . . 0.0 109.753 -179.608 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE2' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.06 138.11 40.34 Favored 'General case' 0 C--N 1.288 -2.081 0 CA-C-O 120.851 0.358 . . . . 0.0 110.147 -179.872 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.495 ' HD3' HD12 ' A' ' 137' ' ' ILE . 36.6 ptt-85 -130.99 144.32 51.39 Favored 'General case' 0 N--CA 1.419 -2.007 0 N-CA-C 105.664 -1.976 . . . . 0.0 105.664 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.575 ' SG ' HD12 ' A' ' 166' ' ' LEU . 84.8 m -92.13 137.9 31.98 Favored 'General case' 0 C--N 1.275 -2.645 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 179.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.646 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 18.8 t30 -97.71 136.04 21.36 Favored Pre-proline 0 N--CA 1.423 -1.822 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.035 -171.082 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.495 ' HD2' ' OD1' ' A' ' 155' ' ' ASN . 88.8 Cg_endo -68.87 154.01 71.75 Favored 'Trans proline' 0 N--CA 1.45 -1.065 0 C-N-CA 123.461 2.774 . . . . 0.0 112.821 179.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.22 172.78 37.17 Favored Glycine 0 N--CA 1.433 -1.544 0 N-CA-C 108.923 -1.671 . . . . 0.0 108.923 176.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 8.1 m -65.32 142.27 58.3 Favored 'General case' 0 C--N 1.307 -1.267 0 C-N-CA 118.544 -1.263 . . . . 0.0 108.643 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.85 -6.13 64.33 Favored Glycine 0 CA--C 1.528 0.895 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.983 -173.647 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 81.69 7.74 87.73 Favored Glycine 0 CA--C 1.531 1.079 0 C-N-CA 121.688 -0.291 . . . . 0.0 113.437 176.398 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 41.3 ttm180 -73.87 134.19 43.24 Favored 'General case' 0 C--O 1.263 1.786 0 CA-C-O 120.737 0.303 . . . . 0.0 110.262 179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -72.91 122.48 21.72 Favored 'General case' 0 N--CA 1.436 -1.156 0 C-N-CA 119.484 -0.887 . . . . 0.0 109.9 178.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.21 9.6 6.41 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.137 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.833 -179.404 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.536 ' CD1' ' HB2' ' A' ' 154' ' ' CYS . 34.1 p90 -131.51 157.0 44.71 Favored 'General case' 0 N--CA 1.441 -0.889 0 N-CA-C 115.056 1.502 . . . . 0.0 115.056 -167.278 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.548 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 74.5 mt-10 -133.94 154.05 51.35 Favored 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.892 -1.892 . . . . 0.0 105.892 171.52 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.69 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.1 tt -123.09 160.0 27.32 Favored 'General case' 0 C--N 1.308 -1.235 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 178.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.69 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.5 t -60.18 -45.21 96.29 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.045 0 O-C-N 122.331 -0.231 . . . . 0.0 110.667 -174.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.449 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 136.54 -8.95 4.02 Favored Glycine 0 CA--C 1.505 -0.587 0 C-N-CA 119.825 -1.179 . . . . 0.0 112.341 177.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -127.24 69.03 73.75 Favored Pre-proline 0 C--N 1.306 -1.305 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 179.646 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -67.79 -19.87 46.54 Favored 'Trans proline' 0 C--N 1.355 0.871 0 C-N-CA 123.438 2.758 . . . . 0.0 115.421 -174.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 24.1 p -107.12 116.26 31.62 Favored 'General case' 0 C--N 1.313 -0.998 0 C-N-CA 120.258 -0.577 . . . . 0.0 111.589 -173.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE2' ' A' ' 152' ' ' TYR . 47.7 pt -124.94 154.56 32.96 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.432 0 CA-C-O 120.851 0.358 . . . . 0.0 110.126 -177.048 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.449 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 35.5 p90 -150.11 162.68 39.95 Favored 'General case' 0 CA--C 1.506 -0.742 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.082 -173.83 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -70.87 114.81 9.31 Favored 'General case' 0 N--CA 1.437 -1.078 0 N-CA-C 107.336 -1.357 . . . . 0.0 107.336 173.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.449 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 7.9 t -116.74 -29.6 6.02 Favored 'General case' 0 C--N 1.343 0.317 0 N-CA-C 113.027 0.751 . . . . 0.0 113.027 -171.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 91.2 p 45.93 11.79 0.01 OUTLIER 'General case' 0 CA--C 1.556 1.177 0 C-N-CA 124.267 1.027 . . . . 0.0 113.485 -173.79 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -94.27 2.64 55.85 Favored 'General case' 0 C--O 1.238 0.452 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . 0.511 ' HB3' HD11 ' A' ' 183' ' ' ILE . 19.4 t70 -106.85 -150.36 0.44 Allowed 'General case' 0 C--N 1.308 -1.239 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 -179.986 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.53 ' O ' HG12 ' A' ' 183' ' ' ILE . 98.4 m-20 -66.47 142.17 57.65 Favored 'General case' 0 N--CA 1.48 1.068 0 CA-C-O 122.112 0.958 . . . . 0.0 113.009 -177.106 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.532 ' HG2' ' H ' ' A' ' 181' ' ' VAL . 54.5 tt0 66.61 176.25 0.24 Allowed 'General case' 0 CA--C 1.567 1.622 0 C-N-CA 125.406 1.483 . . . . 0.0 110.774 176.751 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.532 ' H ' ' HG2' ' A' ' 180' ' ' GLN . 9.9 p -62.54 -43.67 98.62 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 N-CA-C 115.687 1.736 . . . . 0.0 115.687 -172.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -157.15 97.57 0.17 Allowed Glycine 0 N--CA 1.476 1.333 0 C-N-CA 118.937 -1.602 . . . . 0.0 113.839 -177.029 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.573 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.4 pt -132.69 168.22 24.71 Favored 'Isoleucine or valine' 0 C--O 1.255 1.375 0 C-N-CA 123.662 0.785 . . . . 0.0 112.057 -178.697 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.573 ' O ' HD12 ' A' ' 183' ' ' ILE . 91.5 m95 -63.04 166.73 5.52 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 115.123 -0.944 . . . . 0.0 109.699 169.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 75.4 p -62.38 -28.21 69.61 Favored 'General case' 0 CA--C 1.543 0.699 0 CA-C-O 121.022 0.439 . . . . 0.0 110.772 176.832 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 176.59 160.77 24.32 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.592 176.668 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.0 Cg_exo -62.76 148.0 93.97 Favored 'Trans proline' 0 N--CA 1.452 -0.938 0 C-N-CA 122.357 2.038 . . . . 0.0 110.163 174.719 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.72 115.52 0.51 Allowed Pre-proline 0 N--CA 1.479 0.98 0 O-C-N 123.805 0.691 . . . . 0.0 111.042 179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.418 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 23.6 Cg_exo -61.03 145.77 98.61 Favored 'Trans proline' 0 CA--C 1.486 -1.882 0 C-N-CA 122.253 1.969 . . . . 0.0 108.112 177.123 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.451 ' NE2' HG13 ' A' ' 192' ' ' ILE . 11.3 pt20 -101.16 151.17 22.15 Favored 'General case' 0 C--N 1.272 -2.78 0 C-N-CA 120.35 -0.54 . . . . 0.0 111.519 -169.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.548 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 73.3 m -80.07 72.47 6.86 Favored 'General case' 0 N--CA 1.419 -2.009 0 CA-C-O 122.25 1.024 . . . . 0.0 109.699 -179.592 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.451 HG13 ' NE2' ' A' ' 190' ' ' GLN . 47.2 mm . . . . . 0 C--O 1.244 0.782 0 CA-C-N 113.789 -1.55 . . . . 0.0 110.346 179.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 3.7 mttp . . . . . 0 CA--C 1.502 -0.87 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB3' ' NE2' ' A' ' 81' ' ' GLN . 24.8 p -77.85 157.9 29.69 Favored 'General case' 0 N--CA 1.431 -1.381 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.842 175.036 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.544 ' HB3' ' CZ2' ' A' ' 113' ' ' TRP . 0.6 OUTLIER -81.02 176.73 9.57 Favored 'General case' 0 C--N 1.305 -1.326 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 179.68 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.718 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 40.9 ttm180 -64.75 -20.34 66.29 Favored 'General case' 0 C--N 1.319 -0.733 0 C-N-CA 124.015 0.926 . . . . 0.0 113.33 -175.091 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.718 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 115.72 129.48 0.0 OUTLIER Pre-proline 0 N--CA 1.483 1.221 0 N-CA-C 106.355 -1.72 . . . . 0.0 106.355 -169.816 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.748 ' HG3' HG21 ' A' ' 86' ' ' ILE . 0.5 OUTLIER -87.37 -171.45 0.72 Allowed 'Trans proline' 0 C--N 1.316 -1.134 0 C-N-CA 123.682 2.921 . . . . 0.0 116.465 -165.428 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.585 ' HB3' HG23 ' A' ' 117' ' ' THR . 34.2 Cg_exo -49.42 88.37 0.02 OUTLIER 'Trans proline' 0 C--N 1.373 1.828 0 C-N-CA 123.228 2.618 . . . . 0.0 113.367 169.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.468 ' HA ' ' HD2' ' A' ' 69' ' ' PRO . 3.9 p30 -158.45 114.9 1.72 Allowed Pre-proline 0 C--N 1.268 -2.968 0 CA-C-N 114.062 -1.426 . . . . 0.0 108.321 172.118 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.468 ' HD2' ' HA ' ' A' ' 68' ' ' ASP . 24.5 Cg_exo -55.7 141.4 84.29 Favored 'Trans proline' 0 N--CA 1.425 -2.542 0 C-N-CA 120.788 0.992 . . . . 0.0 110.352 179.256 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 81.5 t -74.8 132.37 33.47 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.351 0 CA-C-N 115.173 -0.921 . . . . 0.0 111.381 -173.445 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 59.22 34.57 23.17 Favored 'General case' 0 N--CA 1.446 -0.67 0 CA-C-N 115.124 -0.943 . . . . 0.0 110.655 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.03 -95.82 1.97 Allowed Glycine 0 CA--C 1.49 -1.5 0 C-N-CA 120.108 -1.044 . . . . 0.0 110.928 177.264 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 6.6 tpt -129.65 121.69 27.53 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 177.041 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.3 t -121.6 129.7 75.29 Favored 'Isoleucine or valine' 0 C--O 1.245 0.832 0 C-N-CA 120.003 -0.679 . . . . 0.0 110.882 -178.114 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 71.4 m80 -123.81 4.05 8.8 Favored 'General case' 0 C--O 1.225 -0.214 0 CA-C-N 115.716 -0.674 . . . . 0.0 112.443 174.508 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.43 HG23 ' O ' ' A' ' 76' ' ' VAL . 17.3 m -91.7 52.11 0.11 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.849 1.426 . . . . 0.0 114.849 -170.897 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 92.7 mt -63.47 -43.66 98.48 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 176.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt -113.05 146.83 38.44 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 173.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.7 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . 116.32 0.3 20.56 Favored Glycine 0 CA--C 1.541 1.67 0 C-N-CA 118.485 -1.816 . . . . 0.0 115.79 177.652 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.628 HG22 ' HD3' ' A' ' 66' ' ' PRO . 46.5 pt -98.46 -4.16 9.62 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 CA-C-N 119.401 1.6 . . . . 0.0 111.765 -176.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.608 ' HB2' ' OG ' ' A' ' 84' ' ' SER . 92.8 mm-40 -69.52 178.91 2.27 Favored 'General case' 0 C--N 1.301 -1.527 0 CA-C-N 116.146 -0.479 . . . . 0.0 112.291 -176.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.705 ' HA ' ' HB3' ' A' ' 104' ' ' CYS . 72.0 t80 -58.71 -46.79 86.54 Favored 'General case' 0 CA--C 1.558 1.277 0 N-CA-C 114.2 1.185 . . . . 0.0 114.2 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -88.64 -9.4 68.89 Favored Glycine 0 C--N 1.282 -2.457 0 C-N-CA 120.408 -0.901 . . . . 0.0 111.953 -179.151 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.7 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 7.0 m -76.57 155.0 33.97 Favored 'General case' 0 N--CA 1.429 -1.479 0 N-CA-C 113.436 0.902 . . . . 0.0 113.436 -175.968 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . . . . . . . . . 87.0 mt-30 -134.57 153.32 52.02 Favored 'General case' 0 N--CA 1.448 -0.564 0 CA-C-N 114.655 -1.157 . . . . 0.0 109.86 178.567 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.748 HG21 ' HG3' ' A' ' 66' ' ' PRO . 0.2 OUTLIER -128.57 155.11 40.21 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.593 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.96 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.537 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 10.2 mptt -125.94 140.37 52.68 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 109.62 -0.511 . . . . 0.0 109.62 174.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 73.5 t80 -132.34 126.21 32.72 Favored 'General case' 0 CA--C 1.533 0.304 0 N-CA-C 113.811 1.041 . . . . 0.0 113.811 179.389 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 69.3 m -79.9 152.87 29.37 Favored 'General case' 0 CA--C 1.546 0.825 0 CA-C-N 115.728 -0.669 . . . . 0.0 112.291 177.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.655 ' SG ' HD13 ' A' ' 96' ' ' LEU . 70.8 m -113.69 157.9 21.59 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.347 -0.612 . . . . 0.0 109.347 176.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.7 m -68.54 163.46 23.48 Favored 'General case' 0 C--N 1.315 -0.892 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.8 tttt -62.42 132.5 52.76 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.908 0.861 . . . . 0.0 111.725 -178.4 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 91.15 -1.14 76.73 Favored Glycine 0 N--CA 1.471 1.017 0 CA-C-N 114.745 -1.116 . . . . 0.0 111.371 -179.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.8 m-85 -122.54 144.65 48.95 Favored 'General case' 0 CA--C 1.543 0.705 0 C-N-CA 122.451 0.3 . . . . 0.0 111.187 -178.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.731 ' HE ' ' HD2' ' A' ' 124' ' ' PRO . 47.3 ptt85 -133.32 170.21 15.78 Favored 'General case' 0 CA--C 1.478 -1.799 0 CA-C-O 122.338 1.066 . . . . 0.0 111.476 173.162 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.655 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.8 mm? -78.42 126.77 31.23 Favored 'General case' 0 N--CA 1.397 -3.116 0 CA-C-N 113.194 -1.821 . . . . 0.0 107.325 172.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.413 ' HA ' ' NH1' ' A' ' 95' ' ' ARG . 45.3 mm -69.53 -25.96 30.02 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.862 0 CA-C-O 121.767 0.794 . . . . 0.0 111.737 174.893 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -117.87 -135.78 5.41 Favored Glycine 0 N--CA 1.433 -1.56 0 CA-C-N 114.253 -1.339 . . . . 0.0 110.216 -178.102 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.482 ' O ' ' HG3' ' A' ' 118' ' ' PRO . 5.9 t -103.56 123.34 46.76 Favored 'General case' 0 CA--C 1.491 -1.304 0 C-N-CA 119.923 -0.711 . . . . 0.0 109.333 -179.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.601 ' HB2' ' HG ' ' A' ' 96' ' ' LEU . 11.6 t -60.09 -44.38 94.83 Favored 'General case' 0 CA--C 1.496 -1.116 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 178.776 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.588 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 9.5 m -81.46 147.92 29.5 Favored 'General case' 0 N--CA 1.402 -2.872 0 CA-C-N 115.254 -0.885 . . . . 0.0 109.634 177.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.549 ' HB3' HD11 ' A' ' 86' ' ' ILE . . . -133.32 146.86 51.72 Favored 'General case' 0 CA--C 1.469 -2.141 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.257 177.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.1 m -118.69 128.07 54.17 Favored 'General case' 0 N--CA 1.418 -2.027 0 N-CA-C 107.52 -1.289 . . . . 0.0 107.52 177.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.749 ' SG ' HG22 ' A' ' 111' ' ' VAL . 34.3 t -65.57 130.54 43.66 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.677 -179.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -130.63 165.49 30.79 Favored 'Isoleucine or valine' 0 C--O 1.206 -1.202 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.295 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.478 HG23 ' O ' ' A' ' 110' ' ' THR . 89.2 mt -108.04 128.71 63.2 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.628 0 CA-C-O 121.586 0.708 . . . . 0.0 111.788 -178.354 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 43.2 t -127.65 134.71 49.63 Favored 'General case' 0 N--CA 1.433 -1.283 0 N-CA-C 106.381 -1.711 . . . . 0.0 106.381 173.946 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 62.84 -130.32 42.42 Favored Glycine 0 C--O 1.248 0.976 0 C-N-CA 118.947 -1.597 . . . . 0.0 109.991 -173.631 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.4 t0 -118.15 38.73 3.6 Favored 'General case' 0 C--N 1.312 -1.029 0 CA-C-O 121.752 0.787 . . . . 0.0 108.879 179.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.478 ' O ' HG23 ' A' ' 106' ' ' ILE . 12.9 t -145.07 165.63 27.68 Favored 'General case' 0 N--CA 1.441 -0.913 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.212 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.749 HG22 ' SG ' ' A' ' 104' ' ' CYS . 4.7 p -113.78 126.57 71.28 Favored 'Isoleucine or valine' 0 CA--C 1.56 1.363 0 C-N-CA 118.99 -1.084 . . . . 0.0 108.259 -178.933 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -130.07 164.08 33.82 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.754 0 CA-C-N 114.318 -1.31 . . . . 0.0 112.381 -176.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.544 ' CZ2' ' HB3' ' A' ' 63' ' ' CYS . 97.1 m95 -81.48 135.4 35.61 Favored 'General case' 0 N--CA 1.465 0.287 0 C-N-CA 120.381 -0.528 . . . . 0.0 110.276 -179.175 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.459 ' OD1' HG23 ' A' ' 115' ' ' THR . 42.2 p-10 -69.26 -42.23 75.86 Favored 'General case' 0 CA--C 1.545 0.753 0 CA-C-O 121.447 0.642 . . . . 0.0 112.169 -177.536 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.648 ' O ' ' HG2' ' A' ' 116' ' ' GLU . 73.5 p -71.23 -32.42 68.75 Favored 'General case' 0 C--N 1.31 -1.15 0 N-CA-C 114.459 1.281 . . . . 0.0 114.459 -177.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.648 ' HG2' ' O ' ' A' ' 115' ' ' THR . 17.1 pt-20 62.75 21.77 12.97 Favored 'General case' 0 N--CA 1.488 1.469 0 C-N-CA 126.274 1.83 . . . . 0.0 108.462 -168.154 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.585 HG23 ' HB3' ' A' ' 67' ' ' PRO . 11.3 m 62.67 121.25 0.02 OUTLIER Pre-proline 0 C--N 1.354 0.78 0 CA-C-N 114.27 -1.332 . . . . 0.0 112.235 -178.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.58 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.0 Cg_endo -71.45 158.7 53.43 Favored 'Trans proline' 0 N--CA 1.451 -0.984 0 C-N-CA 123.942 3.094 . . . . 0.0 112.003 177.176 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 86.6 mt -104.76 127.25 59.36 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.219 0 C-N-CA 119.96 -0.696 . . . . 0.0 109.639 -176.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.5 m -73.0 72.93 1.15 Allowed 'General case' 0 C--O 1.215 -0.754 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.244 176.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 57.8 t0 -90.38 179.48 5.87 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 178.032 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 96.0 mtt-85 -71.7 141.9 49.83 Favored 'General case' 0 N--CA 1.428 -1.558 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 -178.914 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.495 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 51.5 mt -55.19 116.54 11.78 Favored Pre-proline 0 C--O 1.216 -0.667 0 O-C-N 123.989 0.805 . . . . 0.0 110.009 -178.961 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.731 ' HD2' ' HE ' ' A' ' 95' ' ' ARG . 52.3 Cg_exo -55.49 -36.64 94.63 Favored 'Trans proline' 0 CA--C 1.498 -1.319 0 C-N-CA 123.872 3.048 . . . . 0.0 113.292 -174.996 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.597 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 81.6 m 51.55 50.93 17.78 Favored 'General case' 0 CA--C 1.545 0.759 0 N-CA-C 109.871 -0.418 . . . . 0.0 109.871 178.942 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.5 158.45 31.78 Favored Glycine 0 C--N 1.353 1.516 0 C-N-CA 120.948 -0.644 . . . . 0.0 111.623 -176.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.647 HD21 ' HG2' ' A' ' 142' ' ' GLU . 7.0 mp -17.15 123.66 0.05 OUTLIER Pre-proline 0 N--CA 1.497 1.876 0 N-CA-C 114.471 1.286 . . . . 0.0 114.471 -173.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.447 ' HD3' ' CB ' ' A' ' 143' ' ' ASN . 55.7 Cg_endo -63.76 161.03 34.04 Favored 'Trans proline' 0 CA--C 1.506 -0.906 0 C-N-CA 123.753 2.968 . . . . 0.0 111.802 -173.201 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -62.3 145.69 95.94 Favored 'Trans proline' 0 N--CA 1.444 -1.437 0 C-N-CA 121.937 1.758 . . . . 0.0 110.897 179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 21.1 p -83.07 167.11 18.16 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.091 -178.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.438 HD12 ' HA ' ' A' ' 131' ' ' ILE . 10.1 tp -115.72 138.61 45.59 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.003 0 C-N-CA 119.165 -1.014 . . . . 0.0 109.079 -177.076 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 14.4 t -62.43 -35.2 78.52 Favored 'General case' 0 N--CA 1.432 -1.373 0 CA-C-N 114.847 -1.07 . . . . 0.0 112.643 -171.853 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -92.79 6.03 49.06 Favored 'General case' 0 CA--C 1.537 0.448 0 N-CA-C 112.583 0.586 . . . . 0.0 112.583 -175.924 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 153.04 -96.58 0.16 Allowed Glycine 0 C--O 1.222 -0.595 0 C-N-CA 117.737 -2.173 . . . . 0.0 115.019 177.786 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 42.9 t0 -149.78 173.7 13.44 Favored 'General case' 0 CA--C 1.54 0.578 0 CA-C-O 121.286 0.565 . . . . 0.0 112.162 -172.822 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . . 39.6 p90 -106.54 165.54 11.21 Favored 'General case' 0 C--O 1.255 1.393 0 CA-C-N 115.826 -0.625 . . . . 0.0 111.746 -175.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.476 HG13 HH11 ' A' ' 153' ' ' ARG . 85.6 mt -105.54 123.56 59.97 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.828 0 CA-C-N 114.077 -1.419 . . . . 0.0 109.233 176.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 40.0 t -156.57 151.83 26.51 Favored 'General case' 0 C--N 1.28 -2.441 0 CA-C-N 116.196 -0.456 . . . . 0.0 109.998 176.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 34.7 p -67.03 -35.92 80.96 Favored 'General case' 0 N--CA 1.433 -1.301 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.473 177.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -118.01 130.98 56.51 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.418 -0.81 . . . . 0.0 111.46 179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 51.7 ttt85 -72.79 134.27 44.86 Favored 'General case' 0 N--CA 1.443 -0.804 0 N-CA-C 109.642 -0.503 . . . . 0.0 109.642 176.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.647 ' HG2' HD21 ' A' ' 127' ' ' LEU . 94.0 mt-10 72.68 136.02 0.05 OUTLIER 'General case' 0 CA--C 1.544 0.728 0 C-N-CA 124.532 1.133 . . . . 0.0 108.748 -174.16 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HB3' ' A' ' 148' ' ' SER . 6.4 t-20 -98.03 142.64 29.49 Favored 'General case' 0 C--N 1.294 -1.816 0 C-N-CA 119.451 -0.9 . . . . 0.0 112.651 -173.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 82.6 m-85 -89.12 -179.13 5.84 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 114.366 -1.288 . . . . 0.0 111.868 -176.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.694 ' CD2' ' HA ' ' A' ' 124' ' ' PRO . 50.0 m80 -47.36 -177.97 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.979 0 N-CA-C 114.769 1.396 . . . . 0.0 114.769 177.601 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.597 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 73.2 t80 -55.62 135.35 51.18 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.352 -173.265 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 95.81 32.19 6.99 Favored Glycine 0 CA--C 1.53 1.02 0 C-N-CA 120.832 -0.699 . . . . 0.0 113.675 -175.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.473 ' HB3' ' OD1' ' A' ' 143' ' ' ASN . 12.0 t -132.64 148.93 52.36 Favored 'General case' 0 CA--C 1.555 1.164 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 178.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.586 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -135.79 149.65 28.13 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.882 0 N-CA-C 113.524 0.935 . . . . 0.0 113.524 -171.026 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 35.5 m -133.34 160.65 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.975 0 C-N-CA 123.05 0.54 . . . . 0.0 109.992 176.584 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.473 ' HB ' ' HB ' ' A' ' 137' ' ' ILE . 90.1 m -124.51 134.71 52.93 Favored 'General case' 0 C--O 1.196 -1.722 0 N-CA-C 111.994 0.368 . . . . 0.0 111.994 -178.683 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . . . . . . . . . 96.7 m-85 -106.63 148.76 27.94 Favored 'General case' 0 C--N 1.307 -1.28 0 CA-C-O 121.77 0.795 . . . . 0.0 111.3 -177.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.476 HH11 HG13 ' A' ' 137' ' ' ILE . 36.3 ptt-85 -133.59 155.45 49.62 Favored 'General case' 0 N--CA 1.437 -1.119 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.233 -175.559 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.519 ' HB2' ' HB3' ' A' ' 164' ' ' PHE . 93.4 m -111.43 152.94 26.8 Favored 'General case' 0 C--O 1.26 1.64 0 N-CA-C 113.329 0.863 . . . . 0.0 113.329 -175.633 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 5.5 m-20 -96.25 139.3 21.67 Favored Pre-proline 0 N--CA 1.466 0.331 0 CA-C-N 114.359 -1.291 . . . . 0.0 112.604 -174.766 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 16.8 Cg_exo -63.07 145.65 94.1 Favored 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 123.227 2.618 . . . . 0.0 110.686 173.353 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -85.85 177.38 49.6 Favored Glycine 0 C--N 1.313 -0.696 0 C-N-CA 119.499 -1.334 . . . . 0.0 111.004 178.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 7.7 m -68.29 144.77 54.72 Favored 'General case' 0 N--CA 1.443 -0.782 0 C-N-CA 120.074 -0.651 . . . . 0.0 109.309 179.8 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 81.14 12.15 82.74 Favored Glycine 0 C--N 1.311 -0.811 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.765 -177.278 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 76.25 22.81 72.66 Favored Glycine 0 C--N 1.335 0.476 0 C-N-CA 120.605 -0.807 . . . . 0.0 112.606 178.565 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 95.9 mtt-85 -78.8 142.38 36.99 Favored 'General case' 0 C--N 1.316 -0.856 0 O-C-N 122.57 -0.371 . . . . 0.0 111.317 -174.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.5 ttmt -85.23 98.12 10.31 Favored 'General case' 0 CA--C 1.509 -0.622 0 N-CA-C 107.869 -1.16 . . . . 0.0 107.869 174.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 32.4 m -117.1 11.96 7.39 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.743 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.634 -178.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.539 ' O ' ' HB3' ' A' ' 191' ' ' CYS . 22.7 m-85 -61.26 -45.78 93.08 Favored 'General case' 0 C--O 1.193 -1.882 0 N-CA-C 112.327 0.491 . . . . 0.0 112.327 -166.532 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 79.0 mm-40 20.52 68.03 0.02 OUTLIER 'General case' 0 C--N 1.282 -2.349 0 C-N-CA 126.64 1.976 . . . . 0.0 114.755 -177.49 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.577 ' HA ' ' O ' ' A' ' 190' ' ' GLN . 7.7 tt -76.3 155.14 34.51 Favored 'General case' 0 C--N 1.292 -1.9 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -179.947 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.531 ' N ' HD23 ' A' ' 166' ' ' LEU . 72.0 t -60.42 -44.77 96.91 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.084 0 CA-C-O 119.17 -0.443 . . . . 0.0 111.753 -171.368 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.02 -21.25 1.59 Allowed Glycine 0 C--O 1.224 -0.481 0 C-N-CA 119.016 -1.564 . . . . 0.0 113.925 179.112 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -127.51 71.39 77.18 Favored Pre-proline 0 C--N 1.31 -1.111 0 O-C-N 122.244 -0.562 . . . . 0.0 109.49 178.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.9 Cg_endo -66.26 -20.23 55.82 Favored 'Trans proline' 0 C--N 1.351 0.705 0 C-N-CA 122.563 2.176 . . . . 0.0 113.448 -176.147 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 12.0 p -97.33 118.64 34.25 Favored 'General case' 0 N--CA 1.426 -1.654 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.523 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.533 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.6 pt -127.09 154.84 37.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 CA-C-N 115.805 -0.634 . . . . 0.0 111.625 -179.184 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.586 ' HB3' ' HB ' ' A' ' 149' ' ' VAL . 46.2 p90 -143.75 157.95 44.02 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.333 -179.544 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.416 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 16.8 t -84.24 104.1 13.99 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -177.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.503 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 6.0 t -125.21 -20.6 4.82 Favored 'General case' 0 C--N 1.348 0.502 0 CA-C-N 114.919 -1.037 . . . . 0.0 112.866 -174.325 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.536 ' HB3' ' HA2' ' A' ' 182' ' ' GLY . 75.3 p 53.82 -4.62 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.935 0 N-CA-C 115.966 1.839 . . . . 0.0 115.966 179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 33.5 p-10 -65.65 -40.8 92.84 Favored 'General case' 0 CA--C 1.553 1.092 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -173.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 22.0 p-10 -64.4 -43.02 95.74 Favored 'General case' 0 N--CA 1.491 1.586 0 N-CA-C 114.221 1.193 . . . . 0.0 114.221 -170.68 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -100.41 -3.78 30.32 Favored 'General case' 0 C--O 1.21 -1.026 0 CA-C-O 121.955 0.883 . . . . 0.0 110.456 179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 61.8 tt0 64.98 29.43 12.28 Favored 'General case' 0 CA--C 1.569 1.705 0 CA-C-N 115.014 -0.994 . . . . 0.0 111.459 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.458 HG23 HG13 ' A' ' 183' ' ' ILE . 35.8 m -133.7 160.14 42.24 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.145 0 CA-C-N 115.225 -0.898 . . . . 0.0 108.714 174.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 176' ' ' SER . . . -69.68 72.56 0.5 Allowed Glycine 0 N--CA 1.49 2.235 0 N-CA-C 114.891 0.716 . . . . 0.0 114.891 -173.273 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.458 HG13 HG23 ' A' ' 181' ' ' VAL . 2.3 pp -129.27 162.19 37.19 Favored 'Isoleucine or valine' 0 C--O 1.218 -0.598 0 C-N-CA 123.812 0.845 . . . . 0.0 112.966 178.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.416 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 79.6 m95 -69.91 170.35 11.37 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 115.168 -0.923 . . . . 0.0 110.979 177.397 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 50.2 m -58.86 -41.31 86.73 Favored 'General case' 0 N--CA 1.445 -0.683 0 CA-C-O 121.384 0.611 . . . . 0.0 109.538 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -161.88 149.72 18.44 Favored Glycine 0 N--CA 1.417 -2.568 0 N-CA-C 110.019 -1.233 . . . . 0.0 110.019 175.093 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.4 Cg_exo -62.0 145.03 96.91 Favored 'Trans proline' 0 N--CA 1.445 -1.343 0 N-CA-C 108.743 -1.291 . . . . 0.0 108.743 175.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -28.32 104.54 0.19 Allowed Pre-proline 0 C--O 1.246 0.888 0 O-C-N 124.141 0.9 . . . . 0.0 112.99 -177.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.82 144.56 97.0 Favored 'Trans proline' 0 CA--C 1.488 -1.825 0 C-N-CA 121.763 1.642 . . . . 0.0 110.506 179.103 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.672 ' HB2' HG13 ' A' ' 192' ' ' ILE . 50.3 mt-30 -112.99 -172.78 2.12 Favored 'General case' 0 N--CA 1.407 -2.59 0 C-N-CA 119.123 -1.031 . . . . 0.0 109.786 -169.577 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.539 ' HB3' ' O ' ' A' ' 164' ' ' PHE . 59.4 m -104.32 47.25 0.88 Allowed 'General case' 0 N--CA 1.41 -2.465 0 N-CA-C 105.213 -2.143 . . . . 0.0 105.213 -178.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.672 HG13 ' HB2' ' A' ' 190' ' ' GLN . 89.0 mt . . . . . 0 C--N 1.382 1.984 0 CA-C-O 117.155 -1.403 . . . . 0.0 110.34 -175.84 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 19.4 tttm . . . . . 0 N--CA 1.429 -1.517 0 N-CA-C 108.514 -0.921 . . . . 0.0 108.514 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.686 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 93.2 p -78.49 163.77 25.3 Favored 'General case' 0 C--N 1.296 -1.743 0 CA-C-N 114.617 -1.174 . . . . 0.0 108.936 177.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.94 -169.45 2.02 Favored 'General case' 0 N--CA 1.426 -1.632 0 C-N-CA 118.006 -1.478 . . . . 0.0 109.184 -177.817 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.844 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 23.1 mmm180 -62.69 -38.02 88.73 Favored 'General case' 0 C--N 1.315 -0.93 0 N-CA-C 114.253 1.205 . . . . 0.0 114.253 -172.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.844 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.1 OUTLIER 113.55 143.12 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.149 0 O-C-N 125.402 1.688 . . . . 0.0 107.616 -171.543 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_exo -53.0 156.64 9.38 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.941 1.761 . . . . 0.0 112.921 -179.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -54.83 -36.81 92.17 Favored 'Trans proline' 0 C--O 1.236 0.378 0 C-N-CA 122.66 2.24 . . . . 0.0 110.565 175.67 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.535 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 30.9 t70 70.81 54.85 0.42 Allowed Pre-proline 0 N--CA 1.487 1.421 0 CA-C-N 113.996 -1.456 . . . . 0.0 111.593 -179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.535 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 21.4 Cg_exo -63.29 142.72 87.19 Favored 'Trans proline' 0 C--N 1.363 1.299 0 C-N-CA 121.574 1.516 . . . . 0.0 110.672 178.296 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 28.4 m -67.27 -38.49 81.07 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.891 0 CA-C-O 122.127 0.965 . . . . 0.0 112.582 173.637 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 82.9 m-20 -62.75 -40.69 98.02 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-N 114.115 -1.402 . . . . 0.0 112.715 -173.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -122.69 148.4 16.89 Favored Glycine 0 N--CA 1.438 -1.226 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.457 -178.58 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.9 mmm -82.19 148.03 28.67 Favored 'General case' 0 CA--C 1.495 -1.143 0 O-C-N 122.457 -0.437 . . . . 0.0 110.931 -177.739 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -119.18 130.76 73.48 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 N-CA-C 108.743 -0.836 . . . . 0.0 108.743 179.382 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 11.1 t-80 -110.7 102.44 10.99 Favored 'General case' 0 N--CA 1.435 -1.19 0 CA-C-O 121.436 0.636 . . . . 0.0 112.04 179.527 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.451 HG21 HG23 ' A' ' 80' ' ' ILE . 2.3 p -130.49 122.88 54.05 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.176 0 CA-C-N 115.663 -0.699 . . . . 0.0 109.245 168.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.579 ' O ' ' HG3' ' A' ' 78' ' ' LYS . 30.6 mm -65.25 -44.27 95.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.063 173.867 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.579 ' HG3' ' O ' ' A' ' 77' ' ' ILE . 99.1 mttt -179.52 -27.94 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.238 0 C-N-CA 125.582 1.553 . . . . 0.0 107.142 -171.417 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.526 ' HA3' ' HB3' ' A' ' 84' ' ' SER . . . -70.74 81.19 0.42 Allowed Glycine 0 N--CA 1.421 -2.347 0 CA-C-N 114.233 -1.349 . . . . 0.0 115.856 -174.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG13 ' HB2' ' A' ' 62' ' ' SER . 12.0 pt -104.82 3.66 10.5 Favored 'Isoleucine or valine' 0 C--O 1.192 -1.93 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 166.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.686 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 64.1 tp60 -73.48 174.0 8.84 Favored 'General case' 0 C--N 1.305 -1.338 0 CA-C-N 113.569 -1.65 . . . . 0.0 113.408 -176.119 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.817 ' HA ' ' HB2' ' A' ' 104' ' ' CYS . 62.0 t80 -56.41 -46.2 80.29 Favored 'General case' 0 N--CA 1.45 -0.454 0 N-CA-C 112.858 0.688 . . . . 0.0 112.858 -174.709 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -98.16 30.29 9.74 Favored Glycine 0 C--N 1.272 -3.018 0 N-CA-C 111.619 -0.592 . . . . 0.0 111.619 179.431 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.526 ' HB3' ' HA3' ' A' ' 79' ' ' GLY . 49.7 m -128.55 156.57 43.09 Favored 'General case' 0 N--CA 1.45 -0.46 0 O-C-N 122.618 -0.342 . . . . 0.0 110.657 -176.308 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.548 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -126.82 156.04 41.94 Favored 'General case' 0 C--O 1.216 -0.67 0 CA-C-O 122.011 0.91 . . . . 0.0 112.062 -175.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.788 ' O ' ' HA ' ' A' ' 101' ' ' SER . 48.3 pt -122.22 149.32 25.61 Favored 'Isoleucine or valine' 0 CA--C 1.508 -0.657 0 N-CA-C 106.958 -1.497 . . . . 0.0 106.958 173.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.533 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 0.1 OUTLIER -124.09 138.53 54.42 Favored 'General case' 0 C--N 1.308 -1.21 0 CA-C-O 121.177 0.513 . . . . 0.0 109.678 -179.244 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.584 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 92.6 t80 -129.69 123.73 31.85 Favored 'General case' 0 CA--C 1.544 0.721 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 -178.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.11 160.09 23.22 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 113.923 1.083 . . . . 0.0 113.923 178.468 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.483 ' SG ' HD13 ' A' ' 96' ' ' LEU . 79.3 m -128.95 161.25 30.33 Favored 'General case' 0 CA--C 1.54 0.576 0 O-C-N 123.253 0.345 . . . . 0.0 111.441 174.427 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 30.8 m -75.43 161.43 29.23 Favored 'General case' 0 CA--C 1.551 0.981 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 174.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 14.3 tmtt? -68.41 131.5 45.42 Favored 'General case' 0 CA--C 1.514 -0.423 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 -179.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.1 -4.86 62.96 Favored Glycine 0 CA--C 1.549 2.208 0 C-N-CA 120.418 -0.896 . . . . 0.0 112.014 -174.076 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.3 m-85 -122.13 139.44 53.73 Favored 'General case' 0 CA--C 1.548 0.894 0 O-C-N 123.888 0.405 . . . . 0.0 111.384 179.198 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.613 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 13.1 ptp180 -125.52 173.34 9.0 Favored 'General case' 0 CA--C 1.49 -1.334 0 CA-C-O 122.119 0.961 . . . . 0.0 111.909 179.604 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.483 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.1 mm? -95.89 128.68 42.98 Favored 'General case' 0 N--CA 1.418 -2.054 0 CA-C-N 113.881 -1.509 . . . . 0.0 108.962 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 47.3 mm -67.98 -24.95 31.05 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 CA-C-N 114.589 -1.187 . . . . 0.0 111.833 175.701 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.755 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -125.48 -128.61 3.24 Favored Glycine 0 N--CA 1.417 -2.619 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.759 -172.366 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.538 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 8.5 t -109.24 121.38 45.05 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 108.932 -0.766 . . . . 0.0 108.932 -176.802 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.456 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 78.1 p -62.84 -23.67 67.4 Favored 'General case' 0 C--N 1.312 -1.023 0 CA-C-O 120.988 0.423 . . . . 0.0 110.479 -177.273 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.788 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.9 m -116.22 120.26 38.4 Favored 'General case' 0 N--CA 1.432 -1.356 0 N-CA-C 108.737 -0.838 . . . . 0.0 108.737 172.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.548 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -101.82 147.88 25.97 Favored 'General case' 0 CA--C 1.488 -1.418 0 C-N-CA 120.205 -0.598 . . . . 0.0 111.51 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 91.6 m -120.32 131.06 54.71 Favored 'General case' 0 C--N 1.285 -2.201 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 177.815 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.817 ' HB2' ' HA ' ' A' ' 82' ' ' PHE 0.313 60.4 m -64.67 145.28 56.42 Favored 'General case' 0 C--N 1.309 -1.183 0 N-CA-C 108.155 -1.054 . . . . 0.0 108.155 176.46 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.1 pp -128.18 160.44 38.13 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.951 0 N-CA-C 106.531 -1.655 . . . . 0.0 106.531 170.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.445 HG12 ' HB ' ' A' ' 111' ' ' VAL . 97.1 mt -111.22 120.31 61.57 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.975 0 C-N-CA 118.218 -1.393 . . . . 0.0 111.67 -179.065 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 12.4 p -80.14 164.99 22.9 Favored 'General case' 0 N--CA 1.434 -1.25 0 N-CA-C 106.213 -1.773 . . . . 0.0 106.213 170.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -61.55 -42.59 99.79 Favored Glycine 0 CA--C 1.535 1.313 0 C-N-CA 117.413 -2.327 . . . . 0.0 111.674 -178.706 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 99.5 m-20 -63.52 -43.47 97.07 Favored 'General case' 0 N--CA 1.477 0.909 0 N-CA-C 114.643 1.349 . . . . 0.0 114.643 177.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.561 HG23 ' N ' ' A' ' 111' ' ' VAL . 0.3 OUTLIER -168.89 176.8 5.28 Favored 'General case' 0 CA--C 1.548 0.899 0 N-CA-C 111.959 0.355 . . . . 0.0 111.959 -176.416 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.561 ' N ' HG23 ' A' ' 110' ' ' THR . 14.7 p -95.77 118.62 42.41 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.795 0 CA-C-O 121.911 0.863 . . . . 0.0 110.307 -179.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.18 162.62 36.21 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.23 -179.626 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.428 ' HB2' ' HA ' ' A' ' 116' ' ' GLU . 97.9 m95 -79.43 133.32 36.54 Favored 'General case' 0 N--CA 1.479 1.024 0 N-CA-C 106.324 -1.732 . . . . 0.0 106.324 -177.184 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 22.9 t70 -62.34 -49.73 74.42 Favored 'General case' 0 CA--C 1.512 -0.485 0 CA-C-O 122.007 0.908 . . . . 0.0 109.886 176.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.474 HG21 ' H ' ' A' ' 99' ' ' SER . 19.9 m -64.75 -44.88 88.69 Favored 'General case' 0 C--N 1.309 -1.165 0 CA-C-N 113.485 -1.689 . . . . 0.0 113.869 176.804 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.428 ' HA ' ' HB2' ' A' ' 113' ' ' TRP . 97.9 mt-10 67.99 24.1 8.01 Favored 'General case' 0 N--CA 1.486 1.357 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.212 -168.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 9.1 m 64.79 127.85 0.03 OUTLIER Pre-proline 0 CA--C 1.52 -0.2 0 CA-C-N 114.198 -1.365 . . . . 0.0 112.258 -177.432 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.755 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 6.8 Cg_exo -68.27 151.91 76.2 Favored 'Trans proline' 0 N--CA 1.444 -1.384 0 C-N-CA 123.501 2.801 . . . . 0.0 111.176 179.586 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.9 mt -106.75 130.02 59.34 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.106 0 N-CA-C 108.096 -1.075 . . . . 0.0 108.096 178.81 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 73.9 m -70.55 116.64 11.11 Favored 'General case' 0 N--CA 1.435 -1.209 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 -179.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 38.7 t70 -111.62 153.35 26.47 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 44.3 ttt180 -74.2 117.86 16.5 Favored 'General case' 0 CA--C 1.496 -1.121 0 N-CA-C 104.18 -2.526 . . . . 0.0 104.18 -176.997 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.802 HD13 ' HA3' ' A' ' 182' ' ' GLY . 62.3 mt -53.41 103.07 0.34 Allowed Pre-proline 0 CA--C 1.47 -2.107 0 CA-C-N 114.053 -1.431 . . . . 0.0 114.616 -165.077 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 145' ' ' HIS . 24.2 Cg_exo -63.32 141.99 84.0 Favored 'Trans proline' 0 N--CA 1.412 -3.272 0 N-CA-C 106.767 -2.051 . . . . 0.0 106.767 166.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.88 4.01 46.28 Favored 'General case' 0 C--N 1.293 -1.86 0 C-N-CA 118.495 -1.282 . . . . 0.0 108.959 169.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.67 -172.13 46.26 Favored Glycine 0 CA--C 1.465 -3.047 0 CA-C-N 113.184 -1.825 . . . . 0.0 110.959 177.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.689 HD12 ' OE1' ' A' ' 142' ' ' GLU . 1.4 mm? -82.51 106.14 6.12 Favored Pre-proline 0 C--N 1.278 -2.52 0 N-CA-C 105.395 -2.076 . . . . 0.0 105.395 172.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.48 ' HD2' ' HB3' ' A' ' 142' ' ' GLU . 1.9 Cg_endo -44.46 153.91 0.34 Allowed 'Trans proline' 0 C--N 1.364 1.37 0 C-N-CA 123.276 2.651 . . . . 0.0 112.798 -173.854 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 32.8 Cg_endo -61.41 143.81 97.83 Favored 'Trans proline' 0 N--CA 1.444 -1.434 0 N-CA-C 109.753 -0.903 . . . . 0.0 109.753 177.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.6 p -79.75 166.84 21.35 Favored 'General case' 0 N--CA 1.408 -2.558 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.633 179.583 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.881 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.4 tp -112.33 147.53 16.04 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.536 0 CA-C-O 122.026 0.917 . . . . 0.0 110.689 -172.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.5 m -60.4 -44.54 95.61 Favored 'General case' 0 C--N 1.29 -1.986 0 CA-C-N 113.866 -1.515 . . . . 0.0 109.635 -174.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.819 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 15.1 m120 -63.79 -40.05 95.73 Favored 'General case' 0 C--N 1.291 -1.937 0 CA-C-O 121.219 0.533 . . . . 0.0 112.143 178.262 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.881 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 160.75 -84.87 0.12 Allowed Glycine 0 CA--C 1.541 1.658 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.957 -175.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -134.69 -173.15 3.21 Favored 'General case' 0 N--CA 1.48 1.026 0 CA-C-O 120.748 0.309 . . . . 0.0 111.249 -173.422 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' CZ ' ' O ' ' A' ' 141' ' ' ARG . 29.5 p90 -115.43 165.31 13.12 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 121.472 0.653 . . . . 0.0 111.826 179.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.531 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 19.7 tt -65.59 -36.23 77.14 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 CA-C-N 115.257 -0.883 . . . . 0.0 111.847 -172.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.433 ' HB2' ' CD1' ' A' ' 136' ' ' PHE . 17.8 m -60.4 141.7 55.98 Favored 'General case' 0 N--CA 1.466 0.36 0 CA-C-O 121.924 0.868 . . . . 0.0 111.038 -174.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 18.9 m -62.53 -45.66 91.94 Favored 'General case' 0 C--O 1.236 0.371 0 CA-C-N 114.965 -1.016 . . . . 0.0 112.943 -173.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 -73.69 130.25 39.61 Favored 'General case' 0 CA--C 1.498 -1.033 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.192 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.591 ' O ' ' CZ ' ' A' ' 136' ' ' PHE . 60.8 ttt85 -61.9 -43.65 98.4 Favored 'General case' 0 C--O 1.189 -2.08 0 N-CA-C 114.898 1.444 . . . . 0.0 114.898 -173.093 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.689 ' OE1' HD12 ' A' ' 127' ' ' LEU . 96.0 mt-10 -145.67 131.23 18.8 Favored 'General case' 0 C--N 1.298 -1.634 0 N-CA-C 108.057 -1.09 . . . . 0.0 108.057 175.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 67.7 m-80 -99.3 143.55 29.43 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 114.047 1.128 . . . . 0.0 114.047 -168.115 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 44.3 m-85 -99.82 145.63 27.52 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.091 -0.959 . . . . 0.0 110.599 -175.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.526 ' HA ' ' HA ' ' A' ' 124' ' ' PRO . 23.3 t-80 74.41 160.03 0.23 Allowed 'General case' 0 C--O 1.24 0.593 0 CA-C-O 123.236 1.494 . . . . 0.0 113.292 172.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.445 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 63.6 t80 -65.67 139.16 58.37 Favored 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 126.403 1.881 . . . . 0.0 113.84 -179.44 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 103.84 1.68 45.89 Favored Glycine 0 C--O 1.216 -0.992 0 CA-C-N 115.176 -0.92 . . . . 0.0 114.167 177.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 20.7 p -75.96 154.95 35.49 Favored 'General case' 0 C--N 1.313 -1.016 0 CA-C-N 117.588 0.694 . . . . 0.0 110.32 178.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.42 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.7 p -135.48 135.53 51.55 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.628 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 174.141 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.3 m -131.2 136.83 56.98 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 122.838 0.455 . . . . 0.0 110.351 178.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.531 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 89.7 m -116.21 130.25 56.7 Favored 'General case' 0 C--N 1.309 -1.174 0 C-N-CA 120.186 -0.606 . . . . 0.0 109.376 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.55 ' CD2' ' HB ' ' A' ' 131' ' ' ILE . 94.6 m-85 -105.96 140.66 38.62 Favored 'General case' 0 C--O 1.203 -1.386 0 CA-C-O 121.455 0.645 . . . . 0.0 111.937 -173.767 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.437 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 48.0 mtm-85 -120.55 147.7 44.83 Favored 'General case' 0 C--N 1.316 -0.857 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -176.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.819 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 91.3 m -86.62 142.16 28.45 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-O 121.669 0.747 . . . . 0.0 110.242 -179.784 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.474 HD22 ' ND2' ' A' ' 133' ' ' ASN . 9.6 p30 -57.62 146.48 65.1 Favored Pre-proline 0 C--O 1.244 0.788 0 N-CA-C 115.89 1.811 . . . . 0.0 115.89 -167.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.543 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 32.4 Cg_exo -65.36 -19.06 61.67 Favored 'Trans proline' 0 N--CA 1.484 0.919 1 C-N-CA 125.531 4.154 . . . . 0.0 114.35 179.733 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . 95.39 -114.56 4.91 Favored Glycine 0 C--N 1.281 -2.501 0 N-CA-C 108.757 -1.737 . . . . 0.0 108.757 -164.443 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 51.0 m -60.63 -41.3 94.59 Favored 'General case' 0 CA--C 1.557 1.242 0 CA-C-N 117.739 0.77 . . . . 0.0 110.32 176.53 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 144.9 18.59 0.18 Allowed Glycine 0 C--N 1.338 0.668 0 C-N-CA 120.095 -1.05 . . . . 0.0 114.44 178.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -134.05 5.33 4.67 Favored Glycine 0 CA--C 1.547 2.089 0 C-N-CA 120.435 -0.888 . . . . 0.0 114.736 179.805 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.543 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 90.3 mtm-85 -131.44 -164.08 1.4 Allowed 'General case' 0 C--O 1.215 -0.758 0 CA-C-O 122.043 0.925 . . . . 0.0 110.909 -176.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -132.63 110.25 10.29 Favored 'General case' 0 CA--C 1.485 -1.541 0 N-CA-C 103.644 -2.724 . . . . 0.0 103.644 162.123 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.435 HG23 ' CD1' ' A' ' 164' ' ' PHE . 24.5 m -109.91 -1.19 9.81 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.741 0 N-CA-C 112.732 0.641 . . . . 0.0 112.732 -173.875 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.669 ' HB2' ' HB3' ' A' ' 154' ' ' CYS 0.254 53.3 m-85 -110.93 145.46 38.32 Favored 'General case' 0 N--CA 1.439 -1.021 0 N-CA-C 116.552 2.056 . . . . 0.0 116.552 -175.584 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.469 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 80.9 tt0 -89.71 141.75 28.32 Favored 'General case' 0 C--O 1.203 -1.343 0 CA-C-N 113.572 -1.649 . . . . 0.0 107.265 -179.12 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.613 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 14.2 tp -116.3 162.58 17.29 Favored 'General case' 0 C--N 1.297 -1.711 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 -178.515 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.613 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 14.1 p -61.25 -27.0 40.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.289 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.964 179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 119.86 -13.35 10.67 Favored Glycine 0 CA--C 1.501 -0.783 0 C-N-CA 120.803 -0.713 . . . . 0.0 114.557 177.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -132.79 83.59 52.47 Favored Pre-proline 0 C--N 1.294 -1.817 0 N-CA-C 109.192 -0.67 . . . . 0.0 109.192 175.462 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_endo -68.28 -18.37 44.66 Favored 'Trans proline' 0 CA--C 1.496 -1.401 0 C-N-CA 122.837 2.358 . . . . 0.0 114.029 -177.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 56.5 m -98.27 123.35 42.31 Favored 'General case' 0 N--CA 1.422 -1.835 0 CA-C-O 122.127 0.965 . . . . 0.0 110.389 -173.236 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.9 pt -124.5 148.57 28.76 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.007 174.383 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.426 ' HA ' ' CZ3' ' A' ' 184' ' ' TRP . 0.0 OUTLIER -147.44 159.8 43.3 Favored 'General case' 0 C--N 1.273 -2.726 0 CA-C-N 114.192 -1.367 . . . . 0.0 110.983 -178.234 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.473 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 0.1 OUTLIER -64.1 91.54 0.07 Allowed 'General case' 0 C--N 1.301 -1.515 0 O-C-N 124.094 0.871 . . . . 0.0 109.56 178.925 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.57 HG23 ' O ' ' A' ' 175' ' ' THR . 15.4 t -109.8 79.7 1.24 Allowed 'General case' 0 C--O 1.212 -0.879 0 CA-C-O 125.534 2.587 . . . . 0.0 107.44 177.901 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.807 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 98.2 p -78.45 -5.89 53.75 Favored 'General case' 0 C--N 1.252 -3.644 0 CA-C-N 110.712 -2.949 . . . . 0.0 111.679 -178.411 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 7.3 m120 -62.18 -39.86 94.08 Favored 'General case' 0 C--N 1.312 -1.038 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.961 179.34 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 26.3 t70 -85.83 116.35 24.03 Favored 'General case' 0 C--N 1.315 -0.921 0 CA-C-O 121.745 0.783 . . . . 0.0 112.791 -175.42 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 99.1 m-20 54.18 -65.55 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.962 0 N-CA-C 116.237 1.94 . . . . 0.0 116.237 179.356 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 86.3 mt-30 -96.46 137.39 35.6 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-O 122.143 0.973 . . . . 0.0 111.279 -176.77 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.807 ' O ' ' HB2' ' A' ' 176' ' ' SER . 59.3 t -63.41 -25.28 38.01 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-N 114.219 -1.355 . . . . 0.0 112.985 -169.576 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.802 ' HA3' HD13 ' A' ' 123' ' ' ILE . . . -146.14 74.51 0.3 Allowed Glycine 0 N--CA 1.471 1.019 0 C-N-CA 118.911 -1.614 . . . . 0.0 115.055 -179.821 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 9.3 pt -130.48 162.28 38.72 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.384 0 CA-C-O 121.303 0.573 . . . . 0.0 112.436 -178.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 96.8 m95 -74.43 177.35 6.01 Favored 'General case' 0 N--CA 1.473 0.715 0 N-CA-C 108.08 -1.081 . . . . 0.0 108.08 166.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.448 ' HA ' ' CG2' ' A' ' 175' ' ' THR . 38.8 t -61.93 -43.05 99.66 Favored 'General case' 0 C--N 1.317 -0.843 0 N-CA-C 109.445 -0.576 . . . . 0.0 109.445 177.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.82 -173.35 40.6 Favored Glycine 0 C--N 1.296 -1.678 0 N-CA-C 109.13 -1.588 . . . . 0.0 109.13 177.178 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -61.66 147.33 95.6 Favored 'Trans proline' 0 N--CA 1.454 -0.807 0 C-N-CA 122.616 2.211 . . . . 0.0 109.646 173.495 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.445 ' HB1' HD13 ' A' ' 131' ' ' ILE . . . -38.1 126.38 1.03 Allowed Pre-proline 0 N--CA 1.474 0.732 0 O-C-N 123.567 0.542 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.642 ' O ' HD11 ' A' ' 131' ' ' ILE . 18.5 Cg_exo -62.04 147.16 95.67 Favored 'Trans proline' 0 CA--C 1.484 -2.02 0 C-N-CA 122.151 1.901 . . . . 0.0 110.341 -176.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.544 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.7 pt20 -127.96 157.4 40.68 Favored 'General case' 0 N--CA 1.395 -3.191 0 C-N-CA 119.615 -0.834 . . . . 0.0 111.208 -171.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.579 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 61.5 m -76.74 70.69 3.25 Favored 'General case' 0 N--CA 1.402 -2.842 0 CA-C-N 113.565 -1.652 . . . . 0.0 111.396 -169.809 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.544 HG12 ' HG3' ' A' ' 190' ' ' GLN . 45.9 mm . . . . . 0 C--O 1.258 1.537 0 CA-C-N 114.294 -1.321 . . . . 0.0 109.625 176.179 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.534 ' HB2' ' CG2' ' A' ' 111' ' ' VAL . 99.2 mttt . . . . . 0 C--O 1.237 0.429 0 N-CA-C 113.033 0.753 . . . . 0.0 113.033 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 96.4 p -81.37 166.67 20.23 Favored 'General case' 0 N--CA 1.435 -1.203 0 CA-C-N 115.261 -0.881 . . . . 0.0 109.052 168.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.705 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.1 m -85.67 -174.91 5.4 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-O 121.561 0.696 . . . . 0.0 112.176 -175.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.657 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 49.6 ttt85 -65.64 -19.49 65.93 Favored 'General case' 0 N--CA 1.444 -0.735 0 CA-C-N 114.755 -1.112 . . . . 0.0 111.399 179.294 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.657 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.2 m120 88.51 141.36 0.05 OUTLIER Pre-proline 0 N--CA 1.479 1.022 0 O-C-N 124.703 1.252 . . . . 0.0 108.367 -170.477 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.557 ' CG ' HG21 ' A' ' 76' ' ' VAL . 29.6 Cg_endo -64.88 173.56 5.66 Favored 'Trans proline' 0 C--N 1.323 -0.809 0 C-N-CA 122.457 2.104 . . . . 0.0 113.128 -179.769 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.506 ' O ' ' HD2' ' A' ' 69' ' ' PRO . 72.2 Cg_endo -74.49 -171.99 1.07 Allowed 'Trans proline' 0 N--CA 1.45 -1.031 0 C-N-CA 122.753 2.302 . . . . 0.0 109.453 172.954 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 37.2 t70 -109.88 82.55 2.45 Favored Pre-proline 0 C--N 1.3 -1.576 0 C-N-CA 120.154 -0.618 . . . . 0.0 112.573 -177.87 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.506 ' HD2' ' O ' ' A' ' 67' ' ' PRO 0.291 17.3 Cg_exo -59.83 141.98 97.75 Favored 'Trans proline' 0 C--N 1.36 1.167 0 C-N-CA 121.233 1.288 . . . . 0.0 113.262 172.847 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 27.1 m -136.92 157.87 36.23 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.36 0 N-CA-C 105.653 -1.981 . . . . 0.0 105.653 166.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 57.29 35.45 26.1 Favored 'General case' 0 CA--C 1.565 1.547 0 CA-C-N 118.483 0.583 . . . . 0.0 111.408 -177.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -164.89 -166.29 23.59 Favored Glycine 0 C--N 1.367 2.26 0 C-N-CA 120.95 -0.643 . . . . 0.0 113.526 -176.506 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . 0.684 ' HG2' ' HB2' ' A' ' 89' ' ' SER . 98.4 mmm -77.82 141.93 38.89 Favored 'General case' 0 N--CA 1.49 1.557 0 N-CA-C 113.132 0.79 . . . . 0.0 113.132 -176.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 27.9 m -124.08 130.47 73.78 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.4 0 CA-C-N 114.547 -1.206 . . . . 0.0 110.202 176.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 83.9 t60 -167.1 80.99 0.21 Allowed 'General case' 0 C--N 1.322 -0.627 0 N-CA-C 109.09 -0.707 . . . . 0.0 109.09 173.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.557 HG21 ' CG ' ' A' ' 66' ' ' PRO . 1.2 p -142.01 18.51 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.306 -1.291 0 CA-C-O 122.638 1.209 . . . . 0.0 110.261 -176.229 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 10.5 tp -63.7 -42.48 96.16 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 O-C-N 121.261 -0.9 . . . . 0.0 111.383 -176.555 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -122.3 6.44 9.65 Favored 'General case' 0 C--N 1.307 -1.259 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 172.207 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -94.66 52.54 2.02 Favored Glycine 0 N--CA 1.431 -1.658 0 N-CA-C 116.035 1.174 . . . . 0.0 116.035 -168.058 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.609 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 25.3 pt -126.59 -2.56 4.63 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.143 0 C-N-CA 117.797 -1.561 . . . . 0.0 110.864 173.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 63.1 tp60 -84.5 171.08 12.83 Favored 'General case' 0 C--N 1.285 -2.229 0 N-CA-C 108.869 -0.789 . . . . 0.0 108.869 -168.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.0 t80 -62.42 130.63 46.08 Favored 'General case' 0 C--N 1.307 -1.251 0 N-CA-C 108.81 -0.811 . . . . 0.0 108.81 177.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.6 7.32 69.23 Favored Glycine 0 CA--C 1.528 0.885 0 C-N-CA 120.818 -0.705 . . . . 0.0 112.347 -175.216 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.819 ' O ' ' HA ' ' A' ' 103' ' ' THR . 31.3 t -78.8 162.13 26.32 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 113.029 0.752 . . . . 0.0 113.029 178.161 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.783 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.6 mt-30 -132.31 121.09 23.01 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 114.453 -1.249 . . . . 0.0 111.069 171.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.628 ' O ' ' HA ' ' A' ' 101' ' ' SER . 42.4 pt -113.58 129.3 69.63 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.533 0 N-CA-C 107.36 -1.348 . . . . 0.0 107.36 171.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.772 ' HA ' ' O ' ' A' ' 100' ' ' SER . 15.5 pttm -127.68 143.98 51.11 Favored 'General case' 0 C--N 1.301 -1.517 0 N-CA-C 115.851 1.797 . . . . 0.0 115.851 -176.771 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 3.0 m-85 -107.5 157.71 17.8 Favored 'General case' 0 CA--C 1.487 -1.464 0 N-CA-C 115.257 1.577 . . . . 0.0 115.257 -175.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . 0.684 ' HB2' ' HG2' ' A' ' 73' ' ' MET . 32.1 t -136.76 143.35 43.21 Favored 'General case' 0 N--CA 1.425 -1.675 0 CA-C-N 112.442 -2.163 . . . . 0.0 106.968 171.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 73.9 m -118.19 162.0 18.95 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.381 -172.681 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 28.5 m -69.34 163.77 24.4 Favored 'General case' 0 CA--C 1.549 0.926 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 178.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -63.56 132.37 51.04 Favored 'General case' 0 C--N 1.345 0.376 0 CA-C-O 121.037 0.446 . . . . 0.0 110.465 -178.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 122' ' ' ARG . . . 92.89 -3.96 74.55 Favored Glycine 0 C--O 1.22 -0.772 0 CA-C-N 115.181 -0.918 . . . . 0.0 111.637 -174.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 91.0 m-85 -120.31 143.72 48.21 Favored 'General case' 0 C--N 1.318 -0.777 0 C-N-CA 122.592 0.357 . . . . 0.0 110.876 -178.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.489 ' HG2' ' HA ' ' A' ' 123' ' ' ILE . 10.5 ptt180 -137.46 172.57 12.78 Favored 'General case' 0 C--N 1.316 -0.884 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 177.716 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.583 HD12 ' HB2' ' A' ' 118' ' ' PRO . 2.3 mm? -87.24 129.15 35.09 Favored 'General case' 0 N--CA 1.431 -1.382 0 N-CA-C 108.203 -1.036 . . . . 0.0 108.203 175.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 46.7 mm -69.09 -25.61 30.19 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.213 0 CA-C-O 121.194 0.521 . . . . 0.0 112.359 176.531 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.643 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.18 -134.91 5.0 Favored Glycine 0 N--CA 1.427 -1.93 0 CA-C-N 115.745 -0.661 . . . . 0.0 112.036 -175.027 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.847 ' HB2' HG21 ' A' ' 115' ' ' THR . 28.1 m -104.8 119.74 39.73 Favored 'General case' 0 CA--C 1.487 -1.477 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 -179.065 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.772 ' O ' ' HA ' ' A' ' 87' ' ' LYS . 80.9 p -59.66 -34.55 72.97 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.583 -173.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.693 ' OG ' ' HB3' ' A' ' 87' ' ' LYS . 14.9 m -110.47 120.45 42.47 Favored 'General case' 0 N--CA 1.419 -2.018 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 178.863 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.783 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -98.39 144.97 27.19 Favored 'General case' 0 CA--C 1.477 -1.848 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.871 179.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.819 ' HA ' ' O ' ' A' ' 84' ' ' SER . 96.1 m -115.34 127.06 55.16 Favored 'General case' 0 N--CA 1.417 -2.114 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 178.464 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.484 ' SG ' ' CZ3' ' A' ' 113' ' ' TRP . 11.2 m -72.32 126.06 28.88 Favored 'General case' 0 C--N 1.3 -1.552 0 CA-C-N 115.888 -0.596 . . . . 0.0 109.43 -178.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 7.6 pt -129.93 166.84 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.092 0 CA-C-N 115.335 -0.848 . . . . 0.0 108.967 179.612 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.464 HG12 HG22 ' A' ' 111' ' ' VAL . 97.9 mt -105.65 117.63 51.71 Favored 'Isoleucine or valine' 0 N--CA 1.425 -1.7 0 C-N-CA 118.986 -1.086 . . . . 0.0 109.415 174.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 11.5 t -62.31 -43.47 98.76 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.383 179.17 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -157.16 -85.06 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.588 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 -179.368 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -91.32 -18.93 23.54 Favored 'General case' 0 C--N 1.305 -1.336 0 N-CA-C 112.729 0.64 . . . . 0.0 112.729 175.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.416 ' O ' HG23 ' A' ' 106' ' ' ILE . 15.1 t -129.18 162.71 27.18 Favored 'General case' 0 CA--C 1.509 -0.6 0 C-N-CA 118.164 -1.414 . . . . 0.0 112.539 -167.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.705 HG12 ' SG ' ' A' ' 63' ' ' CYS . 75.5 t -99.05 118.51 45.74 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.934 0 CA-C-O 122.06 0.933 . . . . 0.0 108.993 -174.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.7 pp -130.22 163.81 34.77 Favored 'Isoleucine or valine' 0 C--O 1.246 0.898 0 CA-C-N 113.207 -1.815 . . . . 0.0 110.938 -176.687 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.484 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 96.9 m95 -82.66 133.22 35.17 Favored 'General case' 0 C--N 1.308 -1.224 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 177.64 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 41.2 p-10 -65.51 -38.41 89.63 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 112.726 0.639 . . . . 0.0 112.726 -177.248 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.847 HG21 ' HB2' ' A' ' 99' ' ' SER . 12.5 p -103.92 -7.78 20.17 Favored 'General case' 0 C--N 1.309 -1.18 0 CA-C-N 115.446 -0.797 . . . . 0.0 112.141 -176.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 94.2 mt-10 62.59 21.55 12.74 Favored 'General case' 0 C--N 1.308 -1.197 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.001 179.276 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 1.8 m 59.1 110.01 0.02 OUTLIER Pre-proline 0 CA--C 1.565 1.524 0 CA-C-O 122.073 0.94 . . . . 0.0 112.108 -176.828 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.643 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 11.2 Cg_exo -61.78 150.21 86.83 Favored 'Trans proline' 0 C--N 1.327 -0.604 0 C-N-CA 124.992 3.795 . . . . 0.0 112.136 -178.062 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 90.3 mt -100.9 131.48 48.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.247 -179.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.469 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 91.9 m -73.53 131.83 42.19 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 107.821 -1.178 . . . . 0.0 107.821 178.548 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 33.9 t70 -142.06 169.75 17.01 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 106.367 -1.716 . . . . 0.0 106.367 176.578 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.409 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 90.7 mtm180 -67.34 135.98 54.12 Favored 'General case' 0 N--CA 1.433 -1.284 0 C-N-CA 117.997 -1.481 . . . . 0.0 107.193 -178.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.541 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 18.7 mt -56.47 110.11 2.14 Favored Pre-proline 0 C--N 1.308 -1.224 0 CA-C-N 115.431 -0.804 . . . . 0.0 112.68 -174.375 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -83.89 82.39 1.97 Allowed 'Trans proline' 0 N--CA 1.409 -3.456 0 N-CA-C 108.771 -1.28 . . . . 0.0 108.771 176.959 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.497 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.3 OUTLIER -102.3 8.53 40.34 Favored 'General case' 0 C--N 1.301 -1.528 0 CA-C-N 113.084 -1.871 . . . . 0.0 108.605 178.78 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.456 ' O ' ' HB3' ' A' ' 142' ' ' GLU . . . -73.1 34.62 0.76 Allowed Glycine 0 N--CA 1.428 -1.836 0 CA-C-N 113.332 -1.758 . . . . 0.0 115.124 -175.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.463 ' HA ' HD13 ' A' ' 127' ' ' LEU . 0.0 OUTLIER -160.56 92.92 1.58 Allowed Pre-proline 0 C--N 1.301 -1.522 0 CA-C-O 122.006 0.908 . . . . 0.0 109.473 171.153 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.64 ' HD3' ' HG3' ' A' ' 142' ' ' GLU . 96.0 Cg_endo -82.22 -177.28 3.4 Favored 'Trans proline' 0 N--CA 1.452 -0.921 0 C-N-CA 123.868 3.046 . . . . 0.0 112.35 -177.152 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.466 ' HD2' ' HB2' ' A' ' 128' ' ' PRO . 26.9 Cg_endo -61.93 142.7 93.94 Favored 'Trans proline' 0 N--CA 1.45 -1.082 0 C-N-CA 121.628 1.552 . . . . 0.0 110.068 171.944 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 44.8 m -88.11 128.9 35.43 Favored 'General case' 0 C--N 1.311 -1.103 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 -179.129 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.577 HG21 ' O ' ' A' ' 134' ' ' GLY . 11.1 tp -59.99 147.15 9.46 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.211 0 O-C-N 124.243 0.964 . . . . 0.0 111.793 -175.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 20.7 m -62.38 -45.88 91.15 Favored 'General case' 0 CA--C 1.576 1.953 0 CA-C-N 114.255 -1.339 . . . . 0.0 114.416 -176.905 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 18.3 m120 -104.7 -17.26 14.71 Favored 'General case' 0 N--CA 1.483 1.185 0 N-CA-C 115.464 1.653 . . . . 0.0 115.464 -171.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.577 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 158.44 129.53 1.09 Allowed Glycine 0 CA--C 1.487 -1.685 0 N-CA-C 109.668 -1.373 . . . . 0.0 109.668 -177.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.462 ' HA ' HG22 ' A' ' 131' ' ' ILE . 1.2 p30 -31.05 -118.7 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.422 0 N-CA-C 118.019 2.6 . . . . 0.0 118.019 -166.042 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.76 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 37.6 p90 -155.79 172.68 17.93 Favored 'General case' 0 C--N 1.272 -2.775 0 N-CA-C 115.341 1.608 . . . . 0.0 115.341 -167.869 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.545 HD13 ' HD3' ' A' ' 153' ' ' ARG . 29.8 mm -63.47 -43.06 98.24 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.005 0 CA-C-N 113.478 -1.692 . . . . 0.0 113.295 -178.446 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 42.2 t -61.23 146.34 48.14 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.068 0.461 . . . . 0.0 110.789 -172.067 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.1 m -62.17 -46.04 90.72 Favored 'General case' 0 N--CA 1.445 -0.7 0 N-CA-C 114.607 1.336 . . . . 0.0 114.607 -169.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 30.8 p-10 -103.01 175.39 5.49 Favored 'General case' 0 C--N 1.297 -1.692 0 C-N-CA 120.524 -0.47 . . . . 0.0 110.69 -179.34 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.76 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 60.9 ttt85 -60.86 -43.9 97.74 Favored 'General case' 0 C--O 1.214 -0.78 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.322 179.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.64 ' HG3' ' HD3' ' A' ' 128' ' ' PRO . 0.1 OUTLIER -165.03 150.2 9.45 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 114.631 1.345 . . . . 0.0 114.631 174.331 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.579 ' HB2' ' HB3' ' A' ' 148' ' ' SER . 10.6 m120 -84.18 142.34 30.39 Favored 'General case' 0 N--CA 1.416 -2.14 0 N-CA-C 106.533 -1.654 . . . . 0.0 106.533 172.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 87.0 m-85 -62.62 -42.09 99.39 Favored 'General case' 0 C--N 1.278 -2.532 0 N-CA-C 116.083 1.883 . . . . 0.0 116.083 -162.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.401 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 75.4 m80 -131.4 -157.61 0.83 Allowed 'General case' 0 CA--C 1.566 1.569 0 CA-C-O 121.827 0.822 . . . . 0.0 113.151 -171.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.541 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 85.4 t80 -64.06 145.59 55.64 Favored 'General case' 0 CA--C 1.536 0.418 0 C-N-CA 124.476 1.111 . . . . 0.0 111.299 -179.621 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 90.49 19.42 45.09 Favored Glycine 0 CA--C 1.49 -1.522 0 CA-C-N 115.512 -0.767 . . . . 0.0 113.072 -179.579 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.579 ' HB3' ' HB2' ' A' ' 143' ' ' ASN . 70.8 m -110.6 147.26 34.61 Favored 'General case' 0 C--N 1.3 -1.57 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 178.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.88 139.32 44.86 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 115.644 -0.707 . . . . 0.0 111.897 -174.184 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.3 m -123.32 133.24 69.69 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.178 178.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.461 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 76.0 m -108.81 123.19 48.66 Favored 'General case' 0 N--CA 1.44 -0.928 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 178.506 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.562 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -87.59 150.19 23.84 Favored 'General case' 0 C--N 1.311 -1.08 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 -179.034 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.545 ' HD3' HD13 ' A' ' 137' ' ' ILE . 44.1 ptt85 -139.72 155.29 47.42 Favored 'General case' 0 C--N 1.31 -1.142 0 CA-C-N 114.635 -1.166 . . . . 0.0 109.341 -176.738 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.633 ' SG ' HD12 ' A' ' 166' ' ' LEU . 89.6 m -112.03 147.29 36.3 Favored 'General case' 0 C--N 1.306 -1.294 0 CA-C-O 121.063 0.459 . . . . 0.0 109.849 -177.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.435 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 89.9 m-20 -85.15 138.78 36.63 Favored Pre-proline 0 C--N 1.316 -0.882 0 N-CA-C 113.238 0.829 . . . . 0.0 113.238 -173.743 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 22.7 Cg_exo -62.52 144.36 94.46 Favored 'Trans proline' 0 N--CA 1.457 -0.667 0 C-N-CA 122.251 1.967 . . . . 0.0 109.139 172.152 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -63.44 -48.78 75.35 Favored Glycine 0 CA--C 1.533 1.171 0 C-N-CA 119.628 -1.272 . . . . 0.0 113.996 -175.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 14.8 m -150.46 -70.79 0.18 Allowed 'General case' 0 N--CA 1.472 0.649 0 C-N-CA 119.982 -0.687 . . . . 0.0 112.032 176.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -91.77 33.26 4.91 Favored Glycine 0 C--N 1.346 1.086 0 CA-C-N 115.831 -0.622 . . . . 0.0 113.046 -177.162 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 88.22 0.19 83.04 Favored Glycine 0 CA--C 1.528 0.865 0 C-N-CA 121.07 -0.586 . . . . 0.0 112.408 -179.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -72.37 136.28 46.08 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 120.354 0.121 . . . . 0.0 111.147 178.779 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.586 ' HD3' ' O ' ' A' ' 162' ' ' LYS . 6.3 tmtt? -78.54 120.76 23.7 Favored 'General case' 0 N--CA 1.437 -1.083 0 CA-C-O 121.38 0.609 . . . . 0.0 110.343 177.344 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.459 HG23 ' CD2' ' A' ' 164' ' ' PHE . 36.0 m -116.83 -2.34 10.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.332 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.45 173.929 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.465 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 74.1 m-85 -129.05 151.13 50.07 Favored 'General case' 0 CA--C 1.493 -1.222 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.665 -175.915 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.532 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 97.3 mt-10 -127.19 143.65 51.21 Favored 'General case' 0 C--O 1.201 -1.497 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 -179.63 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.634 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.8 tt -118.1 144.37 45.7 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.677 -0.861 . . . . 0.0 108.677 -176.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.634 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.2 t -66.58 132.1 32.1 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.114 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.128 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -52.55 10.23 0.01 OUTLIER Glycine 0 N--CA 1.509 3.511 0 N-CA-C 119.263 2.465 . . . . 0.0 119.263 -169.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.416 ' N ' ' O ' ' A' ' 167' ' ' VAL . 0.0 OUTLIER -130.84 71.1 82.56 Favored Pre-proline 0 C--N 1.301 -1.513 0 CA-C-N 118.788 1.294 . . . . 0.0 108.744 174.081 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HB3' HD22 ' A' ' 166' ' ' LEU . 40.7 Cg_endo -67.02 -18.33 51.72 Favored 'Trans proline' 0 C--N 1.363 1.33 0 C-N-CA 123.28 2.653 . . . . 0.0 114.578 -174.179 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.461 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 7.4 t -110.21 127.23 54.84 Favored 'General case' 0 N--CA 1.424 -1.736 0 C-N-CA 118.108 -1.437 . . . . 0.0 110.288 -172.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.428 ' O ' HG23 ' A' ' 149' ' ' VAL . 48.1 pt -124.48 154.83 32.09 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.134 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.073 -179.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.7 p90 -144.43 162.75 35.71 Favored 'General case' 0 C--N 1.298 -1.666 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.325 -173.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 73.4 m -71.18 110.12 5.64 Favored 'General case' 0 C--N 1.312 -1.049 0 N-CA-C 108.041 -1.096 . . . . 0.0 108.041 179.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.496 HG21 ' HA ' ' A' ' 185' ' ' SER . 5.6 t -115.11 15.65 17.09 Favored 'General case' 0 N--CA 1.483 1.213 0 CA-C-O 122.149 0.976 . . . . 0.0 109.678 -176.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.774 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 73.0 p -61.61 -24.9 67.0 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-N 114.376 -1.283 . . . . 0.0 114.204 -174.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.459 HD22 ' HA ' ' A' ' 177' ' ' ASN . 5.8 m120 -64.12 -41.31 97.29 Favored 'General case' 0 C--N 1.303 -1.42 0 N-CA-C 116.017 1.858 . . . . 0.0 116.017 178.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 47.6 p-10 -106.81 -68.34 0.89 Allowed 'General case' 0 N--CA 1.472 0.665 0 N-CA-C 114.08 1.141 . . . . 0.0 114.08 -176.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 21.1 m-20 -95.15 111.33 23.18 Favored 'General case' 0 CA--C 1.506 -0.748 0 CA-C-O 121.228 0.537 . . . . 0.0 112.127 176.507 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.481 ' HB2' HD11 ' A' ' 183' ' ' ILE . 93.8 mm-40 73.63 153.93 0.14 Allowed 'General case' 0 C--O 1.21 -0.987 0 CA-C-N 114.188 -1.369 . . . . 0.0 110.382 -178.014 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 55.9 t -121.52 131.02 74.05 Favored 'Isoleucine or valine' 0 CA--C 1.553 1.086 0 CA-C-O 121.73 0.776 . . . . 0.0 112.551 -172.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.774 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 78.98 12.67 83.89 Favored Glycine 0 N--CA 1.467 0.73 0 CA-C-N 114.453 -1.248 . . . . 0.0 113.287 177.09 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.761 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.1 pp -129.99 163.3 35.82 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.248 0 N-CA-C 114.433 1.271 . . . . 0.0 114.433 -173.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.761 ' O ' HD12 ' A' ' 183' ' ' ILE . 70.6 m95 -77.92 171.86 14.36 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 114.381 -1.281 . . . . 0.0 111.351 176.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.496 ' HA ' HG21 ' A' ' 175' ' ' THR . 79.4 p -63.76 -22.56 66.97 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.319 0.581 . . . . 0.0 111.878 -178.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -178.22 168.31 39.48 Favored Glycine 0 N--CA 1.428 -1.879 0 CA-C-N 115.168 -0.924 . . . . 0.0 111.574 177.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 19.9 Cg_exo -63.02 147.06 94.89 Favored 'Trans proline' 0 N--CA 1.46 -0.472 0 C-N-CA 123.035 2.49 . . . . 0.0 110.937 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.418 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -47.34 111.72 1.75 Allowed Pre-proline 0 C--O 1.243 0.745 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 177.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . . . . . . . . . 24.3 Cg_exo -61.5 144.47 97.94 Favored 'Trans proline' 0 CA--C 1.479 -2.233 0 C-N-CA 121.322 1.348 . . . . 0.0 108.807 -177.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.685 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.8 pt20 -117.14 157.49 25.85 Favored 'General case' 0 C--N 1.289 -2.022 0 C-N-CA 119.835 -0.746 . . . . 0.0 111.574 -167.308 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.532 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 85.0 m -75.69 72.41 2.63 Favored 'General case' 0 N--CA 1.424 -1.727 0 CA-C-N 114.416 -1.265 . . . . 0.0 110.544 -173.7 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.685 HG13 ' HG3' ' A' ' 190' ' ' GLN . 96.2 mt . . . . . 0 C--O 1.254 1.313 0 CA-C-N 113.596 -1.638 . . . . 0.0 109.296 176.875 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 26.5 ttmt . . . . . 0 C--O 1.238 0.499 0 CA-C-O 120.955 0.407 . . . . 0.0 110.713 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 24.3 p -82.72 158.73 22.78 Favored 'General case' 0 N--CA 1.426 -1.635 0 CA-C-N 115.487 -0.778 . . . . 0.0 112.492 174.421 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.518 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 7.0 m -84.81 -172.85 4.4 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-O 121.468 0.651 . . . . 0.0 110.672 179.195 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.639 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 29.7 mmt180 -88.44 -0.4 57.15 Favored 'General case' 0 C--N 1.307 -1.243 0 CA-C-N 115.188 -0.915 . . . . 0.0 112.814 -176.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.639 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 10.9 t-20 78.74 145.59 0.1 Allowed Pre-proline 0 N--CA 1.471 0.62 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 -177.373 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -38.16 150.55 0.06 OUTLIER 'Trans proline' 0 CA--C 1.573 2.471 0 C-N-CA 123.707 2.938 . . . . 0.0 114.585 179.175 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -56.96 -32.0 91.42 Favored 'Trans proline' 0 N--CA 1.498 1.749 0 C-N-CA 124.193 3.262 . . . . 0.0 113.373 -178.469 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . 0.308 0.0 OUTLIER 83.5 75.73 0.09 OUTLIER Pre-proline 0 N--CA 1.479 1.024 0 C-N-CA 124.79 1.236 . . . . 0.0 113.704 177.169 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.529 ' HG2' ' CA ' ' A' ' 72' ' ' GLY . 91.2 Cg_endo -70.42 154.8 64.85 Favored 'Trans proline' 0 N--CA 1.457 -0.641 0 C-N-CA 122.621 2.214 . . . . 0.0 109.94 170.415 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 31.5 m -63.64 -24.63 36.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.003 0 CA-C-O 121.684 0.754 . . . . 0.0 111.926 -178.865 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 3.0 t-20 -104.72 17.64 23.75 Favored 'General case' 0 C--N 1.29 -2.018 0 CA-C-N 114.736 -1.12 . . . . 0.0 108.858 -178.986 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.529 ' CA ' ' HG2' ' A' ' 69' ' ' PRO . . . -68.39 168.62 41.92 Favored Glycine 0 CA--C 1.52 0.367 0 CA-C-N 114.858 -1.064 . . . . 0.0 114.877 -177.118 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.0 mmm -122.72 144.27 49.26 Favored 'General case' 0 C--O 1.242 0.658 0 C-N-CA 123.824 0.85 . . . . 0.0 110.585 -176.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 81.6 t -118.88 93.4 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.76 0 C-N-CA 120.384 -0.526 . . . . 0.0 110.774 175.268 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 53.3 m170 -128.64 -19.7 3.7 Favored 'General case' 0 N--CA 1.478 0.969 0 N-CA-C 112.109 0.411 . . . . 0.0 112.109 173.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.479 ' O ' ' N ' ' A' ' 78' ' ' LYS . 7.1 p -63.17 -44.56 99.43 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.903 0 N-CA-C 116.035 1.865 . . . . 0.0 116.035 -171.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.574 HG23 ' H ' ' A' ' 78' ' ' LYS . 20.6 tt 32.54 -66.06 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.514 2.754 0 C-N-CA 124.916 1.286 . . . . 0.0 114.441 -168.578 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.574 ' H ' HG23 ' A' ' 77' ' ' ILE . 68.6 mttm -117.93 110.56 17.87 Favored 'General case' 0 N--CA 1.432 -1.372 0 O-C-N 121.528 -0.732 . . . . 0.0 109.342 173.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.444 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . 161.28 33.64 0.02 OUTLIER Glycine 0 CA--C 1.484 -1.9 0 N-CA-C 109.621 -1.391 . . . . 0.0 109.621 -176.13 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.518 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.9 pt -117.25 -1.18 9.12 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 CA-C-N 113.704 -1.248 . . . . 0.0 111.477 -178.65 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.618 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 99.3 mt-30 -81.0 -168.78 1.94 Allowed 'General case' 0 C--O 1.209 -1.06 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 -175.378 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 87.8 t80 -65.27 126.37 27.97 Favored 'General case' 0 C--N 1.314 -0.947 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.506 177.177 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 89.06 -4.34 84.67 Favored Glycine 0 CA--C 1.536 1.357 0 CA-C-N 115.825 -0.625 . . . . 0.0 114.394 177.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.515 ' O ' ' HA ' ' A' ' 103' ' ' THR . 28.7 p -78.85 163.92 24.91 Favored 'General case' 0 N--CA 1.442 -0.85 0 CA-C-N 117.66 0.73 . . . . 0.0 111.307 -178.674 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.623 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 87.7 mt-30 -139.03 150.14 45.44 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.552 0.691 . . . . 0.0 112.016 176.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.714 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.9 pt -127.97 152.43 36.05 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-N 114.409 -1.269 . . . . 0.0 108.232 177.517 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.422 ' HA ' ' O ' ' A' ' 100' ' ' SER . 11.4 mptt -120.82 142.73 49.35 Favored 'General case' 0 C--N 1.314 -0.963 0 C-N-CA 120.669 -0.413 . . . . 0.0 110.374 176.337 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.446 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 57.7 t80 -126.55 121.18 31.54 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.074 0.464 . . . . 0.0 111.827 179.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 7.2 m -79.54 146.26 32.72 Favored 'General case' 0 CA--C 1.548 0.883 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.957 -179.574 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.511 ' SG ' HD13 ' A' ' 96' ' ' LEU . 77.4 m -121.62 153.22 38.38 Favored 'General case' 0 C--O 1.241 0.633 0 N-CA-C 109.817 -0.438 . . . . 0.0 109.817 173.176 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 33.7 m -72.72 161.52 30.65 Favored 'General case' 0 CA--C 1.548 0.898 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 173.342 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -63.49 134.47 55.65 Favored 'General case' 0 N--CA 1.473 0.698 0 CA-C-O 120.881 0.372 . . . . 0.0 111.136 -177.558 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 98.84 -11.15 62.55 Favored Glycine 0 CA--C 1.505 -0.593 0 CA-C-N 116.069 -0.514 . . . . 0.0 112.037 -179.047 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.4 m-85 -120.53 139.87 52.29 Favored 'General case' 0 N--CA 1.44 -0.941 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 174.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.61 HH11 HD13 ' A' ' 97' ' ' ILE . 1.9 ppt_? -134.85 164.05 28.44 Favored 'General case' 0 CA--C 1.492 -1.262 0 C-N-CA 120.818 -0.353 . . . . 0.0 110.099 -179.053 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.555 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.9 mm? -77.84 128.2 33.6 Favored 'General case' 0 N--CA 1.428 -1.531 0 CA-C-O 121.835 0.826 . . . . 0.0 110.562 -176.672 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.822 HD11 ' HB3' ' A' ' 121' ' ' ASP . 45.7 mm -64.41 -44.06 97.05 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.079 0 CA-C-N 114.496 -1.229 . . . . 0.0 113.832 179.35 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -103.7 -91.89 2.22 Favored Glycine 0 CA--C 1.483 -1.921 0 C-N-CA 120.012 -1.09 . . . . 0.0 111.894 -172.461 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.561 ' H ' HG21 ' A' ' 115' ' ' THR . 8.6 t -140.97 131.25 25.0 Favored 'General case' 0 N--CA 1.414 -2.254 0 N-CA-C 106.342 -1.725 . . . . 0.0 106.342 176.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.455 ' HA ' ' HG3' ' A' ' 118' ' ' PRO . 78.2 p -64.6 -23.21 67.19 Favored 'General case' 0 N--CA 1.485 1.281 0 CA-C-O 121.267 0.555 . . . . 0.0 110.959 -178.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.714 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 18.7 p -113.68 140.52 48.16 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 115.474 -0.785 . . . . 0.0 109.29 173.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.623 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -124.01 144.85 49.58 Favored 'General case' 0 CA--C 1.479 -1.767 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.476 -179.616 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 84' ' ' SER . 86.2 m -117.82 127.19 53.64 Favored 'General case' 0 N--CA 1.416 -2.158 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 179.727 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.565 ' HB2' ' O ' ' A' ' 81' ' ' GLN . 7.0 m -72.58 127.76 33.53 Favored 'General case' 0 C--N 1.301 -1.513 0 CA-C-O 121.522 0.677 . . . . 0.0 110.375 178.443 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 2.4 pp -127.97 162.3 34.28 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.262 0 CA-C-N 114.964 -1.016 . . . . 0.0 109.027 -179.038 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.404 HG12 ' HB ' ' A' ' 111' ' ' VAL . 88.1 mt -108.42 126.52 65.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.436 0 CA-C-O 121.603 0.716 . . . . 0.0 111.151 -178.336 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.56 ' OG ' HD11 ' A' ' 112' ' ' ILE . 28.1 p -140.42 153.68 46.39 Favored 'General case' 0 N--CA 1.423 -1.788 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 176.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 59.45 -135.15 51.49 Favored Glycine 0 CA--C 1.533 1.202 0 C-N-CA 118.376 -1.869 . . . . 0.0 110.036 -173.099 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 84.2 m-20 -97.35 2.57 50.75 Favored 'General case' 0 C--N 1.307 -1.269 0 C-N-CA 122.798 0.439 . . . . 0.0 112.078 177.275 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 3.5 t -137.18 166.52 23.54 Favored 'General case' 0 N--CA 1.475 0.791 0 N-CA-C 113.169 0.803 . . . . 0.0 113.169 -166.649 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.404 ' HB ' HG12 ' A' ' 106' ' ' ILE . 11.1 p -110.11 123.0 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.388 0 CA-C-O 122.683 1.23 . . . . 0.0 108.282 179.69 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.56 HD11 ' OG ' ' A' ' 107' ' ' SER . 17.4 pt -129.43 162.08 37.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.725 0 CA-C-N 113.071 -1.877 . . . . 0.0 112.269 -175.933 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 94.9 m95 -75.1 134.87 41.22 Favored 'General case' 0 N--CA 1.438 -1.069 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 -177.588 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 50.6 p-10 -65.3 -37.25 86.55 Favored 'General case' 0 N--CA 1.481 1.108 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -178.401 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.561 HG21 ' H ' ' A' ' 99' ' ' SER . 90.9 m -97.92 -15.52 20.11 Favored 'General case' 0 C--N 1.303 -1.45 0 CA-C-N 115.826 -0.624 . . . . 0.0 112.141 -178.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 62.01 20.01 11.23 Favored 'General case' 0 N--CA 1.495 1.804 0 N-CA-C 108.958 -0.756 . . . . 0.0 108.958 -172.144 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 17.1 m 67.95 129.41 0.03 OUTLIER Pre-proline 0 C--O 1.224 -0.25 0 CA-C-N 114.369 -1.287 . . . . 0.0 110.999 -175.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.555 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.5 Cg_endo -70.77 156.56 60.48 Favored 'Trans proline' 0 N--CA 1.441 -1.606 0 C-N-CA 122.843 2.362 . . . . 0.0 112.198 179.804 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.605 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.4 mm -109.48 130.69 62.09 Favored 'Isoleucine or valine' 0 C--N 1.271 -2.81 0 N-CA-C 108.173 -1.047 . . . . 0.0 108.173 -179.093 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.446 ' SG ' ' CE2' ' A' ' 88' ' ' TYR . 79.0 m -73.1 126.16 29.35 Favored 'General case' 0 N--CA 1.426 -1.669 0 N-CA-C 106.171 -1.789 . . . . 0.0 106.171 178.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.822 ' HB3' HD11 ' A' ' 97' ' ' ILE . 43.4 t0 -146.23 169.71 18.22 Favored 'General case' 0 C--N 1.29 -2.002 0 N-CA-C 108.682 -0.859 . . . . 0.0 108.682 -176.74 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.818 ' HD2' ' NE2' ' A' ' 145' ' ' HIS . 91.2 mtm180 -64.63 133.22 51.77 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.569 HG23 ' HG2' ' A' ' 95' ' ' ARG . 47.9 mt -70.27 105.57 1.25 Allowed Pre-proline 0 CA--C 1.491 -1.304 0 CA-C-N 114.468 -1.242 . . . . 0.0 112.629 -171.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.579 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 23.6 Cg_exo -62.85 141.79 86.05 Favored 'Trans proline' 0 N--CA 1.431 -2.164 0 N-CA-C 106.338 -2.216 . . . . 0.0 106.338 171.652 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.457 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 0.5 OUTLIER -84.49 -26.23 28.29 Favored 'General case' 0 C--N 1.275 -2.642 0 CA-C-O 121.762 0.791 . . . . 0.0 112.408 -178.644 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.13 -170.63 54.7 Favored Glycine 0 N--CA 1.424 -2.105 0 CA-C-N 114.663 -1.153 . . . . 0.0 110.653 179.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.42 HD13 ' HG2' ' A' ' 142' ' ' GLU . 3.7 mm? -73.87 119.31 75.49 Favored Pre-proline 0 C--N 1.29 -2.001 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 12.9 Cg_exo -64.56 151.87 83.91 Favored 'Trans proline' 0 C--O 1.247 0.928 0 C-N-CA 122.045 1.83 . . . . 0.0 108.688 179.438 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.624 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 27.4 Cg_exo -60.14 138.52 82.15 Favored 'Trans proline' 0 N--CA 1.44 -1.641 0 N-CA-C 107.691 -1.696 . . . . 0.0 107.691 -179.642 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.4 m -72.81 133.28 44.41 Favored 'General case' 0 C--N 1.298 -1.66 0 C-N-CA 120.276 -0.57 . . . . 0.0 109.675 -178.417 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.645 HG23 ' H ' ' A' ' 134' ' ' GLY . 11.0 tp -70.93 146.15 12.15 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 CA-C-O 121.101 0.476 . . . . 0.0 110.138 -178.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 90.2 m -61.63 -45.82 92.42 Favored 'General case' 0 CA--C 1.563 1.479 0 CA-C-N 115.137 -0.938 . . . . 0.0 112.548 -176.361 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 155' ' ' ASN . 6.2 m120 -63.8 -40.63 97.1 Favored 'General case' 0 N--CA 1.496 1.835 0 N-CA-C 115.13 1.53 . . . . 0.0 115.13 178.645 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.645 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 179.17 -82.94 0.06 OUTLIER Glycine 0 N--CA 1.444 -0.808 0 C-N-CA 120.039 -1.077 . . . . 0.0 112.806 -175.166 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.488 ' O ' HG21 ' A' ' 131' ' ' ILE . 4.0 t70 -145.82 -167.98 2.86 Favored 'General case' 0 CA--C 1.558 1.259 0 CA-C-N 116.753 0.277 . . . . 0.0 110.3 -177.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.706 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 18.5 p90 -111.69 159.1 18.55 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 113.79 1.033 . . . . 0.0 113.79 -173.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.856 HD12 ' HE ' ' A' ' 153' ' ' ARG . 1.1 tt -66.51 -28.53 43.65 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.863 0 CA-C-N 114.383 -1.28 . . . . 0.0 110.973 -174.821 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 21.2 t -62.69 141.32 58.6 Favored 'General case' 0 C--N 1.341 0.208 0 CA-C-O 122.15 0.976 . . . . 0.0 112.436 -169.625 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 41.6 p -67.48 -32.21 72.88 Favored 'General case' 0 N--CA 1.433 -1.282 0 CA-C-N 113.542 -1.663 . . . . 0.0 112.431 -179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 12.0 m120 -91.86 132.59 36.35 Favored 'General case' 0 N--CA 1.441 -0.902 0 N-CA-C 108.334 -0.987 . . . . 0.0 108.334 -177.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.706 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 38.9 ptt180 -65.14 -38.76 91.63 Favored 'General case' 0 C--O 1.199 -1.579 0 N-CA-C 112.398 0.518 . . . . 0.0 112.398 -174.427 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.561 ' HG3' ' HG3' ' A' ' 141' ' ' ARG . 97.3 mt-10 -138.3 146.08 41.99 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.78 -0.575 . . . . 0.0 109.587 -176.014 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.473 ' OD1' ' HH2' ' A' ' 184' ' ' TRP . 10.7 m120 -97.66 110.88 23.36 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.72 -0.474 . . . . 0.0 109.72 178.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 90.6 m-85 -100.21 -2.13 34.72 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.862 -170.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.818 ' NE2' ' HD2' ' A' ' 122' ' ' ARG . 31.2 t-80 -153.62 152.87 31.35 Favored 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 112.54 0.57 . . . . 0.0 112.54 -169.571 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 82.3 t80 -65.18 140.87 58.8 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.154 -0.684 . . . . 0.0 109.154 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 94.62 31.05 8.07 Favored Glycine 0 N--CA 1.438 -1.216 0 C-N-CA 120.211 -0.995 . . . . 0.0 112.33 -175.022 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 71.6 m -125.74 150.39 47.76 Favored 'General case' 0 N--CA 1.442 -0.858 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 177.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.4 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -140.82 140.41 33.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.483 -174.793 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.424 HG22 ' CZ3' ' A' ' 184' ' ' TRP . 30.0 m -123.68 132.57 71.16 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.046 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 174.686 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.528 ' HB ' HG21 ' A' ' 137' ' ' ILE . 89.3 m -111.28 124.88 53.12 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 178.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.567 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 87.1 m-85 -84.08 141.21 31.3 Favored 'General case' 0 C--N 1.277 -2.582 0 CA-C-O 121.335 0.588 . . . . 0.0 111.84 -178.695 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.856 ' HE ' HD12 ' A' ' 137' ' ' ILE . 29.4 mmt180 -125.18 143.91 50.7 Favored 'General case' 0 N--CA 1.41 -2.431 0 N-CA-C 106.769 -1.567 . . . . 0.0 106.769 178.131 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.598 ' SG ' HD12 ' A' ' 166' ' ' LEU . 94.6 m -92.93 124.06 36.64 Favored 'General case' 0 C--N 1.278 -2.507 0 C-N-CA 118.706 -1.198 . . . . 0.0 108.84 178.06 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.557 ' HB3' ' HB3' ' A' ' 133' ' ' ASN . 1.6 t30 -77.84 135.63 63.42 Favored Pre-proline 0 C--N 1.298 -1.635 0 CA-C-N 114.079 -1.419 . . . . 0.0 111.199 -172.054 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -69.68 154.06 68.52 Favored 'Trans proline' 0 N--CA 1.445 -1.36 0 C-N-CA 122.856 2.37 . . . . 0.0 112.044 -178.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.39 178.37 47.56 Favored Glycine 0 N--CA 1.425 -2.066 0 N-CA-C 110.484 -1.047 . . . . 0.0 110.484 179.993 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 21.7 p -73.32 156.57 38.27 Favored 'General case' 0 N--CA 1.418 -2.055 0 C-N-CA 119.955 -0.698 . . . . 0.0 109.15 -178.535 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 80.07 11.64 84.2 Favored Glycine 0 N--CA 1.44 -1.041 0 N-CA-C 111.334 -0.706 . . . . 0.0 111.334 -178.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 74.98 23.76 73.71 Favored Glycine 0 C--N 1.348 1.221 0 C-N-CA 120.99 -0.624 . . . . 0.0 113.958 176.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 91.6 mtm-85 -94.22 135.59 35.44 Favored 'General case' 0 N--CA 1.471 0.611 0 CA-C-N 117.619 0.71 . . . . 0.0 111.863 -178.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 58.7 tptt -86.85 104.36 16.13 Favored 'General case' 0 CA--C 1.495 -1.142 0 N-CA-C 105.684 -1.969 . . . . 0.0 105.684 173.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 30.7 m -113.42 4.6 8.0 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.422 0 CA-C-N 114.894 -1.048 . . . . 0.0 112.75 -174.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.508 ' HD2' ' O ' ' A' ' 155' ' ' ASN . 55.5 m-85 -128.35 150.65 50.0 Favored 'General case' 0 C--N 1.32 -0.696 0 N-CA-C 114.314 1.227 . . . . 0.0 114.314 -173.878 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -122.83 147.22 46.79 Favored 'General case' 0 C--O 1.206 -1.208 0 CA-C-N 113.698 -1.592 . . . . 0.0 108.192 -178.232 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.654 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.6 tt -113.7 157.71 21.84 Favored 'General case' 0 CA--C 1.555 1.156 0 CA-C-N 118.225 0.466 . . . . 0.0 109.915 -178.379 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.654 ' N ' HD23 ' A' ' 166' ' ' LEU . 67.9 t -60.81 -45.26 98.28 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.325 0 N-CA-C 112.283 0.475 . . . . 0.0 112.283 -173.203 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.45 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 152.7 -26.0 0.84 Allowed Glycine 0 N--CA 1.472 1.061 0 C-N-CA 119.416 -1.373 . . . . 0.0 113.888 176.676 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.4 tp10 -126.17 81.78 66.37 Favored Pre-proline 0 C--N 1.309 -1.188 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 176.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.509 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 42.1 Cg_endo -67.06 -20.25 50.63 Favored 'Trans proline' 0 C--N 1.349 0.59 0 C-N-CA 123.004 2.469 . . . . 0.0 113.906 -176.216 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.431 ' HA ' ' HA ' ' A' ' 151' ' ' THR . 14.7 m -96.33 124.62 40.39 Favored 'General case' 0 N--CA 1.438 -1.043 0 CA-C-O 121.076 0.465 . . . . 0.0 111.619 -175.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.4 ' O ' HG23 ' A' ' 149' ' ' VAL . 49.1 pt -126.27 153.65 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.612 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 175.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.736 ' CD2' HG22 ' A' ' 175' ' ' THR . 15.6 p90 -146.9 160.7 42.0 Favored 'General case' 0 CA--C 1.48 -1.739 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.767 -175.722 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 21.9 m -73.8 100.24 3.4 Favored 'General case' 0 C--N 1.305 -1.35 0 N-CA-C 105.512 -2.033 . . . . 0.0 105.512 -178.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.736 HG22 ' CD2' ' A' ' 173' ' ' TYR . 2.0 p -117.64 -14.75 10.21 Favored 'General case' 0 N--CA 1.479 0.977 0 C-N-CA 118.398 -1.321 . . . . 0.0 113.21 -174.022 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 66.7 p 12.09 89.81 0.01 OUTLIER 'General case' 0 N--CA 1.482 1.147 0 O-C-N 124.282 0.988 . . . . 0.0 113.156 -163.495 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 66.2 t30 -154.36 174.83 14.32 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.833 -176.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 63.2 m-20 65.64 49.73 1.73 Allowed 'General case' 0 CA--C 1.519 -0.245 0 CA-C-O 121.915 0.864 . . . . 0.0 111.591 176.269 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 68.4 m-20 60.93 29.15 18.84 Favored 'General case' 0 N--CA 1.485 1.31 0 C-N-CA 126.248 1.819 . . . . 0.0 110.618 178.522 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.412 ' HB3' ' CG1' ' A' ' 183' ' ' ILE . 83.4 mt-30 -133.87 122.92 23.88 Favored 'General case' 0 N--CA 1.43 -1.427 0 N-CA-C 107.165 -1.42 . . . . 0.0 107.165 173.217 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -106.69 11.26 8.95 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.159 0 N-CA-C 116.643 2.09 . . . . 0.0 116.643 -166.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -161.61 36.44 0.39 Allowed Glycine 0 N--CA 1.472 1.087 0 C-N-CA 119.853 -1.165 . . . . 0.0 113.174 -178.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.412 ' CG1' ' HB3' ' A' ' 180' ' ' GLN . 2.3 pp -128.68 162.88 34.71 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.395 0 N-CA-C 113.543 0.942 . . . . 0.0 113.543 -175.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.473 ' HH2' ' OD1' ' A' ' 143' ' ' ASN . 67.7 m95 -69.17 179.76 1.83 Allowed 'General case' 0 C--O 1.21 -1.015 0 CA-C-N 115.068 -0.969 . . . . 0.0 108.528 172.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 76.6 p -61.09 -34.04 74.31 Favored 'General case' 0 C--N 1.317 -0.826 0 O-C-N 122.154 -0.341 . . . . 0.0 111.01 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -177.93 177.41 48.36 Favored Glycine 0 N--CA 1.441 -0.976 0 N-CA-C 111.284 -0.726 . . . . 0.0 111.284 177.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_exo -62.52 146.03 95.46 Favored 'Trans proline' 0 C--O 1.242 0.71 0 C-N-CA 122.68 2.254 . . . . 0.0 110.485 179.28 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.624 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -50.82 123.47 18.5 Favored Pre-proline 0 C--O 1.236 0.386 0 N-CA-C 110.297 -0.26 . . . . 0.0 110.297 -179.275 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.509 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 19.8 Cg_exo -61.11 145.14 99.22 Favored 'Trans proline' 0 CA--C 1.496 -1.406 0 C-N-CA 121.578 1.519 . . . . 0.0 109.444 178.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.483 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.1 pt20 -110.96 139.38 46.35 Favored 'General case' 0 C--N 1.278 -2.513 0 CA-C-O 121.059 0.457 . . . . 0.0 111.688 -173.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . . . . . . . . . 71.1 m -73.56 72.89 1.43 Allowed 'General case' 0 C--N 1.305 -1.367 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.159 -177.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.483 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.265 1.917 0 CA-C-N 114.362 -1.29 . . . . 0.0 109.751 178.151 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.511 ' HB3' ' CG2' ' A' ' 111' ' ' VAL . 4.2 ttmm . . . . . 0 N--CA 1.436 -1.138 0 N-CA-C 109.384 -0.599 . . . . 0.0 109.384 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.654 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 26.2 p -81.45 162.21 23.38 Favored 'General case' 0 C--N 1.317 -0.847 0 N-CA-C 113.47 0.915 . . . . 0.0 113.47 178.76 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.787 ' SG ' HG12 ' A' ' 111' ' ' VAL . 0.8 OUTLIER -90.48 176.03 6.85 Favored 'General case' 0 CA--C 1.51 -0.578 0 CA-C-N 115.805 -0.634 . . . . 0.0 109.948 172.31 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.641 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 62.4 ttp180 -66.24 -18.7 65.51 Favored 'General case' 0 N--CA 1.437 -1.111 0 N-CA-C 113.689 0.996 . . . . 0.0 113.689 179.229 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.641 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 21.7 t-20 92.84 139.41 0.04 OUTLIER Pre-proline 0 N--CA 1.488 1.455 0 O-C-N 124.281 0.988 . . . . 0.0 109.551 -175.364 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.437 ' HA ' ' HD2' ' A' ' 67' ' ' PRO . 24.0 Cg_exo -37.65 113.85 0.14 Allowed 'Trans proline' 0 C--N 1.355 0.908 0 C-N-CA 124.427 3.418 . . . . 0.0 114.824 -179.646 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.437 ' HD2' ' HA ' ' A' ' 66' ' ' PRO . 36.2 Cg_endo -66.79 -19.51 52.99 Favored 'Trans proline' 0 C--N 1.353 0.769 0 C-N-CA 123.735 2.956 . . . . 0.0 111.421 175.664 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -23.82 132.7 0.08 OUTLIER Pre-proline 0 C--O 1.242 0.704 0 C-N-CA 125.954 1.702 . . . . 0.0 114.914 -175.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -65.73 156.16 65.42 Favored 'Trans proline' 0 N--CA 1.444 -1.428 0 C-N-CA 123.834 3.022 . . . . 0.0 112.566 177.695 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 69.8 t -62.98 136.74 25.65 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.076 0 CA-C-N 114.875 -1.057 . . . . 0.0 112.015 -169.427 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.9 m-20 61.75 34.24 17.45 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.669 -175.632 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.91 -168.79 42.23 Favored Glycine 0 N--CA 1.439 -1.132 0 N-CA-C 109.093 -1.603 . . . . 0.0 109.093 170.118 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 66.3 mtt -101.68 136.67 41.11 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-N 118.232 1.016 . . . . 0.0 110.32 177.894 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 53.6 t -121.83 128.94 75.82 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.932 0 N-CA-C 107.185 -1.413 . . . . 0.0 107.185 173.691 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 97.7 m-70 -121.0 10.98 10.9 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.971 -177.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 14.2 p -121.57 130.19 74.84 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.949 0 CA-C-O 121.28 0.562 . . . . 0.0 110.887 -173.789 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.416 HG22 ' HG3' ' A' ' 78' ' ' LYS . 94.1 mt -104.37 -78.57 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.848 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.641 177.475 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.416 ' HG3' HG22 ' A' ' 77' ' ' ILE . 99.5 mttt -97.53 -8.6 28.77 Favored 'General case' 0 N--CA 1.475 0.781 0 CA-C-N 115.132 -0.94 . . . . 0.0 111.305 -178.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.76 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -78.69 4.81 59.33 Favored Glycine 0 C--O 1.185 -2.906 0 CA-C-O 118.329 -1.262 . . . . 0.0 115.739 -168.7 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.767 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 44.2 pt -68.03 -13.15 16.56 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.1 0 C-N-CA 123.947 0.899 . . . . 0.0 111.003 -173.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.654 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 87.1 mt-30 -69.3 -163.37 0.05 OUTLIER 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.165 0.507 . . . . 0.0 111.383 -178.841 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 58.7 t80 -58.39 130.77 48.32 Favored 'General case' 0 C--N 1.299 -1.595 0 CA-C-O 121.684 0.754 . . . . 0.0 110.829 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 92.34 0.73 70.0 Favored Glycine 0 CA--C 1.536 1.355 0 CA-C-N 114.642 -1.163 . . . . 0.0 113.179 -176.994 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.76 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 40.7 t -67.28 143.66 56.32 Favored 'General case' 0 CA--C 1.503 -0.832 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.606 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 26.4 mt-30 -131.61 129.23 40.61 Favored 'General case' 0 C--N 1.309 -1.157 0 CA-C-N 113.844 -1.526 . . . . 0.0 108.787 170.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.528 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.1 pt -119.07 128.98 75.79 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 N-CA-C 109.792 -0.448 . . . . 0.0 109.792 177.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.607 ' HD3' ' HB3' ' A' ' 101' ' ' SER . 75.6 mmtt -97.82 136.37 38.24 Favored 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 120.619 -0.432 . . . . 0.0 110.238 -174.91 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 39.1 t80 -124.91 120.58 32.03 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.105 0.479 . . . . 0.0 111.85 174.263 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 26.9 p -79.41 161.08 26.37 Favored 'General case' 0 CA--C 1.543 0.688 0 CA-C-N 115.883 -0.599 . . . . 0.0 112.214 178.389 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.404 ' SG ' HD22 ' A' ' 96' ' ' LEU . 61.7 m -116.3 147.48 41.49 Favored 'General case' 0 C--N 1.317 -0.805 0 N-CA-C 115.133 1.531 . . . . 0.0 115.133 177.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.8 p -80.64 166.44 21.08 Favored 'General case' 0 N--CA 1.424 -1.76 0 CA-C-N 114.208 -1.36 . . . . 0.0 108.502 173.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.18 131.85 50.84 Favored 'General case' 0 C--N 1.312 -1.041 0 CA-C-O 121.232 0.539 . . . . 0.0 111.735 -177.692 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 88.15 1.71 81.46 Favored Glycine 0 CA--C 1.533 1.211 0 CA-C-N 115.224 -0.898 . . . . 0.0 113.67 177.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.441 ' HB3' ' SG ' ' A' ' 120' ' ' CYS . 95.7 m-85 -122.05 148.11 45.25 Favored 'General case' 0 C--N 1.318 -0.8 0 C-N-CA 123.027 0.531 . . . . 0.0 112.021 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.573 ' O ' ' HA ' ' A' ' 120' ' ' CYS 0.26 32.5 ptt180 -135.27 172.16 13.4 Favored 'General case' 0 CA--C 1.494 -1.211 0 CA-C-O 121.881 0.848 . . . . 0.0 110.43 175.589 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.532 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.7 mm? -80.74 124.23 28.87 Favored 'General case' 0 N--CA 1.413 -2.287 0 CA-C-N 114.283 -1.326 . . . . 0.0 108.533 174.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 49.7 mm -69.58 -26.56 31.24 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 176.365 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.485 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -120.83 -123.7 3.04 Favored Glycine 0 N--CA 1.422 -2.252 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -174.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.488 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 48.1 m -107.45 124.46 49.91 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 177.836 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.457 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.1 m -61.89 -18.43 60.15 Favored 'General case' 0 N--CA 1.483 1.222 0 C-N-CA 123.009 0.524 . . . . 0.0 110.603 -173.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.607 ' HB3' ' HD3' ' A' ' 87' ' ' LYS . 28.4 p -133.59 152.35 51.88 Favored 'General case' 0 N--CA 1.412 -2.352 0 N-CA-C 107.863 -1.162 . . . . 0.0 107.863 171.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.606 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -118.82 147.15 44.23 Favored 'General case' 0 CA--C 1.463 -2.366 0 N-CA-C 108.347 -0.983 . . . . 0.0 108.347 -177.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.572 ' HA ' ' O ' ' A' ' 84' ' ' SER . 88.5 m -112.36 127.18 55.93 Favored 'General case' 0 N--CA 1.413 -2.311 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -179.791 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.747 ' SG ' ' HB3' ' A' ' 84' ' ' SER . 31.8 m -69.64 127.7 33.88 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.54 177.874 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.7 pt -127.94 164.94 28.2 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.965 0 CA-C-N 114.667 -1.151 . . . . 0.0 108.676 -177.581 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.643 HD13 HG22 ' A' ' 111' ' ' VAL . 20.5 mm -98.05 121.7 48.89 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.982 0 C-N-CA 119.822 -0.751 . . . . 0.0 110.454 -172.843 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD12 ' A' ' 112' ' ' ILE . 26.7 t -101.29 167.5 10.15 Favored 'General case' 0 C--N 1.298 -1.655 0 N-CA-C 106.406 -1.702 . . . . 0.0 106.406 167.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -62.24 -47.24 91.1 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 118.379 -1.867 . . . . 0.0 111.798 -179.148 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 66.5 m-20 -63.63 -43.18 97.58 Favored 'General case' 0 N--CA 1.474 0.755 0 N-CA-C 112.698 0.629 . . . . 0.0 112.698 177.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 15.0 t -168.6 -176.33 2.75 Favored 'General case' 0 N--CA 1.441 -0.911 0 C-N-CA 120.403 -0.519 . . . . 0.0 110.636 -170.735 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.787 HG12 ' SG ' ' A' ' 63' ' ' CYS . 26.8 t -96.6 128.84 47.43 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.641 0 CA-C-O 121.848 0.832 . . . . 0.0 108.889 171.788 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.44 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -126.41 163.14 29.09 Favored 'Isoleucine or valine' 0 CA--C 1.491 -1.296 0 CA-C-N 114.428 -1.26 . . . . 0.0 108.243 -177.819 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.412 ' CZ3' ' SG ' ' A' ' 104' ' ' CYS . 61.7 m95 -82.45 130.11 35.04 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 106.558 -1.645 . . . . 0.0 106.558 178.998 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -62.37 -49.52 75.2 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-O 121.462 0.648 . . . . 0.0 110.111 -179.517 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.445 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.2 m -64.45 -44.64 90.49 Favored 'General case' 0 C--N 1.322 -0.596 0 CA-C-N 115.1 -0.955 . . . . 0.0 112.588 177.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.445 ' HB2' ' O ' ' A' ' 115' ' ' THR . 96.5 mt-10 77.01 12.71 2.22 Favored 'General case' 0 N--CA 1.484 1.258 0 C-N-CA 124.971 1.308 . . . . 0.0 109.305 -173.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 30.8 m 65.7 122.4 0.02 OUTLIER Pre-proline 0 CA--C 1.534 0.336 0 CA-C-N 113.771 -1.559 . . . . 0.0 113.056 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HG2' HD12 ' A' ' 96' ' ' LEU . 95.8 Cg_endo -73.56 158.96 46.94 Favored 'Trans proline' 0 N--CA 1.436 -1.856 0 C-N-CA 124.112 3.208 . . . . 0.0 110.661 -179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 88.2 mt -105.7 127.7 60.44 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.1 0 N-CA-C 107.943 -1.132 . . . . 0.0 107.943 176.104 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.573 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 6.2 t -70.64 85.37 0.64 Allowed 'General case' 0 N--CA 1.428 -1.557 0 CA-C-O 121.633 0.73 . . . . 0.0 110.518 179.213 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 50.4 t0 -88.89 175.23 7.53 Favored 'General case' 0 C--N 1.312 -1.037 0 CA-C-N 114.297 -1.32 . . . . 0.0 108.813 179.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 1.015 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 78.1 mtt85 -61.86 129.99 43.57 Favored 'General case' 0 N--CA 1.437 -1.103 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 177.734 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.606 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 47.2 mt -54.23 101.14 0.25 Allowed Pre-proline 0 CA--C 1.488 -1.428 0 O-C-N 123.893 0.746 . . . . 0.0 110.165 -175.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_exo -58.7 -31.35 94.7 Favored 'Trans proline' 0 C--O 1.198 -1.516 0 C-N-CA 122.594 2.196 . . . . 0.0 109.629 179.319 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 54.16 112.83 0.01 OUTLIER 'General case' 0 C--N 1.346 0.446 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.479 -175.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -61.69 151.27 44.14 Favored Glycine 0 N--CA 1.432 -1.574 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 178.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 18.3 mt -39.92 141.58 0.76 Allowed Pre-proline 0 C--O 1.247 0.951 0 N-CA-C 112.47 0.544 . . . . 0.0 112.47 -175.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -57.47 144.11 92.69 Favored 'Trans proline' 0 N--CA 1.431 -2.162 0 C-N-CA 121.758 1.639 . . . . 0.0 109.525 -178.518 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 35.3 Cg_endo -61.97 145.23 96.89 Favored 'Trans proline' 0 N--CA 1.429 -2.308 0 C-N-CA 120.968 1.112 . . . . 0.0 110.612 -179.059 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.7 p -75.6 167.25 22.24 Favored 'General case' 0 N--CA 1.409 -2.476 0 CA-C-N 115.636 -0.711 . . . . 0.0 109.19 179.702 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.571 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.6 tp -120.01 166.15 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.389 -3.495 0 CA-C-O 121.677 0.751 . . . . 0.0 110.509 -169.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.459 ' N ' HG13 ' A' ' 131' ' ' ILE . 18.0 m -62.11 -42.15 98.93 Favored 'General case' 0 N--CA 1.406 -2.664 0 CA-C-N 113.582 -1.645 . . . . 0.0 108.146 179.454 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.786 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 13.6 m120 -69.57 -17.99 63.6 Favored 'General case' 0 C--N 1.29 -1.983 0 C-N-CA 125.091 1.356 . . . . 0.0 113.51 178.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.571 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 100.01 -21.07 46.34 Favored Glycine 0 CA--C 1.53 0.98 0 CA-C-O 119.539 -0.589 . . . . 0.0 114.321 -179.259 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.484 ' O ' HG21 ' A' ' 131' ' ' ILE . 44.8 t0 -160.91 175.5 12.45 Favored 'General case' 0 CA--C 1.56 1.343 0 CA-C-N 117.909 0.855 . . . . 0.0 112.585 -179.185 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.677 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 39.5 p90 -132.98 169.39 16.88 Favored 'General case' 0 N--CA 1.468 0.442 0 C-N-CA 124.459 1.103 . . . . 0.0 112.511 -176.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.492 HD12 ' CG2' ' A' ' 151' ' ' THR . 96.8 mt -61.08 -44.76 98.93 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.75 0 C-N-CA 125.898 1.679 . . . . 0.0 115.525 -175.06 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 33.5 t -56.91 139.12 52.68 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 121.784 0.802 . . . . 0.0 110.851 -168.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 33.6 p -65.72 -33.66 76.4 Favored 'General case' 0 N--CA 1.436 -1.125 0 CA-C-N 114.074 -1.421 . . . . 0.0 111.971 -173.114 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . 0.578 ' HB3' HD21 ' A' ' 143' ' ' ASN . 54.8 t-20 -93.35 108.23 19.92 Favored 'General case' 0 N--CA 1.424 -1.763 0 N-CA-C 107.526 -1.287 . . . . 0.0 107.526 176.028 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.677 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 53.4 ttp180 -61.51 -42.5 98.9 Favored 'General case' 0 C--N 1.315 -0.911 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.746 -174.507 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -114.54 94.34 4.74 Favored 'General case' 0 N--CA 1.414 -2.26 0 C-N-CA 118.72 -1.192 . . . . 0.0 110.857 -175.379 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.578 HD21 ' HB3' ' A' ' 140' ' ' ASN . 10.6 m120 -102.44 138.76 38.93 Favored 'General case' 0 CA--C 1.5 -0.957 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.649 178.749 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 53.6 p90 -139.49 129.43 24.92 Favored 'General case' 0 N--CA 1.445 -0.718 0 CA-C-N 116.119 -0.492 . . . . 0.0 110.937 176.166 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 1.015 ' CE1' ' HB3' ' A' ' 122' ' ' ARG 0.266 4.3 t60 128.52 153.78 0.0 OUTLIER 'General case' 0 C--O 1.205 -1.276 0 C-N-CA 126.892 2.077 . . . . 0.0 111.211 172.546 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.593 ' H ' ' HD1' ' A' ' 145' ' ' HIS . 94.0 t80 -59.37 135.15 57.57 Favored 'General case' 0 N--CA 1.425 -1.704 0 C-N-CA 123.487 0.715 . . . . 0.0 110.411 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.53 -8.85 58.65 Favored Glycine 0 N--CA 1.412 -2.907 0 CA-C-N 114.535 -1.211 . . . . 0.0 111.342 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 26.3 p -74.25 148.99 41.02 Favored 'General case' 0 N--CA 1.441 -0.881 0 N-CA-C 107.709 -1.219 . . . . 0.0 107.709 177.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 3.0 p -142.32 141.29 28.47 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 O-C-N 123.072 0.233 . . . . 0.0 111.219 -178.995 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 34.6 m -131.61 157.29 43.15 Favored 'Isoleucine or valine' 0 CA--C 1.499 -1.003 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 175.436 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.492 ' CG2' HD12 ' A' ' 137' ' ' ILE . 70.6 m -125.77 131.11 52.55 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 107.848 -1.167 . . . . 0.0 107.848 179.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.489 ' CD1' HD13 ' A' ' 131' ' ' ILE . 97.3 m-85 -100.37 141.02 33.79 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 121.039 0.447 . . . . 0.0 111.193 -176.514 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 9.5 ptm180 -134.46 148.47 50.6 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 177.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.786 ' HA ' ' OD1' ' A' ' 133' ' ' ASN . 96.1 m -88.8 141.35 28.57 Favored 'General case' 0 N--CA 1.472 0.648 0 C-N-CA 123.738 0.815 . . . . 0.0 112.746 -171.986 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.64 ' OD1' ' HA ' ' A' ' 133' ' ' ASN . 9.8 m120 -51.33 120.25 14.32 Favored Pre-proline 0 N--CA 1.484 1.259 0 C-N-CA 124.751 1.22 . . . . 0.0 113.077 -175.05 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.529 ' HB3' ' H ' ' A' ' 161' ' ' ARG . 18.1 Cg_exo -65.23 145.48 84.17 Favored 'Trans proline' 0 N--CA 1.448 -1.176 0 C-N-CA 121.777 1.651 . . . . 0.0 109.665 170.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -64.38 -42.53 97.64 Favored Glycine 0 CA--C 1.525 0.697 0 C-N-CA 118.574 -1.774 . . . . 0.0 109.469 172.685 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 62.1 m -152.68 155.19 36.8 Favored 'General case' 0 N--CA 1.445 -0.684 0 C-N-CA 123.887 0.875 . . . . 0.0 108.975 174.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 63.85 -136.67 41.17 Favored Glycine 0 CA--C 1.535 1.295 0 C-N-CA 121.04 -0.6 . . . . 0.0 113.807 -179.846 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -129.62 68.89 0.54 Allowed Glycine 0 C--N 1.348 1.2 0 C-N-CA 121.69 -0.29 . . . . 0.0 113.292 -177.107 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.529 ' H ' ' HB3' ' A' ' 156' ' ' PRO . 2.6 ptp85 -141.15 160.37 40.25 Favored 'General case' 0 C--N 1.311 -1.079 0 N-CA-C 113.389 0.885 . . . . 0.0 113.389 179.199 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.401 ' HE3' ' HA ' ' A' ' 165' ' ' GLU . 62.9 tttp -88.09 119.58 28.61 Favored 'General case' 0 N--CA 1.433 -1.319 0 CA-C-N 115.325 -0.852 . . . . 0.0 109.689 -178.902 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.466 HG23 ' CD2' ' A' ' 164' ' ' PHE . 28.9 m -111.98 -4.54 11.13 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.117 0 CA-C-O 121.146 0.498 . . . . 0.0 110.27 172.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.503 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 95.8 m-85 -130.48 147.36 52.17 Favored 'General case' 0 CA--C 1.507 -0.684 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.423 178.608 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.545 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.1 mt-10 -87.0 153.69 21.35 Favored 'General case' 0 C--O 1.212 -0.889 0 N-CA-C 110.412 -0.218 . . . . 0.0 110.412 179.626 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.624 HD23 ' N ' ' A' ' 167' ' ' VAL . 8.0 tt -116.81 159.11 22.83 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 -179.834 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.624 ' N ' HD23 ' A' ' 166' ' ' LEU . 62.4 t -60.12 -45.46 95.75 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.866 0 N-CA-C 112.524 0.565 . . . . 0.0 112.524 -171.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.47 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.45 -14.27 3.21 Favored Glycine 0 CA--C 1.498 -0.984 0 C-N-CA 119.361 -1.399 . . . . 0.0 112.325 -179.742 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 20.6 tt0 -120.25 63.3 9.43 Favored Pre-proline 0 C--N 1.312 -1.03 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 177.909 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -67.57 -20.88 46.75 Favored 'Trans proline' 0 C--N 1.366 1.482 0 C-N-CA 122.612 2.208 . . . . 0.0 113.453 -175.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 5.1 p -103.95 119.72 39.53 Favored 'General case' 0 N--CA 1.426 -1.628 0 CA-C-O 121.531 0.681 . . . . 0.0 111.702 -177.934 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.7 pt -127.71 155.19 38.94 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.123 0 CA-C-N 115.037 -0.983 . . . . 0.0 110.571 177.321 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 41.7 p90 -147.72 160.2 42.97 Favored 'General case' 0 N--CA 1.432 -1.349 0 CA-C-N 115.78 -0.645 . . . . 0.0 109.882 179.867 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.545 ' HB3' ' HA ' ' A' ' 146' ' ' TYR . 1.1 t -73.08 112.67 9.33 Favored 'General case' 0 C--N 1.316 -0.875 0 N-CA-C 106.832 -1.544 . . . . 0.0 106.832 175.125 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.518 ' C ' ' H ' ' A' ' 177' ' ' ASN . 0.1 OUTLIER -113.65 -33.03 5.97 Favored 'General case' 0 CA--C 1.518 -0.284 0 CA-C-O 121.34 0.59 . . . . 0.0 110.608 -173.648 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . . . . . . . . . 19.5 p 56.33 -9.14 0.02 OUTLIER 'General case' 0 CA--C 1.575 1.92 0 CA-C-N 114.476 -1.238 . . . . 0.0 113.639 -173.64 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.518 ' H ' ' C ' ' A' ' 175' ' ' THR . 94.2 m-20 -64.34 -40.74 96.47 Favored 'General case' 0 N--CA 1.474 0.76 0 C-N-CA 124.653 1.181 . . . . 0.0 112.19 178.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 12.4 p-10 -78.42 -162.74 0.38 Allowed 'General case' 0 C--N 1.316 -0.876 0 CA-C-N 114.697 -1.138 . . . . 0.0 114.06 -171.243 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 14.5 p-10 -66.68 125.22 25.12 Favored 'General case' 0 C--N 1.361 1.071 0 CA-C-O 121.482 0.658 . . . . 0.0 111.993 -174.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 57.6 tt0 73.78 164.89 0.29 Allowed 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.235 -1.348 . . . . 0.0 107.617 -171.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 29.6 m -129.6 159.92 41.13 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.03 0 O-C-N 120.987 -1.071 . . . . 0.0 111.721 -176.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 78.06 20.56 72.72 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.653 -175.168 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.544 HD12 ' O ' ' A' ' 184' ' ' TRP . 1.8 pp -126.88 161.78 32.93 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.756 0 N-CA-C 113.996 1.11 . . . . 0.0 113.996 -173.193 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.544 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.2 m95 -71.68 157.83 37.25 Favored 'General case' 0 C--O 1.213 -0.818 0 C-N-CA 125.031 1.332 . . . . 0.0 109.441 177.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 31.8 t -58.83 -19.72 44.03 Favored 'General case' 0 N--CA 1.478 0.929 0 CA-C-O 121.123 0.487 . . . . 0.0 110.801 -174.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.36 154.99 13.91 Favored Glycine 0 N--CA 1.424 -2.143 0 C-N-CA 120.585 -0.816 . . . . 0.0 111.697 174.669 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 25.3 Cg_exo -62.07 145.69 96.45 Favored 'Trans proline' 0 CA--C 1.507 -0.853 0 C-N-CA 122.299 2.0 . . . . 0.0 109.828 175.086 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -39.49 118.48 1.24 Allowed Pre-proline 0 C--O 1.232 0.138 0 O-C-N 124.44 1.088 . . . . 0.0 112.167 -176.283 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.415 ' O ' HD11 ' A' ' 131' ' ' ILE . 46.9 Cg_endo -65.18 152.92 80.61 Favored 'Trans proline' 0 CA--C 1.486 -1.918 0 C-N-CA 122.994 2.463 . . . . 0.0 110.223 175.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.407 ' O ' HG23 ' A' ' 167' ' ' VAL . 30.2 pt20 -120.16 159.56 24.65 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 119.467 -0.893 . . . . 0.0 111.177 -168.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.545 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 74.0 m -79.16 68.21 5.07 Favored 'General case' 0 C--N 1.299 -1.609 0 CA-C-N 114.099 -1.41 . . . . 0.0 110.665 -177.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.405 ' O ' ' HB2' ' A' ' 165' ' ' GLU . 34.4 mm . . . . . 0 C--O 1.255 1.346 0 CA-C-N 113.42 -1.718 . . . . 0.0 110.695 173.57 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.788 ' HD3' HG23 ' A' ' 111' ' ' VAL . 87.4 mttt . . . . . 0 N--CA 1.528 3.448 0 N-CA-C 116.538 2.051 . . . . 0.0 116.538 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.542 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 4.8 m -147.06 152.58 38.77 Favored 'General case' 0 CA--C 1.544 0.727 0 N-CA-C 107.811 -1.181 . . . . 0.0 107.811 171.012 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.756 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.6 m -80.42 173.81 12.23 Favored 'General case' 0 CA--C 1.516 -0.347 0 N-CA-C 108.142 -1.058 . . . . 0.0 108.142 176.007 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.502 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 94.2 mtt-85 -63.69 -39.33 94.04 Favored 'General case' 0 C--N 1.316 -0.871 0 C-N-CA 122.561 0.344 . . . . 0.0 110.558 -173.402 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.502 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 23.1 t-20 136.85 142.37 0.0 OUTLIER Pre-proline 0 N--CA 1.488 1.465 0 C-N-CA 127.061 2.145 . . . . 0.0 106.202 -173.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.527 ' HB3' HG21 ' A' ' 86' ' ' ILE . 1.5 Cg_endo -49.71 115.58 1.89 Allowed 'Trans proline' 0 CA--C 1.513 -0.536 0 C-N-CA 123.722 2.948 . . . . 0.0 114.009 176.868 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -62.8 144.41 93.59 Favored 'Trans proline' 0 N--CA 1.453 -0.855 0 C-N-CA 121.63 1.554 . . . . 0.0 108.378 170.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -130.43 109.51 16.22 Favored Pre-proline 0 C--N 1.304 -1.398 0 CA-C-O 120.924 0.392 . . . . 0.0 111.043 -175.541 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.536 ' HG2' ' CZ ' ' A' ' 88' ' ' TYR . 94.9 Cg_endo -67.47 152.27 78.87 Favored 'Trans proline' 0 N--CA 1.433 -2.065 0 C-N-CA 123.13 2.553 . . . . 0.0 111.501 174.57 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 19.0 m -73.15 153.66 7.3 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.126 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.832 -174.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 92.2 m-20 60.79 35.46 19.48 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 124.212 0.945 . . . . 0.0 110.963 -174.002 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.402 ' HA3' ' OH ' ' A' ' 88' ' ' TYR . . . -155.84 166.8 33.05 Favored Glycine 0 N--CA 1.442 -0.946 0 CA-C-N 114.39 -1.277 . . . . 0.0 110.618 177.6 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 77.6 mtm -136.5 146.96 46.85 Favored 'General case' 0 N--CA 1.47 0.556 0 O-C-N 122.559 -0.377 . . . . 0.0 110.679 -179.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 46.8 t -123.57 131.83 72.42 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.644 0 C-N-CA 123.566 0.746 . . . . 0.0 109.099 176.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 42.8 t-80 -117.19 94.87 4.74 Favored 'General case' 0 CA--C 1.531 0.216 0 N-CA-C 113.481 0.919 . . . . 0.0 113.481 178.668 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.68 HG21 HG22 ' A' ' 86' ' ' ILE . 1.7 t -129.53 124.28 59.27 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.585 168.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.7 tt -91.37 -45.51 14.55 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.201 0 CA-C-O 122.355 1.074 . . . . 0.0 110.209 172.959 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -137.58 147.61 45.22 Favored 'General case' 0 N--CA 1.424 -1.756 0 CA-C-N 113.785 -1.552 . . . . 0.0 108.49 174.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . 114.05 47.93 0.59 Allowed Glycine 0 C--N 1.289 -2.039 0 C-N-CA 118.37 -1.871 . . . . 0.0 111.772 -176.764 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.756 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 49.2 pt -110.21 -2.65 10.29 Favored 'Isoleucine or valine' 0 C--O 1.21 -1.017 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 171.844 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.542 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 82.4 mt-30 -90.33 -163.31 1.0 Allowed 'General case' 0 C--N 1.305 -1.366 0 CA-C-N 115.032 -0.985 . . . . 0.0 111.739 -172.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 54.9 t80 -58.36 131.0 49.35 Favored 'General case' 0 C--N 1.3 -1.548 0 CA-C-N 114.635 -1.166 . . . . 0.0 111.98 177.046 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 86.59 4.51 82.91 Favored Glycine 0 N--CA 1.435 -1.381 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.604 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.425 ' O ' ' HA ' ' A' ' 103' ' ' THR . 12.0 t -68.67 145.31 53.99 Favored 'General case' 0 C--N 1.313 -1.0 0 N-CA-C 114.635 1.346 . . . . 0.0 114.635 179.062 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.651 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -137.34 125.83 23.54 Favored 'General case' 0 N--CA 1.417 -2.111 0 CA-C-N 113.074 -1.875 . . . . 0.0 108.519 168.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.68 HG22 HG21 ' A' ' 76' ' ' VAL . 44.4 pt -109.37 123.32 65.16 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.974 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 176.329 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 14.0 mptt -87.07 137.0 32.72 Favored 'General case' 0 CA--C 1.489 -1.385 0 CA-C-O 120.562 0.22 . . . . 0.0 110.826 -177.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.536 ' CZ ' ' HG2' ' A' ' 69' ' ' PRO . 92.7 t80 -148.75 163.31 37.73 Favored 'General case' 0 N--CA 1.434 -1.226 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.268 177.809 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 29.1 p -151.78 160.24 43.64 Favored 'General case' 0 N--CA 1.449 -0.51 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 176.099 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.588 ' SG ' HD13 ' A' ' 96' ' ' LEU . 91.0 m -97.78 164.76 12.26 Favored 'General case' 0 N--CA 1.48 1.041 0 N-CA-C 113.368 0.877 . . . . 0.0 113.368 -172.659 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 23.2 m -69.08 160.62 30.69 Favored 'General case' 0 N--CA 1.439 -1.002 0 CA-C-N 114.566 -1.197 . . . . 0.0 107.988 176.461 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 65.7 tttm -63.54 130.96 46.52 Favored 'General case' 0 C--O 1.245 0.855 0 O-C-N 121.818 -0.551 . . . . 0.0 110.671 -176.071 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.14 -6.94 64.12 Favored Glycine 0 C--N 1.343 0.961 0 C-N-CA 121.35 -0.452 . . . . 0.0 112.682 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -121.64 143.44 49.32 Favored 'General case' 0 C--N 1.32 -0.692 0 C-N-CA 122.64 0.376 . . . . 0.0 110.737 177.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.636 ' HE ' HG23 ' A' ' 123' ' ' ILE . 14.0 ptp180 -125.43 164.32 20.71 Favored 'General case' 0 CA--C 1.5 -0.976 0 C-N-CA 119.951 -0.7 . . . . 0.0 109.17 177.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.588 HD13 ' SG ' ' A' ' 90' ' ' CYS . 3.1 mm? -79.97 129.33 34.4 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.531 174.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.436 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.6 mm -68.52 -25.93 32.22 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.657 172.934 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.746 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -128.1 -130.23 3.3 Favored Glycine 0 N--CA 1.421 -2.328 0 C-N-CA 120.718 -0.753 . . . . 0.0 111.949 -172.493 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.687 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 38.4 m -102.69 117.8 35.44 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 122.314 -0.521 . . . . 0.0 111.439 -176.587 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.6 p -60.81 -34.05 73.93 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.834 -177.082 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.659 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 8.7 p -106.85 110.86 23.14 Favored 'General case' 0 N--CA 1.426 -1.666 0 C-N-CA 120.769 -0.372 . . . . 0.0 110.242 174.082 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.651 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -72.08 145.5 48.18 Favored 'General case' 0 CA--C 1.489 -1.378 0 O-C-N 123.612 0.57 . . . . 0.0 110.516 178.323 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.425 ' HA ' ' O ' ' A' ' 84' ' ' SER . 92.0 m -112.37 125.15 53.89 Favored 'General case' 0 C--N 1.29 -2.004 0 N-CA-C 107.864 -1.162 . . . . 0.0 107.864 174.713 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.581 ' SG ' ' CG1' ' A' ' 111' ' ' VAL . 37.2 t -83.33 125.24 31.43 Favored 'General case' 0 C--N 1.298 -1.654 0 C-N-CA 123.36 0.664 . . . . 0.0 110.124 176.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.401 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.5 pp -130.07 163.68 34.91 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.279 0 N-CA-C 113.278 0.844 . . . . 0.0 113.278 -176.629 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.773 HG23 ' NZ ' ' A' ' 61' ' ' LYS . 7.8 mt -105.13 119.61 54.46 Favored 'Isoleucine or valine' 0 C--N 1.345 0.407 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -175.839 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 88.4 p -89.58 -8.8 51.87 Favored 'General case' 0 C--N 1.353 0.735 0 N-CA-C 114.824 1.416 . . . . 0.0 114.824 178.192 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.406 ' O ' ' NZ ' ' A' ' 61' ' ' LYS . . . 149.08 -96.51 0.17 Allowed Glycine 0 CA--C 1.483 -1.952 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -175.945 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 96.4 m-20 -93.51 -2.45 54.36 Favored 'General case' 0 N--CA 1.478 0.934 0 N-CA-C 113.691 0.997 . . . . 0.0 113.691 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.765 ' N ' ' HZ3' ' A' ' 61' ' ' LYS . 15.3 t -143.45 156.11 44.56 Favored 'General case' 0 N--CA 1.435 -1.177 0 C-N-CA 118.327 -1.349 . . . . 0.0 110.556 176.401 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.788 HG23 ' HD3' ' A' ' 61' ' ' LYS . 1.3 t -101.44 126.6 55.26 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.988 0 CA-C-N 114.099 -1.41 . . . . 0.0 111.582 176.356 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 40.2 pt -127.54 161.06 35.92 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.206 0 CA-C-N 114.123 -1.399 . . . . 0.0 109.919 -178.719 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.442 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.3 m95 -81.58 128.81 34.32 Favored 'General case' 0 C--O 1.219 -0.545 0 C-N-CA 119.118 -1.033 . . . . 0.0 109.889 -178.045 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.401 ' HB2' HG12 ' A' ' 105' ' ' ILE . 32.5 t70 -62.66 -48.6 78.62 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 122.132 0.968 . . . . 0.0 110.816 179.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.498 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 18.8 m -63.91 -45.19 90.4 Favored 'General case' 0 N--CA 1.44 -0.953 0 CA-C-N 113.882 -1.508 . . . . 0.0 114.382 -179.705 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 76.3 mt-10 69.66 17.91 7.7 Favored 'General case' 0 N--CA 1.487 1.415 0 CA-C-N 115.513 -0.767 . . . . 0.0 110.633 -171.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 27.6 m 51.71 119.91 0.0 OUTLIER Pre-proline 0 CA--C 1.555 1.165 0 C-N-CA 125.792 1.637 . . . . 0.0 115.134 179.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.746 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 7.8 Cg_exo -64.07 151.35 85.67 Favored 'Trans proline' 0 CA--C 1.509 -0.728 1 C-N-CA 125.395 4.063 . . . . 0.0 112.879 -179.808 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . 0.403 ' O ' HG12 ' A' ' 97' ' ' ILE . 50.3 mm -100.07 129.33 50.92 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.476 0 N-CA-C 108.446 -0.946 . . . . 0.0 108.446 177.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 95.9 m -72.74 112.29 8.65 Favored 'General case' 0 CA--C 1.549 0.932 0 C-N-CA 120.117 -0.633 . . . . 0.0 109.31 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.436 ' HB3' HD11 ' A' ' 97' ' ' ILE . 44.4 t0 -112.09 162.08 15.8 Favored 'General case' 0 CA--C 1.5 -0.975 0 N-CA-C 108.539 -0.911 . . . . 0.0 108.539 178.214 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.441 ' O ' ' HD3' ' A' ' 124' ' ' PRO . 85.3 mtp180 -61.75 132.14 52.19 Favored 'General case' 0 C--O 1.205 -1.268 0 N-CA-C 106.278 -1.749 . . . . 0.0 106.278 -179.282 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.636 HG23 ' HE ' ' A' ' 95' ' ' ARG . 38.2 mt -61.3 101.97 0.28 Allowed Pre-proline 0 CA--C 1.476 -1.867 0 O-C-N 124.02 0.825 . . . . 0.0 111.582 -170.046 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.441 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 17.0 Cg_exo -66.12 125.29 13.85 Favored 'Trans proline' 0 N--CA 1.431 -2.172 0 N-CA-C 107.355 -1.825 . . . . 0.0 107.355 174.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.577 ' SG ' ' CE2' ' A' ' 184' ' ' TRP . 1.9 t -150.35 98.71 2.7 Favored 'General case' 0 N--CA 1.411 -2.419 0 CA-C-O 122.304 1.05 . . . . 0.0 109.688 -179.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.634 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -151.43 159.98 28.5 Favored Glycine 0 N--CA 1.414 -2.782 0 CA-C-N 113.545 -1.661 . . . . 0.0 111.0 -176.058 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.562 HD23 ' HB3' ' A' ' 142' ' ' GLU . 1.6 tm? 53.12 75.46 0.63 Allowed Pre-proline 0 N--CA 1.438 -1.055 0 N-CA-C 107.217 -1.401 . . . . 0.0 107.217 -172.76 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.422 ' HG3' ' CH2' ' A' ' 184' ' ' TRP . 33.5 Cg_exo -55.04 159.05 10.27 Favored 'Trans proline' 0 C--N 1.357 1.024 0 C-N-CA 124.108 3.205 . . . . 0.0 111.733 -175.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_endo -55.15 125.56 19.6 Favored 'Trans proline' 0 C--N 1.355 0.901 0 N-CA-C 108.266 -1.475 . . . . 0.0 108.266 175.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 m -66.51 134.54 52.62 Favored 'General case' 0 N--CA 1.439 -1.01 0 CA-C-O 121.261 0.553 . . . . 0.0 111.587 -175.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.664 HG23 ' H ' ' A' ' 134' ' ' GLY . 9.4 tp -68.44 148.67 11.68 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.067 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.335 -178.968 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 80.4 m -61.47 -44.64 96.73 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.868 -1.06 . . . . 0.0 112.135 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.45 ' ND2' ' HA ' ' A' ' 154' ' ' CYS . 69.9 m-80 -63.62 -40.4 96.8 Favored 'General case' 0 C--N 1.313 -1.002 0 CA-C-N 114.96 -1.018 . . . . 0.0 113.089 -174.107 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.664 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 169.54 -72.72 0.13 Allowed Glycine 0 C--O 1.22 -0.746 0 C-N-CA 120.92 -0.657 . . . . 0.0 112.305 -176.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -157.49 -179.67 8.39 Favored 'General case' 0 CA--C 1.542 0.646 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 179.184 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 141' ' ' ARG . 27.9 p90 -107.86 166.38 10.74 Favored 'General case' 0 C--O 1.215 -0.745 0 CA-C-O 122.014 0.911 . . . . 0.0 113.445 -173.134 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.559 HD12 HG22 ' A' ' 151' ' ' THR . 95.5 mt -63.62 -43.44 98.18 Favored 'Isoleucine or valine' 0 C--O 1.241 0.615 0 C-N-CA 125.791 1.636 . . . . 0.0 114.151 -174.28 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.3 t -63.83 143.45 57.84 Favored 'General case' 0 C--N 1.312 -1.052 0 CA-C-O 121.521 0.676 . . . . 0.0 112.497 -170.613 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 60.1 p -65.16 -31.79 73.16 Favored 'General case' 0 N--CA 1.438 -1.038 0 CA-C-N 114.953 -1.021 . . . . 0.0 109.718 178.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . 0.457 HD21 ' CG ' ' A' ' 143' ' ' ASN . 4.2 t30 -85.95 102.96 14.22 Favored 'General case' 0 N--CA 1.421 -1.886 0 CA-C-N 115.032 -0.986 . . . . 0.0 109.92 -176.624 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 136' ' ' PHE . 60.1 ttt85 -66.43 -42.78 87.18 Favored 'General case' 0 C--N 1.348 0.531 0 N-CA-C 115.815 1.783 . . . . 0.0 115.815 179.484 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.562 ' HB3' HD23 ' A' ' 127' ' ' LEU . 16.3 pt-20 -144.91 157.99 43.96 Favored 'General case' 0 C--N 1.317 -0.829 0 C-N-CA 120.707 -0.397 . . . . 0.0 111.846 -173.236 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.634 ' O ' ' HA3' ' A' ' 126' ' ' GLY . 21.0 m120 -144.2 179.73 7.04 Favored 'General case' 0 CA--C 1.481 -1.697 0 CA-C-O 121.606 0.717 . . . . 0.0 112.847 -171.882 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 97.1 m-85 -130.05 146.15 51.71 Favored 'General case' 0 N--CA 1.419 -2.022 0 N-CA-C 105.934 -1.876 . . . . 0.0 105.934 175.617 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 29.7 m170 59.58 -172.45 0.12 Allowed 'General case' 0 CA--C 1.562 1.408 0 N-CA-C 115.615 1.709 . . . . 0.0 115.615 178.094 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . . . . . . . . . 50.4 t80 -82.06 142.68 32.11 Favored 'General case' 0 CA--C 1.565 1.545 0 C-N-CA 128.153 2.581 . . . . 0.0 112.003 -175.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.624 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 116.93 -10.06 15.69 Favored Glycine 0 C--N 1.354 1.572 0 N-CA-C 116.21 1.244 . . . . 0.0 116.21 175.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 43.8 t -71.45 146.47 48.61 Favored 'General case' 0 C--N 1.315 -0.891 0 CA-C-N 118.384 1.092 . . . . 0.0 112.892 177.522 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.437 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 3.0 p -136.18 137.62 48.16 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.424 0 O-C-N 123.684 0.615 . . . . 0.0 110.614 176.209 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.1 m -133.26 160.35 42.48 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.736 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 175.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.559 HG22 HD12 ' A' ' 137' ' ' ILE . 82.5 m -125.26 129.18 49.52 Favored 'General case' 0 N--CA 1.427 -1.595 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 176.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.52 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 91.2 m-85 -96.51 149.69 21.47 Favored 'General case' 0 CA--C 1.51 -0.561 0 CA-C-O 121.465 0.65 . . . . 0.0 111.994 -177.897 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 16.8 ptt180 -137.07 153.08 50.67 Favored 'General case' 0 N--CA 1.427 -1.62 0 CA-C-N 115.448 -0.797 . . . . 0.0 111.268 -178.884 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.597 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 19.8 m -82.76 155.96 23.98 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 124.156 0.982 . . . . 0.0 111.662 -178.873 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 0.0 OUTLIER -36.5 102.14 0.23 Allowed Pre-proline 0 C--N 1.37 1.479 0 CA-C-O 122.566 1.174 . . . . 0.0 112.771 -178.419 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.475 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 11.7 Cg_exo -67.74 150.83 79.26 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 124.481 3.454 . . . . 0.0 114.373 -178.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.81 171.68 41.22 Favored Glycine 0 N--CA 1.426 -2.015 0 N-CA-C 110.296 -1.122 . . . . 0.0 110.296 171.606 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 78.4 p -61.11 -33.28 73.11 Favored 'General case' 0 C--N 1.304 -1.383 0 CA-C-O 121.379 0.609 . . . . 0.0 110.933 -175.574 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -63.59 -34.15 89.17 Favored Glycine 0 N--CA 1.442 -0.94 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.049 176.204 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 109.76 49.05 0.76 Allowed Glycine 0 N--CA 1.439 -1.148 0 C-N-CA 119.627 -1.273 . . . . 0.0 110.795 -176.729 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.475 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 9.6 ptm180 -137.12 155.81 49.14 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-O 120.768 0.318 . . . . 0.0 111.065 -177.54 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 64.3 tttm -66.39 130.81 44.46 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.165 -0.471 . . . . 0.0 112.038 179.267 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 63.4 t -118.82 -18.75 6.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.787 0 CA-C-N 115.083 -0.962 . . . . 0.0 112.463 -177.519 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.597 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 91.5 m-85 -129.87 152.13 49.68 Favored 'General case' 0 N--CA 1.496 1.83 0 N-CA-C 114.303 1.223 . . . . 0.0 114.303 -172.418 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.477 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 98.5 mt-10 -68.37 139.01 55.82 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.724 -1.125 . . . . 0.0 109.683 -179.054 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.561 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.8 tt -115.19 158.27 22.49 Favored 'General case' 0 C--N 1.308 -1.227 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.561 ' N ' HD23 ' A' ' 166' ' ' LEU . 2.2 p -60.33 -30.12 45.59 Favored 'Isoleucine or valine' 0 CA--C 1.564 1.519 0 N-CA-C 113.074 0.768 . . . . 0.0 113.074 -167.824 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.424 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 139.26 -29.25 2.53 Favored Glycine 0 CA--C 1.506 -0.509 0 C-N-CA 119.427 -1.368 . . . . 0.0 113.828 174.064 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -124.89 77.42 65.98 Favored Pre-proline 0 N--CA 1.443 -0.794 0 O-C-N 121.932 -0.746 . . . . 0.0 109.853 176.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 40.9 Cg_endo -66.89 -20.21 51.76 Favored 'Trans proline' 0 N--CA 1.442 -1.526 0 C-N-CA 122.958 2.438 . . . . 0.0 112.785 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 14.3 p -96.18 120.94 37.38 Favored 'General case' 0 N--CA 1.412 -2.333 0 CA-C-O 121.351 0.596 . . . . 0.0 111.261 -176.922 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 45.2 pt -126.17 154.14 35.16 Favored 'Isoleucine or valine' 0 CA--C 1.484 -1.573 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.078 174.191 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.51 ' CD2' HG22 ' A' ' 175' ' ' THR . 11.2 p90 -145.7 159.54 43.01 Favored 'General case' 0 C--N 1.297 -1.713 0 CA-C-N 116.096 -0.502 . . . . 0.0 109.678 177.851 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.624 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 74.8 m -69.17 91.88 0.53 Allowed 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 -177.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.51 HG22 ' CD2' ' A' ' 173' ' ' TYR . 0.1 OUTLIER -125.96 -14.47 6.1 Favored 'General case' 0 N--CA 1.501 2.088 0 C-N-CA 119.485 -0.886 . . . . 0.0 112.213 -176.008 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.469 ' HB2' ' C ' ' A' ' 181' ' ' VAL . 84.4 p 42.45 9.99 0.0 OUTLIER 'General case' 0 CA--C 1.584 2.275 0 C-N-CA 125.729 1.612 . . . . 0.0 114.47 -171.514 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -64.07 -40.46 96.31 Favored 'General case' 0 N--CA 1.473 0.71 0 N-CA-C 114.685 1.365 . . . . 0.0 114.685 179.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . 0.434 ' HB3' ' O ' ' A' ' 185' ' ' SER . 11.6 t70 -97.31 -93.74 0.22 Allowed 'General case' 0 CA--C 1.564 1.517 0 N-CA-C 116.191 1.923 . . . . 0.0 116.191 -164.763 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 47.2 m-20 -65.2 -39.35 92.7 Favored 'General case' 0 C--N 1.372 1.544 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -173.675 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.449 ' HB3' HG12 ' A' ' 183' ' ' ILE . 49.4 tp60 -147.84 156.74 43.04 Favored 'General case' 0 N--CA 1.433 -1.293 0 N-CA-C 106.922 -1.51 . . . . 0.0 106.922 -178.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.469 ' C ' ' HB2' ' A' ' 176' ' ' SER . 29.2 m -91.99 29.82 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -172.201 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . -152.45 24.2 0.86 Allowed Glycine 0 C--N 1.303 -1.288 0 CA-C-N 115.772 -0.649 . . . . 0.0 112.027 176.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.449 HG12 ' HB3' ' A' ' 180' ' ' GLN . 3.3 pt -132.34 -165.16 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.332 0 CA-C-O 122.418 1.104 . . . . 0.0 111.7 -171.93 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.577 ' CE2' ' SG ' ' A' ' 125' ' ' CYS . 84.4 m95 -73.65 -175.98 2.22 Favored 'General case' 0 N--CA 1.429 -1.479 0 CA-C-N 113.118 -1.856 . . . . 0.0 109.027 175.52 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.434 ' O ' ' HB3' ' A' ' 178' ' ' ASP . 69.2 m -59.89 -40.67 89.5 Favored 'General case' 0 N--CA 1.439 -0.976 0 N-CA-C 108.374 -0.973 . . . . 0.0 108.374 173.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.03 159.71 30.57 Favored Glycine 0 N--CA 1.425 -2.041 0 C-N-CA 120.168 -1.015 . . . . 0.0 112.118 178.673 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 18.0 Cg_exo -63.45 147.32 93.38 Favored 'Trans proline' 0 CA--C 1.504 -0.999 0 C-N-CA 122.729 2.286 . . . . 0.0 110.923 173.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -43.6 110.71 0.98 Allowed Pre-proline 0 CA--C 1.551 0.988 0 O-C-N 123.82 0.7 . . . . 0.0 112.348 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.449 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 89.9 Cg_endo -72.91 159.64 47.68 Favored 'Trans proline' 0 CA--C 1.486 -1.878 0 C-N-CA 125.256 3.97 . . . . 0.0 113.088 179.218 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.454 ' HG3' HG12 ' A' ' 192' ' ' ILE . 12.7 pt20 -136.51 -171.07 2.81 Favored 'General case' 0 C--N 1.292 -1.897 0 O-C-N 121.533 -0.73 . . . . 0.0 111.702 178.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.477 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 21.4 m -81.97 75.71 8.89 Favored 'General case' 0 C--O 1.24 0.598 0 CA-C-N 115.272 -0.876 . . . . 0.0 111.994 -173.994 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.454 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.4 mm . . . . . 0 C--O 1.24 0.564 0 CA-C-O 117.658 -1.163 . . . . 0.0 109.948 176.41 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.54 ' HG2' HG23 ' A' ' 111' ' ' VAL . 55.3 tttt . . . . . 0 CA--C 1.547 0.845 0 N-CA-C 106.253 -1.758 . . . . 0.0 106.253 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 91.9 p -79.75 162.07 25.36 Favored 'General case' 0 C--N 1.321 -0.668 0 O-C-N 121.68 -0.638 . . . . 0.0 111.82 -178.919 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.66 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 1.2 m -81.46 174.6 11.3 Favored 'General case' 0 C--N 1.303 -1.433 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 175.168 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.416 ' O ' ' CB ' ' A' ' 65' ' ' ASN . 73.7 mtt-85 -63.27 -38.7 92.19 Favored 'General case' 0 C--N 1.288 -2.082 0 CA-C-O 119.009 -0.519 . . . . 0.0 111.956 -179.699 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.416 ' CB ' ' O ' ' A' ' 64' ' ' ARG . 4.8 t30 125.28 144.26 0.0 OUTLIER Pre-proline 0 CA--C 1.492 -1.276 0 O-C-N 126.67 2.481 . . . . 0.0 104.724 -171.438 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.578 ' HD3' HG22 ' A' ' 80' ' ' ILE . 51.7 Cg_exo -32.33 119.43 0.09 OUTLIER 'Trans proline' 0 N--CA 1.445 -1.343 0 C-N-CA 123.687 2.925 . . . . 0.0 113.282 -179.153 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.59 ' HD2' ' OG1' ' A' ' 117' ' ' THR . 51.9 Cg_exo -54.37 -37.27 89.02 Favored 'Trans proline' 0 CA--C 1.498 -1.301 0 C-N-CA 122.747 2.298 . . . . 0.0 109.294 174.666 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 13.7 t70 37.92 114.73 0.0 OUTLIER Pre-proline 0 N--CA 1.478 0.942 0 C-N-CA 126.112 1.765 . . . . 0.0 114.818 169.394 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -60.96 146.2 98.03 Favored 'Trans proline' 0 N--CA 1.44 -1.637 0 N-CA-C 108.153 -1.518 . . . . 0.0 108.153 173.751 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 94.2 t -65.05 132.84 30.88 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.808 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.922 -166.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 60.26 34.8 20.9 Favored 'General case' 0 CA--C 1.539 0.522 0 CA-C-N 114.747 -1.115 . . . . 0.0 113.529 -177.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -92.34 -172.6 41.59 Favored Glycine 0 CA--C 1.548 2.104 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 173.271 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 65.8 ttp -119.94 120.92 37.79 Favored 'General case' 0 N--CA 1.471 0.597 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.364 178.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.636 HG12 ' H ' ' A' ' 76' ' ' VAL . 54.9 t -125.77 132.96 70.17 Favored 'Isoleucine or valine' 0 CA--C 1.552 1.051 0 N-CA-C 109.492 -0.558 . . . . 0.0 109.492 176.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.409 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 81.9 t60 -84.06 12.21 6.72 Favored 'General case' 0 N--CA 1.506 2.341 0 C-N-CA 123.368 0.667 . . . . 0.0 111.487 -175.367 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.636 ' H ' HG12 ' A' ' 74' ' ' VAL . 41.9 t -119.64 129.43 75.36 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.261 0 O-C-N 120.718 -1.239 . . . . 0.0 113.455 -175.47 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.595 HG22 ' HG2' ' A' ' 78' ' ' LYS . 49.1 mm -94.37 -66.06 1.03 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.849 0 CA-C-N 114.791 -1.095 . . . . 0.0 108.476 173.021 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.595 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.4 mmtt -116.23 3.25 13.42 Favored 'General case' 0 N--CA 1.487 1.417 0 N-CA-C 115.388 1.625 . . . . 0.0 115.388 179.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.572 ' O ' ' HB3' ' A' ' 84' ' ' SER . . . -73.24 47.33 1.33 Allowed Glycine 0 N--CA 1.48 1.581 0 N-CA-C 111.259 -0.736 . . . . 0.0 111.259 177.147 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.66 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 48.5 pt -106.57 0.98 10.07 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.809 0 C-N-CA 125.313 1.445 . . . . 0.0 109.206 -176.127 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 45.8 tp60 -72.66 170.23 14.95 Favored 'General case' 0 C--N 1.297 -1.693 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.41 -168.468 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 80.1 t80 -63.85 127.23 30.46 Favored 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 118.808 -1.157 . . . . 0.0 109.479 178.85 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 97.69 -20.33 51.1 Favored Glycine 0 N--CA 1.434 -1.497 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.223 -177.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.572 ' HB3' ' O ' ' A' ' 79' ' ' GLY . 22.1 m -74.98 152.51 38.75 Favored 'General case' 0 C--O 1.254 1.306 0 CA-C-O 120.959 0.409 . . . . 0.0 111.499 177.943 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.605 HE22 ' CB ' ' A' ' 103' ' ' THR . 91.9 mm-40 -122.49 136.03 54.79 Favored 'General case' 0 C--N 1.298 -1.656 0 CA-C-N 115.663 -0.698 . . . . 0.0 109.802 -177.235 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.759 ' O ' ' HA ' ' A' ' 101' ' ' SER . 46.4 pt -111.61 119.49 60.0 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 C-N-CA 119.897 -0.721 . . . . 0.0 110.638 176.31 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' O ' ' A' ' 100' ' ' SER . 14.4 mptt -84.01 139.47 32.51 Favored 'General case' 0 C--O 1.247 0.962 0 CA-C-N 116.006 -0.543 . . . . 0.0 111.987 175.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.408 ' CE2' ' SG ' ' A' ' 120' ' ' CYS . 52.5 t80 -132.13 121.13 23.27 Favored 'General case' 0 C--N 1.343 0.326 0 CA-C-N 115.795 -0.639 . . . . 0.0 112.113 175.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.2 t -81.11 146.82 30.38 Favored 'General case' 0 N--CA 1.481 1.086 0 CA-C-N 114.631 -1.168 . . . . 0.0 112.03 179.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.487 ' SG ' HD13 ' A' ' 96' ' ' LEU . 75.1 m -118.82 159.77 23.13 Favored 'General case' 0 C--O 1.239 0.539 0 CA-C-O 120.912 0.387 . . . . 0.0 111.552 175.571 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 24.4 m -69.3 159.21 33.54 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.845 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.521 ' HG3' ' OD1' ' A' ' 177' ' ' ASN . 87.0 tttt -64.89 132.61 49.86 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.945 0.403 . . . . 0.0 110.302 -176.278 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 97.05 -11.76 65.74 Favored Glycine 0 C--O 1.243 0.668 0 CA-C-N 115.565 -0.743 . . . . 0.0 112.061 -177.643 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 89.5 m-85 -122.03 141.6 51.19 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.038 -0.356 . . . . 0.0 110.038 179.893 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.701 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 29.0 ptt180 -123.22 -175.93 3.31 Favored 'General case' 0 C--O 1.21 -0.999 0 CA-C-O 122.684 1.231 . . . . 0.0 111.411 179.283 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.487 HD13 ' SG ' ' A' ' 90' ' ' CYS . 2.7 mm? -92.74 122.19 34.89 Favored 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 113.266 -1.788 . . . . 0.0 107.356 173.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.505 HD11 ' HB3' ' A' ' 121' ' ' ASP . 33.2 mm -64.59 -43.12 96.74 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.104 0 O-C-N 124.042 0.839 . . . . 0.0 112.988 -178.879 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.684 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -98.23 -84.33 1.76 Allowed Glycine 0 CA--C 1.5 -0.896 0 CA-C-N 115.613 -0.722 . . . . 0.0 113.221 -169.019 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.611 ' H ' ' HG3' ' A' ' 118' ' ' PRO . 9.0 t -144.43 128.37 17.44 Favored 'General case' 0 N--CA 1.433 -1.316 0 N-CA-C 107.418 -1.327 . . . . 0.0 107.418 176.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.45 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.1 p -65.42 -18.38 65.27 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.461 0.648 . . . . 0.0 111.816 -175.23 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.759 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 47.2 p -131.19 131.5 44.05 Favored 'General case' 0 N--CA 1.405 -2.702 0 N-CA-C 107.958 -1.127 . . . . 0.0 107.958 172.826 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . . . . . . . . . . . -98.29 127.56 44.29 Favored 'General case' 0 N--CA 1.424 -1.731 0 C-N-CA 119.797 -0.761 . . . . 0.0 110.087 -177.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.605 ' CB ' HE22 ' A' ' 85' ' ' GLN . 41.0 m -87.96 127.18 35.37 Favored 'General case' 0 N--CA 1.403 -2.795 0 N-CA-C 106.935 -1.506 . . . . 0.0 106.935 175.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 22.1 m -71.04 132.61 45.39 Favored 'General case' 0 C--N 1.281 -2.406 0 C-N-CA 120.692 -0.403 . . . . 0.0 110.333 177.09 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.4 pt -128.92 164.41 31.3 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.976 0 N-CA-C 108.863 -0.792 . . . . 0.0 108.863 178.777 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.585 ' CD1' HG22 ' A' ' 111' ' ' VAL . 48.8 mm -108.83 128.45 64.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 C-N-CA 120.537 -0.465 . . . . 0.0 109.869 -179.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 87.0 p -144.84 152.44 40.3 Favored 'General case' 0 N--CA 1.433 -1.289 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 174.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 58.52 -136.53 51.0 Favored Glycine 0 C--N 1.299 -1.506 0 N-CA-C 110.924 -0.87 . . . . 0.0 110.924 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -96.41 5.63 50.48 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 178.651 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 1.8 t -143.68 165.88 26.42 Favored 'General case' 0 CA--C 1.542 0.667 0 N-CA-C 112.487 0.551 . . . . 0.0 112.487 -170.397 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.585 HG22 ' CD1' ' A' ' 106' ' ' ILE . 16.0 t -88.45 128.55 40.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 N-CA-C 108.847 -0.798 . . . . 0.0 108.847 171.462 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.4 pp -129.06 161.92 37.45 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.872 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.96 173.336 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 99.0 m95 -82.07 134.42 35.34 Favored 'General case' 0 C--N 1.288 -2.102 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 -176.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 25.5 t70 -62.84 -40.77 98.48 Favored 'General case' 0 C--O 1.209 -1.05 0 CA-C-O 121.533 0.682 . . . . 0.0 110.801 -177.15 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.532 HG21 ' H ' ' A' ' 99' ' ' SER . 18.9 m -98.41 -16.35 19.31 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 115.064 -0.971 . . . . 0.0 113.35 -176.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.444 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 83.0 tt0 59.37 23.42 11.92 Favored 'General case' 0 C--N 1.355 0.838 0 CA-C-O 122.326 1.06 . . . . 0.0 109.77 -173.802 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.59 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 41.2 m 59.15 123.93 0.02 OUTLIER Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 114.633 -1.167 . . . . 0.0 110.769 -171.979 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.684 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 13.8 Cg_exo -61.74 149.16 91.16 Favored 'Trans proline' 0 N--CA 1.441 -1.604 0 C-N-CA 123.06 2.507 . . . . 0.0 111.77 -178.989 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 92.5 mt -95.61 130.18 44.7 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.126 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.701 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 77.2 m -71.69 118.32 14.38 Favored 'General case' 0 N--CA 1.425 -1.696 0 N-CA-C 106.651 -1.611 . . . . 0.0 106.651 -178.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.505 ' HB3' HD11 ' A' ' 97' ' ' ILE . 37.6 t70 -132.81 170.88 14.64 Favored 'General case' 0 C--N 1.3 -1.553 0 CA-C-N 115.914 -0.585 . . . . 0.0 109.554 -178.697 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.464 ' HG2' ' CE1' ' A' ' 145' ' ' HIS . 36.1 ttp85 -63.97 110.99 2.31 Favored 'General case' 0 CA--C 1.555 1.159 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -176.112 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.789 ' O ' ' HA ' ' A' ' 145' ' ' HIS . 14.5 mt -53.87 97.53 0.13 Allowed Pre-proline 0 N--CA 1.495 1.789 0 N-CA-C 113.485 0.92 . . . . 0.0 113.485 -172.431 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.436 ' O ' ' HB2' ' A' ' 125' ' ' CYS . 43.3 Cg_exo -58.99 -33.11 98.66 Favored 'Trans proline' 0 CA--C 1.563 1.958 0 C-N-CA 123.153 2.568 . . . . 0.0 112.752 -179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.436 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 22.5 m 79.37 -12.6 1.05 Allowed 'General case' 0 N--CA 1.492 1.627 0 C-N-CA 123.94 0.896 . . . . 0.0 112.672 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.97 20.53 67.61 Favored Glycine 0 CA--C 1.521 0.421 0 C-N-CA 120.02 -1.086 . . . . 0.0 114.309 173.592 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.538 ' HG ' ' HB2' ' A' ' 142' ' ' GLU . 1.2 tt 76.03 136.43 0.05 OUTLIER Pre-proline 0 C--N 1.356 0.868 0 C-N-CA 123.282 0.633 . . . . 0.0 111.425 -177.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.512 ' HD2' HD23 ' A' ' 127' ' ' LEU . 35.6 Cg_endo -66.2 145.53 78.69 Favored 'Trans proline' 0 N--CA 1.448 -1.167 0 C-N-CA 121.561 1.508 . . . . 0.0 111.45 -176.852 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.443 ' CG ' ' H ' ' A' ' 188' ' ' ALA . 28.1 Cg_endo -62.45 149.55 90.5 Favored 'Trans proline' 0 N--CA 1.454 -0.827 0 C-N-CA 122.505 2.137 . . . . 0.0 111.772 178.787 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.7 p -76.16 166.23 23.77 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-O 121.409 0.623 . . . . 0.0 110.248 -179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.742 HG21 ' N ' ' A' ' 135' ' ' ASP . 10.8 tp -107.93 147.96 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.096 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.906 -170.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 92.4 m -61.08 -46.11 91.98 Favored 'General case' 0 N--CA 1.426 -1.659 0 N-CA-C 107.832 -1.173 . . . . 0.0 107.832 178.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.621 ' HB3' ' ND2' ' A' ' 155' ' ' ASN . 67.6 m-80 -149.8 133.31 16.63 Favored 'General case' 0 CA--C 1.543 0.682 0 N-CA-C 112.266 0.469 . . . . 0.0 112.266 172.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.567 ' HA3' ' O ' ' A' ' 153' ' ' ARG . . . 106.05 11.24 28.42 Favored Glycine 0 N--CA 1.485 1.938 0 N-CA-C 117.278 1.671 . . . . 0.0 117.278 169.386 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.742 ' N ' HG21 ' A' ' 131' ' ' ILE . 99.0 m-20 44.18 -124.96 0.95 Allowed 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 117.416 0.608 . . . . 0.0 109.524 -176.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . . . . . . . . 0.255 37.4 p90 -146.16 153.91 41.19 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 112.638 0.607 . . . . 0.0 112.638 178.231 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.809 ' HA ' ' NH1' ' A' ' 153' ' ' ARG . 19.0 tt -66.64 -33.63 64.72 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.801 0 CA-C-N 116.078 -0.51 . . . . 0.0 111.684 -171.964 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 32.7 t -63.45 138.37 58.49 Favored 'General case' 0 C--N 1.345 0.401 0 N-CA-C 109.589 -0.523 . . . . 0.0 109.589 -178.038 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 12.3 p -101.76 -10.53 19.86 Favored 'General case' 0 CA--C 1.544 0.744 0 N-CA-C 112.246 0.461 . . . . 0.0 112.246 -177.681 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . 0.575 ' O ' ' HB2' ' A' ' 141' ' ' ARG . 83.8 m-20 -62.94 -41.36 99.48 Favored 'General case' 0 N--CA 1.448 -0.546 0 C-N-CA 120.441 -0.503 . . . . 0.0 112.007 -178.608 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.817 ' HG2' ' H ' ' A' ' 142' ' ' GLU . 49.7 ttt180 137.14 -145.16 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.866 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 172.428 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.817 ' H ' ' HG2' ' A' ' 141' ' ' ARG . 9.3 pt-20 -61.46 141.03 57.95 Favored 'General case' 0 N--CA 1.423 -1.778 0 C-N-CA 124.299 1.04 . . . . 0.0 110.048 -178.545 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.7 ' ND2' ' HB3' ' A' ' 148' ' ' SER . 3.1 t-20 -90.83 114.28 26.65 Favored 'General case' 0 C--N 1.28 -2.452 0 CA-C-N 114.247 -1.342 . . . . 0.0 109.95 -171.536 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.505 ' CE2' ' HG3' ' A' ' 142' ' ' GLU . 77.8 m-85 -101.39 123.12 44.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 113.73 1.011 . . . . 0.0 113.73 -171.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.789 ' HA ' ' O ' ' A' ' 123' ' ' ILE 0.265 36.0 t60 81.76 170.6 0.12 Allowed 'General case' 0 CA--C 1.552 1.029 0 N-CA-C 115.358 1.614 . . . . 0.0 115.358 166.887 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.844 ' HA ' ' CB ' ' A' ' 174' ' ' CYS . 82.4 t80 -54.74 -22.98 15.74 Favored 'General case' 0 CA--C 1.509 -0.617 0 C-N-CA 127.052 2.141 . . . . 0.0 112.783 -175.955 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -101.57 15.4 57.31 Favored Glycine 1 C--N 1.244 -4.556 0 CA-C-N 115.048 -0.978 . . . . 0.0 114.037 -167.698 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.7 ' HB3' ' ND2' ' A' ' 143' ' ' ASN . 68.8 m -126.24 151.96 46.73 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.266 -0.973 . . . . 0.0 110.575 -174.791 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.405 HG23 ' O ' ' A' ' 172' ' ' ILE . 3.1 p -138.82 140.7 38.42 Favored 'Isoleucine or valine' 0 CA--C 1.545 0.781 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.315 -178.593 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.4 ' O ' ' HA ' ' A' ' 171' ' ' SER . 25.7 m -131.64 159.13 43.29 Favored 'Isoleucine or valine' 0 CA--C 1.49 -1.357 0 CA-C-O 121.432 0.634 . . . . 0.0 110.22 175.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.504 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.1 m -125.32 127.26 46.36 Favored 'General case' 0 N--CA 1.429 -1.495 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.468 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 96.0 m-85 -86.93 140.5 29.55 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.607 179.136 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.809 ' NH1' ' HA ' ' A' ' 137' ' ' ILE . 30.5 ptt-85 -131.33 143.47 50.53 Favored 'General case' 0 C--N 1.306 -1.306 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 176.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.558 ' SG ' HD12 ' A' ' 166' ' ' LEU . 87.8 m -90.52 140.41 29.77 Favored 'General case' 0 C--N 1.3 -1.555 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 -176.928 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.621 ' ND2' ' HB3' ' A' ' 133' ' ' ASN . 18.1 p30 -91.0 161.03 36.51 Favored Pre-proline 0 N--CA 1.476 0.86 0 N-CA-C 112.712 0.634 . . . . 0.0 112.712 -173.463 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.509 ' HB2' ' O ' ' A' ' 159' ' ' GLY . 89.7 Cg_endo -70.28 151.56 66.15 Favored 'Trans proline' 0 CA--C 1.538 0.724 0 C-N-CA 123.461 2.774 . . . . 0.0 111.377 174.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -105.99 -82.05 1.5 Allowed Glycine 0 N--CA 1.463 0.499 0 C-N-CA 120.368 -0.92 . . . . 0.0 114.161 -174.516 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 38.4 t -61.42 -42.57 98.95 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.597 0.713 . . . . 0.0 110.431 179.378 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . 0.509 ' O ' ' HB2' ' A' ' 156' ' ' PRO . . . -165.92 -166.26 24.64 Favored Glycine 0 N--CA 1.434 -1.489 0 CA-C-N 113.929 -1.487 . . . . 0.0 109.557 -178.378 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -66.95 64.35 0.2 Allowed Glycine 0 CA--C 1.538 1.506 0 N-CA-C 114.02 0.368 . . . . 0.0 114.02 -177.141 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -148.34 159.01 44.43 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 177.357 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 75.7 mmtt -80.92 133.98 35.64 Favored 'General case' 0 CA--C 1.47 -2.124 0 C-N-CA 117.909 -1.516 . . . . 0.0 111.629 177.029 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 28.4 m -117.98 -4.13 10.71 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.935 0 CA-C-N 113.987 -1.461 . . . . 0.0 109.254 173.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.653 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 40.5 m-85 -129.8 150.18 51.22 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-N 114.878 -1.056 . . . . 0.0 111.666 -175.451 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 49.2 tp10 -120.46 145.08 47.6 Favored 'General case' 0 C--O 1.188 -2.164 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 175.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.661 HD23 ' O ' ' A' ' 167' ' ' VAL . 9.5 tt -117.72 142.76 46.89 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 118.973 0.806 . . . . 0.0 110.116 -173.368 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.661 ' O ' HD23 ' A' ' 166' ' ' LEU . 59.9 t -68.05 131.54 33.25 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.434 0 N-CA-C 106.444 -1.687 . . . . 0.0 106.444 -175.351 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -57.81 30.21 0.02 OUTLIER Glycine 0 CA--C 1.555 2.567 0 N-CA-C 119.399 2.52 . . . . 0.0 119.399 -167.958 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -139.24 58.42 12.53 Favored Pre-proline 0 C--N 1.304 -1.389 0 CA-C-N 118.391 1.095 . . . . 0.0 108.059 171.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.471 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 30.0 Cg_endo -67.91 -18.67 46.76 Favored 'Trans proline' 0 C--N 1.361 1.185 0 C-N-CA 123.087 2.525 . . . . 0.0 112.378 -175.944 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.4 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 12.9 p -91.96 118.3 30.63 Favored 'General case' 0 C--N 1.296 -1.739 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 -178.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.468 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 47.2 pt -124.42 151.18 29.5 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.093 0 N-CA-C 107.743 -1.206 . . . . 0.0 107.743 179.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.482 ' CE1' ' HB ' ' A' ' 175' ' ' THR . 42.8 p90 -145.66 162.49 37.42 Favored 'General case' 0 C--N 1.274 -2.678 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 -176.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.844 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 16.8 m -75.07 115.97 15.29 Favored 'General case' 0 N--CA 1.404 -2.772 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.812 HG21 ' HA ' ' A' ' 185' ' ' SER . 10.7 t -124.59 41.82 3.41 Favored 'General case' 0 N--CA 1.471 0.577 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.228 -172.006 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.64 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 47.2 m -58.23 -42.57 86.61 Favored 'General case' 0 C--N 1.289 -2.046 0 CA-C-N 115.845 -0.616 . . . . 0.0 111.923 -165.567 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.521 ' OD1' ' HG3' ' A' ' 92' ' ' LYS . 9.7 m120 -64.61 -42.51 95.48 Favored 'General case' 0 CA--C 1.544 0.746 0 N-CA-C 114.429 1.27 . . . . 0.0 114.429 178.935 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -65.08 -40.04 94.09 Favored 'General case' 0 N--CA 1.48 1.059 0 N-CA-C 113.64 0.978 . . . . 0.0 113.64 -178.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.428 ' HB3' ' H ' ' A' ' 180' ' ' GLN . 18.4 m-20 -101.92 -155.24 0.51 Allowed 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 115.383 -0.826 . . . . 0.0 112.53 -179.272 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.56 ' HG2' HG12 ' A' ' 181' ' ' VAL . 57.3 tt0 -46.53 -99.75 0.0 OUTLIER 'General case' 0 CA--C 1.558 1.279 0 C-N-CA 123.01 0.524 . . . . 0.0 111.278 -177.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.56 HG12 ' HG2' ' A' ' 180' ' ' GLN . 3.7 p -156.92 135.8 3.31 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 O-C-N 121.533 -0.73 . . . . 0.0 112.309 174.085 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.64 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 61.58 26.27 66.41 Favored Glycine 0 C--O 1.204 -1.756 0 C-N-CA 121.194 -0.526 . . . . 0.0 113.448 172.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 2.0 pp -127.05 162.55 31.69 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.826 0 N-CA-C 114.252 1.205 . . . . 0.0 114.252 -172.611 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.432 ' CH2' ' HB3' ' A' ' 143' ' ' ASN . 94.6 m95 -70.96 172.45 9.0 Favored 'General case' 0 C--N 1.32 -0.684 0 CA-C-N 114.143 -1.39 . . . . 0.0 110.996 178.213 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . 0.812 ' HA ' HG21 ' A' ' 175' ' ' THR . 77.8 p -64.13 -22.8 67.08 Favored 'General case' 0 CA--C 1.515 -0.4 0 CA-C-O 121.477 0.656 . . . . 0.0 111.839 -179.68 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 179.86 159.26 23.39 Favored Glycine 0 N--CA 1.416 -2.636 0 N-CA-C 109.539 -1.424 . . . . 0.0 109.539 177.367 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -65.08 148.86 89.6 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 121.542 1.495 . . . . 0.0 109.008 175.278 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.443 ' H ' ' CG ' ' A' ' 129' ' ' PRO . . . -39.56 113.26 0.84 Allowed Pre-proline 0 N--CA 1.47 0.57 0 O-C-N 124.043 0.839 . . . . 0.0 109.992 -179.087 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.471 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 24.2 Cg_exo -60.81 145.5 98.88 Favored 'Trans proline' 0 CA--C 1.474 -2.491 0 C-N-CA 122.473 2.115 . . . . 0.0 110.505 -179.588 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.689 ' HG3' HG12 ' A' ' 192' ' ' ILE . 30.1 pt20 -104.9 155.56 18.82 Favored 'General case' 0 N--CA 1.413 -2.323 0 CA-C-N 116.085 -0.507 . . . . 0.0 111.621 -164.519 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.653 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 73.9 m -79.04 72.2 5.56 Favored 'General case' 0 N--CA 1.419 -1.976 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.245 -178.521 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.689 HG12 ' HG3' ' A' ' 190' ' ' GLN . 37.7 mm . . . . . 0 C--O 1.259 1.584 0 CA-C-N 113.701 -1.591 . . . . 0.0 110.762 169.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 68.9 mttm . . . . . 0 CA--C 1.502 -0.874 0 CA-C-O 120.499 0.19 . . . . 0.0 111.135 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.408 ' HB3' ' OE1' ' A' ' 81' ' ' GLN . 75.3 p -131.63 155.61 47.27 Favored 'General case' 0 CA--C 1.496 -1.133 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 -175.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.624 ' HB3' ' CE2' ' A' ' 113' ' ' TRP . 1.5 m -80.05 166.0 21.98 Favored 'General case' 0 N--CA 1.419 -2.012 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 -178.014 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.635 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 26.0 mmt180 -63.77 -39.4 94.18 Favored 'General case' 0 N--CA 1.424 -1.756 0 N-CA-C 114.507 1.299 . . . . 0.0 114.507 -169.145 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.635 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 7.6 t30 163.12 146.45 0.03 OUTLIER Pre-proline 0 CA--C 1.559 1.295 0 N-CA-C 114.056 1.132 . . . . 0.0 114.056 -172.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.675 ' HA ' ' CD1' ' A' ' 86' ' ' ILE . 37.9 Cg_endo -67.96 -176.51 1.03 Allowed 'Trans proline' 0 CA--C 1.564 2.009 1 C-N-CA 126.388 4.725 . . . . 0.0 116.147 178.554 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.76 ' HB3' ' CZ ' ' A' ' 88' ' ' TYR . 16.7 Cg_exo -66.3 150.83 84.47 Favored 'Trans proline' 0 C--N 1.381 2.278 0 C-N-CA 125.039 3.826 . . . . 0.0 115.009 -176.053 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.503 ' N ' ' CD ' ' A' ' 69' ' ' PRO . 25.9 t0 -111.42 25.22 0.08 OUTLIER Pre-proline 0 CA--C 1.606 3.12 0 N-CA-C 115.791 1.774 . . . . 0.0 115.791 176.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.568 ' HG3' ' CE2' ' A' ' 88' ' ' TYR . 13.7 Cg_exo -61.24 149.53 88.9 Favored 'Trans proline' 0 C--N 1.381 2.244 0 C-N-CA 122.127 1.884 . . . . 0.0 112.065 173.599 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 50.2 t -113.52 132.4 62.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 108.028 -1.101 . . . . 0.0 108.028 -178.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 60.82 34.24 19.78 Favored 'General case' 0 CA--C 1.554 1.127 0 CA-C-N 114.49 -1.232 . . . . 0.0 110.649 -171.399 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -116.58 -165.19 13.95 Favored Glycine 0 C--O 1.246 0.904 0 N-CA-C 109.636 -1.386 . . . . 0.0 109.636 172.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -97.83 113.21 24.96 Favored 'General case' 0 C--O 1.218 -0.563 0 CA-C-N 118.113 0.956 . . . . 0.0 110.264 177.313 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.3 p -136.76 84.56 0.54 Allowed 'Isoleucine or valine' 0 C--O 1.247 0.925 0 CA-C-O 121.644 0.735 . . . . 0.0 112.233 178.235 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -133.6 123.79 25.71 Favored 'General case' 0 C--N 1.3 -1.581 0 CA-C-N 115.863 -0.608 . . . . 0.0 110.034 173.196 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.584 HG11 ' HG3' ' A' ' 66' ' ' PRO . 4.8 p -140.06 137.21 38.21 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 C-N-CA 118.403 -1.319 . . . . 0.0 112.351 176.204 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 46.4 mm -122.41 118.78 56.36 Favored 'Isoleucine or valine' 0 CA--C 1.494 -1.179 0 N-CA-C 107.448 -1.315 . . . . 0.0 107.448 169.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 75.8 mmtt 45.32 24.58 0.16 Allowed 'General case' 0 C--N 1.309 -1.186 0 CA-C-N 115.169 -0.923 . . . . 0.0 111.669 179.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.442 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -89.24 4.84 84.48 Favored Glycine 0 CA--C 1.49 -1.52 0 C-N-CA 121.103 -0.57 . . . . 0.0 113.024 -175.734 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.667 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 26.4 pt -101.99 -3.21 9.46 Favored 'Isoleucine or valine' 0 C--O 1.21 -0.975 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 -178.261 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.408 ' OE1' ' HB3' ' A' ' 62' ' ' SER . 4.3 tp-100 -71.42 165.42 23.83 Favored 'General case' 0 C--N 1.297 -1.676 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 -174.613 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 59.1 t80 -63.32 129.96 42.49 Favored 'General case' 0 C--N 1.317 -0.84 0 C-N-CA 119.893 -0.723 . . . . 0.0 110.411 177.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 79.85 20.06 68.97 Favored Glycine 0 N--CA 1.416 -2.639 0 CA-C-N 114.959 -1.019 . . . . 0.0 112.145 -177.161 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.442 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 6.0 m -124.42 149.7 46.45 Favored 'General case' 0 C--O 1.206 -1.225 0 N-CA-C 107.079 -1.452 . . . . 0.0 107.079 178.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.726 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 98.7 mt-30 -122.22 133.93 54.71 Favored 'General case' 0 N--CA 1.439 -1.003 0 O-C-N 121.425 -0.797 . . . . 0.0 111.475 -169.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.675 ' CD1' ' HA ' ' A' ' 66' ' ' PRO . 45.3 pt -99.91 134.33 39.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 C-N-CA 123.381 0.672 . . . . 0.0 110.408 174.309 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.1 mptt -104.46 151.28 23.73 Favored 'General case' 0 N--CA 1.486 1.349 0 N-CA-C 114.54 1.311 . . . . 0.0 114.54 -171.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.76 ' CZ ' ' HB3' ' A' ' 67' ' ' PRO . 5.6 m-85 -118.2 147.53 43.28 Favored 'General case' 0 CA--C 1.496 -1.13 0 N-CA-C 116.812 2.152 . . . . 0.0 116.812 179.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 91.9 p -155.06 157.32 37.37 Favored 'General case' 0 N--CA 1.439 -1.013 0 CA-C-N 113.535 -1.666 . . . . 0.0 106.724 170.683 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 1.5 m -150.14 177.45 9.89 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 113.285 0.846 . . . . 0.0 113.285 -179.533 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.522 HG22 ' H ' ' A' ' 92' ' ' LYS . 0.2 OUTLIER -76.55 175.85 8.88 Favored 'General case' 0 CA--C 1.557 1.225 0 CA-C-N 114.951 -1.022 . . . . 0.0 111.407 -178.852 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.522 ' H ' HG22 ' A' ' 91' ' ' THR . 10.3 tmtt? -63.62 132.4 51.03 Favored 'General case' 0 N--CA 1.441 -0.884 0 N-CA-C 113.892 1.071 . . . . 0.0 113.892 -175.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.81 11.66 78.92 Favored Glycine 0 CA--C 1.541 1.71 0 CA-C-N 114.368 -1.287 . . . . 0.0 114.617 -178.383 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.0 m-85 -121.33 145.24 48.09 Favored 'General case' 0 N--CA 1.469 0.517 0 N-CA-C 113.227 0.825 . . . . 0.0 113.227 -179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.596 ' HE ' HG23 ' A' ' 123' ' ' ILE . 16.1 ptp180 -135.94 172.38 13.09 Favored 'General case' 0 CA--C 1.489 -1.402 0 N-CA-C 109.81 -0.441 . . . . 0.0 109.81 175.998 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.433 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.7 mm? -93.26 125.93 38.12 Favored 'General case' 0 N--CA 1.433 -1.281 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 178.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.411 HD11 ' HB3' ' A' ' 121' ' ' ASP . 48.0 mm -68.58 -25.73 31.59 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 CA-C-N 115.234 -0.894 . . . . 0.0 113.015 177.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.429 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -119.62 -128.01 3.66 Favored Glycine 0 N--CA 1.427 -1.962 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.241 -175.172 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.432 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 3.9 t -110.17 122.04 46.69 Favored 'General case' 0 N--CA 1.438 -1.071 0 N-CA-C 107.169 -1.419 . . . . 0.0 107.169 -177.586 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.3 p -64.0 -20.73 66.11 Favored 'General case' 0 N--CA 1.481 1.114 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 -175.139 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.645 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 70.1 m -130.1 150.37 51.39 Favored 'General case' 0 C--N 1.289 -2.04 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 176.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.726 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -127.51 129.55 47.6 Favored 'General case' 0 N--CA 1.431 -1.408 0 CA-C-O 121.241 0.543 . . . . 0.0 111.038 179.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . 0.571 ' HA ' ' HG2' ' A' ' 85' ' ' GLN . 96.5 m -63.96 -43.32 96.13 Favored 'General case' 0 C--N 1.31 -1.111 0 CA-C-N 114.766 -1.106 . . . . 0.0 113.136 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.487 ' HB2' ' CZ3' ' A' ' 113' ' ' TRP . 51.2 t 84.2 120.95 0.04 OUTLIER 'General case' 0 C--N 1.299 -1.614 0 CA-C-N 113.493 -1.685 . . . . 0.0 110.173 -173.069 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.9 pp -127.75 161.9 34.63 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.415 0 CA-C-O 120.863 0.363 . . . . 0.0 111.313 -174.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.78 HG12 HG22 ' A' ' 111' ' ' VAL . 83.7 mt -107.97 120.91 60.16 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.462 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.223 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 70.4 m -61.78 -41.96 98.38 Favored 'General case' 0 N--CA 1.464 0.245 0 CA-C-O 121.817 0.818 . . . . 0.0 110.301 173.16 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.403 ' N ' HG22 ' A' ' 106' ' ' ILE . . . 174.36 -81.34 0.08 OUTLIER Glycine 0 N--CA 1.418 -2.54 0 CA-C-N 114.148 -1.387 . . . . 0.0 109.761 -178.202 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 35.0 p-10 -93.93 0.37 56.06 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 112.923 0.712 . . . . 0.0 112.923 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 2.5 t -146.97 160.73 41.99 Favored 'General case' 0 N--CA 1.438 -1.04 0 O-C-N 121.506 -0.746 . . . . 0.0 111.087 -178.542 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.78 HG22 HG12 ' A' ' 106' ' ' ILE . 42.3 t -118.31 127.62 75.4 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.97 0 CA-C-O 122.138 0.97 . . . . 0.0 112.614 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.583 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -133.85 164.0 35.8 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.861 0 CA-C-N 113.632 -1.622 . . . . 0.0 110.144 177.409 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.624 ' CE2' ' HB3' ' A' ' 63' ' ' CYS . 98.5 m95 -82.87 132.53 35.16 Favored 'General case' 0 C--O 1.217 -0.629 0 O-C-N 121.084 -1.01 . . . . 0.0 108.758 179.365 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -64.38 -42.84 95.92 Favored 'General case' 0 N--CA 1.476 0.86 0 CA-C-O 122.428 1.108 . . . . 0.0 111.102 179.783 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.524 ' O ' ' HB2' ' A' ' 116' ' ' GLU . 19.0 m -63.4 -43.97 96.0 Favored 'General case' 0 C--N 1.305 -1.352 0 CA-C-N 113.68 -1.6 . . . . 0.0 113.883 -179.517 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.524 ' HB2' ' O ' ' A' ' 115' ' ' THR . 77.7 mm-40 81.32 3.07 1.53 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.07 0.948 . . . . 0.0 109.338 -169.321 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.506 ' CG2' ' HE1' ' A' ' 88' ' ' TYR . 27.5 m 65.34 122.05 0.02 OUTLIER Pre-proline 0 CA--C 1.539 0.544 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.307 -179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.432 ' HG3' ' C ' ' A' ' 99' ' ' SER . 92.8 Cg_endo -72.57 155.12 55.01 Favored 'Trans proline' 0 N--CA 1.437 -1.825 0 C-N-CA 123.576 2.851 . . . . 0.0 112.799 -179.205 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 91.1 mt -109.72 130.33 63.01 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.504 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.057 178.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.538 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 84.9 m -71.9 118.95 15.39 Favored 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 177.513 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.411 ' HB3' HD11 ' A' ' 97' ' ' ILE . 8.2 t0 -125.36 176.61 6.67 Favored 'General case' 0 C--N 1.271 -2.83 0 N-CA-C 107.173 -1.417 . . . . 0.0 107.173 -177.4 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.7 mtt-85 -72.07 137.91 47.45 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.902 -0.777 . . . . 0.0 108.902 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.596 HG23 ' HE ' ' A' ' 95' ' ' ARG . 56.3 mt -65.95 109.94 3.91 Favored Pre-proline 0 C--N 1.314 -0.947 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.401 -177.078 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -57.38 -32.38 93.77 Favored 'Trans proline' 0 N--CA 1.442 -1.509 0 C-N-CA 122.89 2.393 . . . . 0.0 111.688 179.817 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.733 ' SG ' ' HA ' ' A' ' 146' ' ' TYR . 76.9 m 59.51 73.17 0.49 Allowed 'General case' 0 C--N 1.36 1.063 0 N-CA-C 107.69 -1.226 . . . . 0.0 107.69 -175.122 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.35 159.8 33.01 Favored Glycine 0 N--CA 1.423 -2.203 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.994 -174.819 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.459 HD22 ' HA ' ' A' ' 142' ' ' GLU . 7.7 mt -41.83 134.39 2.27 Favored Pre-proline 0 C--O 1.245 0.864 0 O-C-N 124.459 0.741 . . . . 0.0 111.169 -175.541 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.558 ' HD3' ' OD1' ' A' ' 143' ' ' ASN . 43.5 Cg_endo -82.49 176.58 7.78 Favored 'Trans proline' 0 CA--C 1.502 -1.092 0 C-N-CA 123.313 2.675 . . . . 0.0 112.639 -166.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -61.56 142.7 95.65 Favored 'Trans proline' 0 N--CA 1.43 -2.216 0 N-CA-C 109.514 -0.995 . . . . 0.0 109.514 177.643 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 24.7 m -77.74 134.1 38.15 Favored 'General case' 0 C--N 1.287 -2.133 0 N-CA-C 107.66 -1.237 . . . . 0.0 107.66 174.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.647 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.9 tp -67.21 158.65 5.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.369 0 CA-C-O 121.897 0.856 . . . . 0.0 111.833 -177.416 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.469 ' N ' HG13 ' A' ' 131' ' ' ILE . 19.1 m -62.37 -44.03 97.42 Favored 'General case' 0 C--N 1.288 -2.102 0 C-N-CA 125.643 1.577 . . . . 0.0 110.395 -177.123 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -93.74 6.37 48.58 Favored 'General case' 0 CA--C 1.539 0.523 0 N-CA-C 114.424 1.268 . . . . 0.0 114.424 -176.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.469 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 150.26 -102.13 0.23 Allowed Glycine 0 N--CA 1.468 0.784 0 C-N-CA 118.593 -1.765 . . . . 0.0 114.926 -179.852 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 15.3 p-10 -136.68 -172.77 3.25 Favored 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 122.673 0.389 . . . . 0.0 111.136 -177.26 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.558 ' HZ ' ' O ' ' A' ' 141' ' ' ARG . 49.0 p90 -110.57 162.92 14.24 Favored 'General case' 0 C--O 1.211 -0.935 0 N-CA-C 113.93 1.085 . . . . 0.0 113.93 -172.438 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.635 HD12 HG22 ' A' ' 151' ' ' THR . 94.2 mt -63.95 -42.96 97.45 Favored 'Isoleucine or valine' 0 C--O 1.246 0.918 0 CA-C-N 113.554 -1.657 . . . . 0.0 112.903 -175.335 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 11.7 m -60.14 139.81 57.29 Favored 'General case' 0 N--CA 1.431 -1.41 0 CA-C-O 121.433 0.635 . . . . 0.0 111.308 -170.781 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 99.6 m -63.12 -45.45 91.96 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 113.986 -1.461 . . . . 0.0 113.054 -172.242 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -82.81 122.83 28.72 Favored 'General case' 0 N--CA 1.436 -1.136 0 C-N-CA 120.386 -0.526 . . . . 0.0 109.627 -178.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.558 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 62.1 ttp180 -62.06 -42.74 99.51 Favored 'General case' 0 C--N 1.313 -0.999 0 CA-C-O 121.231 0.539 . . . . 0.0 109.874 -175.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.459 ' HA ' HD22 ' A' ' 127' ' ' LEU . 49.4 mt-10 -86.18 153.72 21.84 Favored 'General case' 0 N--CA 1.437 -1.086 0 CA-C-N 115.34 -0.846 . . . . 0.0 108.758 175.223 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.558 ' OD1' ' HD3' ' A' ' 128' ' ' PRO . 10.3 m120 -96.92 157.33 15.95 Favored 'General case' 0 C--N 1.302 -1.482 0 CA-C-O 121.304 0.573 . . . . 0.0 112.098 -176.806 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . 0.407 ' HB2' ' OG ' ' A' ' 148' ' ' SER . 84.3 m-85 -81.5 -179.4 7.36 Favored 'General case' 0 CA--C 1.552 1.039 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 176.278 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.403 ' HB3' ' H ' ' A' ' 146' ' ' TYR . 51.5 m80 -65.82 -158.17 0.01 OUTLIER 'General case' 0 N--CA 1.486 1.353 0 CA-C-O 121.54 0.686 . . . . 0.0 112.596 177.317 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.733 ' HA ' ' SG ' ' A' ' 125' ' ' CYS . 90.3 t80 -60.32 138.44 57.96 Favored 'General case' 0 N--CA 1.455 -0.192 0 CA-C-N 115.897 -0.592 . . . . 0.0 111.826 -173.73 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.3 0.9 55.74 Favored Glycine 0 C--O 1.222 -0.614 0 CA-C-N 115.299 -0.864 . . . . 0.0 112.075 -174.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.407 ' OG ' ' HB2' ' A' ' 144' ' ' PHE . 23.4 m -72.34 146.4 47.13 Favored 'General case' 0 N--CA 1.44 -0.933 0 CA-C-O 121.254 0.549 . . . . 0.0 112.026 -179.347 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.8 p -139.42 141.7 34.8 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 CA-C-N 115.228 -0.896 . . . . 0.0 110.908 -179.453 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 31.4 m -129.84 155.61 41.56 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.517 0 N-CA-C 109.152 -0.685 . . . . 0.0 109.152 174.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.635 HG22 HD12 ' A' ' 137' ' ' ILE . 54.4 m -127.47 134.04 49.86 Favored 'General case' 0 N--CA 1.435 -1.179 0 N-CA-C 109.06 -0.718 . . . . 0.0 109.06 -174.594 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.647 ' CD1' ' HB ' ' A' ' 131' ' ' ILE . 95.0 m-85 -106.8 142.45 36.42 Favored 'General case' 0 C--N 1.309 -1.157 0 N-CA-C 113.319 0.859 . . . . 0.0 113.319 -173.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.551 ' HG2' ' CG1' ' A' ' 137' ' ' ILE . 28.1 mmt85 -103.35 156.58 17.64 Favored 'General case' 0 CA--C 1.557 1.212 0 CA-C-N 114.464 -1.244 . . . . 0.0 112.408 177.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.525 ' SG ' HD13 ' A' ' 166' ' ' LEU . 93.8 m -111.61 153.47 26.29 Favored 'General case' 0 N--CA 1.488 1.436 0 C-N-CA 124.004 0.922 . . . . 0.0 111.998 177.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 156' ' ' PRO . 53.0 m-20 -123.33 145.25 46.0 Favored Pre-proline 0 CA--C 1.552 1.043 0 N-CA-C 114.217 1.191 . . . . 0.0 114.217 -176.355 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 155' ' ' ASN . 23.5 Cg_exo -62.43 146.57 95.6 Favored 'Trans proline' 0 C--N 1.368 1.575 0 C-N-CA 123.981 3.121 . . . . 0.0 112.599 177.434 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -94.62 -74.31 1.24 Allowed Glycine 0 CA--C 1.542 1.719 0 N-CA-C 115.83 1.092 . . . . 0.0 115.83 -175.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 45.2 m -60.93 -42.5 98.29 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-O 121.195 0.521 . . . . 0.0 112.135 -176.58 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 137.6 97.62 0.45 Allowed Glycine 0 N--CA 1.445 -0.705 0 N-CA-C 110.636 -0.985 . . . . 0.0 110.636 -177.5 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 79.34 12.05 84.29 Favored Glycine 0 C--O 1.239 0.456 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.792 -177.252 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 68.1 ttt180 -126.16 137.89 53.61 Favored 'General case' 0 C--O 1.244 0.806 0 N-CA-C 111.533 0.197 . . . . 0.0 111.533 -178.686 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.456 ' HE3' ' O ' ' A' ' 164' ' ' PHE . 42.1 tttp -78.69 122.18 25.66 Favored 'General case' 0 N--CA 1.441 -0.924 0 N-CA-C 108.444 -0.947 . . . . 0.0 108.444 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.3 m -117.41 4.07 7.28 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.189 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.514 ' HB2' ' HB3' ' A' ' 191' ' ' CYS . 51.3 p90 -139.72 155.11 47.52 Favored 'General case' 0 C--O 1.248 0.975 0 CA-C-N 115.688 -0.687 . . . . 0.0 112.045 -169.501 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -139.14 131.24 28.03 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 107.056 -1.461 . . . . 0.0 107.056 167.703 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 1.004 HD21 ' HB3' ' A' ' 170' ' ' PRO . 53.8 tp -72.44 150.13 43.61 Favored 'General case' 0 CA--C 1.49 -1.345 0 N-CA-C 109.12 -0.696 . . . . 0.0 109.12 -178.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . . . . . . . . . 1.7 p -61.39 -31.81 51.48 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 N-CA-C 112.491 0.552 . . . . 0.0 112.491 -167.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 133.99 -24.87 3.58 Favored Glycine 0 CA--C 1.5 -0.895 0 C-N-CA 119.892 -1.147 . . . . 0.0 114.025 173.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 5.1 tp10 -131.78 77.16 73.03 Favored Pre-proline 0 C--O 1.211 -0.922 0 N-CA-C 109.507 -0.553 . . . . 0.0 109.507 178.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 1.004 ' HB3' HD21 ' A' ' 166' ' ' LEU . 29.2 Cg_endo -64.93 -24.44 60.66 Favored 'Trans proline' 0 CA--C 1.5 -1.209 0 C-N-CA 122.335 2.023 . . . . 0.0 112.758 -177.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 29.3 t -74.95 132.03 41.11 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-O 122.211 1.005 . . . . 0.0 112.055 -178.507 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 46.9 pt -131.53 154.12 39.95 Favored 'Isoleucine or valine' 0 C--N 1.268 -2.96 0 CA-C-N 114.064 -1.425 . . . . 0.0 108.62 169.526 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 29.1 p90 -146.12 160.64 41.65 Favored 'General case' 0 C--N 1.278 -2.511 0 N-CA-C 112.939 0.718 . . . . 0.0 112.939 -177.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 2.4 t -68.38 93.73 0.5 Allowed 'General case' 0 C--N 1.312 -1.026 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.07 -179.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 4.3 t -120.21 69.06 0.85 Allowed 'General case' 0 C--O 1.242 0.696 0 CA-C-O 123.006 1.384 . . . . 0.0 109.686 -178.503 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.68 ' HB2' ' O ' ' A' ' 181' ' ' VAL . 77.9 p -66.78 -18.69 65.5 Favored 'General case' 0 C--N 1.289 -2.047 0 CA-C-N 113.868 -1.514 . . . . 0.0 112.845 -179.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 23.5 t-20 -62.8 -41.48 99.3 Favored 'General case' 0 C--N 1.297 -1.685 0 N-CA-C 114.078 1.14 . . . . 0.0 114.078 -174.673 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 15.6 t70 -63.89 -45.71 88.17 Favored 'General case' 0 CA--C 1.592 2.588 0 N-CA-C 115.902 1.816 . . . . 0.0 115.902 -167.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 65.5 m-20 -133.82 -42.7 0.82 Allowed 'General case' 0 N--CA 1.509 2.513 0 N-CA-C 116.485 2.032 . . . . 0.0 116.485 -175.344 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.4 mm-40 -132.81 157.71 44.33 Favored 'General case' 0 C--O 1.215 -0.761 0 C-N-CA 120.669 -0.412 . . . . 0.0 110.701 -175.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.68 ' O ' ' HB2' ' A' ' 176' ' ' SER . 90.9 t -61.3 -44.74 99.01 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 CA-C-N 115.831 -0.622 . . . . 0.0 112.624 -164.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.518 ' HA3' ' NH2' ' A' ' 95' ' ' ARG . . . -132.6 87.77 0.27 Allowed Glycine 0 C--O 1.223 -0.573 0 C-N-CA 119.548 -1.311 . . . . 0.0 112.346 177.011 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.578 HG12 ' HA ' ' A' ' 176' ' ' SER . 45.8 pt -130.67 166.15 29.07 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.739 0 CA-C-O 122.434 1.112 . . . . 0.0 113.017 -179.036 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 85.3 m95 -96.58 177.56 5.63 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 113.569 -1.651 . . . . 0.0 108.094 169.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 44.4 m -58.21 -39.27 78.59 Favored 'General case' 0 C--N 1.319 -0.728 0 C-N-CA 122.84 0.456 . . . . 0.0 110.04 -179.667 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . 169.97 -168.55 41.48 Favored Glycine 0 N--CA 1.423 -2.197 0 N-CA-C 111.352 -0.699 . . . . 0.0 111.352 176.447 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -62.44 145.42 95.66 Favored 'Trans proline' 0 CA--C 1.502 -1.079 0 C-N-CA 121.723 1.615 . . . . 0.0 109.588 174.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -45.1 126.61 5.55 Favored Pre-proline 0 CA--C 1.549 0.923 0 CA-C-N 116.028 -0.533 . . . . 0.0 111.833 -178.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.439 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 22.6 Cg_exo -62.52 147.43 94.84 Favored 'Trans proline' 0 CA--C 1.465 -2.929 0 C-N-CA 122.66 2.24 . . . . 0.0 109.755 179.28 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.693 ' HG3' HG12 ' A' ' 192' ' ' ILE . 28.6 pt20 -125.09 166.63 16.06 Favored 'General case' 0 N--CA 1.415 -2.218 0 CA-C-O 122.955 1.359 . . . . 0.0 113.656 -168.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.641 ' HA ' ' HA ' ' A' ' 166' ' ' LEU . 62.5 m -83.11 47.79 1.28 Allowed 'General case' 0 C--N 1.285 -2.201 0 CA-C-N 111.84 -2.437 . . . . 0.0 110.69 -171.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.693 HG12 ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.26 1.654 0 CA-C-O 117.755 -1.116 . . . . 0.0 112.076 178.417 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 86.6 tttt . . . . . 0 N--CA 1.482 1.145 0 CA-C-O 121.902 0.858 . . . . 0.0 111.214 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.705 ' OG ' ' HG3' ' A' ' 81' ' ' GLN . 8.5 m -73.78 148.71 42.27 Favored 'General case' 0 C--N 1.317 -0.838 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.683 178.962 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.578 ' SG ' HG22 ' A' ' 111' ' ' VAL . 65.5 m -77.7 -171.1 2.08 Favored 'General case' 0 C--O 1.218 -0.599 0 CA-C-N 115.141 -0.936 . . . . 0.0 111.564 178.951 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.465 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 48.1 mmt-85 -83.15 11.67 6.14 Favored 'General case' 0 CA--C 1.509 -0.634 0 CA-C-N 115.635 -0.711 . . . . 0.0 111.693 -178.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 5.3 m-20 75.52 152.68 0.14 Allowed Pre-proline 0 N--CA 1.476 0.839 0 O-C-N 123.912 0.757 . . . . 0.0 112.428 176.482 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.511 ' HB3' HD12 ' A' ' 86' ' ' ILE . 14.9 Cg_endo -64.31 129.81 25.13 Favored 'Trans proline' 0 C--O 1.249 1.045 0 C-N-CA 123.465 2.776 . . . . 0.0 114.191 178.025 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.772 ' O ' ' HD3' ' A' ' 69' ' ' PRO . 18.0 Cg_exo -63.16 148.13 93.46 Favored 'Trans proline' 0 N--CA 1.459 -0.522 0 C-N-CA 123.005 2.47 . . . . 0.0 111.012 173.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 6.4 t70 -96.98 96.53 2.88 Favored Pre-proline 0 CA--C 1.561 1.403 0 N-CA-C 112.945 0.72 . . . . 0.0 112.945 -177.617 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.772 ' HD3' ' O ' ' A' ' 67' ' ' PRO . 10.9 Cg_exo -71.71 153.33 59.42 Favored 'Trans proline' 0 CA--C 1.551 1.358 0 C-N-CA 124.534 3.489 . . . . 0.0 112.016 173.538 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 92.6 t -69.56 136.36 26.37 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.565 0 C-N-CA 124.579 1.152 . . . . 0.0 112.667 -179.409 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.81 35.68 16.52 Favored 'General case' 0 N--CA 1.493 1.681 0 N-CA-C 114.171 1.174 . . . . 0.0 114.171 176.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.48 167.8 37.16 Favored Glycine 0 CA--C 1.531 1.047 0 C-N-CA 119.779 -1.2 . . . . 0.0 113.098 178.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 97.7 mtp -126.2 154.86 42.68 Favored 'General case' 0 N--CA 1.462 0.174 0 C-N-CA 122.993 0.517 . . . . 0.0 110.47 -179.814 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 85.6 t -113.52 130.84 66.82 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 109.143 -0.688 . . . . 0.0 109.143 -178.906 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -110.12 113.12 25.56 Favored 'General case' 0 CA--C 1.512 -0.493 0 CA-C-O 121.132 0.491 . . . . 0.0 112.134 -179.008 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.541 HG22 ' H ' ' A' ' 79' ' ' GLY . 10.9 p -129.52 133.97 64.32 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.791 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.774 178.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.478 HG22 ' HG2' ' A' ' 78' ' ' LYS . 48.0 mm -107.99 112.34 39.79 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.907 0 N-CA-C 107.459 -1.311 . . . . 0.0 107.459 170.541 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.478 ' HG2' HG22 ' A' ' 77' ' ' ILE . 19.7 ptpt 34.7 33.32 0.01 OUTLIER 'General case' 0 N--CA 1.502 2.125 0 C-N-CA 124.161 0.984 . . . . 0.0 110.515 179.509 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.665 ' O ' ' HB2' ' A' ' 84' ' ' SER . . . -104.33 13.37 51.55 Favored Glycine 0 N--CA 1.427 -1.943 0 N-CA-C 115.827 1.091 . . . . 0.0 115.827 -167.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 49.2 pt -98.15 -2.93 9.9 Favored 'Isoleucine or valine' 0 C--N 1.258 -3.4 0 N-CA-C 105.953 -1.869 . . . . 0.0 105.953 178.402 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.705 ' HG3' ' OG ' ' A' ' 62' ' ' SER . 0.7 OUTLIER -96.65 75.81 2.81 Favored 'General case' 0 N--CA 1.437 -1.123 0 CA-C-N 113.32 -1.764 . . . . 0.0 110.673 -174.226 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.567 ' CE1' HG12 ' A' ' 106' ' ' ILE . 72.5 t80 42.18 127.93 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 117.94 2.57 . . . . 0.0 117.94 -176.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.36 0.2 88.7 Favored Glycine 0 CA--C 1.49 -1.514 0 CA-C-N 114.779 -1.1 . . . . 0.0 114.186 170.86 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.665 ' HB2' ' O ' ' A' ' 79' ' ' GLY . 49.9 m -100.56 -179.82 4.21 Favored 'General case' 0 C--N 1.282 -2.362 0 O-C-N 122.432 -0.452 . . . . 0.0 110.89 179.573 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.598 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 85.8 mt-30 -133.34 152.4 51.92 Favored 'General case' 0 N--CA 1.429 -1.503 0 CA-C-O 122.158 0.98 . . . . 0.0 111.712 -174.79 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.67 ' O ' ' HA ' ' A' ' 101' ' ' SER . 41.8 pt -116.68 122.11 69.17 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.07 -1.423 . . . . 0.0 108.879 173.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.733 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 57.0 mtmt -109.93 144.59 38.23 Favored 'General case' 0 C--O 1.251 1.175 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.084 -174.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.766 ' HE2' ' SG ' ' A' ' 120' ' ' CYS . 66.8 t80 -144.31 161.5 38.79 Favored 'General case' 0 C--N 1.307 -1.247 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.082 -173.259 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 28.7 p -139.35 155.21 47.83 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 122.939 0.495 . . . . 0.0 109.839 177.581 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . 0.498 ' SG ' HD22 ' A' ' 96' ' ' LEU . 73.2 m -116.16 171.22 7.95 Favored 'General case' 0 CA--C 1.539 0.55 0 CA-C-O 121.355 0.597 . . . . 0.0 111.906 -172.324 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -76.17 167.84 21.13 Favored 'General case' 0 CA--C 1.543 0.711 0 C-N-CA 123.873 0.869 . . . . 0.0 111.065 178.227 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -62.1 131.91 51.1 Favored 'General case' 0 N--CA 1.478 0.949 0 CA-C-O 120.962 0.41 . . . . 0.0 111.301 -173.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.94 2.02 90.65 Favored Glycine 0 N--CA 1.465 0.626 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.04 179.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -121.87 144.12 49.03 Favored 'General case' 0 C--N 1.314 -0.938 0 C-N-CA 122.539 0.336 . . . . 0.0 110.299 179.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.637 ' HD2' ' O ' ' A' ' 96' ' ' LEU . 2.4 ptt180 -135.94 168.98 18.32 Favored 'General case' 0 C--N 1.314 -0.967 0 CA-C-O 120.814 0.34 . . . . 0.0 110.764 179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.637 ' O ' ' HD2' ' A' ' 95' ' ' ARG . 2.7 mm? -81.14 128.47 33.79 Favored 'General case' 0 N--CA 1.432 -1.337 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 174.571 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 44.3 mm -69.25 -25.21 28.95 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 CA-C-O 121.719 0.771 . . . . 0.0 111.869 179.872 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.783 ' H ' ' HB3' ' A' ' 118' ' ' PRO . . . -113.33 -126.01 4.4 Favored Glycine 0 CA--C 1.492 -1.373 0 CA-C-N 114.209 -1.36 . . . . 0.0 110.787 -173.807 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.653 ' N ' ' HG3' ' A' ' 118' ' ' PRO . 34.5 t -112.64 124.57 52.84 Favored 'General case' 0 C--N 1.293 -1.854 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 -179.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.403 ' HA ' ' HG ' ' A' ' 96' ' ' LEU . 78.3 p -63.37 -19.5 64.7 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 120.943 0.402 . . . . 0.0 110.596 -176.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.733 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 15.3 m -117.51 120.86 39.37 Favored 'General case' 0 C--O 1.249 1.037 0 N-CA-C 109.033 -0.728 . . . . 0.0 109.033 173.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.598 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.6 149.3 21.6 Favored 'General case' 0 C--O 1.194 -1.833 0 CA-C-O 121.092 0.472 . . . . 0.0 111.0 176.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 86.4 m -117.76 127.65 54.12 Favored 'General case' 0 N--CA 1.421 -1.894 0 CA-C-N 116.138 -0.483 . . . . 0.0 109.825 -179.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.66 131.27 37.67 Favored 'General case' 0 C--N 1.303 -1.413 0 CA-C-N 115.06 -0.973 . . . . 0.0 110.967 175.592 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . . . . . . . . . 1.2 pt -130.62 164.23 34.19 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.289 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.805 179.089 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.567 HG12 ' CE1' ' A' ' 82' ' ' PHE . 46.6 mm -107.8 126.65 64.23 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.845 0 N-CA-C 109.083 -0.71 . . . . 0.0 109.083 179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.463 ' O ' HG22 ' A' ' 110' ' ' THR . 56.8 p -137.94 130.16 29.0 Favored 'General case' 0 N--CA 1.427 -1.585 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 172.55 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 72.59 23.22 78.29 Favored Glycine 0 C--N 1.319 -0.38 0 C-N-CA 119.754 -1.212 . . . . 0.0 111.701 177.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 58.2 m-20 63.01 34.86 13.59 Favored 'General case' 0 N--CA 1.474 0.743 0 CA-C-O 121.847 0.832 . . . . 0.0 112.598 -175.742 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.463 HG22 ' O ' ' A' ' 107' ' ' SER . 11.6 t -141.49 163.41 33.01 Favored 'General case' 0 N--CA 1.43 -1.441 0 N-CA-C 106.568 -1.642 . . . . 0.0 106.568 174.072 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.578 HG22 ' SG ' ' A' ' 63' ' ' CYS . 11.0 p -117.76 127.23 75.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 C-N-CA 118.706 -1.198 . . . . 0.0 111.496 -172.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 48.4 pt -131.98 163.51 37.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 CA-C-N 113.497 -1.683 . . . . 0.0 112.495 -173.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -93.7 130.78 39.53 Favored 'General case' 0 C--N 1.325 -0.465 0 N-CA-C 107.384 -1.339 . . . . 0.0 107.384 176.39 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . . . . . . . . . 44.2 m-20 -64.82 -40.53 95.35 Favored 'General case' 0 N--CA 1.474 0.73 0 N-CA-C 113.824 1.046 . . . . 0.0 113.824 175.369 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 12.0 p -106.04 -12.51 15.76 Favored 'General case' 0 N--CA 1.447 -0.596 0 N-CA-C 113.501 0.926 . . . . 0.0 113.501 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 47.95 27.18 1.11 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 124.974 1.309 . . . . 0.0 113.427 178.382 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.43 ' OG1' ' HD2' ' A' ' 67' ' ' PRO . 19.7 m 71.13 115.26 0.03 OUTLIER Pre-proline 0 C--N 1.322 -0.587 0 CA-C-O 122.564 1.173 . . . . 0.0 113.907 179.166 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.783 ' HB3' ' H ' ' A' ' 98' ' ' GLY . 8.8 Cg_exo -62.52 151.02 85.52 Favored 'Trans proline' 0 N--CA 1.442 -1.516 0 C-N-CA 124.302 3.335 . . . . 0.0 111.801 175.011 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 51.2 mm -97.43 130.02 46.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.575 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.766 ' SG ' ' HE2' ' A' ' 88' ' ' TYR . 90.2 m -69.15 126.71 30.63 Favored 'General case' 0 C--O 1.244 0.781 0 N-CA-C 108.223 -1.029 . . . . 0.0 108.223 179.066 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -144.59 165.67 27.35 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 -177.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.659 ' HG2' ' NE2' ' A' ' 145' ' ' HIS . 58.6 ttm-85 -69.87 129.5 39.69 Favored 'General case' 0 C--N 1.299 -1.627 0 N-CA-C 105.159 -2.163 . . . . 0.0 105.159 -169.001 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.67 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 22.7 mt -56.57 123.2 55.67 Favored Pre-proline 0 N--CA 1.484 1.232 0 N-CA-C 112.589 0.589 . . . . 0.0 112.589 -170.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . . . . . . . . . 93.5 Cg_endo -81.21 1.8 9.03 Favored 'Trans proline' 0 C--N 1.361 1.197 0 C-N-CA 124.698 3.599 . . . . 0.0 113.995 -175.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.525 ' H ' HG22 ' A' ' 123' ' ' ILE . 2.3 t -39.15 96.56 0.01 OUTLIER 'General case' 0 CA--C 1.506 -0.733 0 CA-C-O 122.127 0.965 . . . . 0.0 111.059 177.915 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 143' ' ' ASN . . . -128.54 -89.47 0.61 Allowed Glycine 0 CA--C 1.48 -2.134 0 CA-C-N 113.746 -1.57 . . . . 0.0 112.994 -175.2 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.475 ' HA ' ' HD3' ' A' ' 128' ' ' PRO . 1.4 tt -51.59 107.79 0.91 Allowed Pre-proline 0 N--CA 1.437 -1.116 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.493 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.475 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 35.9 Cg_endo -86.79 173.57 6.03 Favored 'Trans proline' 0 N--CA 1.425 -2.511 0 C-N-CA 122.748 2.299 . . . . 0.0 111.249 -171.952 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_endo -62.21 142.19 90.81 Favored 'Trans proline' 0 N--CA 1.411 -3.359 0 N-CA-C 108.138 -1.524 . . . . 0.0 108.138 174.471 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 19.3 p -79.55 167.17 21.11 Favored 'General case' 0 CA--C 1.478 -1.809 0 CA-C-N 116.653 -0.249 . . . . 0.0 110.64 -176.24 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.528 ' HB ' ' CD1' ' A' ' 152' ' ' TYR . 10.5 tp -106.71 150.89 8.89 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.745 0 O-C-N 124.091 0.87 . . . . 0.0 111.453 -174.71 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 84.9 m -60.66 -44.32 96.6 Favored 'General case' 0 C--N 1.286 -2.169 0 CA-C-N 113.662 -1.608 . . . . 0.0 111.635 -175.022 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.408 ' HB3' ' OD1' ' A' ' 155' ' ' ASN . 98.8 m-20 -95.73 6.24 49.41 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 114.756 1.391 . . . . 0.0 114.756 -176.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.423 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 147.96 -90.37 0.15 Allowed Glycine 0 CA--C 1.495 -1.203 0 C-N-CA 117.606 -2.235 . . . . 0.0 115.641 178.449 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 44.0 t0 -151.12 -178.56 6.69 Favored 'General case' 0 CA--C 1.557 1.219 0 CA-C-O 121.782 0.801 . . . . 0.0 111.796 -172.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.663 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 26.6 p90 -109.96 163.35 13.64 Favored 'General case' 0 C--O 1.207 -1.137 0 CA-C-N 114.483 -1.235 . . . . 0.0 112.574 -176.16 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.812 ' N ' HH12 ' A' ' 153' ' ' ARG . 7.8 tt -66.49 -27.91 41.76 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.677 0 CA-C-N 115.265 -0.88 . . . . 0.0 112.216 -173.434 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . 0.496 ' HB3' ' CD1' ' A' ' 136' ' ' PHE . 46.6 t -63.6 142.79 58.27 Favored 'General case' 0 C--O 1.216 -0.67 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 -178.909 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.0 p -66.43 -33.59 76.05 Favored 'General case' 0 CA--C 1.543 0.692 0 N-CA-C 115.281 1.586 . . . . 0.0 115.281 -170.801 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 11.9 m120 -101.2 139.29 37.07 Favored 'General case' 0 C--N 1.318 -0.784 0 O-C-N 121.795 -0.566 . . . . 0.0 110.492 -178.734 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.494 ' O ' ' HZ ' ' A' ' 136' ' ' PHE . 48.2 ttt85 -61.76 -43.46 98.81 Favored 'General case' 0 CA--C 1.503 -0.85 0 N-CA-C 114.425 1.269 . . . . 0.0 114.425 -178.353 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -108.91 116.55 32.2 Favored 'General case' 0 C--N 1.275 -2.664 0 CA-C-O 121.908 0.861 . . . . 0.0 109.151 175.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.571 HD22 ' HH2' ' A' ' 184' ' ' TRP . 61.3 t30 -72.11 151.0 43.36 Favored 'General case' 0 C--N 1.309 -1.182 0 CA-C-N 113.428 -1.714 . . . . 0.0 111.497 -172.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 76.1 m-85 -103.76 116.45 32.33 Favored 'General case' 0 N--CA 1.436 -1.138 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 -176.297 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.659 ' NE2' ' HG2' ' A' ' 122' ' ' ARG . 8.0 t-80 57.2 166.93 0.03 OUTLIER 'General case' 0 CA--C 1.59 2.481 0 N-CA-C 117.452 2.389 . . . . 0.0 117.452 166.778 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.67 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 74.3 t80 -60.97 139.77 57.96 Favored 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 127.606 2.363 . . . . 0.0 111.356 -179.008 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.494 ' H ' ' HB2' ' A' ' 174' ' ' CYS . . . 96.79 -4.7 63.6 Favored Glycine 0 N--CA 1.432 -1.571 0 CA-C-N 115.214 -0.903 . . . . 0.0 112.126 -178.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.419 ' CB ' HD21 ' A' ' 143' ' ' ASN . 12.6 t -85.43 159.77 19.89 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 120.285 -0.566 . . . . 0.0 110.431 176.37 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.401 HG23 ' O ' ' A' ' 172' ' ' ILE . 2.7 p -136.41 139.18 45.76 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.876 0 CA-C-O 120.627 0.251 . . . . 0.0 111.627 -177.96 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.7 m -124.19 134.73 65.82 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.922 0 CA-C-O 121.195 0.521 . . . . 0.0 111.252 176.986 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . . . . . . . . . 88.1 m -115.78 129.89 56.63 Favored 'General case' 0 C--O 1.247 0.928 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.833 -178.98 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.663 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -105.16 139.35 39.95 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 112.685 0.624 . . . . 0.0 112.685 -174.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.812 HH12 ' N ' ' A' ' 137' ' ' ILE . 56.4 mtm-85 -128.18 145.45 51.02 Favored 'General case' 0 C--O 1.25 1.084 0 N-CA-C 106.826 -1.546 . . . . 0.0 106.826 -175.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.417 ' HB3' ' CB ' ' A' ' 164' ' ' PHE . 74.3 m -90.78 140.36 29.87 Favored 'General case' 0 C--N 1.289 -2.035 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 -179.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.534 ' O ' ' HD2' ' A' ' 164' ' ' PHE . 12.6 p30 -100.19 149.42 36.01 Favored Pre-proline 0 C--O 1.208 -1.093 0 N-CA-C 112.838 0.681 . . . . 0.0 112.838 -175.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.49 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 25.0 Cg_exo -62.02 141.9 90.7 Favored 'Trans proline' 0 C--O 1.216 -0.609 0 C-N-CA 122.118 1.878 . . . . 0.0 111.594 178.319 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.83 -47.58 54.36 Favored Glycine 0 C--N 1.343 0.951 0 C-N-CA 120.087 -1.054 . . . . 0.0 113.579 176.762 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.2 p -107.53 -2.87 19.95 Favored 'General case' 0 C--N 1.324 -0.504 0 N-CA-C 112.367 0.506 . . . . 0.0 112.367 -177.885 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . 96.96 113.58 3.05 Favored Glycine 0 N--CA 1.434 -1.459 0 C-N-CA 120.173 -1.013 . . . . 0.0 111.807 -176.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 84.08 2.06 89.51 Favored Glycine 0 C--N 1.336 0.551 0 N-CA-C 112.399 -0.28 . . . . 0.0 112.399 178.729 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.49 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 41.6 ttm180 -123.82 123.16 39.85 Favored 'General case' 0 C--N 1.314 -0.952 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 178.83 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -91.98 87.86 6.36 Favored 'General case' 0 N--CA 1.434 -1.238 0 C-N-CA 118.654 -1.218 . . . . 0.0 108.62 179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 35.7 m -70.47 -25.1 26.25 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.049 0 CA-C-N 114.622 -1.172 . . . . 0.0 109.132 175.058 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.606 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 51.3 m-85 -102.59 120.19 40.12 Favored 'General case' 0 N--CA 1.424 -1.765 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.638 -172.165 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.8 mt-10 -98.67 134.7 41.23 Favored 'General case' 0 C--O 1.195 -1.8 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 177.138 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.46 ' HG ' ' N ' ' A' ' 167' ' ' VAL . 35.6 tp -76.56 155.75 33.39 Favored 'General case' 0 C--N 1.309 -1.18 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 -177.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.46 ' N ' ' HG ' ' A' ' 166' ' ' LEU . 1.2 p -63.68 -34.12 65.93 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.303 0 CA-C-N 116.233 -0.439 . . . . 0.0 111.266 -176.395 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . 148.36 -25.97 1.38 Allowed Glycine 0 C--N 1.347 1.164 0 C-N-CA 119.076 -1.535 . . . . 0.0 114.928 177.204 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -142.1 86.71 10.13 Favored Pre-proline 0 C--N 1.313 -1.0 0 CA-C-N 118.058 0.929 . . . . 0.0 111.86 -179.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.607 ' HA ' ' HG2' ' A' ' 189' ' ' PRO . 55.1 Cg_endo -68.56 -19.2 42.69 Favored 'Trans proline' 0 N--CA 1.462 -0.36 0 C-N-CA 123.481 2.787 . . . . 0.0 114.79 -176.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 10.2 p -96.63 119.18 34.63 Favored 'General case' 0 N--CA 1.441 -0.914 0 N-CA-C 112.627 0.602 . . . . 0.0 112.627 -171.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.401 ' O ' HG23 ' A' ' 149' ' ' VAL . 47.4 pt -127.42 153.82 37.07 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.215 0 CA-C-N 115.349 -0.842 . . . . 0.0 111.277 178.207 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 45.2 p90 -144.87 159.61 42.62 Favored 'General case' 0 N--CA 1.437 -1.114 0 CA-C-O 121.377 0.608 . . . . 0.0 110.701 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.494 ' HB2' ' H ' ' A' ' 147' ' ' GLY . 94.0 m -70.33 111.93 6.27 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.47 -178.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 9.1 t -133.21 47.59 2.48 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-O 122.073 0.94 . . . . 0.0 109.4 179.515 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.607 ' O ' ' HB2' ' A' ' 177' ' ' ASN . 7.2 m -64.88 138.48 58.4 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.968 -174.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.607 ' HB2' ' O ' ' A' ' 176' ' ' SER . 52.5 t-20 145.39 -46.51 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 125.823 1.649 . . . . 0.0 108.82 179.602 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -61.67 -48.41 80.93 Favored 'General case' 0 N--CA 1.482 1.134 0 CA-C-O 121.141 0.496 . . . . 0.0 111.267 -178.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.642 ' HB2' HG12 ' A' ' 183' ' ' ILE 0.268 91.3 m-20 -92.38 178.2 5.9 Favored 'General case' 0 N--CA 1.478 0.974 0 N-CA-C 113.152 0.797 . . . . 0.0 113.152 173.853 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 93.8 mm-40 -63.79 -51.14 66.13 Favored 'General case' 0 CA--C 1.559 1.312 0 N-CA-C 114.589 1.329 . . . . 0.0 114.589 -168.41 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.589 ' O ' HG23 ' A' ' 183' ' ' ILE . 2.9 p -141.96 138.77 30.91 Favored 'Isoleucine or valine' 0 C--O 1.213 -0.835 0 O-C-N 121.706 -0.621 . . . . 0.0 111.016 -178.7 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . . . . . . . . . . . 23.23 87.21 0.01 OUTLIER Glycine 0 N--CA 1.499 2.843 0 O-C-N 124.269 0.98 . . . . 0.0 114.171 173.937 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.642 HG12 ' HB2' ' A' ' 179' ' ' ASP . 2.4 pp -126.65 160.95 34.01 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.045 0 CA-C-O 122.265 1.031 . . . . 0.0 113.667 -174.106 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.571 ' HH2' HD22 ' A' ' 143' ' ' ASN . 78.4 m95 -101.26 173.52 6.42 Favored 'General case' 0 C--N 1.28 -2.415 0 CA-C-N 113.669 -1.605 . . . . 0.0 109.644 -179.594 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 40.2 m -58.77 -41.4 86.52 Favored 'General case' 0 C--N 1.309 -1.177 0 N-CA-C 108.606 -0.887 . . . . 0.0 108.606 179.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -158.67 152.17 23.25 Favored Glycine 0 N--CA 1.439 -1.142 0 N-CA-C 110.345 -1.102 . . . . 0.0 110.345 177.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -62.06 145.96 96.36 Favored 'Trans proline' 0 C--O 1.244 0.801 0 C-N-CA 122.167 1.911 . . . . 0.0 109.32 175.817 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -34.2 113.96 0.45 Allowed Pre-proline 0 N--CA 1.48 1.073 0 O-C-N 124.207 0.942 . . . . 0.0 112.794 -175.562 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.607 ' HG2' ' HA ' ' A' ' 170' ' ' PRO . 23.7 Cg_exo -62.01 147.08 95.84 Favored 'Trans proline' 0 CA--C 1.49 -1.685 0 C-N-CA 122.355 2.037 . . . . 0.0 110.541 179.311 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.589 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.2 pt20 -127.6 153.82 45.96 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 114.016 1.117 . . . . 0.0 114.016 -168.481 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.606 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 68.1 m -77.25 72.93 3.83 Favored 'General case' 0 N--CA 1.421 -1.917 0 CA-C-N 113.607 -1.633 . . . . 0.0 110.495 -172.705 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.589 HG12 ' HG3' ' A' ' 190' ' ' GLN . 44.1 mm . . . . . 0 C--O 1.267 1.982 0 C-N-CA 124.575 1.15 . . . . 0.0 110.281 176.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . . . . . . . . . 99.7 mttt . . . . . 0 N--CA 1.445 -0.704 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.452 ' HA ' ' HA ' ' A' ' 81' ' ' GLN . 46.2 p -127.3 151.71 48.39 Favored 'General case' 0 N--CA 1.425 -1.715 0 N-CA-C 106.854 -1.536 . . . . 0.0 106.854 178.295 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.46 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.7 OUTLIER -75.94 177.16 7.22 Favored 'General case' 0 C--N 1.282 -2.342 0 CA-C-O 122.139 0.971 . . . . 0.0 112.388 -172.471 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.567 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 25.8 mmt85 -62.22 -36.1 80.93 Favored 'General case' 0 N--CA 1.398 -3.04 0 CA-C-N 113.08 -1.873 . . . . 0.0 109.136 -176.101 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.567 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 117.02 158.47 0.0 OUTLIER Pre-proline 0 CA--C 1.508 -0.653 0 O-C-N 126.048 2.093 . . . . 0.0 108.754 178.281 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.55 ' HD3' ' CG2' ' A' ' 80' ' ' ILE . 22.0 Cg_exo -40.39 160.37 0.03 OUTLIER 'Trans proline' 0 CA--C 1.55 1.28 0 C-N-CA 123.341 2.694 . . . . 0.0 113.319 177.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.568 ' HG3' ' OG1' ' A' ' 117' ' ' THR . 1.1 Cg_endo -65.2 -22.14 61.4 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 122.302 2.001 . . . . 0.0 111.395 -177.179 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 4.1 p30 30.95 73.91 0.46 Allowed Pre-proline 0 C--N 1.321 -0.664 0 O-C-N 125.136 1.522 . . . . 0.0 114.752 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 20.6 Cg_exo -60.31 147.79 92.51 Favored 'Trans proline' 0 N--CA 1.44 -1.656 0 N-CA-C 108.792 -1.272 . . . . 0.0 108.792 171.706 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 63.0 t -61.93 -22.27 28.25 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 CA-C-O 122.793 1.282 . . . . 0.0 109.65 -175.919 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.3 m-20 -92.51 5.54 50.43 Favored 'General case' 0 C--N 1.296 -1.742 0 CA-C-N 114.868 -1.06 . . . . 0.0 109.869 179.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -131.22 -179.21 15.95 Favored Glycine 0 C--O 1.22 -0.732 0 CA-C-N 116.301 -0.408 . . . . 0.0 112.472 179.596 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 60.3 ttm -130.73 159.95 35.76 Favored 'General case' 0 CA--C 1.541 0.619 0 CA-C-N 116.943 0.371 . . . . 0.0 111.206 -179.73 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 76' ' ' VAL . 69.4 t -62.35 -45.54 98.54 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.68 0 N-CA-C 113.044 0.757 . . . . 0.0 113.044 -176.229 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 64.0 m170 20.45 48.62 0.0 OUTLIER 'General case' 0 N--CA 1.522 3.128 0 N-CA-C 117.014 2.227 . . . . 0.0 117.014 -175.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.516 ' CG1' ' H ' ' A' ' 79' ' ' GLY . 41.7 t -121.79 126.91 75.24 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.85 0 C-N-CA 119.619 -0.832 . . . . 0.0 109.109 173.107 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.499 HG22 ' HG2' ' A' ' 78' ' ' LYS . 33.9 mm -65.87 -44.83 92.56 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.634 0 N-CA-C 115.883 1.808 . . . . 0.0 115.883 -178.557 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.499 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.8 mmtt -169.03 17.64 0.02 OUTLIER 'General case' 0 N--CA 1.508 2.468 0 C-N-CA 124.093 0.957 . . . . 0.0 109.101 -176.795 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.608 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.15 1.21 12.13 Favored Glycine 0 C--N 1.312 -0.787 0 CA-C-N 115.606 -0.724 . . . . 0.0 114.082 -171.884 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.55 ' CG2' ' HD3' ' A' ' 66' ' ' PRO . 48.4 pt -100.38 -4.69 9.27 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 C-N-CA 119.665 -0.814 . . . . 0.0 111.936 -175.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.452 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 37.2 tp60 -80.16 168.47 19.07 Favored 'General case' 0 C--N 1.284 -2.275 0 N-CA-C 107.311 -1.366 . . . . 0.0 107.311 -172.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 88.8 t80 -64.12 130.74 45.18 Favored 'General case' 0 C--N 1.32 -0.714 0 O-C-N 121.252 -0.905 . . . . 0.0 108.736 -178.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.83 21.42 59.57 Favored Glycine 0 C--O 1.242 0.637 0 C-N-CA 119.355 -1.403 . . . . 0.0 112.933 -175.469 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.608 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 51.8 m -126.77 153.74 45.17 Favored 'General case' 0 C--O 1.245 0.834 0 O-C-N 122.041 -0.682 . . . . 0.0 110.91 -178.058 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.44 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -111.34 136.94 49.74 Favored 'General case' 0 N--CA 1.478 0.951 0 N-CA-C 113.161 0.8 . . . . 0.0 113.161 -175.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.468 ' O ' HG13 ' A' ' 86' ' ' ILE . 47.4 pt -111.01 125.16 68.34 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 N-CA-C 107.843 -1.169 . . . . 0.0 107.843 168.278 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.652 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 99.2 mttt -113.38 138.27 50.31 Favored 'General case' 0 N--CA 1.417 -2.116 0 C-N-CA 119.762 -0.775 . . . . 0.0 109.794 -177.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.402 ' HB3' HD11 ' A' ' 96' ' ' LEU . 47.9 t80 -90.6 125.42 35.63 Favored 'General case' 0 C--N 1.306 -1.316 0 CA-C-N 116.22 -0.445 . . . . 0.0 109.849 179.82 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.5 p -82.19 152.43 26.44 Favored 'General case' 0 N--CA 1.444 -0.752 0 C-N-CA 120.367 -0.533 . . . . 0.0 111.828 178.168 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 91.6 m -130.88 148.39 52.64 Favored 'General case' 0 C--N 1.308 -1.233 0 CA-C-O 121.383 0.611 . . . . 0.0 112.167 178.025 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 18.1 p -81.77 167.19 19.34 Favored 'General case' 0 N--CA 1.437 -1.078 0 C-N-CA 122.979 0.511 . . . . 0.0 110.553 170.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.506 ' HE3' ' OH ' ' A' ' 146' ' ' TYR . 57.6 tptt -62.42 131.42 49.15 Favored 'General case' 0 CA--C 1.549 0.909 0 CA-C-O 120.954 0.407 . . . . 0.0 110.641 -177.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.21 -4.61 67.53 Favored Glycine 0 CA--C 1.552 2.388 0 CA-C-N 116.356 -0.384 . . . . 0.0 113.986 178.873 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 96.8 m-85 -117.49 146.88 43.23 Favored 'General case' 0 N--CA 1.491 1.593 0 C-N-CA 122.813 0.445 . . . . 0.0 111.352 177.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.571 ' HB3' HG12 ' A' ' 123' ' ' ILE . 3.9 ptt180 -138.34 166.33 24.51 Favored 'General case' 0 N--CA 1.484 1.269 0 CA-C-O 121.216 0.532 . . . . 0.0 109.93 178.119 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.603 HD12 ' HG2' ' A' ' 118' ' ' PRO . 2.0 mm? -84.51 127.98 34.34 Favored 'General case' 0 N--CA 1.452 -0.368 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.993 177.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 43.6 mm -65.49 -43.66 94.34 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.862 0 CA-C-N 115.505 -0.77 . . . . 0.0 112.321 174.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.512 ' H ' ' CB ' ' A' ' 118' ' ' PRO . . . -104.62 -126.04 5.71 Favored Glycine 0 N--CA 1.44 -1.092 0 CA-C-N 114.47 -1.241 . . . . 0.0 111.297 -174.422 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.402 ' C ' ' HG3' ' A' ' 118' ' ' PRO . 68.1 m -105.12 117.44 34.01 Favored 'General case' 0 N--CA 1.441 -0.917 0 C-N-CA 120.434 -0.507 . . . . 0.0 109.654 179.976 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.561 ' CB ' ' HG ' ' A' ' 96' ' ' LEU . 1.7 m -61.01 -39.26 89.06 Favored 'General case' 0 N--CA 1.474 0.77 0 CA-C-O 121.804 0.811 . . . . 0.0 110.762 -177.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.652 ' OG ' ' HG2' ' A' ' 87' ' ' LYS . 18.9 m -109.26 120.9 43.91 Favored 'General case' 0 N--CA 1.417 -2.098 0 CA-C-N 115.024 -0.989 . . . . 0.0 108.908 -175.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.44 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.15 145.91 26.69 Favored 'General case' 0 N--CA 1.434 -1.268 0 CA-C-N 116.19 -0.459 . . . . 0.0 109.812 175.016 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 88.8 m -118.36 127.08 53.35 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 178.007 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.683 ' SG ' HG22 ' A' ' 111' ' ' VAL . 24.3 t -72.32 121.59 19.72 Favored 'General case' 0 C--N 1.289 -2.061 0 CA-C-N 114.948 -1.023 . . . . 0.0 111.935 -178.668 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.464 HG12 ' OD1' ' A' ' 114' ' ' ASP . 1.1 pt -129.41 164.36 32.15 Favored 'Isoleucine or valine' 0 N--CA 1.475 0.808 0 C-N-CA 124.758 1.223 . . . . 0.0 110.221 -179.205 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.553 ' HA ' ' HA ' ' A' ' 111' ' ' VAL . 80.1 mt -103.83 122.82 57.01 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.932 0 CA-C-O 121.689 0.757 . . . . 0.0 111.68 -176.518 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.428 ' HB2' HD11 ' A' ' 112' ' ' ILE . 34.9 t -86.29 -16.78 36.46 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.062 -0.972 . . . . 0.0 111.901 -179.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 165.46 -110.59 0.42 Allowed Glycine 0 C--N 1.302 -1.312 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -175.565 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 62.7 m-20 -68.98 -17.65 63.96 Favored 'General case' 0 CA--C 1.503 -0.856 0 CA-C-O 120.829 0.347 . . . . 0.0 111.203 179.637 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.9 t -137.56 165.37 26.49 Favored 'General case' 0 N--CA 1.421 -1.904 0 C-N-CA 119.666 -0.814 . . . . 0.0 109.594 -171.749 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.683 HG22 ' SG ' ' A' ' 104' ' ' CYS . 7.7 p -108.48 125.31 65.3 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.056 0 CA-C-O 122.657 1.218 . . . . 0.0 108.126 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.428 HD11 ' HB2' ' A' ' 107' ' ' SER . 2.6 pp -128.61 165.27 28.61 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 113.693 -1.594 . . . . 0.0 112.382 -174.469 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.492 ' HH2' ' HA ' ' A' ' 80' ' ' ILE . 92.6 m95 -82.78 136.4 34.69 Favored 'General case' 0 CA--C 1.569 1.698 0 CA-C-N 115.774 -0.648 . . . . 0.0 110.392 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.464 ' OD1' HG12 ' A' ' 105' ' ' ILE . 39.8 m-20 -64.28 -36.9 85.62 Favored 'General case' 0 CA--C 1.468 -2.173 0 CA-C-O 122.05 0.928 . . . . 0.0 110.065 171.067 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . . . . . . . . . 86.3 m -115.68 124.57 51.2 Favored 'General case' 0 N--CA 1.385 -3.706 0 N-CA-C 107.375 -1.343 . . . . 0.0 107.375 178.771 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 80.7 tt0 -65.18 -34.2 77.82 Favored 'General case' 0 C--N 1.29 -1.99 0 CA-C-N 113.598 -1.637 . . . . 0.0 108.824 179.296 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.568 ' OG1' ' HG3' ' A' ' 67' ' ' PRO . 61.5 m 121.06 124.45 0.0 OUTLIER Pre-proline 0 C--O 1.239 0.517 0 C-N-CA 126.52 1.928 . . . . 0.0 112.129 175.001 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.603 ' HG2' HD12 ' A' ' 96' ' ' LEU . 91.1 Cg_endo -71.55 159.14 52.07 Favored 'Trans proline' 0 N--CA 1.44 -1.634 0 C-N-CA 124.907 3.738 . . . . 0.0 111.93 177.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 87.4 mt -101.68 127.21 55.3 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.511 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 178.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.42 ' HA ' ' O ' ' A' ' 95' ' ' ARG . 1.4 t -75.98 114.38 14.55 Favored 'General case' 0 CA--C 1.49 -1.354 0 N-CA-C 108.045 -1.094 . . . . 0.0 108.045 176.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -122.14 -176.14 3.28 Favored 'General case' 0 C--N 1.284 -2.253 0 CA-C-N 114.048 -1.433 . . . . 0.0 107.494 -175.233 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.795 ' HD2' ' CE1' ' A' ' 145' ' ' HIS . 39.6 mmt180 -68.74 137.23 53.88 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 120.008 -0.677 . . . . 0.0 109.964 176.611 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.726 HD13 ' O ' ' A' ' 181' ' ' VAL . 40.5 mt -67.7 103.86 0.57 Allowed Pre-proline 0 CA--C 1.487 -1.456 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.47 -179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.429 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 41.8 Cg_exo -57.8 -31.85 93.37 Favored 'Trans proline' 0 C--O 1.199 -1.44 0 C-N-CA 123.506 2.804 . . . . 0.0 113.433 -177.282 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 51.42 42.49 29.31 Favored 'General case' 0 N--CA 1.486 1.363 0 CA-C-O 121.349 0.595 . . . . 0.0 109.947 -175.966 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -66.91 145.96 47.46 Favored Glycine 0 CA--C 1.501 -0.836 0 CA-C-N 114.915 -1.039 . . . . 0.0 114.471 -174.169 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER 47.73 92.51 0.06 OUTLIER Pre-proline 0 CA--C 1.538 0.508 0 C-N-CA 125.565 1.546 . . . . 0.0 113.631 179.3 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 33.0 Cg_exo -61.29 151.69 77.47 Favored 'Trans proline' 0 C--N 1.35 0.618 0 C-N-CA 123.229 2.62 . . . . 0.0 110.964 178.03 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.765 ' HG2' ' O ' ' A' ' 187' ' ' PRO . 23.8 Cg_exo -60.84 143.47 99.38 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 121.533 1.488 . . . . 0.0 113.11 179.932 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 18.5 m -68.81 135.49 51.26 Favored 'General case' 0 N--CA 1.421 -1.887 0 CA-C-N 115.062 -0.972 . . . . 0.0 109.747 175.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.437 HD13 ' CD2' ' A' ' 152' ' ' TYR . 10.8 tp -77.08 149.73 6.14 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-O 121.543 0.687 . . . . 0.0 111.14 179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 19.5 m -61.91 -44.62 96.43 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-N 114.036 -1.438 . . . . 0.0 111.569 -175.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.571 HD22 ' HB2' ' A' ' 191' ' ' CYS . 94.2 m-20 -124.9 48.27 2.02 Favored 'General case' 0 CA--C 1.558 1.264 0 N-CA-C 115.164 1.542 . . . . 0.0 115.164 -173.16 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . . . . . . . . . . . 155.35 -119.37 0.92 Allowed Glycine 0 N--CA 1.477 1.405 0 C-N-CA 119.798 -1.191 . . . . 0.0 113.401 178.503 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -151.61 174.34 13.57 Favored 'General case' 0 N--CA 1.473 0.682 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 179.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.591 ' HB2' ' CG1' ' A' ' 150' ' ' VAL . 48.2 p90 -107.49 157.19 18.21 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-O 121.294 0.569 . . . . 0.0 110.785 -177.48 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . . . . . . . . . 49.6 mm -109.32 127.2 66.23 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.924 178.829 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 46.8 t -154.14 171.06 19.74 Favored 'General case' 0 C--N 1.25 -3.747 0 N-CA-C 108.333 -0.988 . . . . 0.0 108.333 177.767 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 46.8 p -65.34 -30.43 71.27 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 123.223 0.609 . . . . 0.0 110.584 -177.778 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 32.2 p30 -143.87 171.09 14.71 Favored 'General case' 0 N--CA 1.442 -0.866 0 C-N-CA 123.475 0.71 . . . . 0.0 109.261 179.305 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . . . . . . . . . 61.9 ttp180 -62.25 -43.09 99.62 Favored 'General case' 0 CA--C 1.497 -1.071 0 C-N-CA 120.367 -0.533 . . . . 0.0 110.63 -175.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . . 7.6 pt-20 -123.88 110.46 14.87 Favored 'General case' 0 N--CA 1.415 -2.179 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.273 179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -82.25 161.12 22.79 Favored 'General case' 0 C--O 1.241 0.62 0 CA-C-N 115.473 -0.785 . . . . 0.0 108.991 -176.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 42.7 p90 -109.87 -149.0 0.43 Allowed 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 113.668 0.988 . . . . 0.0 113.668 -171.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.795 ' CE1' ' HD2' ' A' ' 122' ' ' ARG . 35.4 t60 -38.24 167.26 0.0 OUTLIER 'General case' 0 CA--C 1.559 1.297 0 N-CA-C 117.226 2.306 . . . . 0.0 117.226 -170.748 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.678 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 49.6 t80 -56.11 135.63 52.87 Favored 'General case' 0 N--CA 1.439 -0.99 0 C-N-CA 128.205 2.602 . . . . 0.0 110.938 -175.283 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.79 -13.7 59.16 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.581 -1.191 . . . . 0.0 111.096 -173.055 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 68.1 m -74.86 151.35 39.0 Favored 'General case' 0 CA--C 1.539 0.552 0 C-N-CA 122.619 0.368 . . . . 0.0 110.261 174.393 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 172' ' ' ILE . 2.6 p -133.43 140.7 46.26 Favored 'Isoleucine or valine' 0 CA--C 1.565 1.557 0 N-CA-C 112.269 0.47 . . . . 0.0 112.269 -174.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.591 ' CG1' ' HB2' ' A' ' 136' ' ' PHE . 60.5 t -121.77 134.17 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 177.431 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.409 ' HA ' ' HA ' ' A' ' 171' ' ' SER . 90.2 m -106.1 128.36 53.83 Favored 'General case' 0 C--N 1.307 -1.274 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 -175.829 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.478 ' HE1' ' CD1' ' A' ' 172' ' ' ILE . 93.2 m-85 -103.63 136.1 43.98 Favored 'General case' 0 C--N 1.311 -1.073 0 O-C-N 121.506 -0.746 . . . . 0.0 111.562 -178.437 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 85.3 mtp180 -127.57 147.2 50.34 Favored 'General case' 0 N--CA 1.434 -1.257 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.832 178.12 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.466 ' SG ' HD12 ' A' ' 166' ' ' LEU . 83.0 m -90.26 142.91 27.25 Favored 'General case' 0 C--N 1.303 -1.44 0 CA-C-N 115.69 -0.686 . . . . 0.0 110.334 -175.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.742 ' O ' HG22 ' A' ' 163' ' ' VAL . 1.4 m-20 -41.93 134.37 2.34 Favored Pre-proline 0 N--CA 1.482 1.149 0 CA-C-N 114.848 -1.069 . . . . 0.0 113.771 -175.466 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.881 ' HA ' ' O ' ' A' ' 161' ' ' ARG . 43.9 Cg_exo -60.85 -27.33 84.64 Favored 'Trans proline' 0 CA--C 1.549 1.234 0 C-N-CA 124.457 3.438 . . . . 0.0 114.535 177.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.587 ' HA3' ' CG1' ' A' ' 163' ' ' VAL . . . 87.12 -161.0 32.59 Favored Glycine 0 C--N 1.27 -3.098 0 CA-C-N 115.614 -0.721 . . . . 0.0 114.247 -175.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 35.3 m -60.22 -42.75 95.83 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 113.334 0.865 . . . . 0.0 113.334 -171.796 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -119.94 8.51 11.6 Favored Glycine 0 N--CA 1.47 0.93 0 C-N-CA 119.782 -1.199 . . . . 0.0 115.188 -178.051 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 93.03 107.11 1.78 Allowed Glycine 0 C--N 1.309 -0.944 0 C-N-CA 120.073 -1.06 . . . . 0.0 112.742 -177.604 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.881 ' O ' ' HA ' ' A' ' 156' ' ' PRO . 24.7 ptt-85 -176.73 -154.23 0.04 OUTLIER 'General case' 0 C--N 1.318 -0.802 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.942 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.443 ' HG2' ' O ' ' A' ' 164' ' ' PHE . 86.1 tttt -122.55 103.13 8.49 Favored 'General case' 0 N--CA 1.42 -1.926 0 N-CA-C 106.301 -1.74 . . . . 0.0 106.301 168.75 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.742 HG22 ' O ' ' A' ' 155' ' ' ASN . 28.9 m -70.34 -25.8 27.89 Favored 'Isoleucine or valine' 0 CA--C 1.462 -2.405 0 N-CA-C 113.221 0.823 . . . . 0.0 113.221 -178.015 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.639 ' CD2' HG23 ' A' ' 163' ' ' VAL . 66.0 m-85 -129.04 149.49 50.84 Favored 'General case' 0 C--N 1.304 -1.375 0 C-N-CA 119.551 -0.86 . . . . 0.0 112.012 -174.881 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -89.87 144.27 26.08 Favored 'General case' 0 C--N 1.304 -1.372 0 N-CA-C 107.684 -1.228 . . . . 0.0 107.684 179.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.65 HD23 ' N ' ' A' ' 167' ' ' VAL . 7.0 tt -108.81 166.48 10.78 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -177.033 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.727 HG12 HD12 ' A' ' 192' ' ' ILE . 5.8 m -61.62 -27.34 41.9 Favored 'Isoleucine or valine' 0 CA--C 1.562 1.41 0 C-N-CA 123.277 0.631 . . . . 0.0 111.55 -172.552 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.426 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 124.72 -21.52 6.65 Favored Glycine 0 C--N 1.344 1.026 0 C-N-CA 121.083 -0.579 . . . . 0.0 113.296 176.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 7.2 tp10 -125.31 79.43 66.45 Favored Pre-proline 0 C--N 1.306 -1.293 0 O-C-N 122.052 -0.675 . . . . 0.0 109.38 175.821 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_endo -62.83 -28.97 76.17 Favored 'Trans proline' 0 C--N 1.323 -0.803 0 C-N-CA 122.58 2.186 . . . . 0.0 114.235 -174.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.459 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 15.6 p -81.01 149.24 29.38 Favored 'General case' 0 N--CA 1.42 -1.928 0 CA-C-O 121.747 0.784 . . . . 0.0 112.048 -178.305 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . 0.478 ' CD1' ' HE1' ' A' ' 152' ' ' TYR . 46.5 pt -132.05 153.12 37.94 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 CA-C-N 114.29 -1.323 . . . . 0.0 109.862 173.826 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.61 ' CE2' ' HB ' ' A' ' 175' ' ' THR . 40.3 p90 -147.97 158.07 43.86 Favored 'General case' 0 C--N 1.303 -1.419 0 C-N-CA 120.444 -0.502 . . . . 0.0 110.658 177.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.59 ' CB ' ' HA ' ' A' ' 146' ' ' TYR . 0.1 OUTLIER -67.68 106.57 2.26 Favored 'General case' 0 CA--C 1.51 -0.569 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 178.745 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.61 ' HB ' ' CE2' ' A' ' 173' ' ' TYR . 10.1 t -141.53 34.83 1.64 Allowed 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 121.826 0.822 . . . . 0.0 109.409 -178.252 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.668 ' CB ' ' H ' ' A' ' 183' ' ' ILE . 15.3 t -62.53 138.96 58.59 Favored 'General case' 0 C--N 1.294 -1.806 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.403 -172.231 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 24.6 t-20 -132.53 -87.43 0.45 Allowed 'General case' 0 CA--C 1.561 1.377 0 N-CA-C 114.811 1.412 . . . . 0.0 114.811 -175.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -62.33 -48.81 78.19 Favored 'General case' 0 N--CA 1.492 1.66 0 N-CA-C 116.35 1.981 . . . . 0.0 116.35 -170.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 64.1 m-20 -62.73 -44.64 95.69 Favored 'General case' 0 N--CA 1.488 1.439 0 CA-C-O 121.195 0.521 . . . . 0.0 109.962 178.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . 0.615 ' HG3' ' H ' ' A' ' 182' ' ' GLY . 13.7 pt20 176.91 -164.52 0.03 OUTLIER 'General case' 0 N--CA 1.424 -1.755 0 CA-C-N 113.765 -1.561 . . . . 0.0 107.483 179.439 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . 0.726 ' O ' HD13 ' A' ' 123' ' ' ILE . 5.9 m -106.63 6.0 9.99 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.958 0 N-CA-C 114.213 1.19 . . . . 0.0 114.213 -178.713 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.615 ' H ' ' HG3' ' A' ' 180' ' ' GLN . . . -101.93 18.75 51.68 Favored Glycine 0 CA--C 1.548 2.124 0 N-CA-C 119.027 2.371 . . . . 0.0 119.027 -172.075 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.668 ' H ' ' CB ' ' A' ' 176' ' ' SER . 1.1 pt -125.0 161.2 29.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 CA-C-N 118.884 1.342 . . . . 0.0 113.71 179.319 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.432 ' O ' HD12 ' A' ' 183' ' ' ILE . 93.6 m95 -74.56 176.77 6.57 Favored 'General case' 0 N--CA 1.473 0.715 0 CA-C-N 114.488 -1.233 . . . . 0.0 111.362 -179.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 35.3 m -60.16 -41.75 93.48 Favored 'General case' 0 N--CA 1.473 0.708 0 CA-C-O 122.271 1.034 . . . . 0.0 109.529 -179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -159.44 150.68 21.24 Favored Glycine 0 CA--C 1.483 -1.919 0 N-CA-C 107.122 -2.391 . . . . 0.0 107.122 176.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . 0.765 ' O ' ' HG2' ' A' ' 129' ' ' PRO . 44.2 Cg_exo -54.97 -45.2 42.78 Favored 'Trans proline' 0 C--O 1.208 -1.002 0 CA-C-N 120.094 1.947 . . . . 0.0 111.282 -176.138 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . 179.86 116.3 0.21 Allowed Pre-proline 1 C--N 1.238 -4.245 0 CA-C-N 114.794 -1.094 . . . . 0.0 110.632 179.944 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.568 ' HB3' HG21 ' A' ' 167' ' ' VAL . 18.7 Cg_exo -61.83 147.85 94.35 Favored 'Trans proline' 0 C--O 1.213 -0.729 0 C-N-CA 122.697 2.264 . . . . 0.0 109.889 176.501 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.559 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.2 pt20 -115.68 153.57 31.08 Favored 'General case' 0 C--N 1.314 -0.949 0 C-N-CA 119.413 -0.915 . . . . 0.0 113.327 -167.792 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.571 ' HB2' HD22 ' A' ' 133' ' ' ASN . 79.4 m -75.22 72.32 2.29 Favored 'General case' 0 C--N 1.3 -1.583 0 CA-C-N 114.897 -1.047 . . . . 0.0 108.277 -177.093 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.727 HD12 HG12 ' A' ' 167' ' ' VAL . 96.9 mt . . . . . 0 C--O 1.252 1.236 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.267 178.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.784 ' O ' ' HB ' ' A' ' 111' ' ' VAL . 99.4 mttt . . . . . 0 C--O 1.194 -1.837 0 N-CA-C 113.16 0.8 . . . . 0.0 113.16 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.532 ' HB3' HG13 ' A' ' 80' ' ' ILE . 9.3 m -60.25 147.19 41.03 Favored 'General case' 0 C--N 1.295 -1.801 0 C-N-CA 119.47 -0.892 . . . . 0.0 108.88 -178.409 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.805 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 0.8 OUTLIER -60.35 164.91 3.92 Favored 'General case' 0 CA--C 1.501 -0.907 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.379 -169.228 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.551 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 87.7 mmt-85 -65.14 -7.46 12.6 Favored 'General case' 0 C--N 1.315 -0.892 0 CA-C-N 115.231 -0.895 . . . . 0.0 112.551 -167.194 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.551 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 28.0 t-20 84.48 139.79 0.05 OUTLIER Pre-proline 0 N--CA 1.483 1.222 0 C-N-CA 123.472 0.709 . . . . 0.0 109.893 -179.573 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.467 ' HA ' ' HD3' ' A' ' 67' ' ' PRO . 86.8 Cg_exo -36.77 152.75 0.03 OUTLIER 'Trans proline' 0 CA--C 1.551 1.367 0 C-N-CA 124.032 3.155 . . . . 0.0 113.585 176.811 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . 0.467 ' HD3' ' HA ' ' A' ' 66' ' ' PRO . 46.0 Cg_exo -60.45 -24.37 77.72 Favored 'Trans proline' 0 C--O 1.213 -0.747 0 C-N-CA 123.586 2.857 . . . . 0.0 110.122 176.956 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.451 ' N ' ' HD3' ' A' ' 69' ' ' PRO 0.31 4.2 p30 68.46 65.41 0.57 Allowed Pre-proline 0 CA--C 1.502 -0.866 0 C-N-CA 126.344 1.858 . . . . 0.0 112.478 -179.091 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.451 ' HD3' ' N ' ' A' ' 68' ' ' ASP . 23.6 Cg_exo -62.3 145.31 96.02 Favored 'Trans proline' 0 N--CA 1.452 -0.931 0 C-N-CA 122.684 2.256 . . . . 0.0 110.444 177.34 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 82.3 t -70.59 132.3 33.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 C-N-CA 119.984 -0.686 . . . . 0.0 111.299 -175.515 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 94.3 m-20 58.67 34.63 23.94 Favored 'General case' 0 N--CA 1.456 -0.156 0 CA-C-N 114.915 -1.039 . . . . 0.0 112.111 -179.23 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -90.96 177.28 41.47 Favored Glycine 0 N--CA 1.466 0.653 0 N-CA-C 111.195 -0.762 . . . . 0.0 111.195 174.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 99.7 mtp -88.67 133.75 34.11 Favored 'General case' 0 C--N 1.319 -0.76 0 CA-C-N 117.262 0.531 . . . . 0.0 110.82 179.977 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 55.9 t -123.22 130.4 74.34 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.674 0 N-CA-C 108.422 -0.955 . . . . 0.0 108.422 174.4 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 99.0 m-70 -149.41 39.79 0.83 Allowed 'General case' 0 C--N 1.31 -1.132 0 C-N-CA 124.156 0.982 . . . . 0.0 109.252 179.262 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.531 HG23 ' HA3' ' A' ' 79' ' ' GLY . 2.5 p -124.93 131.13 73.0 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 C-N-CA 120.356 -0.537 . . . . 0.0 111.908 -172.95 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.676 HG23 ' H ' ' A' ' 78' ' ' LYS . 16.5 tt -110.57 -67.14 1.21 Allowed 'Isoleucine or valine' 0 CA--C 1.552 1.036 0 CA-C-N 114.97 -1.013 . . . . 0.0 110.928 174.778 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.676 ' H ' HG23 ' A' ' 77' ' ' ILE . 20.0 ptpt -105.78 3.9 29.31 Favored 'General case' 0 C--O 1.219 -0.513 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 174.57 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.599 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -63.73 7.9 0.4 Allowed Glycine 0 C--O 1.219 -0.803 0 CA-C-N 114.837 -1.074 . . . . 0.0 114.637 -169.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.805 ' O ' ' HB2' ' A' ' 63' ' ' CYS . 40.6 pt -106.56 -5.15 10.1 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.731 0 C-N-CA 119.763 -0.775 . . . . 0.0 109.839 -177.544 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.498 ' HG2' ' H ' ' A' ' 82' ' ' PHE . 57.2 tt0 -85.21 176.89 8.08 Favored 'General case' 0 C--N 1.316 -0.883 0 C-N-CA 119.747 -0.781 . . . . 0.0 108.976 -170.49 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.515 ' CD1' HG13 ' A' ' 106' ' ' ILE . 56.7 t80 -56.2 131.46 47.88 Favored 'General case' 0 C--O 1.218 -0.594 0 C-N-CA 119.43 -0.908 . . . . 0.0 111.571 175.861 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 81.42 21.23 62.68 Favored Glycine 0 N--CA 1.434 -1.443 0 CA-C-N 114.979 -1.01 . . . . 0.0 113.687 179.884 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.599 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 69.0 m -126.74 155.42 42.76 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-O 120.642 0.258 . . . . 0.0 111.3 -177.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.456 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.2 mt-30 -127.78 153.8 46.15 Favored 'General case' 0 CA--C 1.507 -0.686 0 CA-C-O 121.293 0.568 . . . . 0.0 111.535 -174.418 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.721 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.7 pt -125.97 152.26 32.98 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 N-CA-C 108.104 -1.072 . . . . 0.0 108.104 175.619 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HG3' ' OG ' ' A' ' 101' ' ' SER . 3.3 mptp? -118.58 138.26 52.69 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 120.63 -0.428 . . . . 0.0 111.521 178.2 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . . . . . . . . . 77.9 t80 -131.11 120.05 22.82 Favored 'General case' 0 N--CA 1.469 0.523 0 N-CA-C 113.105 0.78 . . . . 0.0 113.105 176.417 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 23.1 p -82.56 161.17 22.39 Favored 'General case' 0 CA--C 1.551 1.004 0 CA-C-N 115.536 -0.756 . . . . 0.0 112.425 177.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 97.5 m -128.86 160.11 33.65 Favored 'General case' 0 C--N 1.322 -0.617 0 C-N-CA 124.094 0.958 . . . . 0.0 111.789 177.64 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.0 p -79.13 165.47 23.29 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 174.048 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 88.6 tttt -63.75 133.44 53.51 Favored 'General case' 0 CA--C 1.536 0.422 0 CA-C-O 121.233 0.54 . . . . 0.0 111.89 -175.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.428 ' O ' HG13 ' A' ' 123' ' ' ILE . . . 96.39 -4.06 64.16 Favored Glycine 0 CA--C 1.532 1.129 0 CA-C-N 116.062 -0.517 . . . . 0.0 113.434 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 93.4 m-85 -119.52 147.42 44.48 Favored 'General case' 0 N--CA 1.437 -1.111 0 C-N-CA 122.76 0.424 . . . . 0.0 110.738 179.478 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.705 ' HE ' HG23 ' A' ' 123' ' ' ILE . 10.2 ptp180 -133.73 171.5 14.05 Favored 'General case' 0 C--N 1.313 -0.998 0 CA-C-O 121.897 0.856 . . . . 0.0 109.83 176.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.421 HD22 ' N ' ' A' ' 96' ' ' LEU . 2.5 mm? -94.98 127.28 40.92 Favored 'General case' 0 N--CA 1.427 -1.592 0 CA-C-N 114.646 -1.161 . . . . 0.0 108.78 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.2 mm -64.91 -43.72 96.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.253 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.907 178.247 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -98.2 -127.37 5.77 Favored Glycine 0 C--N 1.297 -1.613 0 CA-C-N 114.692 -1.14 . . . . 0.0 110.602 -175.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.532 ' O ' ' HD3' ' A' ' 118' ' ' PRO . 72.8 m -114.68 120.47 40.21 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 122.305 -0.526 . . . . 0.0 110.298 -179.555 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 78.2 p -61.34 -34.38 75.18 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.674 -0.693 . . . . 0.0 110.613 -178.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.721 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 73.2 m -111.77 98.65 7.55 Favored 'General case' 0 C--N 1.303 -1.437 0 C-N-CA 119.921 -0.712 . . . . 0.0 109.302 174.55 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -69.71 143.93 52.95 Favored 'General case' 0 CA--C 1.484 -1.573 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.552 178.097 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 87.5 m -113.67 123.71 50.55 Favored 'General case' 0 N--CA 1.41 -2.426 0 N-CA-C 108.41 -0.959 . . . . 0.0 108.41 172.589 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.498 ' SG ' HG12 ' A' ' 111' ' ' VAL . 22.5 t -77.67 127.51 32.58 Favored 'General case' 0 C--N 1.291 -1.954 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.381 -177.906 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.578 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.0 pp -130.11 165.39 30.39 Favored 'Isoleucine or valine' 0 C--N 1.352 0.692 0 C-N-CA 123.09 0.556 . . . . 0.0 111.277 -175.096 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 1.02 HG12 HG22 ' A' ' 111' ' ' VAL . 85.8 mt -102.2 119.93 51.2 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.64 0 CA-C-O 121.239 0.543 . . . . 0.0 111.601 -179.356 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.6 t -62.92 -42.5 99.82 Favored 'General case' 0 N--CA 1.439 -0.984 0 CA-C-N 114.508 -1.224 . . . . 0.0 109.551 175.362 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 159.78 -71.94 0.23 Allowed Glycine 0 N--CA 1.43 -1.716 0 CA-C-N 113.65 -1.614 . . . . 0.0 110.328 -179.485 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 48.6 p-10 -65.8 -36.36 83.29 Favored 'General case' 0 N--CA 1.439 -1.016 0 N-CA-C 113.281 0.845 . . . . 0.0 113.281 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . . . . . . . . . 14.0 t -144.27 179.72 7.06 Favored 'General case' 0 N--CA 1.428 -1.544 0 CA-C-N 116.273 -0.422 . . . . 0.0 110.318 -175.044 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 1.02 HG22 HG12 ' A' ' 106' ' ' ILE . 41.0 t -108.78 126.02 65.72 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.493 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 -179.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 2.6 pp -131.76 163.15 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.384 0 CA-C-N 114.371 -1.286 . . . . 0.0 112.292 -177.504 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . 0.734 ' HB3' ' O ' ' A' ' 115' ' ' THR . 98.1 m95 -78.13 132.14 37.54 Favored 'General case' 0 CA--C 1.535 0.366 0 C-N-CA 118.336 -1.345 . . . . 0.0 108.498 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.578 ' HB2' HG12 ' A' ' 105' ' ' ILE . 33.4 t70 -65.44 -41.31 93.63 Favored 'General case' 0 CA--C 1.488 -1.441 0 CA-C-O 123.841 1.781 . . . . 0.0 106.772 173.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.734 ' O ' ' HB3' ' A' ' 113' ' ' TRP . 91.0 m -116.96 123.78 47.78 Favored 'General case' 0 N--CA 1.385 -3.686 0 N-CA-C 104.336 -2.468 . . . . 0.0 104.336 172.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . . . . . . . . . 16.7 pt-20 -65.62 -37.26 86.08 Favored 'General case' 0 C--N 1.285 -2.198 0 O-C-N 123.303 0.377 . . . . 0.0 111.628 -176.44 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . 0.403 HG23 ' HD2' ' A' ' 118' ' ' PRO . 22.6 m 144.53 128.58 0.0 OUTLIER Pre-proline 0 C--N 1.312 -1.049 0 C-N-CA 128.043 2.537 . . . . 0.0 105.241 178.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.532 ' HD3' ' O ' ' A' ' 99' ' ' SER . 90.4 Cg_endo -70.51 156.88 60.46 Favored 'Trans proline' 0 N--CA 1.446 -1.31 0 C-N-CA 122.564 2.176 . . . . 0.0 113.149 -176.077 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 89.4 mt -103.27 127.13 57.45 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 N-CA-C 107.346 -1.353 . . . . 0.0 107.346 177.674 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 1.5 t -82.64 118.93 23.68 Favored 'General case' 0 N--CA 1.417 -2.087 0 C-N-CA 118.983 -1.087 . . . . 0.0 109.571 -178.031 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -125.74 176.89 6.6 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 106.501 -1.666 . . . . 0.0 106.501 -176.079 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -70.41 137.95 50.86 Favored 'General case' 0 C--N 1.308 -1.198 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 -179.232 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.705 HG23 ' HE ' ' A' ' 95' ' ' ARG . 30.5 mt -64.24 109.15 2.4 Favored Pre-proline 0 C--O 1.208 -1.121 0 N-CA-C 109.067 -0.716 . . . . 0.0 109.067 -178.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 126' ' ' GLY . 38.3 Cg_endo -68.23 -17.12 44.98 Favored 'Trans proline' 0 N--CA 1.449 -1.103 0 C-N-CA 122.835 2.357 . . . . 0.0 111.038 -179.371 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.472 ' HB2' ' O ' ' A' ' 124' ' ' PRO . 95.5 m 73.0 -38.27 0.41 Allowed 'General case' 0 N--CA 1.489 1.522 0 CA-C-N 115.062 -0.972 . . . . 0.0 110.414 -176.135 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 124' ' ' PRO . . . 76.83 -162.32 51.77 Favored Glycine 0 N--CA 1.42 -2.399 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.601 177.821 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.6 mm? -73.08 116.35 49.79 Favored Pre-proline 0 N--CA 1.408 -2.537 0 CA-C-O 120.787 0.327 . . . . 0.0 110.246 176.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.39 165.56 5.61 Favored 'Trans proline' 0 C--N 1.357 0.99 0 C-N-CA 122.877 2.385 . . . . 0.0 111.507 -179.856 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.504 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 22.3 Cg_exo -61.28 145.35 98.53 Favored 'Trans proline' 0 CA--C 1.5 -1.177 0 C-N-CA 121.505 1.47 . . . . 0.0 109.237 178.696 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 17.0 p -78.02 166.87 22.3 Favored 'General case' 0 C--N 1.304 -1.394 0 C-N-CA 120.447 -0.501 . . . . 0.0 111.352 179.995 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.731 HG21 ' O ' ' A' ' 134' ' ' GLY . 10.4 tp -125.35 146.13 31.55 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.163 0 CA-C-O 122.217 1.008 . . . . 0.0 112.497 -171.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 98.8 m -62.46 -46.39 88.73 Favored 'General case' 0 CA--C 1.571 1.755 0 CA-C-N 113.801 -1.545 . . . . 0.0 114.191 -178.599 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 -102.47 6.12 39.9 Favored 'General case' 0 N--CA 1.495 1.786 0 N-CA-C 117.164 2.283 . . . . 0.0 117.164 -175.027 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.731 ' O ' HG21 ' A' ' 131' ' ' ILE . . . 126.58 145.22 6.26 Favored Glycine 0 N--CA 1.485 1.942 0 C-N-CA 120.25 -0.976 . . . . 0.0 110.988 -178.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 28.3 p30 -62.5 175.79 0.73 Allowed 'General case' 0 N--CA 1.491 1.603 0 CA-C-O 123.379 1.562 . . . . 0.0 114.85 -166.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.424 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 45.8 p90 -79.92 152.47 29.56 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-N 112.447 -2.16 . . . . 0.0 115.87 -174.093 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.448 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 11.2 tp -66.67 -26.44 37.31 Favored 'Isoleucine or valine' 0 CA--C 1.572 1.801 0 C-N-CA 126.79 2.036 . . . . 0.0 113.451 -175.312 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 38.7 t -60.34 -44.46 95.5 Favored 'General case' 0 C--N 1.309 -1.154 0 N-CA-C 117.241 2.312 . . . . 0.0 117.241 -162.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 1.8 p -154.45 26.23 0.46 Allowed 'General case' 0 C--N 1.298 -1.663 0 C-N-CA 118.031 -1.467 . . . . 0.0 114.26 -171.19 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . 0.454 ' O ' ' HB3' ' A' ' 141' ' ' ARG . 10.9 m120 58.7 35.45 24.42 Favored 'General case' 0 C--O 1.21 -1.016 0 C-N-CA 120.329 -0.548 . . . . 0.0 109.846 -175.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.498 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 46.6 ttt85 85.02 82.43 0.02 OUTLIER 'General case' 0 CA--C 1.556 1.188 0 N-CA-C 116.463 2.023 . . . . 0.0 116.463 175.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . . . . . . . . 0.313 11.8 pt-20 168.09 176.47 0.03 OUTLIER 'General case' 0 N--CA 1.504 2.252 0 C-N-CA 124.285 1.034 . . . . 0.0 113.677 166.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.643 HD21 ' HB2' ' A' ' 148' ' ' SER . 14.2 t-20 -134.16 138.41 45.16 Favored 'General case' 0 CA--C 1.511 -0.527 0 CA-C-N 116.119 -0.491 . . . . 0.0 111.942 -176.925 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.9 m-85 -81.38 -62.82 1.54 Allowed 'General case' 0 CA--C 1.549 0.935 0 C-N-CA 120.815 -0.354 . . . . 0.0 111.43 177.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . . . . . . . . . 70.1 m80 -164.46 -170.82 2.15 Favored 'General case' 0 N--CA 1.485 1.276 0 C-N-CA 123.825 0.85 . . . . 0.0 111.09 -178.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.497 ' HB2' ' HB ' ' A' ' 123' ' ' ILE . 80.9 t80 -63.27 140.07 58.84 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 123.806 0.842 . . . . 0.0 111.097 -179.176 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.37 -5.14 57.17 Favored Glycine 0 CA--C 1.493 -1.286 0 CA-C-N 114.741 -1.118 . . . . 0.0 111.395 -176.69 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.643 ' HB2' HD21 ' A' ' 143' ' ' ASN . 68.6 m -73.24 147.58 44.49 Favored 'General case' 0 N--CA 1.438 -1.036 0 N-CA-C 109.934 -0.395 . . . . 0.0 109.934 177.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.7 p -133.24 140.74 46.36 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.429 ' O ' ' HA ' ' A' ' 171' ' ' SER . 34.4 m -130.09 156.08 42.0 Favored 'Isoleucine or valine' 0 C--O 1.217 -0.621 0 N-CA-C 109.395 -0.595 . . . . 0.0 109.395 179.666 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.448 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 63.5 m -127.26 132.47 50.34 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.035 -176.146 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.424 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.6 m-85 -104.23 131.07 51.94 Favored 'General case' 0 CA--C 1.501 -0.918 0 C-N-CA 119.905 -0.718 . . . . 0.0 111.928 179.307 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 84.7 mtp180 -109.02 136.01 49.24 Favored 'General case' 0 C--N 1.302 -1.471 0 CA-C-N 114.9 -1.045 . . . . 0.0 109.57 176.457 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.569 ' HB3' ' HB2' ' A' ' 164' ' ' PHE . 86.4 m -75.91 -22.18 56.34 Favored 'General case' 0 C--N 1.297 -1.697 0 N-CA-C 113.948 1.092 . . . . 0.0 113.948 -179.481 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . 0.48 ' HB2' ' O ' ' A' ' 154' ' ' CYS . 86.0 m-20 78.62 159.57 0.14 Allowed Pre-proline 0 C--N 1.291 -1.971 0 O-C-N 124.758 1.286 . . . . 0.0 112.714 174.771 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . 0.5 ' HA ' ' HA ' ' A' ' 162' ' ' LYS . 92.4 Cg_endo -72.41 155.07 55.84 Favored 'Trans proline' 0 C--N 1.364 1.362 0 C-N-CA 123.899 3.066 . . . . 0.0 113.119 -178.995 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -104.85 -99.19 2.57 Favored Glycine 0 CA--C 1.536 1.395 0 C-N-CA 120.237 -0.982 . . . . 0.0 114.762 -176.731 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 84.4 p -82.93 -5.6 59.11 Favored 'General case' 0 C--N 1.316 -0.852 0 C-N-CA 123.754 0.822 . . . . 0.0 112.847 -175.093 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -178.26 -144.72 5.69 Favored Glycine 0 N--CA 1.439 -1.134 0 N-CA-C 111.486 -0.646 . . . . 0.0 111.486 -176.649 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -62.82 -33.55 87.27 Favored Glycine 0 C--O 1.218 -0.899 0 N-CA-C 109.918 -1.273 . . . . 0.0 109.918 177.385 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 56.5 ttm-85 -63.96 134.13 54.5 Favored 'General case' 0 C--O 1.25 1.112 0 CA-C-O 122.565 1.174 . . . . 0.0 111.899 179.175 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.5 ' HA ' ' HA ' ' A' ' 156' ' ' PRO . 88.6 tttt -82.83 129.86 35.05 Favored 'General case' 0 C--N 1.305 -1.364 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 173.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . . . . . . . . . 29.7 m -104.07 0.7 10.29 Favored 'Isoleucine or valine' 0 CA--C 1.483 -1.599 0 C-N-CA 120.564 -0.454 . . . . 0.0 111.105 -175.273 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.569 ' HB2' ' HB3' ' A' ' 154' ' ' CYS . 67.3 m-85 -118.2 132.73 56.3 Favored 'General case' 0 N--CA 1.416 -2.132 0 C-N-CA 119.685 -0.806 . . . . 0.0 110.238 -178.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.439 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 96.2 mt-10 -99.23 148.98 23.56 Favored 'General case' 0 C--N 1.317 -0.823 0 N-CA-C 107.368 -1.345 . . . . 0.0 107.368 176.391 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.51 HD23 ' N ' ' A' ' 167' ' ' VAL . 5.7 tt -109.62 163.98 12.96 Favored 'General case' 0 C--N 1.296 -1.727 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.51 ' N ' HD23 ' A' ' 166' ' ' LEU . 78.1 t -61.57 -44.32 98.43 Favored 'Isoleucine or valine' 0 CA--C 1.556 1.206 0 N-CA-C 112.195 0.443 . . . . 0.0 112.195 -171.435 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.4 ' H ' HD23 ' A' ' 166' ' ' LEU . . . 147.01 -10.42 1.37 Allowed Glycine 0 C--N 1.311 -0.806 0 C-N-CA 119.153 -1.499 . . . . 0.0 111.782 178.673 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 30.7 tt0 -136.18 78.7 45.53 Favored Pre-proline 0 N--CA 1.437 -1.087 0 CA-C-O 121.742 0.782 . . . . 0.0 109.303 175.051 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . . . . . . . . . 37.9 Cg_endo -66.52 -20.19 54.15 Favored 'Trans proline' 0 C--N 1.367 1.54 0 C-N-CA 122.816 2.344 . . . . 0.0 112.269 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . 0.429 ' HA ' ' O ' ' A' ' 150' ' ' VAL . 14.7 m -106.9 122.88 47.28 Favored 'General case' 0 N--CA 1.417 -2.122 0 CA-C-N 115.81 -0.632 . . . . 0.0 111.266 -174.874 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 47.5 pt -124.7 157.01 33.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.505 0 CA-C-N 114.892 -1.049 . . . . 0.0 108.89 179.634 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 47.8 p90 -142.57 159.19 42.72 Favored 'General case' 0 CA--C 1.496 -1.097 0 O-C-N 123.429 0.456 . . . . 0.0 110.47 -176.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 15.0 m -75.69 119.6 19.93 Favored 'General case' 0 N--CA 1.43 -1.463 0 C-N-CA 120.112 -0.635 . . . . 0.0 111.035 -179.565 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -121.1 -32.23 3.97 Favored 'General case' 0 C--O 1.221 -0.398 0 CA-C-N 115.564 -0.744 . . . . 0.0 111.737 179.675 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.807 ' OG ' ' HA2' ' A' ' 182' ' ' GLY . 7.8 t 39.18 20.94 0.0 OUTLIER 'General case' 0 CA--C 1.566 1.579 0 N-CA-C 115.915 1.82 . . . . 0.0 115.915 -179.335 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 90.4 m-20 -63.44 -42.06 98.67 Favored 'General case' 0 C--O 1.245 0.867 0 N-CA-C 114.468 1.284 . . . . 0.0 114.468 -176.671 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.5 p-10 -120.18 4.89 10.8 Favored 'General case' 0 N--CA 1.49 1.569 0 N-CA-C 116.861 2.171 . . . . 0.0 116.861 -175.202 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . 0.411 ' OD2' HG23 ' A' ' 183' ' ' ILE . 1.9 p-10 -91.47 172.92 8.19 Favored 'General case' 0 C--N 1.307 -1.259 0 CA-C-N 119.727 1.149 . . . . 0.0 111.852 -177.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 91.3 mm-40 -63.71 -46.57 84.82 Favored 'General case' 0 CA--C 1.564 1.483 0 N-CA-C 114.275 1.213 . . . . 0.0 114.275 -179.985 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 65.2 t -117.17 -50.92 4.39 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 N-CA-C 114.29 1.218 . . . . 0.0 114.29 -171.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.807 ' HA2' ' OG ' ' A' ' 176' ' ' SER . . . 160.14 108.0 0.23 Allowed Glycine 0 N--CA 1.44 -1.052 0 N-CA-C 110.379 -1.088 . . . . 0.0 110.379 -175.937 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.411 HG23 ' OD2' ' A' ' 179' ' ' ASP . 23.7 pt -129.39 165.93 28.17 Favored 'Isoleucine or valine' 0 C--O 1.252 1.194 0 CA-C-O 122.133 0.968 . . . . 0.0 112.394 -174.801 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 80.8 m95 -74.38 178.57 5.13 Favored 'General case' 0 N--CA 1.436 -1.134 0 CA-C-N 113.14 -1.845 . . . . 0.0 110.083 173.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 37.8 m -59.85 -41.27 91.08 Favored 'General case' 0 C--N 1.318 -0.762 0 N-CA-C 110.129 -0.323 . . . . 0.0 110.129 -179.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -160.76 170.97 36.78 Favored Glycine 0 N--CA 1.439 -1.118 0 N-CA-C 110.402 -1.079 . . . . 0.0 110.402 175.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -62.69 146.25 95.2 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 122.031 1.821 . . . . 0.0 109.345 174.73 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.504 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -38.25 121.17 1.07 Allowed Pre-proline 0 CA--C 1.548 0.898 0 O-C-N 124.158 0.911 . . . . 0.0 110.972 -178.968 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.413 ' HD2' ' CD2' ' A' ' 152' ' ' TYR . 34.4 Cg_endo -61.99 147.58 94.86 Favored 'Trans proline' 0 CA--C 1.488 -1.783 0 C-N-CA 122.482 2.121 . . . . 0.0 111.997 179.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.445 ' HG3' HG12 ' A' ' 192' ' ' ILE . 13.3 pt20 -110.76 147.8 33.69 Favored 'General case' 0 C--N 1.298 -1.636 0 CA-C-N 114.656 -1.156 . . . . 0.0 111.843 -171.656 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 82.5 m -78.35 73.63 4.9 Favored 'General case' 0 C--N 1.284 -2.242 0 CA-C-N 114.457 -1.247 . . . . 0.0 109.495 -176.213 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.445 HG12 ' HG3' ' A' ' 190' ' ' GLN . 47.5 mm . . . . . 0 C--O 1.252 1.19 0 CA-C-N 113.674 -1.603 . . . . 0.0 111.089 -179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.591 ' HD3' HG23 ' A' ' 111' ' ' VAL . 10.1 tttt . . . . . 0 CA--C 1.539 0.538 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.599 ' HB2' ' CD ' ' A' ' 81' ' ' GLN . 26.5 t -138.53 167.13 22.59 Favored 'General case' 0 C--N 1.309 -1.178 0 C-N-CA 122.292 0.237 . . . . 0.0 110.778 -175.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.446 ' HB2' ' O ' ' A' ' 80' ' ' ILE . 3.5 m -74.99 170.49 15.88 Favored 'General case' 0 CA--C 1.495 -1.151 0 CA-C-N 116.244 -0.435 . . . . 0.0 109.894 -179.074 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.431 ' O ' ' HB2' ' A' ' 65' ' ' ASN . 72.5 mtm-85 -64.19 -39.01 93.09 Favored 'General case' 0 N--CA 1.422 -1.848 0 C-N-CA 119.547 -0.861 . . . . 0.0 110.691 -176.483 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.431 ' HB2' ' O ' ' A' ' 64' ' ' ARG . 0.2 OUTLIER 138.0 151.47 0.0 OUTLIER Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 126.26 2.225 . . . . 0.0 107.686 -172.096 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.584 ' HB3' HD13 ' A' ' 86' ' ' ILE . 40.0 Cg_endo -74.11 131.71 15.75 Favored 'Trans proline' 0 N--CA 1.454 -0.848 0 C-N-CA 122.415 2.076 . . . . 0.0 111.96 174.046 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -55.29 -37.33 94.57 Favored 'Trans proline' 0 C--O 1.242 0.688 0 C-N-CA 122.128 1.885 . . . . 0.0 111.293 175.091 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . . . . . . . . . 38.8 t70 57.27 87.28 0.14 Allowed Pre-proline 0 C--O 1.243 0.727 0 CA-C-N 114.154 -1.384 . . . . 0.0 111.907 -177.425 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.454 ' HB2' ' OH ' ' A' ' 88' ' ' TYR . 11.9 Cg_exo -68.06 152.77 76.26 Favored 'Trans proline' 0 N--CA 1.442 -1.546 0 C-N-CA 122.641 2.227 . . . . 0.0 110.901 176.227 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . . . . . . . . . 98.0 t -57.28 142.71 12.64 Favored 'Isoleucine or valine' 0 C--O 1.214 -0.793 0 C-N-CA 123.967 0.907 . . . . 0.0 111.354 -174.544 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . . . . . . . . . 98.5 m-20 61.57 35.01 17.53 Favored 'General case' 0 N--CA 1.48 1.059 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.932 -176.551 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -97.47 -178.76 33.98 Favored Glycine 0 N--CA 1.451 -0.323 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 173.31 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 98.9 mtp -102.11 127.76 48.87 Favored 'General case' 0 N--CA 1.426 -1.636 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 2.6 t -108.81 117.62 54.62 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 C-N-CA 119.135 -1.026 . . . . 0.0 112.103 -175.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . . . . . . . . . 79.1 t60 -167.09 105.16 0.56 Allowed 'General case' 0 CA--C 1.485 -1.519 0 N-CA-C 105.983 -1.858 . . . . 0.0 105.983 170.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.532 HG22 HG23 ' A' ' 80' ' ' ILE . 10.0 p -155.92 58.31 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.297 -1.68 0 CA-C-O 122.232 1.015 . . . . 0.0 110.082 -177.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.8 tt -67.73 -42.38 86.21 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.871 0 CA-C-N 115.688 -0.687 . . . . 0.0 111.395 178.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -125.95 9.33 7.5 Favored 'General case' 0 CA--C 1.533 0.306 0 C-N-CA 122.833 0.453 . . . . 0.0 110.939 176.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.502 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -77.34 1.99 63.47 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 115.416 -0.811 . . . . 0.0 114.569 -172.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.568 HG22 ' HD3' ' A' ' 66' ' ' PRO . 24.5 pt -101.64 -3.78 9.38 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.108 0 CA-C-O 121.881 0.848 . . . . 0.0 110.195 -175.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.599 ' CD ' ' HB2' ' A' ' 62' ' ' SER . 41.4 tp60 -81.05 169.68 17.17 Favored 'General case' 0 C--N 1.297 -1.704 0 N-CA-C 108.515 -0.921 . . . . 0.0 108.515 -167.63 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . . . . . . . . . 82.3 t80 -64.88 129.7 40.71 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 175.833 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.22 20.84 61.8 Favored Glycine 0 C--O 1.214 -1.12 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.13 -175.214 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.502 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 68.1 m -126.09 153.85 43.92 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-O 120.957 0.408 . . . . 0.0 110.031 179.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.406 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 99.4 mt-30 -131.85 150.02 52.28 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-O 122.22 1.01 . . . . 0.0 111.74 -174.777 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.605 ' O ' ' HA ' ' A' ' 101' ' ' SER . 45.2 pt -118.53 129.18 75.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-N 113.682 -1.599 . . . . 0.0 107.996 174.778 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.605 ' HG2' ' OG ' ' A' ' 101' ' ' SER . 56.0 mtmt -112.51 115.55 28.84 Favored 'General case' 0 N--CA 1.425 -1.701 0 C-N-CA 118.857 -1.137 . . . . 0.0 110.592 -174.741 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.454 ' OH ' ' HB2' ' A' ' 69' ' ' PRO . 50.0 t80 -100.46 134.52 43.29 Favored 'General case' 0 CA--C 1.561 1.372 0 CA-C-N 115.168 -0.924 . . . . 0.0 112.616 -177.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 32.9 t -133.5 148.14 51.67 Favored 'General case' 0 CA--C 1.545 0.78 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 -179.372 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 67.0 m -123.69 -173.71 2.81 Favored 'General case' 0 C--O 1.219 -0.515 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -175.529 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . . . . . . . . . 17.8 p -75.77 166.63 23.24 Favored 'General case' 0 N--CA 1.427 -1.591 0 CA-C-N 114.965 -1.016 . . . . 0.0 111.751 -179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . 0.691 ' HG3' HD21 ' A' ' 177' ' ' ASN . 88.0 tttt -64.19 133.11 52.24 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 114.947 -1.024 . . . . 0.0 111.675 -173.21 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 95.3 -3.45 66.35 Favored Glycine 0 N--CA 1.444 -0.802 0 CA-C-N 115.211 -0.904 . . . . 0.0 113.157 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . . . . . . . . . 92.3 m-85 -116.38 142.95 46.18 Favored 'General case' 0 C--N 1.322 -0.606 0 O-C-N 122.268 -0.548 . . . . 0.0 110.442 -179.973 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.469 ' O ' ' HA ' ' A' ' 120' ' ' CYS . 7.1 ptp180 -128.04 172.99 10.44 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.421 -0.354 . . . . 0.0 110.2 173.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . 0.613 HD13 ' SG ' ' A' ' 120' ' ' CYS . 2.1 mm? -91.03 129.44 37.03 Favored 'General case' 0 CA--C 1.502 -0.871 0 CA-C-N 114.924 -1.035 . . . . 0.0 109.74 179.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . . . . . . . . . 45.7 mm -68.94 -26.38 32.37 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 114.954 -1.021 . . . . 0.0 111.878 177.617 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . . . . . . . . . . . -116.2 -126.37 3.93 Favored Glycine 0 C--N 1.302 -1.333 0 CA-C-N 115.269 -0.878 . . . . 0.0 111.238 -176.13 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.562 ' HB2' HG21 ' A' ' 115' ' ' THR . 47.3 m -113.19 120.72 42.22 Favored 'General case' 0 C--N 1.306 -1.31 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.026 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . . . . . . . . . 77.4 p -61.16 -33.74 73.91 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-O 121.769 0.795 . . . . 0.0 109.89 -177.055 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.605 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 19.7 m -106.63 120.59 42.37 Favored 'General case' 0 N--CA 1.409 -2.488 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 176.767 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.406 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -95.61 147.79 23.21 Favored 'General case' 0 CA--C 1.487 -1.479 0 C-N-CA 120.04 -0.664 . . . . 0.0 110.962 -179.925 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 85.6 m -120.28 128.3 53.18 Favored 'General case' 0 N--CA 1.415 -2.205 0 N-CA-C 107.918 -1.141 . . . . 0.0 107.918 179.126 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . 0.461 ' HB3' ' CG1' ' A' ' 111' ' ' VAL . 72.9 m -71.42 131.2 43.02 Favored 'General case' 0 C--N 1.292 -1.915 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.903 178.184 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.424 HG12 ' HB2' ' A' ' 114' ' ' ASP . 2.2 pp -130.45 164.05 34.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.447 0 CA-C-N 114.951 -1.022 . . . . 0.0 108.26 179.374 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.729 HG12 HG22 ' A' ' 111' ' ' VAL . 85.0 mt -105.1 120.28 55.45 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 C-N-CA 119.563 -0.855 . . . . 0.0 112.52 -176.894 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.492 ' HB3' ' CD1' ' A' ' 112' ' ' ILE . 78.4 p -66.27 -34.47 78.07 Favored 'General case' 0 C--O 1.235 0.309 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.878 175.731 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 161.75 -77.4 0.17 Allowed Glycine 0 N--CA 1.435 -1.398 0 CA-C-N 114.001 -1.454 . . . . 0.0 110.071 -177.703 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 15.0 p-10 -91.46 -1.0 57.7 Favored 'General case' 0 C--N 1.319 -0.743 0 N-CA-C 112.39 0.515 . . . . 0.0 112.39 -179.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.493 HG23 HG23 ' A' ' 112' ' ' ILE . 14.6 t -148.12 171.45 15.86 Favored 'General case' 0 C--O 1.249 1.054 0 O-C-N 121.438 -0.788 . . . . 0.0 111.105 179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 HG12 ' A' ' 106' ' ' ILE . 31.8 t -110.98 127.84 67.82 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.31 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 174.334 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.493 HG23 HG23 ' A' ' 110' ' ' THR . 45.5 pt -129.98 163.61 34.99 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.364 0 CA-C-N 112.678 -2.056 . . . . 0.0 112.909 -176.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 96.0 m95 -80.46 125.12 29.55 Favored 'General case' 0 C--N 1.308 -1.216 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 -177.53 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.424 ' HB2' HG12 ' A' ' 105' ' ' ILE . 34.8 t70 -63.8 -42.0 97.8 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 121.817 0.818 . . . . 0.0 112.025 -179.077 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.562 HG21 ' HB2' ' A' ' 99' ' ' SER . 43.7 p -89.06 -16.97 30.28 Favored 'General case' 0 N--CA 1.435 -1.222 0 CA-C-N 114.222 -1.353 . . . . 0.0 112.47 -174.774 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.443 ' HG2' ' O ' ' A' ' 116' ' ' GLU . 81.9 tt0 61.93 16.48 8.1 Favored 'General case' 0 CA--C 1.562 1.42 0 C-N-CA 124.715 1.206 . . . . 0.0 109.243 -177.523 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 8.9 m 62.33 117.56 0.02 OUTLIER Pre-proline 0 CA--C 1.551 1.013 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.996 -178.573 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.465 ' HG2' HD12 ' A' ' 96' ' ' LEU . 90.7 Cg_endo -70.41 157.23 59.74 Favored 'Trans proline' 0 C--O 1.244 0.782 0 C-N-CA 124.553 3.502 . . . . 0.0 113.785 -176.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 95.3 mt -108.75 131.0 60.58 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 CA-C-N 114.406 -1.27 . . . . 0.0 108.207 178.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . 0.613 ' SG ' HD13 ' A' ' 96' ' ' LEU . 99.3 m -78.5 132.57 37.28 Favored 'General case' 0 N--CA 1.438 -1.065 0 C-N-CA 119.729 -0.788 . . . . 0.0 110.621 -179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -130.42 170.18 14.52 Favored 'General case' 0 C--N 1.282 -2.335 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.083 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.654 ' HB3' ' NE2' ' A' ' 145' ' ' HIS . 90.0 mtm180 -66.29 135.7 54.78 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 109.133 -0.691 . . . . 0.0 109.133 -176.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.432 ' HB ' ' HB2' ' A' ' 146' ' ' TYR . 50.8 mt -67.67 104.97 0.75 Allowed Pre-proline 0 C--O 1.212 -0.899 0 C-N-CA 122.935 0.494 . . . . 0.0 110.736 -174.446 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.484 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 51.1 Cg_exo -56.95 -34.05 96.6 Favored 'Trans proline' 0 CA--C 1.503 -1.031 0 C-N-CA 123.087 2.525 . . . . 0.0 111.766 179.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . 0.524 ' O ' ' HB2' ' A' ' 143' ' ' ASN . 84.6 m 64.9 91.6 0.08 Allowed 'General case' 0 N--CA 1.443 -0.781 0 N-CA-C 108.339 -0.986 . . . . 0.0 108.339 -174.601 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -62.79 161.56 32.0 Favored Glycine 0 CA--C 1.496 -1.121 0 CA-C-O 119.061 -0.855 . . . . 0.0 111.031 -175.789 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . 0.501 HD21 ' HG2' ' A' ' 142' ' ' GLU . 4.3 mp -38.85 135.07 1.0 Allowed Pre-proline 0 C--O 1.252 1.235 0 O-C-N 124.376 0.692 . . . . 0.0 112.044 -176.322 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 127' ' ' LEU . 4.5 Cg_exo -62.99 169.5 8.91 Favored 'Trans proline' 0 CA--C 1.5 -1.198 0 C-N-CA 122.271 1.981 . . . . 0.0 111.206 -175.528 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . 0.652 ' HB2' ' HB2' ' A' ' 188' ' ' ALA . 25.1 Cg_exo -61.36 145.56 98.13 Favored 'Trans proline' 0 N--CA 1.442 -1.542 0 N-CA-C 108.692 -1.311 . . . . 0.0 108.692 173.996 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 16.7 p -76.71 167.58 21.58 Favored 'General case' 0 C--N 1.3 -1.576 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 -178.711 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.772 HG23 ' H ' ' A' ' 134' ' ' GLY . 10.7 tp -119.22 160.73 18.97 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.589 0 CA-C-O 121.968 0.889 . . . . 0.0 110.042 -172.575 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . 0.613 HG21 ' HB2' ' A' ' 191' ' ' CYS . 73.1 m -61.39 -44.96 96.26 Favored 'General case' 0 C--N 1.286 -2.188 0 CA-C-N 114.104 -1.407 . . . . 0.0 112.132 -178.623 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . 0.565 ' OD1' ' HA ' ' A' ' 154' ' ' CYS . 57.2 m-80 -63.61 -40.42 96.86 Favored 'General case' 0 N--CA 1.478 0.942 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.749 179.113 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.772 ' H ' HG23 ' A' ' 131' ' ' ILE . . . 135.11 -25.7 3.31 Favored Glycine 0 N--CA 1.423 -2.192 0 CA-C-N 115.339 -0.846 . . . . 0.0 112.49 -178.892 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . 0.7 ' O ' HG21 ' A' ' 131' ' ' ILE . 16.9 p-10 -151.96 176.92 10.99 Favored 'General case' 0 N--CA 1.489 1.482 0 N-CA-C 113.424 0.898 . . . . 0.0 113.424 178.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.555 ' HB3' ' CE1' ' A' ' 152' ' ' TYR . 49.3 p90 -132.47 155.7 48.08 Favored 'General case' 0 CA--C 1.499 -0.994 0 C-N-CA 124.375 1.07 . . . . 0.0 110.954 -174.592 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.651 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 15.8 tt -100.59 119.29 48.5 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.196 0 CA-C-O 122.69 1.233 . . . . 0.0 108.052 -175.815 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 10.5 p -157.48 166.66 32.39 Favored 'General case' 0 C--N 1.279 -2.466 0 CA-C-N 113.835 -1.53 . . . . 0.0 108.207 -176.315 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 20.8 p -61.58 -44.13 97.59 Favored 'General case' 0 C--N 1.305 -1.365 0 CA-C-N 118.432 0.56 . . . . 0.0 112.27 -175.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . . . . . . . . . 10.7 m120 -140.71 150.0 42.9 Favored 'General case' 0 N--CA 1.479 1.002 0 C-N-CA 123.209 0.604 . . . . 0.0 110.675 178.241 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.495 ' O ' ' HB2' ' A' ' 142' ' ' GLU . 61.2 ttp180 -69.08 134.98 50.1 Favored 'General case' 0 C--N 1.317 -0.826 0 C-N-CA 120.603 -0.439 . . . . 0.0 111.034 178.233 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.501 ' HG2' HD21 ' A' ' 127' ' ' LEU . 49.9 mt-10 90.6 170.04 0.03 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 O-C-N 124.973 1.42 . . . . 0.0 108.707 -178.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.524 ' HB2' ' O ' ' A' ' 125' ' ' CYS . 89.8 m-20 -103.83 130.45 51.38 Favored 'General case' 0 CA--C 1.502 -0.895 0 C-N-CA 119.21 -0.996 . . . . 0.0 113.223 -175.159 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 94.3 m-85 -63.22 -45.01 93.67 Favored 'General case' 0 CA--C 1.542 0.637 0 O-C-N 124.054 0.846 . . . . 0.0 112.62 177.132 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.654 ' NE2' ' HB3' ' A' ' 122' ' ' ARG . 22.9 t-80 170.74 -176.62 0.04 OUTLIER 'General case' 0 CA--C 1.568 1.636 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.943 -169.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.481 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 83.8 t80 -60.89 136.42 58.07 Favored 'General case' 0 CA--C 1.515 -0.378 0 CA-C-O 121.511 0.672 . . . . 0.0 110.282 177.186 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 99.51 -2.35 57.41 Favored Glycine 0 N--CA 1.43 -1.757 0 CA-C-N 115.373 -0.83 . . . . 0.0 112.502 -175.522 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . . . . . . . . . 21.6 m -71.72 143.73 49.54 Favored 'General case' 0 N--CA 1.439 -1.001 0 CA-C-N 116.661 0.23 . . . . 0.0 110.435 177.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.414 ' HB ' ' HB3' ' A' ' 173' ' ' TYR . 2.6 p -134.65 139.22 48.11 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.907 0 N-CA-C 109.443 -0.577 . . . . 0.0 109.443 -178.766 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 32.8 m -131.15 158.27 43.3 Favored 'Isoleucine or valine' 0 CA--C 1.496 -1.132 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 -178.952 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.651 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 87.4 m -125.66 131.81 52.56 Favored 'General case' 0 C--N 1.31 -1.121 0 C-N-CA 119.85 -0.74 . . . . 0.0 111.433 -179.563 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.555 ' CE1' ' HB3' ' A' ' 136' ' ' PHE . 94.9 m-85 -104.92 135.94 45.33 Favored 'General case' 0 C--N 1.297 -1.683 0 C-N-CA 120.016 -0.674 . . . . 0.0 109.847 -176.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . . . . . . . . . 5.2 ptp180 -136.91 145.51 44.39 Favored 'General case' 0 CA--C 1.497 -1.081 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.353 179.253 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.8 ' SG ' ' HB2' ' A' ' 166' ' ' LEU . 82.8 m -104.28 151.0 23.94 Favored 'General case' 0 N--CA 1.491 1.606 0 CA-C-N 115.407 -0.815 . . . . 0.0 109.499 -171.198 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 32.0 p30 -63.94 140.69 97.91 Favored Pre-proline 0 CA--C 1.564 1.5 0 CA-C-O 121.453 0.644 . . . . 0.0 111.239 177.063 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.4 Cg_endo -72.5 156.32 54.21 Favored 'Trans proline' 0 C--O 1.243 0.764 0 C-N-CA 122.89 2.393 . . . . 0.0 112.468 -178.021 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.697 ' CA ' HG13 ' A' ' 163' ' ' VAL . . . -71.65 -133.7 0.13 Allowed Glycine 0 N--CA 1.432 -1.582 0 N-CA-C 116.519 1.368 . . . . 0.0 116.519 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 39.7 t -60.89 -43.27 98.7 Favored 'General case' 0 C--O 1.232 0.167 0 N-CA-C 109.927 -0.397 . . . . 0.0 109.927 -175.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -121.1 -87.59 0.96 Allowed Glycine 0 N--CA 1.43 -1.731 0 C-N-CA 120.034 -1.079 . . . . 0.0 110.761 176.127 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . -124.95 29.74 4.8 Favored Glycine 0 C--N 1.3 -1.431 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 178.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . 0.897 ' HG2' ' H ' ' A' ' 162' ' ' LYS . 58.5 ttm-85 -90.91 -128.95 0.09 Allowed 'General case' 0 C--O 1.242 0.69 0 C-N-CA 120.537 -0.465 . . . . 0.0 111.054 -175.645 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.897 ' H ' ' HG2' ' A' ' 161' ' ' ARG . 53.6 tptt -159.15 112.5 2.29 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.354 -2.462 . . . . 0.0 104.354 -171.332 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.697 HG13 ' CA ' ' A' ' 157' ' ' GLY . 2.9 m -104.31 -6.93 9.6 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.791 0 CA-C-O 122.11 0.957 . . . . 0.0 112.073 179.603 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.619 ' HB3' ' HB3' ' A' ' 191' ' ' CYS . 64.2 m-85 -129.93 147.02 51.65 Favored 'General case' 0 C--N 1.276 -2.627 0 N-CA-C 105.566 -2.013 . . . . 0.0 105.566 171.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . . . . . . . . . 83.0 tt0 -111.06 128.98 56.04 Favored 'General case' 0 C--N 1.27 -2.867 0 C-N-CA 119.24 -0.984 . . . . 0.0 109.671 -174.475 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.8 ' HB2' ' SG ' ' A' ' 154' ' ' CYS . 9.8 tt -106.86 140.82 39.08 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 -170.511 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.599 ' O ' HD23 ' A' ' 166' ' ' LEU . 98.5 t -64.53 131.29 30.25 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.232 0 N-CA-C 106.613 -1.625 . . . . 0.0 106.613 -172.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . 0.41 ' O ' ' HD3' ' A' ' 170' ' ' PRO . . . -28.23 -41.91 0.02 OUTLIER Glycine 0 N--CA 1.503 3.128 0 N-CA-C 118.63 2.212 . . . . 0.0 118.63 -170.056 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . 0.467 ' HG2' ' O ' ' A' ' 169' ' ' GLU . 0.9 OUTLIER -107.06 88.44 3.74 Favored Pre-proline 0 N--CA 1.424 -1.743 0 CA-C-N 119.407 1.603 . . . . 0.0 111.564 -177.604 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.41 ' HD3' ' O ' ' A' ' 168' ' ' GLY . 43.2 Cg_endo -67.64 -18.1 48.17 Favored 'Trans proline' 0 C--N 1.351 0.671 0 C-N-CA 123.238 2.625 . . . . 0.0 113.274 -176.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 30.5 m -103.7 121.24 42.57 Favored 'General case' 0 N--CA 1.432 -1.371 0 C-N-CA 119.976 -0.689 . . . . 0.0 111.167 -171.877 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.2 pt -128.45 160.03 39.21 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.033 0 CA-C-N 115.497 -0.774 . . . . 0.0 110.666 -178.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . 0.691 ' CE2' HG22 ' A' ' 175' ' ' THR . 30.4 p90 -142.42 157.96 44.21 Favored 'General case' 0 C--N 1.305 -1.339 0 C-N-CA 122.603 0.361 . . . . 0.0 111.016 179.313 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . 0.499 ' HA ' ' HA ' ' A' ' 184' ' ' TRP . 3.9 t -76.07 86.52 2.96 Favored 'General case' 0 C--N 1.285 -2.239 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.412 179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.691 HG22 ' CE2' ' A' ' 173' ' ' TYR . 2.6 p -86.81 -20.97 26.77 Favored 'General case' 0 CA--C 1.503 -0.847 0 N-CA-C 107.29 -1.374 . . . . 0.0 107.29 -175.788 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.788 ' HB3' ' H ' ' A' ' 182' ' ' GLY . 66.1 m 50.48 -14.47 0.0 OUTLIER 'General case' 0 N--CA 1.44 -0.961 0 N-CA-C 117.355 2.354 . . . . 0.0 117.355 -178.141 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . 0.691 HD21 ' HG3' ' A' ' 92' ' ' LYS . 89.6 m-20 -103.16 4.89 37.42 Favored 'General case' 0 C--N 1.323 -0.584 0 N-CA-C 115.753 1.76 . . . . 0.0 115.753 -172.884 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -73.47 -69.26 0.44 Allowed 'General case' 0 N--CA 1.482 1.155 0 C-N-CA 117.297 -1.761 . . . . 0.0 112.187 -177.102 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -66.91 -41.85 86.39 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.38 0.61 . . . . 0.0 111.55 176.933 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 65.3 tp60 -177.32 -101.56 0.0 OUTLIER 'General case' 0 C--N 1.354 0.796 0 CA-C-N 114.971 -1.013 . . . . 0.0 111.722 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 53.3 t -127.58 134.66 65.11 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.037 0 N-CA-C 114.755 1.391 . . . . 0.0 114.755 -177.096 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.788 ' H ' ' HB3' ' A' ' 176' ' ' SER . . . 75.75 26.98 63.75 Favored Glycine 0 N--CA 1.472 1.055 0 N-CA-C 118.232 2.053 . . . . 0.0 118.232 170.379 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . 0.555 ' O ' ' HA ' ' A' ' 176' ' ' SER . 2.5 pp -125.73 161.34 30.88 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.147 0 N-CA-C 114.064 1.135 . . . . 0.0 114.064 -177.792 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . 0.499 ' HA ' ' HA ' ' A' ' 174' ' ' CYS . 69.2 m95 -73.64 -178.87 3.29 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-N 116.327 -0.397 . . . . 0.0 111.773 -177.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 19.5 m -59.06 -41.4 87.82 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.95 -1.13 . . . . 0.0 107.95 177.59 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -172.61 -179.4 43.37 Favored Glycine 0 N--CA 1.423 -2.208 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 177.24 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 21.1 Cg_exo -62.73 146.76 95.23 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 122.136 1.89 . . . . 0.0 109.596 176.524 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . 0.652 ' HB2' ' HB2' ' A' ' 129' ' ' PRO . . . -46.21 116.85 3.76 Favored Pre-proline 0 CA--C 1.502 -0.881 0 O-C-N 123.518 0.511 . . . . 0.0 110.138 -177.134 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.525 ' HB3' ' HB ' ' A' ' 167' ' ' VAL . 22.8 Cg_exo -61.61 143.48 96.83 Favored 'Trans proline' 0 N--CA 1.411 -3.371 0 N-CA-C 105.141 -2.677 . . . . 0.0 105.141 173.571 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.558 ' O ' ' HA ' ' A' ' 166' ' ' LEU . 19.8 pt20 -145.19 163.35 34.65 Favored 'General case' 1 C--N 1.236 -4.347 0 N-CA-C 113.755 1.02 . . . . 0.0 113.755 -165.767 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.619 ' HB3' ' HB3' ' A' ' 164' ' ' PHE . 32.3 m -74.87 65.64 1.42 Allowed 'General case' 0 N--CA 1.426 -1.651 0 CA-C-N 114.374 -1.284 . . . . 0.0 107.907 -173.062 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.436 ' CD1' ' HG3' ' A' ' 190' ' ' GLN . 46.5 mm . . . . . 0 C--O 1.252 1.189 0 CA-C-N 113.545 -1.661 . . . . 0.0 110.949 177.837 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LYS . . . . . 0.599 ' O ' HG21 ' A' ' 111' ' ' VAL . 73.2 tttt . . . . . 0 CA--C 1.499 -0.99 0 N-CA-C 116.297 1.962 . . . . 0.0 116.297 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . 0.557 ' HB2' HG13 ' A' ' 80' ' ' ILE . 93.6 p -85.08 168.82 14.52 Favored 'General case' 0 N--CA 1.429 -1.506 0 CA-C-N 113.745 -1.57 . . . . 0.0 108.518 167.314 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' CYS . . . . . 0.429 ' SG ' HG12 ' A' ' 111' ' ' VAL . 1.9 m -70.18 175.7 4.38 Favored 'General case' 0 C--N 1.308 -1.204 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 173.838 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ARG . . . . . 0.688 ' O ' ' HB3' ' A' ' 65' ' ' ASN . 28.7 mmt85 -63.84 -38.54 91.47 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.998 -1.001 . . . . 0.0 110.554 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.688 ' HB3' ' O ' ' A' ' 64' ' ' ARG . 0.4 OUTLIER 126.99 152.56 0.0 OUTLIER Pre-proline 0 CA--C 1.491 -1.314 0 C-N-CA 127.3 2.24 . . . . 0.0 105.299 -175.058 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -44.39 160.04 0.1 Allowed 'Trans proline' 0 CA--C 1.554 1.513 0 C-N-CA 122.7 2.267 . . . . 0.0 113.514 177.677 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -63.76 -21.68 69.54 Favored 'Trans proline' 0 CA--C 1.533 0.463 0 C-N-CA 121.846 1.698 . . . . 0.0 109.134 175.125 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ASP . . . . . 0.431 ' N ' ' HD3' ' A' ' 69' ' ' PRO . 0.7 OUTLIER 60.4 63.43 2.9 Favored Pre-proline 0 N--CA 1.467 0.404 0 CA-C-N 113.786 -1.552 . . . . 0.0 112.687 -179.924 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . 0.72 ' HD2' ' OH ' ' A' ' 88' ' ' TYR . 15.5 Cg_exo -63.07 151.01 86.93 Favored 'Trans proline' 0 N--CA 1.444 -1.406 0 C-N-CA 123.906 3.071 . . . . 0.0 111.009 170.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' VAL . . . . . 0.469 ' O ' ' HB2' ' A' ' 71' ' ' ASN . 43.7 t -111.73 134.64 53.51 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.276 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -178.299 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' ASN . . . . . 0.469 ' HB2' ' O ' ' A' ' 70' ' ' VAL . 98.2 m-20 96.33 33.11 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.213 0 C-N-CA 126.39 1.876 . . . . 0.0 109.629 -165.524 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -162.27 163.36 34.93 Favored Glycine 0 C--O 1.248 0.986 0 CA-C-N 114.546 -1.206 . . . . 0.0 111.439 175.588 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' MET . . . . . . . . . . . . . 64.5 ttp -132.66 131.51 41.41 Favored 'General case' 0 N--CA 1.475 0.814 0 CA-C-N 116.653 0.227 . . . . 0.0 111.186 -178.202 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.0 t -123.18 131.94 72.3 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.604 0 CA-C-O 120.882 0.372 . . . . 0.0 110.563 179.456 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' HIS . . . . . 0.41 ' O ' ' CG ' ' A' ' 75' ' ' HIS . 31.6 p-80 -99.68 74.32 1.86 Allowed 'General case' 0 C--O 1.215 -0.713 0 CA-C-O 121.902 0.858 . . . . 0.0 109.901 179.4 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.718 HG21 HG22 ' A' ' 86' ' ' ILE . 38.1 t -124.04 129.34 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.428 0 N-CA-C 113.88 1.067 . . . . 0.0 113.88 179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.439 HG22 ' HG2' ' A' ' 78' ' ' LYS . 46.8 mm -106.13 -65.89 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.381 0 CA-C-N 115.19 -0.914 . . . . 0.0 110.163 172.274 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' LYS . . . . . 0.439 ' HG2' HG22 ' A' ' 77' ' ' ILE . 75.6 mmtt -111.45 8.55 21.2 Favored 'General case' 0 CA--C 1.515 -0.38 0 CA-C-N 114.271 -1.331 . . . . 0.0 108.268 -177.628 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.46 ' HA2' ' HB3' ' A' ' 84' ' ' SER . . . -69.33 4.49 6.39 Favored Glycine 0 C--O 1.216 -0.975 0 CA-C-N 114.565 -1.198 . . . . 0.0 113.074 -174.976 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.557 HG13 ' HB2' ' A' ' 62' ' ' SER . 47.6 pt -101.59 -2.68 9.56 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.96 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 -179.823 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.548 ' HA ' ' HA ' ' A' ' 62' ' ' SER . 65.1 tp60 -76.47 171.76 14.07 Favored 'General case' 0 C--N 1.299 -1.617 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 -176.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PHE . . . . . 0.521 ' CD1' HG12 ' A' ' 106' ' ' ILE . 65.2 t80 -59.41 131.88 52.3 Favored 'General case' 0 C--N 1.316 -0.884 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.839 178.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . 82.91 19.06 63.96 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.039 -1.076 . . . . 0.0 113.771 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' SER . . . . . 0.46 ' HB3' ' HA2' ' A' ' 79' ' ' GLY . 67.0 m -128.47 154.55 45.97 Favored 'General case' 0 CA--C 1.548 0.872 0 CA-C-N 117.103 0.452 . . . . 0.0 110.945 178.671 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLN . . . . . 0.45 ' HA ' ' O ' ' A' ' 102' ' ' ALA . 4.1 mt-30 -132.79 163.47 28.99 Favored 'General case' 0 C--N 1.349 0.547 0 CA-C-O 121.937 0.875 . . . . 0.0 109.709 -173.177 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . 0.718 HG22 HG21 ' A' ' 76' ' ' VAL . 43.8 pt -117.68 129.25 74.4 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.025 0 CA-C-N 114.758 -1.11 . . . . 0.0 108.133 175.789 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 5.9 mptp? -101.38 138.37 38.48 Favored 'General case' 0 C--N 1.313 -0.983 0 C-N-CA 120.096 -0.641 . . . . 0.0 111.659 -177.086 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' TYR . . . . . 0.72 ' OH ' ' HD2' ' A' ' 69' ' ' PRO 0.306 37.6 m-85 -120.81 144.53 48.28 Favored 'General case' 0 CA--C 1.496 -1.104 0 N-CA-C 115.93 1.826 . . . . 0.0 115.93 174.201 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' SER . . . . . . . . . . . . . 70.3 m -129.61 151.16 50.52 Favored 'General case' 0 C--N 1.315 -0.897 0 CA-C-N 114.488 -1.233 . . . . 0.0 108.493 176.598 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' CYS . . . . . . . . . . . . . 71.2 m -114.79 174.02 6.18 Favored 'General case' 0 C--N 1.308 -1.214 0 N-CA-C 108.191 -1.04 . . . . 0.0 108.191 -178.06 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' THR . . . . . 0.841 HG23 ' HD2' ' A' ' 94' ' ' TYR . 5.0 t -86.53 171.19 11.25 Favored 'General case' 0 C--O 1.253 1.254 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 177.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 87.2 tttt -64.99 133.8 52.5 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.901 0.381 . . . . 0.0 111.004 -172.241 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 90.71 -0.55 77.1 Favored Glycine 0 C--O 1.244 0.772 0 N-CA-C 110.648 -0.981 . . . . 0.0 110.648 -178.105 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' TYR . . . . . 0.841 ' HD2' HG23 ' A' ' 91' ' ' THR . 83.6 m-85 -123.61 141.52 51.93 Favored 'General case' 0 C--O 1.241 0.641 0 C-N-CA 122.278 0.231 . . . . 0.0 111.216 179.04 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ARG . . . . . 0.427 ' CZ ' HG23 ' A' ' 123' ' ' ILE . 9.5 ptp85 -134.58 165.94 24.06 Favored 'General case' 0 C--N 1.321 -0.66 0 N-CA-C 108.617 -0.883 . . . . 0.0 108.617 175.922 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -79.27 135.92 36.9 Favored 'General case' 0 N--CA 1.436 -1.156 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 175.802 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 121' ' ' ASP . 49.2 mm -74.62 -4.07 5.32 Favored 'Isoleucine or valine' 0 CA--C 1.554 1.099 0 CA-C-O 121.852 0.834 . . . . 0.0 111.063 178.746 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' GLY . . . . . 0.412 ' CA ' ' HB3' ' A' ' 118' ' ' PRO . . . -144.51 -131.53 2.42 Favored Glycine 0 N--CA 1.437 -1.286 0 CA-C-N 115.385 -0.825 . . . . 0.0 111.713 -175.806 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' SER . . . . . 0.56 ' HB2' ' CG2' ' A' ' 115' ' ' THR . 75.8 m -104.22 120.69 41.7 Favored 'General case' 0 C--O 1.205 -1.27 0 CA-C-O 121.409 0.623 . . . . 0.0 109.99 -178.658 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' SER . . . . . 0.406 ' HB2' ' O ' ' A' ' 88' ' ' TYR . 77.8 p -66.52 -18.04 65.14 Favored 'General case' 0 C--N 1.312 -1.061 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.369 -178.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . 0.712 ' HA ' ' O ' ' A' ' 86' ' ' ILE . 29.6 p -127.58 123.61 36.14 Favored 'General case' 0 N--CA 1.406 -2.661 0 CA-C-O 121.547 0.689 . . . . 0.0 109.962 177.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ALA . . . . . 0.45 ' O ' ' HA ' ' A' ' 85' ' ' GLN . . . -99.39 141.47 32.12 Favored 'General case' 0 CA--C 1.481 -1.706 0 CA-C-N 114.272 -1.331 . . . . 0.0 107.852 175.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' THR . . . . . . . . . . . . . 93.5 m -112.91 126.92 55.99 Favored 'General case' 0 N--CA 1.415 -2.197 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -178.848 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' CYS . . . . . . . . . . . . . 13.5 m -69.04 121.84 17.49 Favored 'General case' 0 C--N 1.303 -1.437 0 CA-C-N 114.193 -1.367 . . . . 0.0 110.002 -179.835 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' ILE . . . . . 0.412 HG12 ' HB2' ' A' ' 114' ' ' ASP . 1.2 pp -128.68 163.73 32.59 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.695 -176.305 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ILE . . . . . 0.729 ' CD1' HG22 ' A' ' 111' ' ' VAL . 39.0 mm -105.24 125.79 60.34 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.18 0 CA-C-N 115.352 -0.84 . . . . 0.0 109.916 178.934 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 47.8 t -112.2 122.84 48.87 Favored 'General case' 0 N--CA 1.423 -1.783 0 N-CA-C 103.784 -2.672 . . . . 0.0 103.784 168.029 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 63.64 -121.6 24.19 Favored Glycine 0 CA--C 1.526 0.77 0 C-N-CA 118.249 -1.929 . . . . 0.0 109.605 -172.948 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -117.01 26.64 9.65 Favored 'General case' 0 CA--C 1.559 1.306 0 CA-C-O 121.837 0.827 . . . . 0.0 108.865 177.345 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' THR . . . . . 0.44 HG22 HG23 ' A' ' 112' ' ' ILE . 97.9 m -122.94 132.88 54.35 Favored 'General case' 0 N--CA 1.436 -1.173 0 C-N-CA 123.571 0.748 . . . . 0.0 111.987 -172.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' VAL . . . . . 0.729 HG22 ' CD1' ' A' ' 106' ' ' ILE . 65.4 t -98.62 116.04 40.51 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.952 0 CA-C-O 121.482 0.658 . . . . 0.0 109.943 -178.851 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.44 HG23 HG22 ' A' ' 110' ' ' THR . 43.1 pt -131.05 161.29 41.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 114.115 -1.402 . . . . 0.0 110.935 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' TRP . . . . . . . . . . . . . 97.8 m95 -87.18 124.33 33.17 Favored 'General case' 0 CA--C 1.548 0.88 0 N-CA-C 106.654 -1.609 . . . . 0.0 106.654 -179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ASP . . . . . 0.412 ' HB2' HG12 ' A' ' 105' ' ' ILE . 24.2 t70 -65.37 -40.58 93.72 Favored 'General case' 0 N--CA 1.483 1.198 0 N-CA-C 114.011 1.115 . . . . 0.0 114.011 -178.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' THR . . . . . 0.56 ' CG2' ' HB2' ' A' ' 99' ' ' SER . 90.3 m -63.22 -44.61 94.81 Favored 'General case' 0 CA--C 1.57 1.732 0 N-CA-C 115.981 1.845 . . . . 0.0 115.981 -170.469 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' GLU . . . . . 0.435 ' HB2' ' O ' ' A' ' 115' ' ' THR . 95.9 mt-10 90.47 -7.89 0.32 Allowed 'General case' 0 N--CA 1.518 2.958 0 C-N-CA 125.542 1.537 . . . . 0.0 109.804 -173.251 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' THR . . . . . . . . . . . . . 2.8 m 72.35 118.36 0.03 OUTLIER Pre-proline 0 CA--C 1.546 0.805 0 N-CA-C 115.258 1.577 . . . . 0.0 115.258 176.267 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' PRO . . . . . 0.412 ' HB3' ' CA ' ' A' ' 98' ' ' GLY . 92.4 Cg_endo -73.24 158.55 48.62 Favored 'Trans proline' 0 C--O 1.239 0.529 1 C-N-CA 125.359 4.039 . . . . 0.0 114.52 178.624 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' ILE . . . . . . . . . . . . . 97.1 mt -114.87 132.16 64.91 Favored 'Isoleucine or valine' 0 CA--C 1.499 -0.981 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.602 177.213 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' CYS . . . . . . . . . . . . . 98.1 m -69.64 131.83 45.23 Favored 'General case' 0 CA--C 1.537 0.454 0 N-CA-C 108.225 -1.028 . . . . 0.0 108.225 177.932 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ASP . . . . . 0.528 ' HB3' HD11 ' A' ' 97' ' ' ILE . 45.9 t0 -146.92 172.59 13.46 Favored 'General case' 0 C--N 1.295 -1.769 0 N-CA-C 107.293 -1.373 . . . . 0.0 107.293 179.868 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.978 ' HB3' ' CE1' ' A' ' 145' ' ' HIS . 94.8 mtt-85 -69.09 138.72 54.54 Favored 'General case' 0 N--CA 1.422 -1.872 0 C-N-CA 118.941 -1.104 . . . . 0.0 109.939 -177.072 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' ILE . . . . . 0.569 ' N ' ' HE1' ' A' ' 145' ' ' HIS . 25.3 mt -75.19 96.96 0.17 Allowed Pre-proline 0 CA--C 1.499 -1.01 0 C-N-CA 123.784 0.834 . . . . 0.0 112.61 -174.292 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' PRO . . . . . 0.679 ' HD3' ' O ' ' A' ' 122' ' ' ARG . 71.7 Cg_endo -70.91 143.8 46.23 Favored 'Trans proline' 0 N--CA 1.414 -3.165 0 CA-C-N 120.272 1.133 . . . . 0.0 110.027 171.678 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -101.84 131.77 47.99 Favored 'General case' 0 N--CA 1.407 -2.611 0 C-N-CA 118.685 -1.206 . . . . 0.0 108.848 175.07 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . -80.59 -175.1 48.93 Favored Glycine 0 N--CA 1.427 -1.941 0 CA-C-N 115.089 -0.96 . . . . 0.0 111.223 -179.786 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -43.14 119.14 2.64 Favored Pre-proline 0 C--O 1.245 0.838 0 C-N-CA 122.617 0.367 . . . . 0.0 110.928 179.059 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -55.7 158.38 13.6 Favored 'Trans proline' 0 CA--C 1.507 -0.863 0 C-N-CA 122.272 1.981 . . . . 0.0 109.297 177.922 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -61.52 142.67 95.76 Favored 'Trans proline' 0 CA--C 1.504 -1.007 0 CA-C-N 119.019 0.685 . . . . 0.0 110.911 -178.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' THR . . . . . . . . . . . . . 7.2 m -72.28 144.26 48.45 Favored 'General case' 0 C--N 1.285 -2.21 0 CA-C-N 114.706 -1.134 . . . . 0.0 110.819 -178.3 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.799 HG21 ' C ' ' A' ' 134' ' ' GLY . 10.9 tp -99.39 150.66 5.07 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.195 0 CA-C-O 121.786 0.803 . . . . 0.0 111.0 -170.983 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' THR . . . . . . . . . . . . . 86.4 m -61.2 -45.81 93.06 Favored 'General case' 0 C--N 1.3 -1.582 0 CA-C-N 114.594 -1.185 . . . . 0.0 111.289 -179.355 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' ASN . . . . . . . . . . . . . 93.6 m-20 -108.75 -66.95 1.01 Allowed 'General case' 0 N--CA 1.492 1.674 0 N-CA-C 116.032 1.864 . . . . 0.0 116.032 -178.817 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' GLY . . . . . 0.799 ' C ' HG21 ' A' ' 131' ' ' ILE . . . -131.48 141.58 12.9 Favored Glycine 0 CA--C 1.488 -1.605 0 CA-C-O 117.302 -1.832 . . . . 0.0 109.246 -175.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' ASP . . . . . . . . . . . . . 18.3 p-10 -48.68 -115.3 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 115.11 1.522 . . . . 0.0 115.11 -168.001 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' PHE . . . . . 0.421 ' HB3' ' CD2' ' A' ' 152' ' ' TYR . 50.5 p90 -153.64 163.53 39.84 Favored 'General case' 0 C--N 1.253 -3.61 0 O-C-N 121.469 -0.77 . . . . 0.0 111.407 -176.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' ILE . . . . . 0.616 ' CG2' ' HB ' ' A' ' 151' ' ' THR . 18.7 tt -113.36 129.17 69.59 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.925 0 CA-C-O 122.506 1.145 . . . . 0.0 108.492 -179.213 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' SER . . . . . . . . . . . . . 47.5 t -157.95 160.84 37.99 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 106.688 -1.597 . . . . 0.0 106.688 -179.584 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' THR . . . . . . . . . . . . . 37.4 p -64.68 -36.25 83.67 Favored 'General case' 0 C--N 1.303 -1.417 0 C-N-CA 118.871 -1.132 . . . . 0.0 110.902 -178.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' ASN . . . . . 0.414 ' HA ' HD22 ' A' ' 140' ' ' ASN . 9.6 m120 -129.45 141.04 51.12 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.341 -0.845 . . . . 0.0 108.824 171.184 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ARG . . . . . 0.45 ' O ' ' HG2' ' A' ' 142' ' ' GLU . 77.4 ttt-85 -67.76 136.04 53.6 Favored 'General case' 0 N--CA 1.444 -0.736 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 176.767 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLU . . . . . 0.45 ' HG2' ' O ' ' A' ' 141' ' ' ARG . 14.9 pt-20 59.33 82.64 0.14 Allowed 'General case' 0 N--CA 1.485 1.289 0 O-C-N 124.056 0.847 . . . . 0.0 112.064 -179.27 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' ASN . . . . . 0.743 ' HB3' ' OG ' ' A' ' 148' ' ' SER . 6.5 t30 -69.41 142.75 53.81 Favored 'General case' 0 N--CA 1.451 -0.389 0 CA-C-N 115.504 -0.771 . . . . 0.0 111.35 -176.623 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' PHE . . . . . . . . . . . . . 92.9 m-85 -62.14 -43.93 97.74 Favored 'General case' 0 C--N 1.308 -1.225 0 CA-C-N 113.659 -1.609 . . . . 0.0 114.611 -165.853 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' HIS . . . . . 0.978 ' CE1' ' HB3' ' A' ' 122' ' ' ARG . 54.1 t60 -149.32 172.89 14.16 Favored 'General case' 0 CA--C 1.562 1.404 0 N-CA-C 114.474 1.287 . . . . 0.0 114.474 -168.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' TYR . . . . . 0.523 ' N ' ' CG ' ' A' ' 145' ' ' HIS . 71.6 t80 -51.7 137.48 25.25 Favored 'General case' 0 C--N 1.374 1.648 0 C-N-CA 125.174 1.389 . . . . 0.0 108.149 179.188 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . 100.2 -4.98 57.37 Favored Glycine 0 N--CA 1.433 -1.535 0 N-CA-C 108.182 -1.967 . . . . 0.0 108.182 -167.52 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' SER . . . . . 0.743 ' OG ' ' HB3' ' A' ' 143' ' ' ASN . 29.6 t -65.72 138.81 58.21 Favored 'General case' 0 CA--C 1.496 -1.108 0 CA-C-N 114.745 -0.727 . . . . 0.0 109.446 173.513 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 2.9 p -140.58 140.05 34.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.108 177.687 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.6 m -132.11 156.8 42.83 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.312 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 177.067 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' THR . . . . . 0.616 ' HB ' ' CG2' ' A' ' 137' ' ' ILE . 85.6 m -126.03 128.36 47.31 Favored 'General case' 0 C--N 1.297 -1.695 0 C-N-CA 119.237 -0.985 . . . . 0.0 110.805 176.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' TYR . . . . . 0.421 ' CD2' ' HB3' ' A' ' 136' ' ' PHE . 97.6 m-85 -92.38 140.81 29.21 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 120.958 -0.297 . . . . 0.0 110.206 -177.814 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' ARG . . . . . 0.502 ' HA ' ' CD1' ' A' ' 166' ' ' LEU . 8.7 ptm180 -140.96 145.91 36.64 Favored 'General case' 0 C--N 1.304 -1.379 0 CA-C-O 121.551 0.691 . . . . 0.0 110.479 178.035 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.483 ' SG ' HD12 ' A' ' 166' ' ' LEU . 72.7 m -83.97 145.77 28.36 Favored 'General case' 0 C--N 1.315 -0.921 0 C-N-CA 124.299 1.039 . . . . 0.0 110.58 -171.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' ASN . . . . . . . . . . . . . 20.0 p30 -71.67 147.6 92.15 Favored Pre-proline 0 CA--C 1.561 1.386 0 N-CA-C 115.614 1.709 . . . . 0.0 115.614 -171.784 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -73.06 155.25 52.63 Favored 'Trans proline' 0 CA--C 1.56 1.818 0 C-N-CA 124.646 3.564 . . . . 0.0 114.473 173.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.99 -129.36 5.95 Favored Glycine 0 N--CA 1.477 1.414 0 N-CA-C 115.698 1.039 . . . . 0.0 115.698 -176.047 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' SER . . . . . . . . . . . . . 28.8 m -59.78 -43.19 94.5 Favored 'General case' 0 N--CA 1.442 -0.839 0 CA-C-N 114.909 -0.646 . . . . 0.0 111.106 -173.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' GLY . . . . . . . . . . . . . . . -170.19 95.18 0.11 Allowed Glycine 0 N--CA 1.442 -0.917 0 C-N-CA 120.086 -1.054 . . . . 0.0 113.864 177.645 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' GLY . . . . . . . . . . . . . . . 78.93 20.25 70.94 Favored Glycine 0 CA--C 1.538 1.509 0 N-CA-C 115.136 0.814 . . . . 0.0 115.136 173.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' ARG . . . . . . . . . . . . . 57.9 ttm-85 -125.08 138.53 54.18 Favored 'General case' 0 N--CA 1.482 1.142 0 CA-C-N 118.048 0.924 . . . . 0.0 111.512 -178.309 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . 0.414 ' HE3' ' HB2' ' A' ' 154' ' ' CYS . 36.8 tptt -71.33 116.27 11.46 Favored 'General case' 0 CA--C 1.508 -0.635 0 N-CA-C 107.576 -1.268 . . . . 0.0 107.576 177.698 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' VAL . . . . . 0.511 ' HB ' ' CD2' ' A' ' 164' ' ' PHE . 7.0 t -66.7 -44.13 89.76 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.618 0 CA-C-O 122.108 0.956 . . . . 0.0 111.748 179.682 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' PHE . . . . . 0.511 ' CD2' ' HB ' ' A' ' 163' ' ' VAL . 94.8 m-85 -128.29 149.94 50.27 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-N 113.877 -1.51 . . . . 0.0 112.776 -165.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' GLU . . . . . 0.528 ' O ' ' HA ' ' A' ' 191' ' ' CYS . 95.2 mt-10 -88.03 155.06 20.01 Favored 'General case' 0 N--CA 1.439 -0.99 0 CA-C-N 113.989 -1.46 . . . . 0.0 108.396 178.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' LEU . . . . . 0.589 HD23 ' O ' ' A' ' 167' ' ' VAL . 8.0 tt -127.15 142.96 51.37 Favored 'General case' 0 C--N 1.314 -0.961 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 -174.4 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' VAL . . . . . 0.589 ' O ' HD23 ' A' ' 166' ' ' LEU . 2.1 p -66.56 133.95 30.6 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.718 0 N-CA-C 109.167 -0.679 . . . . 0.0 109.167 -179.134 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' GLY . . . . . . . . . . . . . . . -58.79 31.47 0.03 OUTLIER Glycine 0 CA--C 1.546 2.002 0 N-CA-C 117.158 1.623 . . . . 0.0 117.158 -176.313 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' GLU . . . . . . . . . . . . . 28.2 tt0 -138.81 48.95 1.98 Allowed Pre-proline 0 CA--C 1.564 1.492 0 CA-C-N 117.68 0.74 . . . . 0.0 109.114 174.978 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' PRO . . . . . 0.638 ' HA ' ' HG3' ' A' ' 189' ' ' PRO . 49.2 Cg_endo -67.14 -20.06 50.33 Favored 'Trans proline' 0 C--N 1.386 2.526 0 C-N-CA 123.726 2.951 . . . . 0.0 114.639 -174.491 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' SER . . . . . . . . . . . . . 20.0 m -107.53 121.74 45.24 Favored 'General case' 0 C--N 1.306 -1.314 0 C-N-CA 120.349 -0.54 . . . . 0.0 111.368 -171.422 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' ILE . . . . . . . . . . . . . 48.0 pt -127.75 160.31 37.4 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.546 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.52 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' TYR . . . . . . . . . . . . . 38.6 p90 -146.96 161.16 41.34 Favored 'General case' 0 C--N 1.306 -1.305 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.725 -176.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -64.97 112.23 3.22 Favored 'General case' 0 CA--C 1.533 0.315 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -178.959 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' THR . . . . . 0.513 HG23 ' O ' ' A' ' 175' ' ' THR . 15.2 t -149.87 76.47 1.29 Allowed 'General case' 0 CA--C 1.565 1.526 0 CA-C-O 123.625 1.678 . . . . 0.0 111.104 177.573 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' SER . . . . . 0.69 ' HB2' ' H ' ' A' ' 182' ' ' GLY . 78.0 p -66.68 -18.6 65.46 Favored 'General case' 0 C--N 1.271 -2.841 0 N-CA-C 117.102 2.26 . . . . 0.0 117.102 179.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' ASN . . . . . . . . . . . . . 32.4 p-10 -62.6 -40.8 98.08 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 118.471 2.767 . . . . 0.0 118.471 -165.074 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' ASP . . . . . . . . . . . . . 7.1 m-20 -63.21 -43.61 97.65 Favored 'General case' 0 C--O 1.264 1.828 0 N-CA-C 115.201 1.556 . . . . 0.0 115.201 -170.845 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 179' ' ' ASP . . . . . . . . . . . . . 16.4 p-10 -153.82 131.41 11.43 Favored 'General case' 0 C--O 1.248 1.007 0 CA-C-N 118.586 0.63 . . . . 0.0 110.647 174.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 180' ' ' GLN . . . . . . . . . . . . . 92.2 mm-40 68.64 179.62 0.24 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-O 121.312 0.577 . . . . 0.0 111.163 -175.585 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 181' ' ' VAL . . . . . . . . . . . . . 54.5 t -126.43 134.28 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.144 0 N-CA-C 113.383 0.883 . . . . 0.0 113.383 -173.182 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 182' ' ' GLY . . . . . 0.69 ' H ' ' HB2' ' A' ' 176' ' ' SER . . . 85.5 44.15 6.27 Favored Glycine 0 N--CA 1.471 0.985 0 N-CA-C 115.884 1.114 . . . . 0.0 115.884 174.161 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 183' ' ' ILE . . . . . . . . . . . . . 25.4 pt -125.92 162.9 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.09 0 CA-C-O 122.385 1.088 . . . . 0.0 112.65 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 184' ' ' TRP . . . . . . . . . . . . . 84.0 m95 -79.64 -179.14 6.72 Favored 'General case' 0 C--O 1.203 -1.367 0 CA-C-N 114.685 -1.143 . . . . 0.0 109.772 172.898 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 185' ' ' SER . . . . . . . . . . . . . 38.9 m -59.23 -41.47 88.77 Favored 'General case' 0 C--O 1.244 0.802 0 CA-C-O 120.833 0.349 . . . . 0.0 110.821 177.659 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 186' ' ' GLY . . . . . . . . . . . . . . . -174.93 177.08 47.1 Favored Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 121.044 -0.598 . . . . 0.0 111.796 177.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 187' ' ' PRO . . . . . . . . . . . . . 23.3 Cg_exo -61.76 145.63 97.18 Favored 'Trans proline' 0 C--O 1.236 0.418 0 C-N-CA 122.724 2.283 . . . . 0.0 111.195 177.284 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 188' ' ' ALA . . . . . . . . . . . . . . . -46.58 128.96 8.24 Favored Pre-proline 0 CA--C 1.529 0.169 0 O-C-N 124.066 0.854 . . . . 0.0 112.604 -179.82 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 189' ' ' PRO . . . . . 0.638 ' HG3' ' HA ' ' A' ' 170' ' ' PRO . 94.1 Cg_endo -68.59 156.13 66.58 Favored 'Trans proline' 0 N--CA 1.444 -1.396 0 C-N-CA 123.148 2.565 . . . . 0.0 110.676 176.598 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 190' ' ' GLN . . . . . 0.548 ' HG3' HG13 ' A' ' 192' ' ' ILE . 13.6 pt20 -129.25 161.64 29.72 Favored 'General case' 0 C--N 1.288 -2.092 0 C-N-CA 119.641 -0.824 . . . . 0.0 112.568 -170.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 191' ' ' CYS . . . . . 0.528 ' HA ' ' O ' ' A' ' 165' ' ' GLU . 70.2 m -74.67 71.84 1.94 Allowed 'General case' 0 C--N 1.298 -1.632 0 CA-C-N 114.308 -1.315 . . . . 0.0 111.584 -173.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 192' ' ' ILE . . . . . 0.582 HD12 ' HB ' ' A' ' 167' ' ' VAL . 55.0 mt . . . . . 0 C--O 1.27 2.166 0 CA-C-N 112.622 -2.081 . . . . 0.0 110.452 176.985 . . . . . . . . 1 1 . 1 stop_ save_